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ABSTRACT 
MICRONUTRIENT INTAKE AND PREMENSTRUAL SYNDROME 
SEPTEMBER 2011 
PATRICIA O. CHOCANO-BEDOYA, M.D., UNIVERSITY OF 
SAINT AGUSTIN, AREQUIPA, PERU 
PH.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed by: Professor Elizabeth Bertone-Johnson 
 
Premenstrual syndrome (PMS) is characterized by the presence of physical 
and psychological symptoms restricted to the late luteal phase of the menstrual 
cycle and associated with substantial impairment in life activities. In the U.S. about 
8 to 15% of women of reproductive age suffer from PMS. Many micronutrients are 
potentially involved in the development of this disorder due to their role in the 
synthesis of neurotransmitters and hormones or in their regulation, but few 
previous studies have evaluated the effects of micronutrients on PMS. 
The first study examined the association between B vitamin intakes, and 
PMS development among women participating in the Nurses' Health Study 2 
(NHS2). We found that high thiamin and high riboflavin intake from food sources 
were associated with lower risk of PMS. There were not significant associations 
between niacin, vitamin B6, folate, and vitamin B12 dietary intake and incident 
PMS.  Intakes of B vitamins from supplements were not associated with lower risk 
of PMS. 
vii 
 
The second study evaluated the association between selected mineral 
intakes and PMS development in the NHS2. In this study, high iron intakes were 
associated with lower risk of PMS. Although there was no association between 
zinc and PMS risk, high intake of zinc relative to copper was associated with lower 
risk of PMS. There were no associations between of magnesium, copper, and 
manganese intakes and PMS. We observed a significantly higher risk of PMS in 
women with high intakes of potassium from food sources. 
The third study focused on the association between dietary intakes of B 
vitamins, zinc, magnesium, iron, potassium, and sodium and some biomarkers and 
PMS prevalence among younger women. In this study, we found an association 
between zinc intake and lower prevalence of PMS. Each 1 mg/d increase in  
vitamin B6 from foods was associated with a lower PMS symptom score. Blood 
magnesium levels were higher in women with PMS compared to women without 
PMS. 
We observed that intakes of some micronutrients were associated with 
lower risk of PMS, but further studies should be conducted. This dissertation 
contributes to the research on modifiable risk factors for PMS. 
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CHAPTER 1 
PREMENSTRUAL SYNDROME REVIEW 
 
A syndrome is a group of symptoms and signs with a common etiologic factor. 
Accordingly, premenstrual syndrome (PMS) involves a group of psychological and 
physical symptoms and signs that occur cyclically during the late luteal phase of the 
menstrual cycle and resolve within a few days of the onset of menstruation (1). This 
syndrome affects millions of women of reproductive age worldwide (1, 2). Despite many 
decades of research, there is still controversy about the etiology and treatment of PMS.  
The establishment of a universally accepted definition and set of diagnostic criteria, the 
understanding of the pathophysiology and the identification of effective treatments are 
problems yet to be solved.  This chapter focuses on the diagnosis, burden, 
pathophysiology and treatment of PMS as an introductory review  
 
1.1 Definition and Diagnosis 
The definition and diagnostic criteria of premenstrual syndrome have varied 
substantially over the years, and controversy persists (3, 4).  Moreover, the disagreement 
about the medical definition of PMS has been used to support the position that PMS is 
not a “physiologic condition but a cultural/ideological construct” (5). 
“Premenstrual tension” was first described in the scientific literature by Frank in 
1931 (6). However, it was not until 1953 that Greene and Dalton adopted the term 
“premenstrual syndrome” because they believed that the term “premenstrual tension” did 
2 
 
not include all the potential symptoms that women experienced during the late luteal 
phase (7). Despite this, some authors continued to use the term ‘premenstrual tension’ up 
to the 1990’s. 
Between the 1950’s and 1960’s most researchers focused on the somatic 
complaints of PMS, rather than the psychological complaints (5). But at the same time, 
many standardized questionnaires for symptom measurement were proposed by 
psychologists (5) one of the most important ones being the Menstrual Distress 
Questionnaire, designed by Moos.(8) This questionnaire included 47 symptoms evaluated 
on a six-point scale and reported for different phases of a current and a past cycle (8). Up 
until 1990, there were additional attempts to standardize the diagnosis of PMS and 
premenstrual dysphoric disorder (PMDD), but most studies still used “non-standardized 
poorly validated methods” (5, 9). 
In 1990 Mortola et al. designed the “Calendar of Premenstrual Experiences” 
(COPE) (9). In the validation study, behavioral items were compared to the Beck 
Depression Inventory and the Profile of Mood States, both of which are well-validated 
psychiatric questionnaires designed to measure depression. The authors concluded that 
the COPE had a 0% false positive rate and 2.8% false negative rate, as well as high 
reliability (9).   
Over 150 symptoms have been associated with PMS. With regards to affective 
symptoms, irritability, depression and fatigue are the most important and most frequently 
reported (10). Other affective symptoms such as labile mood and frequent crying are also 
very common (75% and 66% respectively) (10).Approximately 50% of women report 
3 
 
difficulty in concentrating and forgetfulness. Of physical symptoms, the most common 
are bloating, headache and breast tenderness. Approximately 48% of women with PMS 
have gastrointestinal upset, and 18% suffer from hot flushing (10). The nature and 
frequency of the symptoms vary between women and also in different cycles in the same 
women (11). 
In the year 2000, the American College of Obstetricians and Gynecologists 
(ACOG) (1) published a set of diagnostic criteria for PMS adapted from those suggested 
by Mortola et al (9). These criteria include the presence of at least one of 6 affective 
symptoms and at least 1 of 4 somatic symptoms (Table 1) during the 5 days previous to 
the onset of menstruation in each of three previous menstrual cycles. Symptoms are 
reported prospectively in a self-maintained diary. The intensity of the symptoms must be 
severe enough to cause social dysfunction and/or to affect work performance. Symptoms 
should subside completely within 4 days of the onset of menses and should not reappear 
until after day 13 of the menstrual cycle. The ACOG emphasized that the symptoms 
should be assessed prospectively and other differential diagnoses like clinical major 
depression should be excluded (1). 
Overall, definitions of PMS may vary in their criteria for symptom inclusion, but 
their restriction to the luteal phase is essential (9).  Another indispensable condition is 
that symptoms are not caused by another physical or mental disorder. Differential 
diagnoses include dysphoric disorder and generalized anxiety disorders (13). 
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Premenstrual Dysphoric Disorder (PMDD) and PMS. 
The revised third edition of the Diagnostic and Statistical Manual of Mental 
Health Disorders (DSM-III-R)(14) of the American Psychiatric Association (APA) 
included research diagnostic criteria for severe luteal phase symptoms under the name of 
“late luteal phase dysphoric disorder”. For the text revision of the fourth edition of the 
DSM-IV-TR (2000)(12) this condition was renamed “premenstrual dysphoric disorder” 
(PMDD).  The official inclusion of a diagnostic code for PMDD is very important for 
medical record coding and for potential insurance reimbursement. In fact, in 2003, the 
new version of the International Classification of Diseases (ICD-9-CM) included 
“premenstrual tension syndrome” under the code 625-4, though it lacked specific 
diagnostic criteria.(5) 
The DSM-IV-TR includes four criteria for a diagnosis of PMDD. The first 
criterion is the presence of at least 5 of the 11 symptoms listed in table 1, and at least one 
must be emotional. The second criterion is that symptoms must cause impairment in at 
least one facet of the woman’s daily life (e.g., school, work, interpersonal relationships). 
The third criterion is that symptoms cannot be an exacerbation of other psychiatric 
disorders. Finally, symptom experience must be confirmed by prospective daily ratings of 
symptoms during two consecutive cycles.(12) 
The relationship between PMS and PMDD is not clear (4). Several of the APA 
criteria for PMDD overlap with the ACOG criteria for PMS. While PMDD has been 
considered as a different entity than PMS by some clinicians and researchers (15), it has 
been also referred to as a severe form of PMS by others (16) . 
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Assessment of PMS: Prospective vs. Retrospective 
Assessment of PMS using retrospective self-report of PMS symptoms has drawn 
criticism, with some researchers asserting that accuracy could be affected by learned 
expectations and stereotypes about premenstrual suffering, which in turn could lead to the 
Table 1. Common symptoms present in the definitions of PMS and PMDD according 
to the ACOG (1) and APA (12) respectively.  
Symptoms PMS (ACOG) PMDD (DSM IV-TR) 
Affective Depression 
Irritability  
Anxiety  
Angry outbursts 
Confusion 
Social withdrawal 
Depressed mood 
Anxiety, tension 
Affective lability 
Anger or irritability 
Difficulty in concentrating 
Decreased interest in usual activities 
A sense of being overwhelmed 
Somatic Breast tenderness 
Abdominal bloating 
Headache 
Swelling of extremities 
Lethargy 
Change in appetite 
Hypersomnia or insomnia 
Breast tenderness/swelling/joint or 
muscle pain/sensation of 
bloating/weight gain 
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overestimation of PMS (5). Therefore, most of the definitions for PMS require 
prospective symptom reporting. Different types of questionnaires and diaries have been 
designed for prospective charting. For example, the “Daily Symptom Report” (DSR) 
designed by Freeman et al. consists of a diary were patients daily indicate the presence of 
17 PMS symptoms and rate their severity from 0 (“none”) to 4 (“severe”) over 2 to 3 
months (17) . 
Although prospective recording of symptoms appears to provide more accurate 
means of diagnosis, other validated methods are also needed. Women seeking treatment 
tend to be those with more severe symptoms (18), and it is important to provide them 
with prompt treatment. These patients are likely to be unwilling to accept the delay in 
treatment due to three months of prospective recording (18). Additionally, it may not be 
feasible to use prospective symptom recording in large epidemiologic studies, which are 
essential to identifying factors associated with PMS occurrence. In view of this challenge, 
Bertone-Johnson et al.(2007) (19), evaluated the validity and  reliability of using 
prospective self report of clinical diagnosis of PMS with a retrospective menstrual 
symptom questionnaire among women participating in the Nurses’ Health Study II, using 
PMS cases diagnosed prospectively as an ‘alloyed’ gold standard. The authors found that 
the menstrual symptom occurrence, timing, severity and personal impact of women who 
met case criteria based on those proposed by Mortola et al (9) as assessed by a 
retrospective questionnaire were essentially identical to those who reported having 
completed prospective charts as part of their medical diagnosis (19). Therefore, 
prospective self report combined with retrospective questionnaires may be a sensitive 
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enough method of identifying PMS cases to study risk factors for this disorder in large 
prospective studies. 
 
Summary of definition and diagnosis 
In summary, historically the definition of PMS has been controversial. Although 
guidelines for PMS have been published by the ACOG, and PMDD is recognized in the 
DSM-IV-TR, there is no current agreement on several aspects of PMS and PMDD 
diagnosis. Prospective charting is recommended for the clinical diagnosis of PMS, but 
retrospective questionnaires may be a valid option for use in large population-based 
studies.  
 
1.2 Incidence, Prevalence and Burden of PMS 
Despite increasing interest in PMS over time by the medical community, the 
incidence of PMS remains largely unknown due to the fact that most studies have 
collected information retrospectively on symptom frequency, using different instruments 
and criteria to define premenstrual disorders (3, 20).  Estimation of true incidence 
remains largely unfeasible. Because symptoms could develop during any menstrual cycle 
from menarche to menopause and may not be present every menstrual cycle, estimation 
of incidence would require study participants to prospectively record symptoms every 
cycle for many years.  
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Prevalence: 
According to the ACOG, around 15 to 20% of women of reproductive age suffer 
from PMS (1). A prevalence of 8.3% in 1994 was reported by Deuster et al.(21) who 
conducted a cross-sectional population-based study in Virginia. Using random digit 
dialing, 874 women were contacted and completed an interview that included a 
“Shortened Premenstrual Assessment Form” (SPAF), where women  recalled the 
presence of 10 symptoms the week before menses and rated the severity of them on a 6-
point scale (1=no change, 6=extreme change). Women were classified as having PMS if 
they rated five or more of the 10 symptoms as 5=severe or 6=extremely severe, and 
reported at least one affective symptom.   
According to the APA, 3 to 8% of women of reproductive age meet the DSM-IV 
criteria for PMDD (12). In 2008, Gehlert et al.(22) conducted a study to estimate the 
prevalence of PMDD according to the DSM IV criteria among 1246 women aged 13 to 
55 years living in two urban sites of Chicago. Daily symptom questionnaires and urine 
specimens were collected for two consecutive cycles to estimate ovulation time and 
timing of symptoms. The authors found a prevalence of PMDD of 1.3% which was lower 
than the prevalence previously reported by the APA.  In Germany, Wittchen et al.(23) 
conducted a study among 1488 women aged 14 to 24 followed over 4 years. A 
questionnaire based on DSM-IV criteria was conducted by trained interviewers at the end 
of every year. The authors reported a 12-month prevalence of 5.8% and an increase of 
new cases of 2.5% after 4 years. 
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Burden: 
Some authors assert that the burden associated with PMDD is comparable to that 
of major depressive disorder (24). The overall burden of PMS and PMDD is high largely 
because of relatively high prevalence and long duration of the symptoms, which could 
last throughout a woman’s reproductive years. Halbreich et al.(2003) (24) calculated that 
the disability adjusted life years (DALYs) for PMDD are 3.8 per women, assuming a 
reproductive period from ages 14 to 51 years and 2 pregnancies, for a total of 459 
menstrual cycles, 6.1 days of PMS symptoms per cycle and a global burden of disease 
severity weight of 0.5. If the prevalence of PMDD is estimated to be 5% in the U.S. 
population as of 2000 census, the total DALYs would be approximately 14.5 million for 
all women of reproductive age in the US. 
The economic burden associated with PMS includes direct medical costs as well 
as indirect costs. Medical costs include physician visits, laboratory tests and the cost of 
treatment. Indirect costs include those related to work/school absenteeism as well as to 
impaired productivity at work (2, 25). 
Borenstein et al (2005) (25)  estimated the direct and indirect costs of PMS among 
a sample of 374 women aged 18 to 45 years in Southern California. Participants 
completed a Daily Rating of Severity of Problems (DRSP) diary for 64 days, which 
measured recurrence of 11 symptoms, rated from 1 to 6 (1=not at all, 6=extreme). A 
diagnosis of PMS was made if participants reported an increase in score of ≥30% during 
the luteal phase, with at least 3 symptoms with an average score ≥ 3. Under these criteria, 
29.6% participants were diagnosed with PMS. Direct costs of PMS were quantified 
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according to administrative claims and the Medicare Fee Schedule, and were estimated to 
be $59 per year per person, including outpatient visits, laboratory analysis and radiology 
services. Indirect costs were estimated based on number of workdays missed due to 
health reasons (i.e. absenteeism) and self-reported proportion of days with at least 50% 
reduced work productivity compared to typical levels (loss of productivity). Using data 
on the median weekly wage of the female population from the U.S. Bureau of Labor 
Statistics Report 2000, indirect costs were estimated to be higher than $4,000 per person 
per year (25).   
Hence, days of work loss and decreased productivity appear to contribute more 
than direct costs to the economical burden of PMS. In the same population as the 
previous study, Dean and Borenstein (2004) (26) concluded that participants with PMS 
reported higher days of work absenteeism as compared to women without PMS (2.5 days 
vs. 1.3 days, p=0.006). Impairment in work and school productivity as well as household 
activities was significantly higher among women with PMS as compared to those in 
women without the disorder.  In a cross-sectional study by Robinson et al (2000) (18), the 
authors found that 20% of women with premenstrual symptoms missed work due to PMS 
during the year previous to the study. Moreover, participants surveyed reported greater 
impairment of interpersonal relationships than work performance. 
Direct and indirect costs both may be underestimated (2, 24). Not all women with 
PMS seek medical attention (18), and symptoms of PMS mimic other psychiatric or 
somatic disorders, which may lead to a substantial number of misdiagnoses (27). Days of 
work lost due to PMS may be underreported because of the stigma associated with it or 
because it might not be regarded as a “legitimate” reason for missing work (28). 
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Assessment of impaired productivity can be challenging and requires different 
methodologies for different occupations (24). 
In summary, the estimated prevalence of PMS ranges substantially from 8.3 to 
20% (1, 21), and depends on the criteria and methodology selected. Even if we consider 
the lowest prevalence reported to be accurate, the number of women suffering from PMS 
over many years is high.  
 
1.3 Pathophysiology 
The physiology of the menstrual cycle has been well studied and there is 
continuous research on the associated pathologies. However, the underlying 
pathophysiology of PMS remains unclear. Because of the timing and nature of the 
symptoms most studies have hypothesized that PMS is caused by interactions among sex 
hormones and neurotransmitters in the central nervous system.   
 
Overview of the Menstrual Cycle 
In order to describe the theories about the physiopathology of PMS, it is important 
first to provide a brief overview of the menstrual cycle, as summarized well by Guyton 
(2006) (29). The female hormonal system includes the hypothalamus, located in the 
central part of the base of the brain, the anterior pituitary, located underneath the 
hypothalamus, and the ovaries. This system is known as the hypothalamic-pituitary-
ovarian axis.  The hypothalamus secretes gonadotropin releasing hormone (GnRH) in 
short pulses, approximately once every 90 minutes. Variation in the frequency and size of 
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GnRH pulses stimulates the anterior pituitary to secrete the gonadotropins follicle-
stimulating hormone (FSH) and luteinizing hormone (LH), which stimulate the 
production of estrogen and progesterone in the ovary. FSH and LH secretion starts 
around the age of 9 to 12 years in normal females (i.e., at the onset of puberty) and 
changes rhythmically during the menstrual cycle in response to positive and negative 
feedback from the ovarian steroid hormones as well as other factors (29, 30). 
Each menstrual cycle has an average duration of 28 days, although cycle length 
can range from 20 to 45 days (29, 30). The first day of menstruation is considered as the 
first day of the cycle. During the first days of each cycle, there is a slight to moderate 
increase in the secretion of FSH and to a lesser extent in the secretion of LH. FSH causes 
proliferation of the granulosa cells surrounding oocytes in the ovary and increases FSH 
receptors in these cells. A layer of cells surrounding the granulosa cells is then formed, 
which is called the ‘theca’ (Figure 1). Thecal cells exposed to low levels of LH produce 
androgens, which are then converted to estrogen by CYP19 aromatase in the granulosa 
cells. This enzyme action is induced by FSH. Therefore there is biological interaction 
between both layers of cells, which leads to increased estrogen levels. Estrogen has an 
initial positive feedback on FSH production, inducing the granulosa cells to produce 
more FSH receptors. As estrogen levels increase, the luminal layer of the endometrium 
begins to proliferate. Therefore the first part of the menstrual cycle is also called the 
proliferative phase.  
Eventually, high estrogen levels down-regulate FSH secretion (i.e., negative 
feedback) (29). Usually, only a single follicle maintains a high estrogen 
microenvironment without the influence of FSH, and the rest of the follicles involute and 
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become atresic. Two days before ovulation, there is a 6 to 10 fold increase in the 
secretion of LH, which is required for the final stage of follicular growth and ovulation.  
After the release of the oocyte, the remaining granulosa and theca cells are 
converted into lutein cells, forming the corpus luteum (Figure 1) (29). Lutein cells secrete 
large amounts of progesterone and a small amount of estrogen. Additionally, they 
produce inhibin A, which suppresses the production of FSH and LH. The estrogens 
secreted by the luteal cells lead to slight additional proliferation of the endometrial tissue, 
whereas the high levels of progesterone lead to swelling and secretory development of 
the endometrium. Therefore, this phase is alsocalled the secretory phase as well as the 
luteal phase. In the absence of fertilization, the corpus luteum starts involution 8 to 12 
days after ovulation, when it becomes the ‘corpus albicans’ (Figure 1). This change leads 
to marked decreases in the levels of progesterone and  estrogen, which eventually leads to 
menstruation. After the involution of the corpus luteum and suppression of FSH, FSH 
levels begin to increase again, leading to the start of a new menstrual cycle. Menstruation 
occurs at the first day of every cycle through mechanisms that may involve 
prostaglandin-mediated vasoconstriction and contractions of the uterine muscle. 
 
Figure 1. Changes in the ovarian cells during the menstrual cycle. 
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Theories about Premenstrual Syndrome Etiology:  
• Fluctuation in ovarian hormones 
The hypothalamus not only regulates the menstrual cycle but also integrates 
multiple activities such as thirst, hunger, temperature control and sexual behavior. 
Consequently, there may be a relationship between the menstrual cycle and multiple 
aspects of human behavior related to PMS.  
PMS was initially thought to be caused by a hormonal imbalance, particularly an 
estrogen excess (6) or a deficiency in progesterone secretion from the corpus luteum (7). 
However most studies comparing hormonal levels have failed to demonstrate that 
absolute levels of estrogen and progesterone are different in women with PMS or PMDD 
compared to women without PMS or PMDD (20, 31). More recently it has been 
suggested that women with PMS might have a higher vulnerability to rhythmic hormonal 
changes during the menstrual cycle (20, 32). However, it is not yet clear which specific 
hormonal changes are associated with PMS symptoms; the preovulatory peak in estrogen, 
the postovulatory increase in progesterone and the drop in progesterone levels in the late 
luteal phase have all been proposed as potential triggers for PMS symptoms. Other 
hormones such as melatonin, cortisol, thyroid-stimulating hormone and prolactin have 
been studied as potential contributors of symptom occurrence (20, 33). Another hormone 
associated with PMS symptoms, particularly mastalgia, is prolactin. Usually under 
inhibition of the hypothalamus, prolactin is secreted by the tuberoinfundibular cells in the 
anterior pituitary (29). It is suspected that women with PMS have an increased secretion 
of prolactin during the luteal phase (11, 34). However, at least one study did not report 
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differences in fluctuations of prolactin during the menstrual cycle in women with PMS 
compared to controls (35).  
It appears that rhythmical changes in specific hormonal levels during the 
menstrual cycle cannot alone explain the wide variety of symptoms associated with PMS 
(20, 31). Many other factors may be involved in the etiology of PMS, and different 
symptoms may have different underlying causal mechanisms.  
  
• Interaction of hormones with neurotransmitters in the brain: 
The psychological symptoms of PMS (i.e., depression, irritability, anxiety) 
suggest an interaction of the cyclical hormonal changes with neurotransmitters in the 
central nervous system (20). After ovulation, a series of changes in neurotransmitter 
functioning are triggered. Ovarian hormones have the capacity to modulate the γ-
aminobutyric acid (GABA) and serotonin neurotransmitter systems (20, 32, 36). Because 
they are steroid hormones and therefore lipophilic, they have the ability to diffuse across 
the blood-brain-barrier. Therefore, plasma levels of steroid hormones are correlated with 
concentrations in brain (37). We will explore in detail the association of estrogen and 
progesterone with the neurotransmitters serotonin and GABA. 
- Serotonin: 
The neurotransmitter serotonin is synthesized by the neurons of the raphe nuclei, 
located between the lower pons and the medulla. Its precursor, the amino acid tryptophan, 
is hydroxylated into 5-hydroxytryptophan and then decarboxylated into serotonin. These 
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reactions require the presence of micronutrients, including magnesium, zinc, and many of 
the B vitamins. There are many types of serotonin receptors on the brain, spinal cord and 
gut, which lead to a broad range of effects of serotonin, including regulation of body 
temperature, sleep, mood, appetite, and pain, as well as to the modulation of the output of 
cortisol and prolactin (29). 
Estrogen levels have been positively associated with serotoninergic activity 
through the regulation of synthesis and degradation of serotonin (38). Animal studies 
have suggested that both serotonin and serotonin receptor levels fluctuate during the 
estrous cycle (39). Decreased serotonin activity is associated with depression and specific 
symptoms such as carbohydrate cravings and sleep disturbances (11). 
Some studies (40-42), but not all (43, 44), have suggested women with 
premenstrual disorders have lower serotonin (or serotonin metabolites) levels during the 
luteal phase as compared to controls. For example, in 1987, Rapkin et al.(42) conducted a 
study among 14 women aged 18 to 25 years old with moderate to severe premenstrual 
symptoms and 13 age-matched controls without PMS symptoms. Timing of the late 
follicular, ovulatory, midluteal, late luteal and premenstrual phases were determined 
according to basal body temperature charts, and confirmed by the date of onset of the 
next menstrual period. The premenstrual phase was defined as 3 days after the late luteal 
phase. Blood samples were collected for every participant at each different phase to 
determine whole-blood serotonin levels. Serotonin levels were found to be significantly 
lower during the midluteal, late luteal and premenstrual phases among women with PMS 
as compared to controls. For example, in the premenstrual phase, mean (±SE) serotonin 
levels among cases was 176.5 (±13) ng/mL vs. 298.6 (±43) ng/mL among controls. There 
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was no significant difference in serotonin levels during the follicular and ovulatory 
phases. Moreover, cases and controls showed similar estradiol and progesterone levels 
during all phases.  
Dietary intake of tryptophan may affect serotonin levels. To evaluate the 
serotonin response to tryptophan load, Rasgon et al. (2000) (45) conducted a clinical trial 
among five women with prospectively diagnosed PMS and five controls to evaluate the 
serotonin response to an infusion of intravenous L-tryptophan (LTP) over one menstrual 
cycle. During the follicular phase, LTP was found to increase serotonin levels equally 
among women with and without PMS. However, during the luteal phase, cases 
demonstrated a blunted response to LTP infusion while controls did not. Moreover, 
women who had PMS had significantly higher baseline cortisol levels during the luteal 
phase, as compared to controls. To date, the underlying mechanisms by which L-
tryptophan  is handled differently in women with and without PMS are unknown. 
Overall, this study supports a role of serotonin and its precursor tryptophan in the 
pathophysiology of PMS.  
- Allopregnanolone and GABA: 
GABA is the major inhibitory neurotransmitter in the brain and is secreted by 
neurons in the cortex, cerebellum, basal ganglia and the spinal cord. The GABA pathway 
provides negative feedback from the caudal nucleus and putamen to the globus pallidus 
and substantia nigra (29). GABA exerts its effects by binding to two distinct receptors, 
GABA-A and GABA-B, resulting in inhibition of neural activity (46).  
 
18 
 
One consistent finding with regards to the pathophysiology of PMS is that 
symptom development during the luteal phase generally requires ovulation and the 
consequent formation of the corpus luteum. The corpus luteum formed during the luteal 
phase secretes a variety of hormones, one of them being allopregnanolone, a neuroactive 
metabolite of progesterone that has high affinity for GABA-A receptors in the brain (32, 
47).  Allopregnanolone can be also be synthesized in the brain de novo from cholesterol 
(48). 
It has been proposed that high concentrations of allopregnanolone activate 
GABA-A receptors  resulting in anxiolytic, anesthetic and anticonvulsivant effects, while 
low concentrations result in an anxiogenic effect (32, 47, 49). For example, in an animal 
study conducted by Lovick et al. (37)  among female rats, decreases in allopregnanolone 
levels led to a predisposition to increased anxiety and hyperalgesia and increased 
expression of the GABA-A receptor in the periaqueductal grey matter.  
Women with PMDD may have decreased sensitivity to GABA-A receptor 
modulators such as benzodiazepines, alcohol and pregnanolone during the luteal phase, 
compared to that during the follicular phase or to controls (50-53). Some studies suggest 
that fluctuations of allopregnanolone at physiologic concentration across the reproductive 
cycle can be modulated by preferential sensitivity of individual GABA-R subunits (47, 
54, 55). This decreased effect of allopregnanolone on GABA-A receptors is probably due 
to the expression of a different type of GABA-A receptors that is insensitive to 
allopregnanolone elicited by continuous exposure and withdrawal of this neurosteroid 
(32, 55, 56).   
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Some studies have suggested that women with PMS have lower allopregnanolone 
levels in the follicular and luteal phases (57, 58), but others have found no difference (50, 
56, 59). In a study by Monteleone et al. (58), blood samples from 28 women aged 18 to 
32 years diagnosed with PMS and 28 age-matched controls were collected during the 
follicular phase (days 5 – 8)  and the luteal phase (days 22 - 26) during three consecutive 
menstrual cycles. The authors found that luteal phase allopregnanolone concentrations 
were significantly lower in women with PMS as compared to those in their matched 
controls (mean  ±  SE allopregnanolone concentration at the third month =1.54  ±  0.20 
nmol/l among cases vs. 3.76  ±  0.09 nmol/l among controls,  p < 0.001). Progesterone 
concentrations were lower among women with PMS,in both the follicular and the luteal 
phases as compared to those in controls ( p < 0.001). There was no statistically significant 
difference in estradiol levels among the groups.  In contrast, in a study by Epperson et al. 
(59), blood samples were collected during the follicular (days 3-8 of the cycle), mid-
luteal (3 to 8 days after LH peak, approx. days 17-22 of the cycle) and late-luteal 
phases(1-5 days before onset of menses) from  9 women diagnosed with PMDD and 14 
healthy controls.  The authors found no difference in allopregnanolone levels in any of 
the phases, but observed significantly higher progesterone, pregnenolone and estradiol 
levels among cases as compared to controls during the luteal phase (p =0.01 for 
progesterone and pregnenolone, p =0.02 for estradiol).  
Overall, there is a clear involvement of the GABA system in the pathophysiology 
of PMS through its interaction with allopregnanolone. Whether women with PMS have 
abnormally lower allopregnanolone levels during the luteal phase or a different 
sensitivity of the GABA-A receptors to allopregnanolone is still under continuous study.  
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- Other neurotransmitters: 
Other neurotransmitters may also be associated with PMS. For example glutamate 
is in ‘balance’ with GABA; it has an ‘excitatory effect’(29) and has been associated with 
depression (60, 61). N-methyl-d-aspartate (NMDA) receptors bind to glutamate and 
NMDA receptor agonists, such as zinc, show effects similar to antidepressants (62-64). 
Moreover, estradiol may be associated with an increased sensitivity of the NMDA 
receptor to glutamate, thereby leading to excitation of the nervous system (65). Because 
depression and PMS may have some common mechanisms, glutamate and the NMDA 
receptor should also be considered for the pathophysiology of PMS (49). 
 
• The renin-angiotensin-aldosterone system 
The renin-angiotensin system (RAS) is potentially involved in premenstrual 
syndrome. Renin is an enzyme secreted in the kidneys as prorenin. When arterial pressure 
is low, prorenin is converted into renin and released into the circulatory system. Renin 
acts on angiotensinogen to release angiotensin I and angiotensin II, which lead to 
vasoconstriction and increased blood pressure.  Renin also causes adrenal glands to 
secrete aldosterone, a mineralocorticoid, which increases sodium and water reabsorption 
and potassium secretion in the kidney, leading to increased extracellular fluids and blood 
pressure. Additionally, high dietary intake of potassium, and to a lesser extent sodium, 
increases the levels of aldosterone secretion (29). 
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Some studies have found that aldosterone levels are higher during the luteal than 
during the follicular phases of normal premenopausal women (66-68). For example, 
Szmuilowicz et al.(67) conducted a randomized clinical trial among 60 women aged 25 to 
41 years receiving either a high sodium (Na) (200 mEq) or a low Na diet (10 mEq) for 7 
days. The authors found that among women with the high Na diet, urinary and serum 
aldosterone was significantly greater among those who were in the luteal than in those 
who were in the follicular phases, and that progesterone levels were positively correlated 
to aldosterone levels. No differences were shown among those with a low Na diet.  
Because aldosterone is associated with water and Na retention, a high excretion of 
aldosterone during the luteal phase has been postulated as a contributor to symptoms of 
PMS such as swelling of extremities and abdominal bloating (31). 
Calcium intake and metabolism may also contribute to symptoms associated with 
PMS (69). Studies have shown that calcium and calcium-regulating hormones fluctuate 
during the menstrual cycle and that follicular and luteal phase calcium levels may be 
different in women with PMS as compared to those in asymptomatic women  (70, 71). 
Additionally, PMS shares some of the same symptoms as hypocalcemia, including 
fatigue, depression, anxiety and muscle cramps (69). In 2005, Bertone-Johnson et al. (72) 
conducted a nested case-control study among the Nurses’ Health Study II (NHS2) PMS 
subgroup to evaluate the association between calcium intake and the development of 
PMS. The authors concluded that a higher dietary intake of calcium and vitamin D 
(approximately 1200 mg of calcium and 400 IU of vitamin D) was associated with a 
lower risk of incident PMS.  For example, women in the highest quintile of calcium 
intake from food sources (median=1285 mg/d) had 30% lower risk of developing PMS 
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(95% confidence interval=0.50-0.97) compared to women in the lowest quintiles (P=0.02 
for trend). 
Summary of pathophysiology 
Multiple mechanisms may be associated to the pathophysiology of PMS, but none 
of them appears to completely explain all of the diverse symptoms. Hence, PMS etiology 
might involve a combination of all these mechanisms. 
The menstrual cycle is complex and involves interactions among different 
systems in the body such as the gonadal and adrenal hormones and brain 
neurotransmitters. Although differences in sex steroid hormone levels have been 
proposed as contributors to PMS, most studies have not found differences in hormonal 
levels in women with PMS as compared to those in women without PMS. Some evidence 
suggests that women with PMS instead have increased sensitivity to normal cyclical 
hormonal changes. While ample data suggests that interactions between neurotransmitters 
and ovarian hormones also contribute to symptom recurrence, further research is needed 
to better understand these relationships. 
 
1.4 Treatment 
Not all women who suffer from PMS seek medical attention for treating their 
symptoms. In a study by Robinson and Swindle (18), women who were older, those with 
more frequent and severe symptoms and women with greater overall use of medical 
services were more likely to seek medical treatment for PMS.  
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The competing theories for the definition and on the etiology of PMS have led to 
a variety of treatments for relieving PMS symptoms, though in some cases there is little 
scientific evidence supporting their use. The placebo effect in PMS is potentially high 
(73). Nevertheless, various treatments have been shown to be more effective for some 
symptoms than for others (74); therefore, treatment of patients with PMS should be 
individualized according to the symptomatology reported (20).   
Treatments for PMS recommended by the ACOG include SSRIs, oral 
contraceptives and alprazolam (1), but other potential therapies have been also studied.  
Currently, only three selective serotonin reuptake inhibitors (SSRIs) are specifically 
approved by the U.S. Food and Drug Administration (FDA) for the treatment of PMS: 
fluoxetine, sertraline and controlled release paroxetine (75-77). Treatment for PMS 
symptoms may be required for many years, as cessation of any treatment may lead to 
symptom reappearance. Because PMS is a disorder that lasts until menopause, treatment 
options should be evaluated for long-term use, particularly in relation to efficacy, safety, 
tolerability and the potential side effects.  We review specific treatment options below. 
 
 Pharmacologic Treatments 
• Selective serotonin reuptake inhibitors (SSRIs): 
As serotonin might be involved in the pathophysiology of PMS, SSRIs have been 
studied as treatment options. Many clinical trials have found SSRIs to be effective in the 
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treatment of mood symptoms and somatic complaints associated with PMS and PMDD, 
as well as to improve quality of life and social functioning (73, 75). Therefore, they are 
considered as a first line treatment for PMS patients with severe mood symptoms (1, 20, 
76, 78).   
One of the most studied SSRIs is fluoxetine (i.e. Prozac), which has shown to be 
effective in reducing the frequency and severity of PMS (79-81) and PMDD(28, 90, 91, 
93) symptoms in several studies. Using the COPE (Calendar of Premenstrual 
Experiences(9)) to identify women with PMS,  Ozeren et al.(79) conducted a randomized 
clinical trial to evaluate the effects of fluoxetine on PMS symptoms. During 3 
consecutive cycles, 18 women received 20 mg of fluoxetine and 17 women received 
placebo. The authors found that fluoxetine was significantly better than placebo in 
reducing the severity and frequency of physical and behavioral symptoms (p<0.0001). 
Although fluoxetine was effective in relieving PMS symptoms, it was associated with 
significant side effects. Two women receiving fluoxetine dropped from the study due to 
intolerable nausea and skin rash, and five other in the treatment group had mild side 
effects (gastrointestinal disturbance, insomnia, sexual dysfunction).  
Other SSRIs are potentially effective, for example setraline(82-85) and 
paroxetine.(86-89) Halbreich et al. in 2002 conducted a RCT among 281 women with 
PMDD to evaluate the efficacy of sertraline restricted to the luteal phase as compared to 
placebo. Diagnosis of PMDD was based on prospective ratings for two months and 
DSM-IV criteria. The Daily Record of Severity of Problems (DRSP) and the Clinical 
Global Impression Severity and Improvement (CGISI) scales were used to evaluate 
efficacy of the drug.  At the end of study, the authors found a significant reduction on the 
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DRSP score in the sertraline group as compared to placebo (mean sertraline DRSP =27.6, 
SD =26.8 vs. mean placebo DRSP =17.6, SD =23.3;  p <0.002) as well as a significant 
improvement of the CGISI score (mean sertraline =2.3, SD =1.1 vs. mean placebo=2.7, 
SD =1.1; p <0.001) as compared to placebo. However, 11 women in the active treatment 
group dropped from the study due to severe side effects, including:headache, nausea, dry 
mouth and decreased libido. These were significantly higher than in the placebo group. 
The benefits of SSRIs on PMS are probably beyond their antidepressant effects. 
This is supported by the fact that other types of antidepressant drugs are not effective in 
relieving PMDD/PMS symptoms (87, 90). The effects of SSRIs are beneficial for 
physical symptoms (91)  in addition to the psychological symptoms of PMS(28, 75, 92). 
Moreover, the benefits of SSRIs on PMS appear in a shorter time as compared to their 
effects on depression and other affective disorders (20). 
Antidepressants that predominantly affect noradrenergic transmission are not as 
effective as SSRIs (87, 90). For example, in a randomized controlled trial conducted by 
Pearlstein et al. (1997)(90) among 34 women with PMDD, bupropion, an antidepressant 
with no serotonergic effects, showed no significant improvement in symptoms as 
compared to placebo. In another trial conducted by Eriksson (1995) (87) among 65 
women with severe PMS, an antidepressant that inhibits noradrenaline uptake 
(Maprotiline) was compared to paroxetine and to placebo. The authors found that 
symptom reduction with paroxetine was significantly higher than maprotiline, and that 
maprotiline was no different than placebo. 
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Despite their effectiveness in ameliorating PMS symptoms, there are two 
substantial limitations associated with long term use of SSRIs: the high cost of the 
medications and the likelihood of significant adverse effects. Side effects of SSRIs 
include nausea at the beginning of treatment, headaches, insomnia, fatigue, 
gastrointestinal disturbances and sexual dysfunction, which persist for the duration of 
treatment (1, 75). To reduce the recurrence of these effects, the ACOG recommends that 
SSRIs can be taken only during the luteal phase of the cycle (1). This treatment regime 
has shown to be as effective as continuous therapy on SSRIs (75, 89, 92, 93).  Moreover, 
in a recent review by Halbreich (2008), the percentage of PMDD symptom reduction 
affected by SSRIs ranges from 53% to 71% in large studies, compared to placebo 
response rates from 28% to 49% (73). 
 
• Ovulation Suppression: 
The hormonal changes of ovulation appear directly related to PMS symptoms. 
Therefore, ovulation suppression has been targeted as a potential treatment for PMS, 
although as with SSRIs, most of these therapies have substantial adverse effects. 
Ovulation suppression methods can range from oral contraceptives to surgical 
sterilization. 
Oral contraceptive pills (OCPs) can prevent ovulation and replace the cyclical 
variation in ovarian hormones with stable hormone levels. The use of OCPs is 
recommended by the ACOG for treatment of physical symptoms, but in addition, OCPs 
have been associated with reduction in psychological symptoms in some studies.(1, 20, 
94) A clinical trial by Yonkers et al (2005)(94) was conducted among 450 women with 
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symptoms of PMDD randomized to take a new OCP containing drospirenone, an 
analogue of spironolactone or to take placebo in a regimen of 24 of 28 days each cycle. 
After 3 months of treatment or placebo, women taking the OCP had a significant 
improvement of PMDD symptoms as compared to placebo (Total DRSP score was 
reduced -37.5 points for drospirenone compared to -30.0 points for placebo, p<0.001) . 
Moreover, treatment with OCPs was associated with a 49% of reduction in premenstrual 
depression. Side effects associated with drospirenone were nausea, intermenstrual 
bleeding and asthenia. However, in some women, OCPs may worsen psychological 
symptoms. A nested case-control study was conducted by Joffe et al (2003) (95)  among 
658 women aged 36 to 45 years taking OCPs to evaluate the predictors of mood change 
in OCP users.  A questionnaire and a structured psychiatric (Structured Clinical Interview 
for Diagnosis) interview were used to collect information on OCP use, mood changes 
related to OCPs, and psychiatric and reproductive history. With regard to mood changes 
associated with OCP use, 16.3% of participants reported mood deterioration, and 12.3% 
reported mood improvement. Among women with a history of depression before start of 
use of OCP, 25.4% reported deterioration of mood (OR=2.0, 95%CI: 1.1-3.8). In 
contrast, an improvement of premenstrual mood was observed among those participants 
who suffered from dysmenorrhea (19.4%, OR=2.3, 95%CI: 1.4-3.9) or who had an early-
onset premenstrual mood disturbance (23%, OR=3.1, 95%CI: 1.9-5.2).  
Gonadotropin-releasing hormone (GnRH) agonists lower estrogen and 
progesterone levels to those of menopausal women causing a ‘chemical sterilization’ and 
have been shown to effectively relieve the symptoms of PMS.(56, 96) However, these 
drugs lead to an increased risk of osteoporosis and cardiovascular disease because of the 
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lower estrogen levels (20, 96). Studies evaluating addition of estrogen and progesterone 
indicate that these may lead to symptom recurrence (56, 96). Because of these important 
side effects, in addition to high cost, the ACOG recommends use of GnRH only in severe 
cases of PMS that do not respond to other treatments (1).   
The most radical method for preventing ovulation is the bilateral salpingo-
oophorectomy. Because it is not reversible, this method should be restricted to severe 
cases that strictly meet the diagnostic criteria and who have not responded to other 
treatments but have received benefits from GnRH agonists. In fact, GnRH agonists 
should be prescribed for at least 3 months prior to surgery in order to confirm the 
effectiveness of oophorectomy (1). 
 
• Other pharmacological treatments 
Some studies(97, 98) have found beneficial effects for the treatment of 
premenstrual symptoms with alprazolam (Xanax), a benzodiazepine commonly used to 
treat anxiety disorders, through its agonist effect on GABA receptors. In 1995, 
Freeman(98) conducted a RCT to evaluate the effects of oral progesterone or alprazolam 
vs. placebo among 185 women with severe PMS. Daily Symptom Records were 
completed by patients to confirm PMS diagnosis during a 3-month screening period and 
to evaluate effects during the 3-month treatment phase. Treatment was administered four 
times a day during the days 18 to 2 of the next cycle, with an average daily dose of 
alprazolam of 1.5 mg. At the end of the treatment phase, 37% of patients receiving 
alprazolam reported a 50% reduction in total DSR scores. The alprazolam group had a 
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significantly greater improvement of DSR scores as compared to the progesterone and 
placebo groups (p=0.04).  
However, not all studies have found beneficial effects of alprazolam on 
premenstrual symptoms.(99, 100) In 1993, Schimdt et al. (100) conducted a double-blind 
crossover trial among 22 women with PMS assessed using prospective recording. 
Participants were randomized to receive alprazolam in increasing doses (0.25, 0.50 or 
0.75 three times a day for each cycle) or placebo for three cycles. During the treatment 
phase, patients completed daily self-report of symptoms ratings; also completed, but at 
intervals of 2 months where other psychiatric tests like the Beck Depression Inventory. 
At the end of the study, the authors did not find any significant difference between both 
groups in the premenstrual symptom ratings. Moreover, the highest dose of alprazolam 
was not well tolerated by 10 participants because of its sedative effects.  
Although alprazolam is recommended by the ACOG, its use must be limited to 
the luteal phase because of the potential for dependency and tolerance of this drug. It is 
recommended for those patients who do not improve by other interventions and who 
primarily complain of agitation and anxiety.(1) 
Spironolactone is an aldosterone receptor antagonist that has antiandrogenic and 
potassium-sparing diureticeffects.(101, 102)  In 1995, Wang et al.(102) conducted a 
cross-sectional study of 35 women aged 25 to 45 years with ‘late luteal phase dysphoric 
disorder’ according to the DSM-III-R.(14) Participants received 100 mg spironolactone 
(n=17) or placebo (n=16) on days 14-28 of the cycle for 3 cycles, and then crossed over 
the other group for another 3 cycles.  Over the entire study period, participants rated daily 
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psychological and somatical symptoms and their effects using a visual analogue scale. .At 
the end of the first 3 cycles, women who started with spironolactone had a significant 
decrease in all symptoms (p<0.001) as compared to women who started with placebo, 
and those did not worsen after cross-over to placebo. Women who started with placebo 
had a significant decrease in negative mood and somatic symptoms (p<0.001) after the 
crossover to spironolactone. Overall, side effects associated with spironolactone use 
include breast complaints and hyperkalemia.(101) 
 
Non-Pharmacologic Treatments 
• Psychological  therapy 
Supportive therapies have been recommended by the ACOG as a primary 
treatment for women with mild to moderate symptoms, and as adjunctive treatment for 
those with more severe symptoms (1, 78). However, the studies in this area have been 
limited, and there is no conclusive evidence of the effects of psychotherapy. 
Cognitive and behavioral therapy (CBT) involves a group of client-centered, 
collaborative, structured and relatively brief psychotherapy techniques applied to modify 
thoughts, emotions and behaviors that might be problematic.(103) Its efficacy in PMS 
and PMDD is based on the theory that women may be valorizing physical premenstrual 
changes (i.e., bloating, breast changes) in ways that exacerbate emotional reactions to 
them (i.e., anxiety) (103, 104) . 
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In a study by Hunter et al. (105), CBT was compared to fluoxetine in a 
randomized trial among 108 women with PMDD confirmed by prospective recording 
over 2 months, and fulfilling the DSM-IV criteria (12). Over 6 months, women were 
randomized into 3 groups: CBT (10 sessions), fluoxetine (20 mg daily) and combined 
therapy (CBT plus fluoxetine). The authors found that fluoxetine was associated with a 
more rapid decrease on premenstrual scores, but CBT was associated with a better 
maintenance of treatment effects. There was no additional benefit from combining both 
treatments (105) . 
Busse et al. (104) conducted a meta-analysis of 9 randomized clinical trials that 
evaluated the effects psychological interventions on PMS.   Although the evidence was 
considered low quality due to problems in design and implementation of the studies, it 
was concluded that CBT consistently reduced the symptoms of anxiety (effect size=-0.58, 
95%CI:-1.15 to -0.01) and depression (effect size=-0.55, 95%CI: -1.15 to -0.01) 
associated with PMS (104). 
In 1990, Goodale et al.(106) conducted a randomized clinical trial of 46 women 
with PMS to evaluate the effects of relaxation on their symptoms. The relaxation 
response was elicited while sitting with closed eyes concentrating on a repetitive mental 
activity for 15 to 20 minutes twice each day during 3 months. One control group was 
instructed to spend 15 to 20 minutes daily reading leisure material and the other control 
group only charted their symptoms daily, as the rest of the participants did. After 3 
months, the intervention group had a significantly higher reduction in PMS symptoms, in 
particular those with severe PMS, as compared to the other 2 groups (106). 
32 
 
In summary, psychological therapies including CBT and relaxation may be 
helpful in treating premenstrual symptoms. Their main advantage is that there are no 
drug-related side effects and the potential that their beneficial effects are long-term. 
Further studies are needed to compare the effectiveness of different psychological 
therapies (CBT vs. relaxation alone) and to evaluate their effects on specific symptoms of 
PMS. 
• Dietary supplements and herbal therapy 
The overall use of herbal treatments and dietary supplements consumption has 
increased over the past decade (107, 108). Approximately 16% of U.S. women who 
responded to the 2000 National Health Interview Survey Cancer Supplement reported 
having taken at least one herbal supplement in 1999 (109). The popularity of dietary 
supplements is largely due to the belief that they are associated with less frequent side 
effects as compared to pharmacologic treatments (107, 110). Among the most frequently 
studied dietary supplements used to treat PMS are calcium, magnesium, and vitamin B 6. 
Evening Primrose oil, vitex agnus castus and dong quai are among the most frequently 
studied herbal products used for PMS treatment. 
Dietary calcium has been suggested to be involved in the etiology of premenstrual 
syndrome (111). Several randomized clinical trials have studied the use of calcium 
carbonate as a treatment for PMS and have found a significant benefit in reducing PMS 
symptoms,(111-114). In 1998, Thys-Jacobs et al.(112) conducted a randomized clinical 
trial among 466 women aged 18 to 45 years of age who were diagnosed with PMS by 
prospective charting. During 3 menstrual cycles, participants received 1200 mg of 
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calcium or placebo on a daily basis (divided in 600 mg twice a day). After the 3rd cycle, 
women receiving calcium had an overall 48% reduction of a 17-parameter symptom 
complex score, compared to a 30% reduction among those who received placebo. It is 
noteworthy that two subjects of this study developed renal stones as an adverse effect, 
although the dose of the supplement was only moderately higher than the estimated 
adequate intake for that age group (1000 mg/day) and bellow the tolerable upper intake 
limit (2500 mg/day) (112). 
Several studies have suggested that vitamin B6 might improve premenstrual 
depressive symptoms, but most of the studies have had potential methodological bias 
(115, 116). This and other B vitamins suggested as treatments for PMS will be discussed 
in the next chapters.  
A North American wildflower called evening primrose was used therapeutically 
among Native Americans (117). Evening primrose oil (EPO) has been widely 
recommended as a treatment for PMS symptoms (118), particularly for mastalgia (117, 
119). The potential mechanisms by which EPO can potentially help in the treatment of 
PMS is through effects on plasma fatty acids levels. The oil of the seeds contains high 
levels of linoleic (65%) and gamma-linolenic (8%) acids, which are precursors of 
prostaglandin E. It has been hypothesized that women with PMS have an underlying 
deficiency in linoleic and gamma-linolenic acid, thereby leading to a decreased 
availability of prostaglandin E, which may lead to decreased prolactin levels (119-121).  
Nevertheless, most clinical trials have not found an improvement in PMS 
symptoms with primrose oil as compared to placebo (122, 123). Moreover, according to a 
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review by Budeiri, most studies lacked sufficient power to identify a moderate effect 
(118). In 1990 Khoo et al. (122) conducted a randomized placebo controlled crossover 
study to evaluate the effects of EPO on 38 women aged 20 to 40 years, with PMS defined 
as at least one symptom of fluid retention or breast discomfort, and two symptoms of 
mood changes.  After six cycles of treatment (8 capsules per day, containing 45 mg of 
gamma linolenic acid per capsule) or placebo, the authors found that both EPO and 
placebo reduced a PMS score of symptoms, but with no significant difference between 
treatment and placebo(122)  Side effects associated with EPO are few, and include 
nausea, softening of the stools and headache (120). Although its effectiveness in reducing 
PMS symptoms is controversial, it has been commonly marketed for treatment of PMS 
(107). 
Another herbal product used for treating PMS symptoms, particularly mastalgia, 
is vitex agnus castus (VAC) (117, 125).  This dried ripe fruit of the chaste tree contains 
essential oils, iridoids, and flavonoids as potentially active constituents (117, 125). 
Progesterone, hydroxyprogesterone, testosterone, and androstenedione have been also 
isolated from the flower and leaves of the chaste tree, but in very small amounts (117). 
VAC may improve the symptoms of mastalgia by decreasing prolactin secretion through 
its dopaminergic effects (11, 34). Moreover, it has been suggested that the flavonoids 
present in VAC (particularly apigenin) have selective estrogen receptor activity (34, 124).  
 Benefits of VAC in treating PMS symptoms have been observed in some trials 
but not in all (107, 110, 117). In a study by Berger (126) 43 women with PMS diagnosis 
based on DSM-III criteria received 20 mg of VAC over 3 cycles. Patients self-reported 
symptoms using a MMDQ (1968) completed at baseline at the end of the 3 cycles of 
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treatment and 3 cycles after treatment stopped. The authors found that after 3 months of 
treatment there was an overall 42.5% reduction of MMDQ scores (p<0.001) compared to 
baseline. Three months after treatment, reduction of the symptom was 20% compared to 
baseline. There was no apparent effect on serum prolactin levels, which did not differ 
between baseline and treatment.(126) VAC extract has been approved by the ‘German 
Commission E’, an analogue of the U.S. Food and Drug Administration, for the treatment 
of PMS symptoms, indicating that they considered that there was a reasonable proof of 
efficacy and safety (125). Side effects are rare and include upset stomach, headache, 
menstrual disorders, acne, and rash (107). 
In summary, although there has been increased interest in herbal therapies and 
dietary supplements for relieving PMS symptoms, scientific research is limited and 
results are inconsistent. Additional research on each agent is needed, using large well 
designed placebo-controlled trials.  
• Complementary and alternative therapies (CAM) 
Many women who do not find relief from PMS symptoms with conventional 
medicine, or because of the side effects of conventional medicine have opted for other 
alternatives of treatment, among them CAM.(110)  
Acupuncture and moxibustion are examples of CAM used to treat symptoms of 
PMS.(127) Hand acupuncture therapy (HAT) is believed to relieve pain by stimulation of 
the autonomic nervous system and to alleviate excess heat though cold stimulation. Hand 
moxibustion therapy (HMT) acts by heating points of the hand, which in theory 
stimulates the nervous system and releases chemicals that can alleviate pain or regulate 
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internal systems of the body.  In a recent study(127) of 22 Korean nurses aged 20 to 35 
years old, women receiving 10 sessions of HAT and HMT for 4 weeks reported 
significantly less abdominal pain, bloating and mood changes than those receiving no 
treatment. Patients in the HAT group also reported a significant reduction of hot flashes, 
and women in the HMT group reported less water retention symptoms and less anxiety 
and depression, as compared to controls.(127) 
 
Summary of treatment 
Women with severe symptoms are advised to take SSRIs or to opt for ovulation 
suppression.(1) However, treatments proposed are only for relieving symptoms, and may 
require long term use. Side effects should be particularly considered and weighed with 
respect to the other potential benefits and the severity of the disease. A variety of 
treatment options exist for women with moderate to mild PMS, including behavioral 
therapy or dietary supplements. 
 
1.5 Conclusion 
 Despite decades of research, PMS remains an understudied condition that affects 
millions of reproductive aged women.  Questions remain concerning prevalence, etiology 
and diagnostic criteria. Continued research in this area is of primary importance. 
Moreover, the identification of modifiable risk factors and a clearer understanding of the 
pathophysiology would lead to significant advances in this area, including improved 
options for primary prevention as well as treatment.  
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CHAPTER 2 
DIETARY B VITAMIN INTAKE AND PREMENSTRUAL SYNDROME 
 
2.1 Background 
 
2.1.1 Introduction 
Premenstrual syndrome (PMS) is characterized by the presence of physical and 
psychological symptoms that appear only during the luteal phase of the menstrual cycle 
and that lead to a substantial impairment and reduced quality of life. In the U.S., PMS 
affects 8 to 15% of women of reproductive age (1). The economic burden associated with 
PMS is high and includes not only direct medical costs but also indirect costs due to work 
absenteeism and lack of productivity (2-4). Currently prescribed treatments include  
antidepressants and hormones that suppress ovulation (e.g., oral contraceptives and 
gonadotropin releasing hormone agonists), which involve significant side effects (5-7). 
Despite several decades of research, the pathophysiology of PMS is still controversial, 
and effective treatments with fewer adverse effects are still under study. Therefore, it is 
of particular importance to identify modifiable risk factors such as aspects of diet that 
may prevent the onset of this disorder.  
The proposed theories for the pathophysiology of PMS include an interaction of 
ovarian hormones with neurotransmitters such as serotonin and gamma-amino butyric 
acid (GABA) and other endocrine systems (8-10). The B vitamins, in particular thiamin, 
riboflavin, niacin, vitamin B6, folate, and vitamin B12, are potentially involved in the 
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metabolic pathways of the neurotransmitters GABA and serotonin (11, 12). Therefore, 
they may play a role in the development of PMS.  
To date, some studies (13-19) have focused on vitamin supplements as potential 
treatments for PMS, but few have evaluated the effects of diet on the initial development 
of the disorder (20). Among the B vitamin supplements, only B6 supplements have been 
individually studied as potential treatments for PMS (13-15, 17, 18). However dietary 
supplements of folate and vitamin B12 have been studied as potential treatments for 
major depression (21, 22), conditions with pathophysiology potentially similar to PMS 
(8, 23, 24). Niacin supplements have been studied as potential treatment for 
dysmenorrhea (25), a disorder characterized by cramping during menstruation (26). The 
individual effects of dietary thiamin, niacin, folate and vitamin B12 on the development 
of PMS remain unstudied.  
This study examines the association between thiamin, riboflavin, niacin, vitamin 
B6, folate and vitamin B12 and incidence of PMS among a subset of women participating 
in the Nurses’ Health Study II. 
 
2.1.2 Physiologic Mechanisms 
Several potential mechanisms have been proposed to explain the pathophysiology 
of PMS, including fluctuations of neurotransmitter levels in the brain in response to 
cyclic changes in ovarian hormones, to which women with PMS may be sensitive (8, 9, 
27). The B vitamins thiamin, riboflavin, niacin, vitamin B6, folate, and vitamin B12 are 
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involved directly or indirectly in the metabolism of the neurotransmitters serotonin and 
GABA and may also be involved in the development of PMS (12). 
 
a) Role of serotonin and GABA in PMS: 
- Serotonin: 
There is substantial evidence for a role of serotonin in PMS. Serotonin is involved 
in the regulation of mood, appetite, sleep and other functions (28). Abnormal serotonin 
metabolism has been associated with premenstrual symptoms of depression, irritability 
and aggression (29, 30). Additionally, ovarian sex hormones have been proposed to have 
a role in the metabolism and activity of serotonin and serotonin receptors (23, 29).  
Moreover, during the late luteal phase, women with PMS may have lower serotonin 
levels (30) and may be less responsive to infusion of tryptophan (31), a precursor of 
serotonin (32), as compared to women without the disorder. Most importantly, selective 
serotonin reuptake inhibitors (SSRIs) have been found to be effective treatments for PMS 
symptoms in most studies (5, 33-37). 
Serotonin is synthesized from the amino acid tryptophan, which is hydroxylated 
into 5-hydroxytryptophan and then decarboxylated into serotonin. These reactions require 
folate, vitamin B12 and vitamin B6 (12). There are many types of serotonin receptors in 
the brain, spinal cord and gut, which are responsible for a broad range of effects of 
serotonin, including regulation of body temperature, sleep, mood, appetite and pain as 
well as the modulation of cortisol and prolactin (28). Estrogen has been associated with 
an increase in serotoninergic activity by regulating the synthesis and degradation of 
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serotonin (38). Animal studies have suggested that serotonin and serotonin receptor levels 
fluctuate during the estrous cycle (39).  
Some studies in humans (30, 40, 41), but not all (42, 43), have suggested women 
with premenstrual disorders have lower levels of serotonin or serotonin metabolites 
during the luteal phase as compared to controls. Rapkin et al. found significant 
differences between whole blood serotonin levels during the luteal phase in PMS cases as 
compared to controls (30). The authors recruited 14 women aged 18 to 25 years old with 
moderate to severe premenstrual symptoms and 13 age-matched controls without PMS 
symptoms. Blood samples were collected during the late follicular phase, ovulatory 
phase, midluteal phase, late luteal phase and “premenstrual phase” (three days after the 
previous sample), according to basal body temperature charts, and confirmed by the date 
of onset of the next menstrual period. At the end of the study, the authors found that 
whole-blood serotonin levels were significantly lower during the midluteal, late luteal 
and premenstrual phases among women with PMS as compared to controls. For example, 
in the premenstrual phase, mean (±SE) serotonin levels among cases was 176.5 (±13) 
ng/mL vs. 298.6 (±43) ng/mL among controls. In contrast, during the follicular and 
ovulatory phases, there was no significant difference between serotonin levels. Moreover, 
cases and controls showed similar serum estradiol and progesterone levels during all 
phases (30).  
To evaluate whether serotonin response to intravenous L- tryptophan (LTP)  
infusion was different between women with PMS and women without PMS, Rasgon et al. 
(2000)(31) conducted a clinical study among 5 women with PMS diagnosed by 
prospective symptom charting and 5 controls without PMS. The authors found that 
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during the follicular phase, LTP infusion increased serotonin levels equally among 
women with and without PMS. However, during the luteal phase, increases in serotonin 
levels were similar to those of the follicular phase only in controls but significantly lower 
in cases. To date, the underlying mechanisms by which L-tryptophan may be metabolized 
differently in women with and without PMS are unknown (31).  
An additional piece of evidence supporting a role of serotonin in PMS is the 
association of selective serotonin reuptake inhibitors (SSRIs) with reduced symptom 
severity in PMS and PMDD (1, 5, 33, 34, 36, 37, 44). For example, in 2002 Halbreich et 
al.(37) conducted a randomized clinical trial among 281 women with PMDD to evaluate 
the efficacy of sertraline restricted to the luteal phase as compared to placebo. Diagnosis 
of PMDD was based on prospective ratings for two months and DSM-IV criteria. The 
Daily Record of Severity of Problems (DRSP) and the Clinical Global Impression 
Severity and Improvement (CGISI) scales were used to evaluate the efficacy of the drug.  
At the end of study, the authors found a significant reduction in the DRSP score in the 
sertraline group as compared to placebo (mean sertraline DRSP score=27.6 (26.8) vs. 
mean placebo DRSP score=17.6 (23.3); p<0.002) as well as a significant improvement in 
CGISI score (mean sertraline CGISI score=2.3  (1.1) vs. mean placebo CGISI 
score=2.7(1.1); p<0.001) on mood symptoms. It is noteworthy that SSRIs may not only 
be beneficial in treating mood symptoms, but also for physical symptoms of PMS.(33) 
The beneficial effects of SSRIs appear in a shorter time for PMS than for other disorders 
such as depression.(27) However, there are significant adverse effects associated with 
SSRIs including nausea, headaches, insomnia, and sexual dysfunction,(5-7) which may 
limit their use and efficacy.  
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- GABA: 
Another neurotransmitter system potentially involved in the pathophysiology of 
PMS is gamma-amino-butyric acid (GABA). GABA is the major inhibitory 
neurotransmitter in the brain and is secreted by neurons in the cortex, cerebellum, basal 
ganglia and the spinal cord. GABA is synthesized by the decarboxylation of glutamate, a 
reaction catalyzed by the enzyme glutamate decarboxylase and dependent on pyridoxal-
5’-phosphate (PLP; Figure 2.1) (28). In the mitochondria, the thiamin dependent 2-
oxoglutarate dehydrogenase complex (OGDHC) is a group of enzymes required for the 
synthesis and degradation of glutamate and GABA during de novo synthesis of glutamate 
from glucose. It includes the pyruvate dehydrogenase and the α-ketoglutarate 
dehydrogenase, which converts α-ketoglutarate (also known as 2-oxoglutarate) into 
glutamate (Figure 2.1) (45). 
Figure 2.1 Synthesis of GABA from glucose. 
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Dysfunction of the GABA system has been associated with mood disorders, such 
as depression and mania (24). Some studies (46, 47) have found GABA levels in plasma 
and in cortical neurons to be lower among women with PMDD compared to women 
without PMDD. For example in 2002, Epperson et al.(46) conducted a study among 9 
women aged 26 to 39 years old diagnosed with PMDD, based on the DSM-IV criteria, 
and 14 women aged 21 to 45 years old without PMDD. Brain GABA concentrations 
across the menstrual cycle were measured using serial proton magnetic resonance 
spectroscopy. Additionally, on each scan day, blood samples were collected for 
measuring gonadal hormones and neurosteroid levels. Compared to controls, women with 
PMDD had reduced cortical GABA levels during the follicular phase (mean GABA 
levels 0.78 mmol/kg among cases vs. 1.67 mmol/kg among controls, p < 0.001), but there 
was no statistically significant difference during the mid luteal phase (1.27 mmol/kg 
among cases vs. 1.15 mmol/kg  among controls, p = 0.7) or the late luteal phase (1.27 
mmol/kg among cases vs. 1.12 mmol/kg  among controls, p = 0.4). The authors found 
that cortical GABA levels declined across the menstrual cycle in healthy women, but for 
women with PMDD there was an increase in cortical GABA levels from the follicular 
phase to the mid luteal and late luteal phases. Additionally, progesterone, pregnenolone, 
and estradiol levels were significantly higher among cases as compared to controls during 
the luteal phase only (p = 0.01 for progesterone and pregnenolone,  p = 0.02 for 
estradiol). In the analyses of covariance, the authors found that estradiol, progesterone 
and allopregnanolone were negatively correlated with GABA levels among healthy 
women, but that there was a positive correlation of estradiol and progesterone with 
GABA levels among women with PMDD. Therefore, this study contributes to the 
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hypothesis that GABA concentrations in the brain fluctuate across the menstrual cycle, 
and that GABA fluctuations may be different among women with PMDD than in women 
without PMDD.  
It has been proposed that women with PMS may have a lower sensitivity to 
GABA (8, 9, 48). In 1998, Sundström et al.(48) conducted a study among 12 women 
diagnosed with PMS and 12 controls aged 25 to 45 years, to measure the saccadic eye 
velocity (SEV), a quantifiable and sensitive measure of central nervous system 
depression and GABA-A receptor sensitivity, in response to intravenous pregnanolone. A 
saccade is a rapid movement of the eye from one fixation point to another, which is 
generated in brain regions rich in GABA-A receptors, like the substantia nigra. SEV has 
been shown to be decreased linearly in response to benzodiazepines, which are GABA-A 
positive modulators (49). At baseline, women with PMS had a lower SEV than controls 
during the follicular phase, but not during the luteal phase. After pregnanolone injections 
in the follicular and luteal phase, controls had a dose-dependent decrease in SEV. 
Women with PMS had a dose-dependent decrease in SEV during the follicular phase but 
not during the luteal phase. The authors concluded that the GABA response to 
pregnanolone was reduced during the luteal phase of women with PMS as compared to 
controls (48). 
Despite growing evidence for a role of GABA in PMS, the effectiveness of 
alprazolam, a GABA agonist, for the amelioration of PMS symptoms is still inconclusive. 
Some studies (50, 51), but not all (52, 53), have found improvement in of premenstrual 
symptoms after treatment with alprazolam. For example, Freeman et al.(50) evaluated the 
effects of three months of oral progesterone or alprazolam vs. placebo among 185 women 
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with severe PMS. Daily symptom records (DSR) were completed by patients to confirm 
PMS diagnosis. Treatment was administered during menstrual cycle day 18 to day 2 of 
the next cycle, four times a day, with an average daily dose of alprazolam 1.5 mg. At the 
end of the treatment phase, 37% of patients receiving alprazolam reported an average 
50% reduction in total DSR scores. The alprazolam group had a significantly greater 
reduction of DSR scores as compared to the progesterone and the placebo groups (p = 
0.04). In contrast, in a crossover study by Schmidt et al.(52) among 22 women with PMS, 
participants were randomized to receive alprazolam in increasing doses (0.25, 0.50 or 
0.75 three times a day) or placebo for three cycles. At the end of the study, the authors 
did not find any significant difference between groups in premenstrual symptom ratings. 
Moreover, the highest dose of alprazolam was not well tolerated by 10 participants 
because of its sedative effects.  
 
b) Role of B vitamins in neurotransmitter metabolism: 
Thiamin (vitamin B1, recommended dietary allowance (RDA) for adults = 1.0 to 
1.2 mg/day) (54) is necessary for the metabolism of glucose, and indirectly related with 
the metabolism of GABA (Figure 2.1) (12).  Thiamin deficiency may lead to symptoms 
such as irritability, introversion, depression and cramps (11, 55). all of  which are also 
symptoms of PMS. Moreover, improvement of thiamin status has been associated with 
improved mood and energy levels (55).  
Niacin (RDA for adults = 14 - 16 mg/day)(56) is converted to nicotinamide 
adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP), 
which are required for many physiological reactions. In the presence of niacin deficiency, 
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tryptophan is converted into niacin (Figure 2.2) in the liver by the kynurenine metabolic 
pathway, thereby leading to tryptophan depletion and decreasing its metabolism to 
serotonin (12, 42). 
Vitamin B6 (RDA for adults = 1.3 mg/day)(56) is involved in one-carbon 
metabolism and has been widely studied for a potential role in depression through its 
effect on the metabolism of serotonin and other neurotransmitters (11, 56). Riboflavin 
(vitamin B2, RDA for adults = 2–2.5 mg/day)(56) is the precursor of flavin-adenin 
dinucleotide (FAD), which is essential for many biochemical reactions, particularly 
conversion of pyridoxine (vitamin B6) into its active form: pyridoxal-5’-phosphate 
(PLP). PLP is a coenzyme in the decarboxylation reactions involved in the synthesis of 
serotonin (Figure 2.2), dopamine, norepinephrine, and GABA (Figure 2.1). 
Lower levels of folate (RDA for adults = 400 µg/day) and vitamin B12 (RDA for 
adults=2.4 µg/day)(56) have been associated with depression or with lack of response to 
SSRI treatment in depression (21, 57), and may also be associated PMS. There are two 
potential mechanisms recognized for the association of folate and B12 with depression.  
First, folate and vitamin B12 are required for the conversion of dietary methionine 
into S-adenosine-methionine (SAMe), the major methyl donor in the body (12). Among 
the methylation processes in which SAMe is required are the conversion of serotonin to 
melatonin (Figure 2) and of dopamine to norepinephrine.(22) The product of methylation 
reactions is S-adenosylhomocysteine (SAH), a methylation inhibitor, that is later 
converted into homocysteine. Homocysteine is an amino acid not present in diet that can 
be metabolized either by transulfuration to cysteine, for which it requires vitamin B6, or 
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by remethylation to methionine, for which vitamin B12 and folate are required (57, 58). 
Homocysteine may indirectly (through SAH) inhibit monoamine neurotransmitter 
metabolism (58). As described above, these pathways may be involved in the 
development of PMS. 
Secondly, folate and vitamin B12 are also required for the formation of 
tetrahydrobiopterin (BH4). BH4 is a cofactor in the conversion of phenylalanine to 
tyrosine and in the hydroxylation of tyrosine, the rate-limiting step for synthesis of 
dopamine and norepinephrine. BH4 is also a cofactor of tryptophan hydroxylase, which is 
the rate-limiting enzyme for the conversion of tryptophan into serotonin (Figure 2.2) (12, 
58) and therefore potentially associated with the pathophysiology of PMS. 
 
c) Summary 
The pathophysiology of PMS is not well understood, but interactions between 
ovarian hormones and neurotransmitters are likely to play a role in the etiology of the 
disorder. B vitamins are involved directly or indirectly in the metabolic pathways 
required for proper function of endocrine systems and neurotransmitter pathways. 
Riboflavin, B6, folate and B12 are involved in many metabolic reactions of the synthesis 
of serotonin. Thiamin, folate and B12 are additionally involved in the synthesis of 
GABA. Niacin deficiency may lead to depletion of levels of tryptophan, the amino acid 
required for the synthesis of serotonin. Although the mechanisms by which thiamin, 
riboflavin, niacin, folate, vitamins B6 and B12 are not fully understood, there is 
substantial evidence for a role of B vitamins in the pathophysiology of PMS.  
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Figure 2.2 Role of B vitamins in the synthesis of serotonin and melatonin. 
 
 
 
2.1.2 Epidemiologic Evidence 
There are no previous studies of the effects of thiamin, niacin, riboflavin, vitamin 
B6, folate and vitamin B12 and the incidence of PMS. Since the 1980’s the use of 
vitamin B6 as a treatment for PMS has been widespread and there have been many 
studies of vitamin B6 supplementation to reduce symptoms of PMS. Some studies (13, 
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14, 17, 59, 60), but not all (15, 61-63), have found vitamin B6 to reduce the occurrence 
and severity of symptoms. 
With regards of the other vitamins of the B complex, because studies have been 
restricted to randomized clinical trials of supplements that contained a wide variety of 
micronutrients (64-67) it is not possible to isolate the individual effect of each vitamin on 
PMS. Thiamin (25) has been studied as a potential treatment for primary dysmenorrhea, a 
disorder characterized by cramping during menstruation, with results showing beneficial 
effects. More recent studies have focused on the association of folate and vitamin B-12 
levels with depression with inconsistent results (68-70).  
 
a) Randomized clinical trials of vitamin B6 and prevalent PMS: 
The most recent studies of vitamin B-6 supplementation as a treatment for PMS 
have been conducted by Kashanian et al.(2007) (13) and Sharma et al.(2007) (14). In the 
randomized clinical trial by Kashanian et al.(13) the authors recruited 94 college students 
who reported at least one behavioral and one somatic symptom from a list of 17 
symptoms for three consecutive cycles prior to randomization. A daily dose of 80 mg of 
pyridoxine (46 women) was compared with placebo (48 women) for a period of two 
consecutive menstrual cycles. Participants continued recording their symptoms during the 
treatment period. At the end of the second cycle, there were statistically significant lower 
PMS symptom scores in both the placebo (p < 0.05) and the pyridoxine group (p < 0.05) 
as compared to baseline for both somatic and psychological symptoms. The pyridoxine 
group reported a significantly greater reduction of overall and psychological symptoms (p 
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< 0.05) than the placebo group but there was no significant difference in somatic 
symptoms (13). 
Sharma et al. (2007) (14) conducted a randomized clinical trial among 60 women 
aged 20 to 45  to evaluate the effects of vitamin B6 or bromocriptine, a dopamine agonist 
and prolactin blocker, on prevalent PMS for two to three menstrual cycles.  During this 
period, women reported symptoms of PMS occurrence and severity, following the 
methodology proposed by Steiner et al. (2003). (71) Briefly, the severity of each 
physical, psychological, and behavioral symptom was graded from 0 (no symptoms) to 3 
(severe/disabling symptoms). Possible total scores ranged from 0 to 60, and women were 
classified as having PMS if their total score was higher than 5. Over three months, 
participants received one of three treatments: 100 mg/day of ferrous sulphate as placebo, 
1.25 mg/day of bromocriptine, or 100 mg/day of vitamin B6. The authors found a 
statistically significant reduction in symptoms after one, two, and three months of 
treatment with bromocriptine, as well as after two to three months of treatment with 
vitamin B6. A higher proportion of women receiving vitamin B6 reported symptom 
improvement by the third month than in the bromocriptine group (14). 
Although both studies found positive results with supplementation of pyridoxine, 
no study has evaluated the potential of vitamin B6 to prevent the development of PMS. 
Despite evidence of efficacy of B6 supplementation to treat or prevent PMS, there are 
substantial limitations. The doses used in both studies were 80 mg/day (13) and 100 
mg/day (14) of pyridoxine, substantially greater than the average dietary intake of 
vitamin B-6 recommended for adult women of 1.3 mg/day for adult women (54). Doses 
of B6 above the upper intake limit (UL) of 100 mg/day (54) have been associated with 
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substantial side effects like sensory neuropathy (72). In fact, in the study by Sharma et 
al., two women in the B6 group reported nausea, one reported diarrhea, and another 
reported dizziness as a side effect (14). Therefore, because of potential side effects, high 
doses of B6 supplementation may not be appropriate for the prevention of PMS.  
To evaluate the side effects of B6 supplementation, in 1985 Dalton et al.(73) 
conducted a study among 58 women (mean age 42 years) of whom 27 reported taking 
vitamin B6 supplements (50 to 300 mg/day) for treatment of premenstrual syndrome. At 
baseline, 23 participants taking B6 had serum levels above normal levels (range 3 to 18 
ng/ml). The author found that more than 40% of all women reported depression, 
headache, tiredness, irritability and bloating, but the prevalence of symptoms was even 
higher among B6 users. For example, headache was reported by 48% of all women and 
70% of vitamin B6 users (no statistical test reported). Then, women who took B6 were 
recommended to stop taking vitamin, mineral and herbal supplements for two months. 
After this time, participants reported a significant improvement in all symptoms (p < 
0.02). Nevertheless, this study had substantial limitations, including the lack of controls 
without PMS and lack of assessment of symptoms before B6 supplementation. 
Overall, there is substantial evidence that vitamin B6 may affect PMS symptoms, 
but to date no studies have evaluated whether dietary intake of vitamin B6 is involved in 
the development of PMS.  
 
b) Other B-vitamins and PMS: 
Several studies have evaluated supplements that contain a variety of 
micronutrients, including B vitamins, as treatment of premenstrual syndrome. Most of 
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these studies have used supplements that were created specifically as over-the-counter 
treatments for PMS, including SillixDonna (67) and Optivite (64, 65). 
In Italy, Facchinetti et al. (1997) (67) conducted a randomized clinical trial to 
evaluate the effects of a daily supplement containing 1.5 mg of vitamin B6, 200 μg of 
folate, 12 mg of vitamin E, 400 mg of magnesium, 4 mg of copper, and 1g of S. 
cerevisiae on premenstrual symptoms. The authors recruited 40 women aged 18 to 50 
years old (mean 28 years) classified as having mild to moderate premenstrual syndrome 
as assessed with prospective administration of the Moos Menstrual Distress 
Questionnaire (MDQ) (76) during two consecutive menstrual cycles. Participants were 
randomized to one of two groups, with 20 of them receiving the supplement and 20 
receiving placebo over six menstrual cycles. Difference in MDQ scores between the 
follicular and luteal phase were assessed for both groups at the end of the 2nd, 4th and 6th 
months. The mean MDQ baseline difference between the follicular and luteal phase was 
29.95 in the active group and 29.20 in the placebo group. In the active treatment group, 
MDQ score differences (MDQ follicular – MDQ luteal) were consistently lower over 
time (p<0.01), and lower than in the placebo group (p < 0.02) indicating lower 
premenstrual symptom severity. At the end of 6 months, women in the supplement group 
reported a mean MDQ difference of 5.55 (SD=7.71), which was substantially lower than 
their MDQ scores at baseline and the MDQ of women in the placebo group (MDQ 
difference 18.13, SD = 13.41). Although the authors found a significant reduction of 
PMS symptoms with supplementation, the impact of individual micronutrients in relation 
to alleviation of PMS cannot be determined. A limitation of the study that may have 
attenuated the effect was is the low compliance with the study proposal, as 5 participants 
64 
 
in the control group discontinued participation in the study at the end to the 2nd and 3rd 
month due to lack of improvement of symptoms (67).  
Another randomized clinical trial was conducted by London et al. (1991) (64) to 
evaluate the effects of supplementation with 25 mg of thiamin, 25 mg of riboflavin, 25 
mg of niacinamide, 300 mg of vitamin B6, 200 μg of folate and 62.5 μg of vitamin B12 
among other micronutrients per dose (6 tablets). Participants were 44 women aged 18 to 
44 years old classified as having premenstrual tension (PMT) according to a modified 
version of the menstrual symptom questionnaire (MSQ) developed by Abraham et al.(75) 
On the MSQ, women were asked to grade their symptoms using a four point scale (from 
0=none to 3=severe/disabling), with symptoms grouped into four categories: PMT-A 
(anxiety, irritability, mood swings), PMT-H (weight gain, breast tenderness, swelling and 
bloating), PMT-C (cravings, fatigue, headaches) and PMT-D (depression, insomnia, 
forgetfulness). To be classified as having PMT and be eligible for the study, women had 
to have rated their luteal phase symptoms in at least one subgroup as moderate or severe 
and to have rated all symptoms as mild or absent during the follicular phase. All 
participants were randomly divided into four groups: 1) 6 supplement tablets per day 
(n=15 women); 2) 12 supplement tablets per day (n=13 women); 3) 6 placebo tablets per 
day containing 25 mg of riboflavin total or 4) 12 placebo tablets per day. The two 
placebo groups were combined for analysis (n=15 women). Riboflavin was chosen as a 
placebo as a blinding strategy to patients because it produces noticeable yellow coloration 
of urine. After three months, the authors compared the MDQ scores during the luteal 
phase before and after treatment. Among women receiving 12 tablets/day of the 
supplement, they found a statistically significant decrease in MSQ symptoms scores for 
65 
 
all symptom subgroups as compared to baseline(p < 0.003). Women receiving 6 
tablets/day experienced statistically significant improvement of PMT-A (p < 0.013), 
PMT-C (p < 0.009) and PMT-D (p < 0.005) symptoms but non-significant improvement 
for PMT-H (p=0.28) symptoms. Interestingly, the placebo group had also a statistically 
significant improvement in PMT-A (p < 0.017) and PMT-C (p < 0.022) symptoms. 
Limitations of this study include the lack of a control group with no riboflavin 
supplements. The decreased MSQ scores seen in the placebo group could potentially be 
attributed to riboflavin, though there was no way to ascertain this. Additionally, the doses 
of vitamin B6 were substantially higher than the upper limit set for this vitamin (100 
mg/d) though only one participant reported tingling in the fingers, a side effect of B6 
overdose.  
Although in both studies the authors observed significant reduction in PMS 
symptoms after   supplementation with B vitamins, it is not possible to isolate the effects 
of these vitamins from the other components of the supplement. Nevertheless, evaluating 
the effects of multiple B vitamins simultaneously on PMS is important, as in regular diet, 
B vitamins are consumed simultaneously, along with other compounds. 
 
c) B vitamins and outcomes related to PMS: 
Folate and vitamin B12 have been studied in relation to depression (21, 57), a 
psychiatric disorder also suspected to be caused by serotonin deficiency. Thiamin has 
been studied as a potential treatment for primary dysmenorrhea (25), which  is 
characterized by menstrual pain beginning at the time of menstruation (26). The 
underlying pathophysiology of dysmenorrhea is also unclear but the condition may be 
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associated with high levels of prostaglandins (26, 76) and inflammation, which may also 
be associated with cramping during the premenstrual phase (77). 
- Depression 
Because folate, vitamin B12, and B6 are implicated in the metabolic pathways of 
serotonin and other neurotransmitters, these vitamins have been considered as potential 
treatments for depression (21, 56, 57). 
Recently, Beydoun et al.(2010) (68) conducted a cross-sectional study among the 
prospective Healthy Aging in Neighborhoods of Diversity across the Lifespan Study in 
order to evaluate the effects of folate on depression and potential effect modification by 
sex. The authors selected a subset of 1681 participants aged 34 to 64 years with 
completed baseline and follow up information, including two diet recalls and plasma 
folate status. Depression was assessed using the Center of Epidemiologic Studies-
Depression scale (CES-D) which asks participants to rate 20 statements about six 
depression symptoms: depressed mood, guilt or worthlessness, helplessness or 
hopelessness, psychomotor retardation, loss of appetite and sleep disturbance.  A total 
CES-D score ≥ 16 is suggestive of moderate/severe level of depressive symptoms.  The 
authors found a significant inverse association between plasma folate levels and 
moderate/severe depressive symptoms among women but not among men.  Women in the 
highest tertile of plasma folate had a 44% lower risk of having a CES-D score  ≥ 16 (95% 
CI = 0.42 - 0.86). In contrast, men in the highest tertile of plasma folate had a non-
statistically significant OR of 0.77 (95%CI = 0.48 - 1.24) as compared to those in the 
lowest tertile. Although dietary consumption of total folate was higher among men (mean 
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= 408.7 µg/d, SD = 281.1) than among women (mean = 316.8µg/d, SD = 203.1, p < 
0.001), additional adjustment for dietary folate produced similar results.  This study 
suggested that there is differential impact of folate on depression in men than in women. 
However as this was a cross-sectional study, it was not possible to evaluate the temporal 
relationship between folate levels and depression. Moreover, dietary folate was measured 
using two 24 hr diet recalls conducted over an unspecified time interval. Thus, this might 
not reflect long term intake, which is likely important for the development of  a chronic 
state such as depression (68). 
In Japan, Murakami et al.(2008) (70) conducted a cross-sectional study among 
309 men and 208 women between 21 and 67 years of age to evaluate the association 
between intake of riboflavin, B6, folate, and B12, as well as omega-3 fatty acids, and 
depressive symptoms. Diet during the preceding month was assessed using a self-
administered brief diet history questionnaire, which included 56 food items common in 
the Japanese diet. The use of dietary supplements was not included in the analysis 
because of low frequency of use (3.7% for multivitamins).  Depressive symptoms were 
assessed using a Japanese version of the aforementioned CES-D scale. The authors found 
a statistically significant inverse association between folate intake and depressive 
symptoms among men only, but not among women. Men in the highest quartile for folate 
intake (median = 235 μg/1000 Cal, n = 77) had a 50% lower risk of having depressive 
symptoms (95%CI: 0.25-1.06) as compared to men in the lowest quartile of folate intake 
(median = 119 μg/1000 Cal).  Women in the highest quartile of folate intake 
(median=292 μg/1000 Cal, n = 52) had a OR of 0.63 (95%CI = 0.26-1.51) as compared to 
women in the lowest quartile (median = 150 μg/1000 Cal). There was no statistically 
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significant association between the intake of riboflavin, vitamin B6, or vitamin B12 from 
foods and depressive symptoms. However, the study had a relatively small sample size 
and some associations could have been missed due to insufficient statistical power (70). 
As seen in these examples, the association of folate and depression may be 
modified by sex, though results are inconsistent. The underlying mechanisms by which 
folate may act differently in women and in men remains unclear and underlines a 
potential interaction of sex hormones with folate and depression. This is particularly 
important for the potential role of folate in PMS, as the underlying pathophysiology 
suggests an interaction of sex hormones with neurotransmitters. Beydoun et al.(68) and 
Murakami et al.(70) used the CES-D scale to define their outcome, but exposure to folate 
was measured in different ways. Beydoun et al.(68) focused on plasma folate adjusted by 
folate intake reported by two diet recalls, whereas Murakami et al.(70) did not measure 
plasma folate but relied on a short term frequency questionnaire. Because depression and 
PMS are chronic diseases, assessment of exposure over a long period of time before 
diagnosis is of particular importance.  
 
- Dysmenorrhea 
Although thiamin has not been individually studied for an association with PMS, 
it has been considered as a potential treatment for primary dysmenorrhea by Gokhale et 
al.(1996) (25).  
 The authors conducted a crossover randomized clinical trial among 556 women 
ages 12 to 21 years who reported moderate to severe dysmenorrhea. Participants were 
divided into two groups. The first group received 100 mg/day of thiamin for 90 days, 
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followed by 60 days of placebo. The second group received placebo for 60 days, 
followed by 100 mg/day thiamin for 90 days. After the first month of thiamin intake, 
18.8% of women in the first group and 39.9% from the second group reported complete 
disappearance of pain. During the first 60 days of placebo, women in the second group 
reported no relief of symptoms. At the end of the study 87% of all participants reported 
absence of pain. Although the authors concluded that thiamin has curative effects on 
dysmenorrhea, no statistical test was conducted to compare their results. Additionally, 
non-differential misclassification of dysmenorrhea was likely. Dysmenorrhea was self-
reported and not diagnosed by a physician, and there was no procedure to confirm self-
report of pain during the follow-up (25). 
Although dysmenorrhea occurs during the menstrual phase and not during the 
luteal phase, it  is noteworthy for research in PMS, as both disorders have common 
symptoms of lower abdominal pain and cramps.  
 
d) Summary of epidemiologic evidence: 
Among the B vitamins, B6 has been the most extensively evaluated as a treatment 
for PMS. Several randomized clinical trials  have evaluated the effects of this vitamin on 
prevalent PMS with significant benefits observed with doses ranging from 50 to 500 
mg/day (13, 14, 17, 59, 60, 78). Other randomized clinical trials have evaluated the 
effects of supplements containing several B vitamins on symptoms of PMS, and observed 
significant improvement of symptoms (64, 65, 67). Limited evidence also suggests that B 
vitamins may be beneficial as treatments for depression (21) and dysmenorrhea (25). 
Results from these studies could be relevant for research on PMS because these disorders 
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potentially share some common etiologic features with PMS. However, the association 
between B vitamins thiamin, riboflavin, niacin, folate, B6, and B12 and the initial 
development of PMS has not been studied before.  
 
2.1.4 Summary 
Premenstrual syndrome affects a substantial proportion of women of reproductive 
age, resulting in reduced quality of life and impairment in social functioning during the 
luteal phase when the symptoms appear. Despite its high prevalence, relatively little is 
known about the pathophysiology of PMS and its prevention. 
The pathophysiology of PMS likely involves multiple mechanisms. Symptoms are 
likely caused by the interaction of the neurotransmitters serotonin and GABA with 
ovarian hormones (8-10). B vitamins likely play a role in these interactions (11, 12). For 
instance, thiamin is required for the metabolism of glucose and is a cofactor in the 
formation of glutamate, a precursor of GABA (12, 45). Niacin deficiency may lead to a 
depletion of tryptophan, an amino acid required for the synthesis of serotonin. Vitamin 
B6, riboflavin, folate and vitamin B12 are associated with the synthesis of serotonin (12). 
Hence, B vitamins provide basic elements required for the function and synthesis of 
neurotransmitters.  
There are no previous epidemiologic studies of the association of B vitamins and 
incident PMS. Large doses of vitamin B6 have been widely studied as potential treatment 
for PMS. (13, 14, 17, 59, 60)  Kashanian et al.(13) and Sharma et al.(14) have reported 
that doses of 80 to 100 mg/day improved symptoms significantly after two months of 
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treatment as compared to placebo. Facchinetti et al.(67) and London et al.(64) evaluated 
the effects of supplements containing several B vitamins and other micronutrients on 
prevalent symptoms of PMS, and found them to significantly reduce PMS symptoms vs 
placebo.  B vitamins have been studied in relation to other disorders with similar features 
to PMS. For example, Beydoun et al.(68) found a significant reduction of depressive 
symptoms among women with high levels of plasma folate, but not among men, whereas 
Murakami et al.(70) reported a beneficial effect of dietary folate among women but not 
among men. Niacin supplementation (25) may be effective as treatment for 
dysmenorrhea.  
In conclusion, there is substantial evidence supporting a role of B vitamins in the 
metabolism of neurotransmitters involved in PMS. Although B6 has been considered as a 
potential treatment for PMS, none of the other B vitamins have been studied 
independently in randomized clinical trials. Most importantly, no studies have been 
conducted to date to determine the effects of dietary intake of B vitamins on the 
development of PMS. Therefore, we conducted a prospective study nested in the Nurses’ 
Health Study II cohort to evaluate the effects of B vitamin intake before diagnosis on the 
development of PMS.  
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2.1.5 Specific Aims and Hypotheses 
Specific Aim: 
To examine the relationship between thiamin, riboflavin, niacin, vitamin B6, folate, and 
vitamin B12 intake and the development of premenstrual syndrome among a subset of 
women participating in the Nurses’ Health Study II. 
Secondary Aims: 
1) To evaluate the effects of B vitamins intake from food sources 2 to 4 years before 
reference time on the development of PMS. 
2) To evaluate the effects of B vitamin intake from supplement sources 2 to 4 years 
before reference time on the development of PMS. 
3) To compare the effects of B vitamins intake assessed at baseline (1991), and 0 to 2 
years before the reference.   
4) To evaluate effect modification of the association between B vitamins and PMS by 
age, body mass index (BMI), smoking, and alcohol intake.  
Hypothesis: 
There is an inverse relationship between dietary intake of thiamin, riboflavin, niacin, 
vitamin B6, folate, and vitamin B12 and the risk of developing premenstrual syndrome. 
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2.2 Methods 
2.2.1 Study design and population 
To examine the association between B-vitamin intake and PMS we conducted a 
case-control study nested within the Nurses' Health Study II (NHS II).  The NHS II is a 
prospective study that started in 1989 with the enrollment of 116,678 female registered 
nurses aged 25 to 42 years old who lived in any of 14 states in the U.S. Participants 
completed a mailed questionnaire about their medical history and lifestyle, which 
included a question about physician diagnosis of PMS. Every two years, cohort members 
completed follow up questionnaires to update information on risk factors and medical 
events, including reporting a new diagnosis of PMS. As of 2003, the response rate for all 
questionnaire cycles has been at least 89%. 
The establishment of the NHS II PMS Sub-study has been described in detail in 
previous studies (20, 79). From among all NHS II participants who had not reported a 
diagnosis of PMS in 1989 or 1991, 3,430 women reported a new clinician-made 
diagnosis of PMS on an NHS2 questionnaire between 1993 and 2001 and were 
considered as potential cases. The authors assigned each woman a “reference year” equal 
to their diagnosis year, which was used to determine eligibility for the study, as well as to 
assess menstrual symptom experience and diet. The authors then identified 2,570 women, 
selected from a random sample, who did not report a diagnosis of PMS at any time 
between 1989 and 2001 to serve as potential controls; for these women, a randomly 
chosen year between 1993 and 2001 was assigned as their reference year.   
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To prevent the inclusion of women with menstrual symptoms attributed to causes 
other than PMS, women with a diagnosis of cancer, endometriosis, usual irregular 
menstrual cycles, or infertility before their reference year were excluded from the initial 
selection of participants. Women who had a hysterectomy or who had reported 
menopause were excluded to ensure participation of only premenopausal women.  
Because the study was designed to focus on dietary factors and PMS, participants who 
did not complete the food frequency questionnaires (FFQs) in 1991 and 1995 or who 
reported an implausible total calorie intake (<500 and ≥ 3500 cal/day on their FFQ) were 
also excluded from the study.  
 
 
2.2.2 Exposure Assessment 
To evaluate individual intake of selected nutrients, NHS2 participants completed 
a semi quantitative food frequency questionnaire (FFQ) in 1991, 1995 and 1999.  
The FFQs included 133 items, with a standard portion size for each, which aimed 
to reflect natural portion sizes whenever possible (e.g. a slice of bread, an egg, a fruit).  
Participants were asked how often they consume the specific food item, on average, with 
9 response options: ">6  per day", "4 to 6 per day", "2 to 3 per day", "1 per day", "5 to 6 
per week", "2 to 4 per week", "1 per week", "1 to 3 per month" and "never or less than 
once per month". 
The FFQ included additional questions about types of fat used, brand and type of 
cold cereal consumed, and supplements used. For supplement use, participants were 
asked to report whether they currently took multivitamins, how many they took per week 
75 
 
(<2, 3-5, 6-9, ≥10 tablets) and the specific brand used.  Additional questions on regular 
use of niacin, vitamin B6, folate, and B complex supplements (yes/no) were also 
included.  In addition, a specific question about vitamin B6 dosage (<50, 50 – 99, 100 – 
149, ≥150 mg/day) was included on the 1991, 1995 and 1999 questionnaires. Niacin 
supplement dosage (<50, 50-300, 400-800, ≥900 mg/day) was specifically included in the 
1999 questionnaire, along with frequency of use. 
For each B vitamin, total intake was calculated by multiplying the relative 
frequency of consumption of each food item, converted to number of servings per day, by 
the nutrient content of the specified portion size, according to the United States 
Department of Agriculture database and manufacturers sources as needed. Finally, 
adjustment for total calorie intake was performed using the residual method (80) . 
 
Validity and Reproducibility of Exposure Assessment: 
The validity and reproducibility of the FFQ has been widely studied before.(81, 82)  
In 1985, Willett et al.(81) conducted a validation study among 194 women who 
participated in the first Nurses’ Health Study. A 61-item semi quantitative FFQ was 
administered twice with an interval of one year (1980 to 1981). During that period four 1-
week diet records were also collected to serve as a "gold" standard because they are 
minimally dependent on memory and allow direct measurement of food quantities. 
Participants were instructed by a trained dietitian on how to record detailed information 
on food and beverages consumed for a one-week period, using a provided dietetic scale.  
76 
 
Reproducibility was measured by comparing nutrient scores from both 
questionnaires. Intraclass correlation coefficients ranged from 0.49 for vitamin A without 
supplements to 0.79 for vitamin B6 with supplements. Validity was calculated by 
comparing nutrient intake assessed by the FFQ to the nutrient intake assessed by the 
average of the four one-week diet records. For vitamin B6 without supplements, the 
correlation coefficient was 0.43 for the first questionnaire and 0.54 for the second 
compared to mean nutrient scores from diet records (p < 0.05).  
Additionally, participants’ nutrient scores from the questionnaire and the mean of 
the four one-week diet records were categorized into quintiles and the joint classification 
was compared. For vitamin B6, among the participants classified in the lowest quintile 
according diet records, 47% were also in the lowest quintile and 88% were in the two 
lowest quintiles for the questionnaire. Among the participants classified in the highest 
quintiles according to diet records, 74% was in the highest quintile and 88% in the two 
highest and 3% were misclassified in the lowest quintile according to the questionnaire. 
In conclusion, the reproducibility and validity of nutrient scores for B vitamins calculated 
from the food frequency questionnaire were found to be acceptable (81). 
 
2.2.3 Outcome Assessment 
Case and control status was ascertained using information from a supplementary 
menstrual symptom questionnaire sent in 2002 to the 6000 selected sub-study participants 
including 3430 women who reported a diagnosis of PMS made by a clinician between 
1993 and 2001 and 2570 women who did not report a diagnosis of PMS. The 
supplementary questionnaire was based on the Calendar of Premenstrual Experiences 
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designed by Mortola et al.(83)  Participants reported if they experienced any of 26 listed 
symptoms ‘most months of the year for at least several days each month before their 
menstrual period began’ during the specified 2 years prior to their reference year. For 
example, if their reference year was 1995, the specified period was 1993 to 1995. 
Symptoms queried included headaches, abdominal bloating, swelling of extremities, food 
cravings, change in appetite, fatigue, insomnia, abdominal cramping, breast tenderness, 
hot flashes, acne, palpitations, lower back pain, dizziness, nausea, diarrhea or 
constipation, depression, irritability, mood swings, angry outbursts, confusion, anxiety or 
nervousness, hypersensitivity, tendency to cry easily, desire to be alone, and 
forgetfulness. Women experiencing any symptoms were asked to report the age at which 
symptoms started, and the timing of symptom onset and cessation during an average 
menstrual cycle, as well as overall symptom severity and whether symptoms interfered 
with five specified life activities and interpersonal relationships. Completed 
questionnaires were received from 2966 (86.5%) potential cases and 2504 (97.8%) 
potential controls.  
Validated PMS cases were self-reported cases who met the following criteria 
based on those proposed by Mortola et al. in 1991 (83). 
1) Occurrence of at least 1 physical and 1 affective menstrual symptom; 
2) Overall symptom severity moderate or severe, or the effect of symptoms of 
life and social relationships classified as moderate or severe;  
3) Symptoms beginning within 14 days of the onset of menstruation;  
4) Symptoms ending within 4 days of the onset of menstruation and;  
5) Symptoms absent in the week after end of menses.  
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From the 2966 potential cases who replied to the questionnaire, 1057 women (35.6%) 
met these criteria. 
 
Validated controls were women not reporting PMS during the follow-up who met 
the following criteria: 
1) Complete absence of symptoms or only mild symptoms 
2) Mild overall symptom severity 
3) No substantial effect on life activities and interpersonal relationships  
4) Confirmed no diagnosis of PMS. 
From the 2540 potential controls who replied to the questionnaire, 1968 women (78.6%) 
met these criteria. 
 
Validity of Outcome Assessment 
The validity of this approach for assessing PMS symptoms was evaluated 
previously by Bertone-Johnson et al (79). Participants from the PMS Sub-study who 
reported a diagnosis of PMS for the first time in 2001 (n=138) and controls whose 
reference year was 2001 (n=377) completed a retrospective questionnaire that inquired 
about premenstrual symptoms  and PMS diagnosis during the 2-years prior to 
diagnosis/reference year. Potential cases were classified in four groups: 1) women who 
met the Mortola criteria and kept prospective symptom charts as part of their diagnosis  
(Chart/Mortola cases=36); 2) women who kept prospective charts for diagnosis but did 
not met the Mortola criteria (Chart cases=31); 3) women who met the Mortola criteria but 
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did not keep prospective symptom charts as part of their diagnosis (Mortola cases=30); 
and 4) women who neither did met Mortola criteria, nor kept prospective charts (Self-
report-only cases=38). The first group was considered the most accurate diagnostic group 
and was used as an “alloyed gold standard” for comparisons with the other groups. 
Potential controls were classified in ‘confirmed controls’ if they met the control criteria 
detailed before (absence or mild symptoms with no interference on normal life activities) 
and ‘unconfirmed controls’ otherwise.  
The authors found that both "Chart/Mortola cases" and "Mortola cases" were 
similar with regard to symptom timing and severity, as well as to the presence of physical 
symptoms. The groups only differed in the number of affective symptoms reported 
(mean=5.3 for the "Chart/Mortola cases" vs. 4.3 for the "Mortola cases", p=0.04).  In 
contrast, the other 2 case groups ("Chart cases" and "Self-report-only" cases) differed in 
multiple ways from the alloyed gold standard "Chart/Mortola cases". The authors 
concluded that women who did not report prospective symptom charting as part of their 
diagnosis but who met the Mortola criteria were essentially identical to those who 
reported prospective charting and who met the modified Mortola criteria for PMS (79).  
 
2.2.4 Covariate Assessment 
Information on several factors potentially associated with PMS and B vitamin 
intake, such as age, smoking status, weight, pregnancy history, tubal ligation, oral 
contraceptive use, and other micronutrient intakes was collected on biennial 
questionnaires throughout the study period.   
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Some studies (84, 85) have found that PMS prevalence is inversely associated 
with age. For our analysis, age was calculated using information on date of birth collected 
at the baseline questionnaire.  An elevated body mass index (BMI) has been found to be 
associated with PMS in this population (86), as well as in other previous studies (84, 87). 
BMI for all participants was calculated as the current weight in kilograms divided by the 
square of the height in meters. Weight and height were self-reported in the baseline 
questionnaire (1989), and current weight is queried on each follow up questionnaire. 
Aspects of reproductive history such as parity, tubal ligation and use of oral 
contraceptives have been assessed on the main NHS II questionnaires. These factors may 
be potential confounders of the association between B vitamins and PMS. For example, 
tubal ligation has been associated with premenstrual syndrome in some studies (88). 
Parity is directly related to PMS via progesterone sensitization, and will be assessed as 
the number of pregnancies that lasted more than 6 months. Oral contraceptives (OCs) are 
recommended as treatment for PMS (89), but also may worsen some symptoms such as 
depression and anxiety (90). In addition, oral contraceptive use has been associated with 
lower levels of vitamin B6, which could be explained by an increased excretion of 
tryptophan metabolites (91).   
Smoking information was collected in the biannual NHS2 questionnaires and was 
categorized into quintiles of pack-years of smoking. Alcohol information was collected in 
the FFQs of 1991, 1995 and 1999, and was categorized into quintiles of intake. Cigarette 
smoking and alcohol use may be associated with PMS through associations with levels of 
sex steroids (92, 93) and neurotransmitters.(94, 95) Two recent studies using data from 
the  NHS II PMS-Sub study have evaluated the effects of cigarette smoking (96)  and 
81 
 
alcohol use (97) on incidence of PMS. In 2008, Bertone-Johnson et al.(96) found that 
women who were current smokers had a two-fold increased risk for developing PMS 
over the next 2 to 4 years (RR = 2.10, 95% CI = 1.56 - 2.83) as compared to never 
smokers. There was a strong dose-response relationship with pack-years of smoking (p 
trend = 0.03). With regard of alcohol intake, Bertone-Johnson et al.(97) found that among 
leaner women (BMI < 25 kg/m2) there was a significant association between alcohol 
intake and PMS. Lean women in the highest quintile of drinking-years of alcohol had a 
RR of 1.74 (95% CI = 1.11 - 2.72) compared to never drinkers. Smoking and alcohol 
may also be correlated with B vitamins. Smoking has been associated with lower plasma 
levels of vitamin B6.(98, 99) Folate and B12 levels are lower among smokers(98, 100) 
and alcohol users.(101) Therefore, we controlled for these potential confounders by 
including them in the multivariate models.  
Calcium intake and vitamin D have been also reported to be associated with 
incidence of PMS in our study population (20). Information on these micronutrients, as 
well as others potentially associated to PMS, has been collected FFQs and was 
categorized by quintiles of total intake.  
 
2.2.5 Data Analysis 
 
Univariate Analysis: 
We  presented the number of self-reported cases and controls who were selected 
from the NHS2 to participate in the PMS sub-study, the number and percentage of those 
who replied to the ‘Menstrual Symptom Questionnaire’ and the number and percentages 
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of women who fulfilled the validation criteria and were validated as cases and as controls 
(Table 2.1). 
For the six B vitamins, we presented the recommended dietary allowance (RDA) 
among women of reproductive age as well as the mean, standard deviation (SD), median, 
and interquartile range of their total intakes (Table 2.2),  intakes from food sources only 
(Table 2.3) and intakes from supplement sources only (Table 2.4).   
 
Bivariate Analysis: 
To evaluate the relationship between incident PMS or B vitamin intakes and 
important covariates, we cross tabulated age-standardized covariate levels at baseline by 
PMS status (Table 2.5) or by quintiles of total B vitamin intake (Tables 2.6a to 2.6f). 
Continuous covariates included were age, BMI at baseline and at age 18, age at menarche 
and at first birth, number of full-term pregnancies, and physical activity. Categorical 
covariates were history of tubal ligation, use of oral contraceptives, smoking status, use 
of antidepressants, and history of severe childhood trauma. We used t-tests and chi-
square tests to compare continuous and categorical variables.  
To examine the interrelationships among the individual B vitamins, we calculated 
Spearman correlation coefficients for B vitamin total intake (Table 2.7), from food 
sources (Table 2.8) and from supplemental sources (Table 2.9).  
For each B vitamin total and from food sources only intakes 2 to 4 years before 
reference year, we used logistic regression to calculate age-adjusted relative risks (RRs) 
and 95% confidence intervals (CIs) for women in the highest quintiles using the lowest 
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quintile as the reference (Tables 2.10 and 2.11). For supplemental intake of each B 
vitamin, we selected non-users of supplements as the reference group and compared these 
women with those who used supplements categorized by tertiles of intake (Table 2.12). 
To assess dose-response relationships, we calculated the p for trend by including the 
median of B vitamin intakes in each category as a continuous variable in the regression 
model. For supplemental intakes, we calculated the p for trend among supplement users 
only. Medians and case to control ratios are additionally reported in each category. 
 
Multivariable analyses: 
The multivariable models included those potential confounders whose addition to 
the model changed the age-adjusted relative risks by more than 10%, as well as those 
variables that have been identified as important predictors of PMS risk in previous 
studies.  The following covariates were included in the final models of total B vitamin 
intake 2 to 4 years before reference year (Table 2.13): age (<30, 30-34, 35-39 or ≥ 40 
years), year of diagnosis (1993, 1994-1995, 1996-1997, 1998-1999 or 2000-2001), BMI 
(<20.0, 20.0-22.4, 22.5-24.9, 25.0-27.4, 27.5-29.9 or ≥ 30.0 kg/m2),  number of full term 
pregnancies (pregnancies that lasted more than 6 months), tubal ligation (no vs. yes), 
duration of oral contraceptive use (never, 1-23, 24-71, 72-119, or ≥120 months), 
antidepressant use (never vs. ever), pack-years of smoking (quintiles), history of severe 
childhood trauma score (5, 6-10, 11-15, or ≥16), and intake of alcohol, vitamin D, 
calcium and potassium in quintiles during 2 to 4 years before reference year.  
For B vitamin intakes from food sources, we additionally adjusted the RRs for 
their respective intake from supplements (Model 1; Table 2.14). In addition, we evaluated 
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a second model that included additional adjustment of each B vitamin for the effects of 
the others (Model 2; Table 2.14). 
B vitamin intakes from supplement sources were likewise adjusted for their 
respective intake from food sources. P for trends were calculated among supplement 
users only. Results of this analysis was included in table 2.16, summarized with 
additional results on supplements.  
 
Baseline and cross-sectional analysis 
To evaluate the effects of a longer gap (2-10 years) between intakes of B vitamins 
and PMS diagnosis, we  calculated age and multivariable adjusted RRs and 95% CIs for 
B vitamin intake from food (Table 2.15) and supplement sources (Table 2.16) at baseline 
(1991).   
To evaluate the potential of self-medication with B vitamin supplements, we 
additionally calculated RRs and 95% CIs for B vitamin intakes from supplements 0 to 2 
years before the reference year and for B vitamin intakes at baseline excluding cases who 
reported presence of symptoms before 1991. Results of these analyses are presented in 
table 2.16, in addition to those on B vitamin intake from supplements 2 to 4 years before 
reference year and baseline analysis. 
 
Effect modification 
To evaluate effect modification, we stratified participants into  two categories of 
two categories of age ( < 40 years, n = 1289; and ≥ 40 years, n = 1735), two categories of 
BMI ( < 25 kg/m2, n = 1890; and  ≥ 25 kg/m2, n = 1048), ever smokers (n = 897) vs. 
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never smokers (n = 2120), and alcohol intake (drinker, n = 1764; vs. non-drinkers, n = 
1255). Then we assessed the B vitamin and PMS relationship within each stratum.  We 
created multiplicative interaction terms by multiplying these potential effect modifiers by 
quintiles of the specific B vitamin intakes from food sources. We used the likelihood 
ratio tests in multivariate models to test if the addition of the interaction term improves 
the fitness of the model. Results from theses analysis for  BMI, age, smoking, and alcohol 
were reported in tables 2.17, 2.18, 2.19 and 2.20.  
All analyses were conducted using the Statistical Analysis System (SAS Institute, 
Cary, NC) for Unix, version 9.1 
 
2.3 Results 
The original study sample (Table 2.1) consisted of 3,430 women who reported a 
PMS diagnosis between 1993 and 2001 and were considered potential cases, and 2,570 
women who did not report a diagnosis of PMS between 1991 and 2001 and were 
considered potential controls.  Among the potential cases, 2,966 (86.5%) replied to the 
Menstrual Symptom Questionnaire and 1057 (35.6%) met the Mortola criteria used for 
case validation. Among the potential controls, 2,504 (97.4%) replied to the Menstrual 
Symptom Questionnaire and 1968 (78.6%) were validated as controls according to 
control criteria.  
The mean total thiamin intake for the population for the period of 2 to 4 years 
before reference year was 3.7 mg (SD = 8.5 mg) and the median total intake was 1.9 mg 
(Table 2.2).  Median intakes for total riboflavin, niacin, vitamin B6, folate and B12 were 
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2.4 mg, 27.8 mg, 2.5 mg, 386 µg and 7 µg respectively. Except for folate, all median B 
vitamin intakes were higher than their respective recommended dietary allowances 
(RDAs). Mean total intakes were substantially higher than the medians, indicating a 
positively skewed distribution. 
 Median intakes for thiamin, riboflavin, niacin, vitamin B6, folate and B12 from 
food sources only were 1.6 mg, 1.9 mg, 23.3 mg, 2.0 mg, 305 µg and 5.4 µg respectively, 
and except for folate they were higher than their respective RDAs (Table 2.3). Median 
intakes for thiamin, riboflavin, niacin, vitamin B6, folate and B12 from supplement 
sources only were 1.5 mg, 1.9 mg, 20 mg, 1.2 mg, 400 µg and 3.1 µg, respectively (Table 
2.4).   
We compared baseline age-standardized characteristics of cases and controls in 
table 2.5. Compared with controls, cases were slightly younger and had a higher mean 
BMI at baseline (p < 0.0001 for both). Cases were more likely than controls to report ever 
use of oral contraceptives than controls (OC; 85.7% of users among cases vs. 77.7% 
among controls, p < 0.001), to be current or past smokers ( 12.3% of current smokers and 
26.5% of past smokers among cases vs. 6.5% and 18.2% among controls, p < 0.0001), 
report ever use of antidepressants (12% among cases vs. 4.7% among controls, p < 
0.0001), and to have a history of severe childhood trauma (14.8% among cases vs. 7.9 
among controls, p < 0.0001).  There were no significant differences in BMI at age 18, age 
at menarche, age at first birth, physical activity, and history of tubal ligation between 
cases and controls.  
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In addition, we compared age-standardized characteristics of the population by 
quintiles of intakes of thiamin, riboflavin, niacin, vitamin B6, folate, and vitamin B12 
(Tables 2.6a to 2.6f). Overall, women in the highest quintiles of intake of any B vitamin 
were younger (p < 0.0001) and were less likely to report tubal ligation (p = 0.05 - 0.001) 
or to be current smokers (p= 0.08 - 0.002), compared to women in the lowest quintiles. 
Among parous women, those in the highest quintiles of B vitamin intake were older when 
they had their first child (p < 0.0001) and had fewer children compared to women in the 
lowest quintiles (p < 0.0001).  Except for niacin and vitamin B12, women in the highest 
quintiles of B vitamin intakes were more active than those in the lowest quintiles (p < 
0.0001). Women in the highest quintiles of vitamin B6 intakes were less likely to be 
current users of OCs (p = 0.03) and more likely to report smoking in the past (p < 0.0001) 
compared to women in the highest quintiles (Table 2.6d). Women in the highest quintiles 
of folate intake were less likely to report current use of oral contraceptives (p=0.02) 
compared to women in the lowest quintile (Table 2.6f). 
There were strong correlations between total intakes of vitamins B6, riboflavin, 
niacin and thiamin (range of Spearman correlation coefficients: 0.68 – 0.91; all p < 
0.0001; Table 2.7). The correlation between thiamin and riboflavin was the highest (r = 
0.91). Total niacin intake was also strongly correlated with thiamin and vitamin B6 (r = 
0.86 for both). Correlations between dietary intakes of vitamins B6, riboflavin, niacin and 
thiamin from food sources were smaller but still significant (range of Spearman 
correlation coefficients: 0.16 – 0.64; all p < 0.0001; Table 2.8). Intakes of niacin and 
vitamin B6 (r = 0.64) and thiamin and riboflavin (r = 0.57) from foods were the most 
strongly correlated.  Intake of vitamin B12 was modestly correlated with intake of other 
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B vitamins.  In contrast, intakes of B vitamins from supplement sources were very highly 
correlated (range of Spearman correlation coefficients: 0.81 – 0.99; all p < 0.0001; Table 
2.9). The correlation between thiamin and riboflavin intakes from supplement sources 
was very high (r=0.99). The lowest correlation was found between vitamin B6 and 
vitamin B12 (r=0.81). 
Adjusting only for age, we observed no significant association between total 
intakes of thiamin, riboflavin, folate, and vitamin B12 2 to 4 years before reference year 
and premenstrual syndrome (Table 2.10). For example, women in the highest quintile of 
thiamin intake had an age-adjusted relative risk (RR) of 1.10 (95% confidence interval 
(CI) = 0.86 - 1.40) compared to women in the lowest quintile. In contrast, there was an 
increased risk of premenstrual syndrome among women in the highest quintiles of niacin 
and vitamin B6 intake (RR=1.45, 95% CI=1.14-1.85 for niacin and RR=1.48, 
95%CI=1.16-1.90 for vitamin B6) compared to women in the lowest quintile.  
For B vitamins from food sources only, there was an inverse association between 
thiamin and riboflavin and risk of PMS in age-adjusted analyses (Table 2.11).  Women in 
the highest quintiles of thiamin intake from foods had an age-adjusted RR of 0.76 (95% 
CI = 0.60 - 0.97, p trend = 0.01) compared to women in the lowest quintile.  Women in 
the highest quintile of riboflavin intake had 32% lower risk of developing PMS (RR = 
0.68, 95%CI = 0.53 - 0.87, p trend = 0.004) compared to women in the lowest quintile. 
There was no significant association between intakes of niacin, vitamin B6, folate, and 
vitamin B12 from foods and risk of PMS.  
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We presented age-adjusted relative risks for B vitamin intakes from supplement 
sources and PMS 2 to 4 years before reference year and risk of PMS in table 2.12. 
Women in the highest tertile of thiamin, niacin and vitamin B6 intakes had age-adjusted 
relative risks of 1.28 (95 % CI = 1.03 - 1.59), 1.32 (1.05 - 1.66) and 1.48 (1.21 - 1.82) 
respectively, compared to women who did not use supplements.  There was no 
association between supplemental intake of riboflavin, folate and vitamin B12 and 
incidence of PMS. 
We adjusted relative risks of total B vitamin intake and PMS for age in 1989, year 
of diagnosis, number of fulltime pregnancies, BMI, pack-years of smoking, tubal ligation, 
duration of oral contraceptive use, antidepressant use, history of childhood trauma and 
total intakes of alcohol, potassium, calcium and vitamin D intake 2 to 4 years before 
reference year (Table 2.13). There was no significant association between total intakes of 
thiamin, riboflavin, folate, and vitamin B12 and incident PMS. However, niacin and 
vitamin B6 were associated with an increased risk of PMS.  For example, women in the 
highest quintile of total niacin intake had a multivariate adjusted RR of 1.71 (95% CI = 
1.23 - 2.39, p trend = 0.002) compared to women in the lowest quintile. Women in the 
highest quintile of total vitamin B6 intake had a multivariate adjusted RR of 1.77 (95% 
CI = 1.26 - 2.48, p trend < 0.001) compared to women in the lowest quintile.  
B vitamin from food sources were additionally adjusted for intakes of each 
vitamin from respective supplemental sources (Model 1; Table 2.14). In a subsequent 
analysis, we adjusted each vitamin for the effect of the other B-vitamins (Model 2; Table 
2.14). In model 1, thiamin and riboflavin from food sources were inversely associated 
with risk of PMS. Women in the highest quintile of thiamin intakes from foods had a RR 
90 
 
of 0.75 (95%CI = 0.56-1.00, p trend = 0.04) compared to women in the lowest quintile. 
Women in the highest quintile of riboflavin intakes from foods had a RR of 0.65 (95%CI 
= 0.46 - 0.93, p trend = 0.03) compared to women in the lowest quintile. After adjustment 
for other B vitamins, these results were no longer significant, although relative risks did 
not change substantially. For example, in model 2, women in the highest quintile of 
riboflavin intakes from foods had a RR of 0.67 (95%CI = 0.43-1.05, p trend = 0.09) 
compared to women in the lowest quintile. There was no association between intakes of 
niacin, vitamin B6, folate and vitamin B12 from foods and incident PMS. 
We further evaluated intakes of B vitamins from food sources at baseline and risk 
of PMS, after adjustment for all covariates selected at baseline and for supplement use of 
each vitamin (Table 2.15). Results were similar compared to those for intake 2 to 4 years 
before reference, but slightly attenuated. Women in the highest quintile of thiamin intake 
from foods at baseline had a multivariate adjusted RR of 0.76 (95%CI=0.57-1.01, p trend 
0.02) compared to women in the lowest quintile. Women in the highest quintile of 
riboflavin intake from foods at baseline had a multivariate adjusted RR of 0.84 
(95%CI=0.58-1.20, p trend 0.28) compared to women in the lowest quintile. 
B vitamin intakes from supplements were additionally adjusted for intake of each 
vitamin from food sources. Results for the association of B vitamins supplemental intakes 
at 2-4 years before reference year, at baseline and at 0-2 years before reference year are 
presented in table 2.16. In general, women with supplemental intake of B vitamins had a 
higher risk of PMS as compared to non-users. For example, compared to women with no 
intake of thiamin from supplements during the 2 to 4 years before reference, relative risks 
in tertiles one through three were 1.41, 1.54, and 1.66, respectively (P for trend among 
91 
 
users of thiamin supplements=0.22). Relative risks were attenuated when we evaluated 
supplement intake measured at baseline, and higher when we assessed supplement intake 
0 to 2 years before reference year. For example, for thiamin, relative risks for tertiles 1-3 
vs. non-users were 1.44, 1.45 and 1.50, respectively (P for trend =0.68) for supplemental 
intake at baseline, and 1.35, 1.44 and 1.77 (P for trend = 0.07) for supplement use 0-2 
years before reference year. In the sub-analysis excluding women reporting that their 
symptoms began before the start of follow-up in 1991, use of B vitamin supplements was 
not associated with increased risk of PMS.  For example, relative risks in tertiles 1-3 of 
thiamin use vs. non-use were 1.16, 1.00, and 0.91, respectively (P for trend = 0.62).  
Finally, after stratification of relative risks by quintiles of total intake, and testing 
of multiplicative interaction terms, we found no evidence that the relationships between 
B vitamin intake and incidence of PMS were modified by age (Table  2.17), BMI (Table 
2.18), ever smoking (Table 2.19) or alcohol intake (Table 2.20), though our power for 
this analysis was relatively low. 
 
2.4 Discussion 
In this subset of women from a large cohort of nurses, we found an inverse 
association between thiamin and riboflavin intakes from food sources and the 
development of PMS. There was no significant association between niacin, vitamin B6, 
folate, and vitamin B12 from food sources and incident PMS.  We found that use of B 
vitamin supplements during the 2 to 4 years before the reference year was associated with 
an increased risk of PMS, but there was no association between B vitamin supplement 
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use at baseline and PMS when we excluded all cases with PMS symptoms before 1991. 
In contrast, relative risks were higher when we compared B vitamin supplemental intake 
closer to the reference year. The relationship between B vitamin intakes and PMS was 
not modified by age, BMI, smoking and alcohol. To our knowledge, this is the first 
prospective study on dietary B vitamin intake and PMS.  
For both thiamin and riboflavin, the level of intake at which we observed a benefit 
was considerably above current recommendations.  For thiamin (RDA = 1.1 mg.day),(54)  
we found that women consuming approximately 1.9 mg per day had a 25% lower risk of 
PMS than those consuming approximately 1.2 mg/day. This level of intake can be 
achieved by consuming 2-3 servings per day of thiamin rich foods such as fortified 
cereals, legumes, nuts, and red meats such as pork.  For riboflavin (RDA = 1.1 mg/day) 
(54)  women consuming approximately 2.5 mg/day had a 35% lower risk compared to 
those consuming approximately 1.4 mg/day.  This level of intake can be achieved with 1-
2 servings/day of fortified cereal, or 6-7 servings of riboflavin rich foods such as cow’s 
milk or soy milk, spinach, and red meats. 
Previous randomized clinical trials have found a beneficial effect of vitamin B6 
supplementation on PMS symptoms using doses up to 100 mg/day (13, 14, 17). For 
example, in 2007, Sharma et al.(14) conducted a randomized clinical trial among 60 
women who reported premenstrual symptoms, and found that women who received a 
supplement of 100 mg/day of pyridoxine for 3 months showed a significant reduction of 
premenstrual symptoms as compared to placebo or bromocriptine (P < 0.01). In the same 
year, Kashanian et al.(13)  conducted a randomized clinical trial among 94 college 
students who received either 80 mg of pyridoxine or placebo for 2 months. The authors 
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observed a greater reduction of PMS psychological symptom scores in the group 
receiving pyridoxine compared to those receiving placebo. In our population, the doses of 
vitamin B6 from supplements consumed were very low compared to those used in 
intervention studies; the median B6 intake from supplements in the highest tertile was 
4.98 mg/day. Hence, because of the low intakes in our population, we were unable to 
evaluate association with "therapeutic" doses of vitamin B6 in incident cases of PMS, and 
could have missed the potential beneficial effects.  
No other studies have evaluated the effects of individual supplements of thiamin 
or riboflavin and PMS supplementation, but few clinical trials have evaluated the effects 
of supplements containing riboflavin, folate, and vitamin B12, among other 
micronutrients in PMS symptoms (64, 65). In 1991, London et al.(64) conducted a 
randomized clinical trial among 44 women with premenstrual tension, divided into three 
treatment groups receiving different doses of a multivitamin containing thiamin, 
riboflavin, niacin, vitamin B6, folate and vitamin B12 among others and a placebo group, 
which received riboflavin only. The authors observed that all groups significantly 
improved PMS symptoms after three months compared to baseline (p<0.0003). Although 
there was no proper comparison for B vitamin supplementation, this study suggests that B 
vitamin supplements, including riboflavin only supplements, may relieve PMS symptoms 
after three months of intake.  
The pathophysiology of PMS may include an interaction of ovarian hormones 
with brain neurotransmitters, such as serotonin and GABA (8, 9). The B vitamins 
evaluated in this analysis are involved in the metabolism of neurotransmitters through 
different mechanisms, and their dietary intakes may affect neurotransmitter levels in the 
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brain (11). Thiamin is required for the metabolism of glucose and precursors of GABA. 
Riboflavin is needed to activate vitamin B6, which is a cofactor in the generation of 
serotonin from the amino acid tryptophan. Niacin deficiency may lead to depletion of 
tryptophan, thereby reducing its availability to form serotonin (12). Vitamins B12, B6, 
and folate are associated with the formation of s-adenosyl-methionine and 
tetrahydrobiopterin, both of which are required for the metabolism of serotonin and 
dopamine (22, 57). 
 
Study limitations 
We observed an increased risk of PMS associated with any supplemental intake of 
B vitamins. These results likely reflect of the use of B vitamins to treat menstrual 
symptoms developing before diagnosis. Despite the lack of consistent evidence, 
deficiencies in B vitamins have been believed to be associated with menstrual symptom 
occurrence and severity, and supplements may be recommended by physicians for 
treatment of mild symptoms (1, 6, 102, 103). To evaluate the likelihood that the observed 
increased risks were due to this type of confounding by indication, we conducted separate 
analyses of the association of intake of B vitamin supplements at three time periods, 
hypothesizing that risks would be higher when supplement use was assessed closer in 
time to diagnosis.  We did in fact find that associations were strongest for riboflavin and 
folate when supplement use was assessed 0 to 2 years before diagnosis and attenuated 
when use was assessed at baseline (i.e., 2 to 10 years before diagnosis).  Moreover, when 
we conducted a separate analysis excluding women who reported that their symptoms 
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had already begun before the start of our follow-up period (1991), intake of B vitamins 
from supplements was not associated with PMS risk. 
To evaluate B vitamin intakes from foods and supplement sources, we used 
information collected on self-reported FFQs of the NHS II. These questionnaires have 
been validated before in similar populations (80, 81). Nevertheless, it may be difficult to 
accurately recall dietary intake over the past year, therefore some misclassification is 
likely. To minimize within person variability in reporting, specific portion sizes were 
included for each item. Additionally, we excluded from the analysis women who reported 
intakes below 500 or above 3500 calories per day, because of such small and large 
intakes are likely to be due to misreport. Misclassification is more likely between 
adjacent quintiles than distant quintiles, thus we focused our analysis on comparisons 
between the highest versus the lowest quintile (reference) and the trend over quintiles. 
Dietary assessment was conducted independently from the outcome assessment, therefore 
any misclassification would be non-differential and could have attenuated our results.  
Participants prospectively reported new PMS diagnosis over the follow-up period 
and completed a retrospective menstrual symptom questionnaire in 2002. From this group 
of women, cases were selected using specific criteria for PMS based on those proposed 
by Mortola in 1991 and accepted by the ACOG (1, 83). For the selection of controls, we 
identified a sub-set of women who did not report PMS diagnosis during follow-up years, 
and selected only those with complete absence of symptoms or only mild symptoms with 
no impact on functioning. Thus our aim was to compare women at  the ends of the 
spectrum of premenstrual symptoms, and therefore to minimize misclassification 
occurring in the middle of the spectrum.  Because of the prospective design of our study 
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and the large number of participants, we were unable to use prospective charting (i.e. 
recording of daily symptoms for at least two cycles) for identification of PMS cases, as is 
the gold standard for PMS assessment in clinical studies and recommended by the ACOG 
(1).  The lack of prospective charting of symptoms could have contributed to some 
misclassification of the outcome, leading to exclusion of potential cases from our sample 
or inclusion of women without PMS among the cases. Nevertheless, in the validation 
study of our method (79), the authors found that women who reported prospective 
charting and who met PMS criteria based on those defined by Mortola et al.(83) were 
essentially identical to those who did not report prospective charting but who met the 
Mortola criteria assessed in the retrospective questionnaire. Because PMS assessment 
was conducted independently of diet assessment, any misclassification of PMS status 
would be non-differential and could have attenuated our results.  
Throughout the follow-up period, the NHS II questionnaires collected information 
on a large number of variables, many of which may be associated with B vitamin intake 
and PMS. Although we  tried to minimize confounding by including all known risk 
factors for PMS as potential confounders, it is possible that there are potential 
confounders yet unknown as risk factors for PMS and associated with B vitamin intakes, 
thus leading to residual confounding. 
Participants in this study arise from the population of the a cohort of mostly white 
women and generally more educated than the general population. It is possible that they 
have a better diet quality than the general population, and therefore a different range of 
intake of B vitamins. Nevertheless, we have no reason to believe that B vitamin intake 
physiologically affects PMS in women from this cohort in a different manner as other 
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women. Therefore, we can generalize these results to other premenopausal women with 
the same range of intakes of B vitamins.  
 
Conclusion 
The results of this study suggest a possible benefit of high intakes of riboflavin 
and thiamin from food sources on the incidence of PMS. No significant associations 
between niacin, vitamin B6, folate, and vitamin B12 dietary intake and incident PMS 
were observed. Intakes of B vitamins from supplements were not associated with lower 
risk of PMS, but were likely to be influenced by self-medication. Because this is the first 
prospective study to evaluate the effects of these vitamins, additional studies of these 
relationships are warranted, including randomized clinical trials of thiamin and riboflavin 
for the prevention and possibly the treatment of PMS.   
 
2.5 Significance 
Premenstrual syndrome affects approximately 15% of women of reproductive age 
and is associated with substantial impact on quality of life and high economical burden. 
Proposed treatments for PMS have significant side effects and have limited efficacy. 
Although prevention of PMS through identification of modifiable risk factors is of 
primary importance, few studies to date have studied PMS development. This is the first 
study to evaluate the association between intakes of thiamin, riboflavin, niacin, vitamin 
B6, folate, and vitamin B12 and development of PMS. The potential benefit of thiamin 
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and riboflavin in PMS development should be further studied before suggesting specific 
dietary changes to prevent PMS. 
 
2.6 Human Subject Protection 
This study has been approved by the University of Massachusetts, Amherst and 
the Brigham and Women’s Hospital (BWH) institutional review boards.  
Participants in the NHS2 are identified through a confidential identification 
number only. Documents containing the names corresponding to each ID as well as the 
questionnaires are kept separately in the Channing Laboratory in locked fire-proof 
cabinets.  
There are no invasive procedures involved in this sub-study. There are no known 
risks involved in filling in questionnaires, except for the consequences of potential 
disclosure of confidential data. Women will not benefit directly from participating in this 
study. 
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2.7 Permission to Access Data 
I give Patricia Chocano-Bedoya permission to access relevant data from my grant 
funded research for her dissertation on "Micronutrients and Premenstrual Syndrome". 
 
Elizabeth Bertone-Johnson, Sc.D. 
Associate Professor of Epidemiology 
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Table 2.1  Number of cases and controls before and after validation, and 
response rates: NHS2 PMS Sub-study, 1991-2001. 
  Potential Cases Potential Controls 
Original study sample 3430 2570 
Replied to Menstrual  Symptom 
Questionnaire 
2966 (86.5%) 2504 (97.4%) 
Validated  as cases or controls 1057 (35.6%) 1968 (78.6%) 
 
 
 
 
Table 2.2 Distribution of total intake of B vitamins 2 to 4 years before reference 
year: NHS2 PMS Sub-study, 1991-2001. 
 
Recommended 
Dietary Allowance1
Mean 
Standard 
Deviation 
Median 
Interquartile 
Range 
Thiamin (mg/d) 1.1 3.7 8.5 1.9 1.5 - 3.0 
Riboflavin (mg/d) 1.1 4.1 8.3 2.4 1.8 - 3.6 
Niacin (mg/d) 14 35.9 27.6 27.8 22.6 - 40.0
Vitamin B6 (mg/d) 1.3 7.3 21.8 2.5 2.0 - 4.2 
Folate (µg/d) 400 487 285 386 284 - 635 
Vitamin B12 (µg/d) 2.4 9.9 13.4 7.0 5.0 - 11.0 
1Recommended dietary allowance for women aged 20 to 40 years. 
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Table 2.3 Distribution of intakes of B vitamins from food sources 2 to 4 years 
before reference year: NHS2 PMS Sub-study, 1991-2001. 
  Mean 
Standard 
Deviation Median 
Interquartile 
Range 
Thiamin (mg/d) 1.6 0.4 1.6 1.4 - 1.8 
Riboflavin (mg/d) 2.0 0.6 1.9 1.6 - 2.2 
Niacin (mg/d) 23.9 5.4 23.3 20.5 - 26.4 
Vitamin B6 (mg/d) 2.1 0.5 2.0 1.8 - 2.3 
Folate (µg/d) 321 108 305 251 - 370 
Vitamin B12 (µg/d) 6.1 3.6 5.4 4.3 - 6.9 
 
 
 
 
Table 2.4 Distribution of intakes of B vitamins from supplement sources1 2 to 
4 years before reference year: NHS2 PMS Sub-study, 1991-2001. 
  Mean 
Standard 
Deviation Median 
Interquartile 
Range 
Thiamin (mg/d) 4.3 11.4 1.5 0.9 - 3.0 
Riboflavin (mg/d) 4.4 11.3 1.7 1.0 - 3.4 
Niacin (mg/d) 25.0 32.3 20.0 11.4 - 20.0 
Vitamin B6 (mg/d) 7.0 23.1 1.2 0.04 - 2.6 
Folate (µg/d) 364 261 400 228 - 400 
Vitamin B12 (µg/d) 5.4 13.3 3.1 0.4 - 6.1 
1Includes multivitamin and individual supplement users. 
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Table 2.5 Age-standardized characteristics of premenstrual syndrome cases 
and controls at baseline: NHS2 PMS Sub-study, 1991-2001. 
Cases Controls 
(n=1057) (n=1968) 
 Characteristics1 Mean (SE) Mean (SE) p-value4 
Age in years2 34.4 (4.3) 35.0 (3.9) <0.0001 
BMI (kg/m2) 
At baseline (1991) 24.6 (0.2) 23.7 (0.1) <0.0001 
At the age of 18 years 21.4 (0.1) 21.1 (0.1) 0.03 
Age at menarche, years 12.4 (0.1) 12.5 (0.03) 0.08 
Age at first birth, years3 25.9 (0.1) 26.1 (0.1) 0.22 
Number of full-term pregnancies 1.7 (0.04) 1.7 (0.03) 0.52 
MET of physical activity per week 23.0 (1.8) 23.3 (1.3) 0.88 
  
% % p-value5 
History of tubal ligation 16.8 18.2 0.34 
Oral contraceptive use 
Ever 85.7 77.0 <0.0001 
Current 10.7 9.9 0.51 
Duration > 4years 42.0 36.6 0.04 
Smoking status 
Current smoker 12.3 6.5 <0.0001 
Past smoker 26.5 18.2 <0.0001 
Ever used antidepressant 12.1 4.7 <0.0001 
History of childhood trauma 18.0 9.0 <0.0001 
1 All characteristics, except for age,  standardized to the age distribution of participants in 1991. 
2 For age, the value in parentheses is the standard deviation instead of the standard error. 
3 Limited to parous women. 
4 Calculated using the t statistic. 
5 Calculated using the chi-square statistics. 
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Table 2.6a Age-standardized characteristics of the population by total thiamin 
intake at baseline: NHS2 PMS Sub-study, 1991-2001. 
  Total thiamin intake in 1991, mg/d  
 
Q1
 (n=531) 
Q2
 (n=603) 
Q3 
(n=671) 
Q4 
(n=643) 
Q5 
 (n=577)  
 Characteristics1 
Mean 
(SE) 
Mean 
(SE) 
Mean 
(SE) 
Mean 
(SE) 
Mean 
(SE) 
Pvalue4 
Age in years2 35.0 (4.2) 35.2 (4.0) 35.1 (4.0) 34.2 (4.0) 34.3 (4.0) <0.0001
BMI (kg/m2)       
At baseline (1991) 24.6 (0.2) 24.2 (0.2) 23.7 (0.2) 23.8 (0.2) 24.0 (0.2) 0.01
At the age of 18 yrs 21.3 (0.1) 21.5 (0.1) 21.1 (0.1) 21.0 (0.1) 21.1 (0.1) 0.06
Age at menarche, years 12.5 (0.1) 12.5 (0.1) 12.5 (0.1) 12.4 (0.1) 12.5 (0.1) 0.80
Age at first birth, years3 25.6 (0.2) 25.6 (0.2) 25.5 (0.2) 26.9 (0.2) 26.4 (0.2) <0.0001
Number of full-term 
pregnancies 1.5 (1.2) 1.8 (1.2) 1.9 (1.2) 1.6 (1.2) 1.5 (1.3) <0.0001
MET of physical 
activity per week 17.5 (4.0) 24.4 (4.0) 19.4 (4.0) 30.1 (4.0) 23.0 (4.0) 0.001 
  % % % % % Pvalue5 
History of tubal ligation 19 19 20 16 14 0.04
Oral contraceptive use       
Current user 13 11 9 9 9 0.18
Ever user 82 83 81 77 81 0.06
Smoking Status       
Current smoker 12 10 7 8 7 0.002
Past smoker 18 22 22 21 22 0.46
Ever used 
antidepressants 8 8 6 7 8 0.35 
History of severe 
childhood trauma  11 11 10 11 10 0.68 
1 All characteristics, except for age,  standardized to the age distribution of participants in 1991. 
2 For age, the value in parentheses is the standard deviation instead of the standard error. 
3 Limited to parous women. 
4 Calculated using the t statistic. 
5 Calculated using the F statistic. 
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Table 2.6b Age-standardized characteristics of the population by total riboflavin 
intake at baseline: NHS2 PMS Sub-study, 1991-2001. 
  Total riboflavin intake in 1991, mg/d  
 
Q1 
(n=535) 
Q2 
(n=591) 
Q3 
(n=659) 
Q4 
(n=646) 
Q5 
(n=594)  
 Characteristics1 
Mean 
(SE) 
Mean 
(SE) 
Mean 
(SE) 
Mean 
(SE) 
Mean 
(SE) 
Pvalue4 
Age in years2 35.4 (4.1) 35.0 (4.0) 35.0 (4.1) 34.3 (4.1) 34.1 (4.0) <0.0001 
BMI (kg/m2)       
At baseline (1991) 24.6 (0.2) 23.8 (0.2) 23.9 (0.2) 23.9 (0.2) 24.0 (0.2) 0.11
At the age of 18 yrs 21.3 (0.1) 21.2 (0.1) 21.3 (0.1) 21.1 (0.1) 21.1 (0.1) 0.83
Age at menarche, years 12.5 (0.1) 12.5 (0.1) 12.4 (0.1) 12.4 (0.1) 12.5 (0.1) 0.43
Age at first birth, years3 25.5 (0.2) 25.4 (0.2) 25.6 (0.2) 26.6 (0.2) 26.9 (0.2) <0.0001 
Number of full-term 
pregnancies 1.6 (0.1) 1.8 (0.05) 1.8 (0.05) 1.7 (0.05) 1.5 (0.05) <0.0001 
MET of physical 
activity per week 17.0 (2.5) 21.1 (2.4) 23.7 (2.3) 28.4 (2.3) 24.2 (2.4) 0.01 
  % % % % % Pvalue5 
History of tubal ligation 20 18 21 16 13 0.001 
Oral contraceptive use       
Current user 11 14 9 10 9 0.18 
Ever user 80 85 79 78 81 0.06 
Smoking Status       
Current smoker 12 11 6 8 7 0.002 
Past smoker 18 23 21 22 22 0.46 
Ever used 
antidepressants 8 9 6 7 8 0.35 
History of severe 
childhood trauma  11 11 9 12 10 0.68 
1 All characteristics, except for age,  standardized to the age distribution of participants in 1991. 
2 For age, the value in parentheses is the standard deviation instead of the standard error. 
3 Limited to parous women. 
4 Calculated using the t statistic. 
5 Calculated using the F statistic. 
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Table 2.6c Age-standardized characteristics of the population by total niacin 
intake at baseline: NHS2 PMS Sub-study, 1991-2001. 
  Total niacin intake in 1991, mg/d  
 
Q1 
(n=579) 
Q2 
(n=589) 
Q3 
(n=662) 
Q4 
(n=609) 
Q5  
(n=594)  
 Characteristics1 
Mean 
(SE) 
Mean 
(SE) 
Mean 
(SE) 
Mean 
(SE) 
Mean 
(SE) 
Pvalue4 
Age in years2 35.2 (4.1) 34.7 (4.1) 35.1 (3.9) 34.1 (4.0) 34.7 (4.0) <0.0001 
BMI (kg/m2)       
At baseline (1991) 23.8 (0.2) 24.3 (0.2) 24.2 (0.2) 23.9 (0.2) 24.0 (0.2) 0.33
At the age of 18 yrs 20.9 (0.1) 21.4 (0.1) 21.4 (0.1) 20.9 (0.1) 21.3 (0.1) 0.01
Age at menarche, years 12.6 (0.1) 12.4 (0.1) 12.4 (0.1) 12.5 (0.1) 12.4 (0.1) 0.32
Age at first birth, years3 25.8 (0.2) 25.4 (0.2) 25.6 (0.2) 26.8 (0.2) 26.4 (0.2) <0.0001 
Number of full-term 
pregnancies 1.7 (0.05) 1.8 (0.05) 1.8 (0.05) 1.6 (0.05) 1.4 (0.05) <0.0001 
MET of physical 
activity per week 20.5 (2.4) 21.3 (2.3) 20.5 (2.4) 25.6 (2.3) 27.1 (2.4) 0.14 
  % % % % % Pvalue5 
History of tubal ligation 20 20 20 14 15 0.005
Oral contraceptive use       
Current user 13 11 8 8 10 0.03
Ever user 82 81 82 76 82 0.04
Smoking Status       
Current smoker 9 11 8 7 8 0.082
Past smoker 15 19 26 22 24 <0.0001
Ever used 
antidepressants 6 8 7 6 9 0.22 
History of severe 
childhood trauma  10 9 11 11 12 0.72 
1 All characteristics, except for age,  standardized to the age distribution of participants in 1991. 
2 For age, the value in parentheses is the standard deviation instead of the standard error. 
3 Limited to parous women. 
4 Calculated using the t statistic. 
5 Calculated using the F statistic. 
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Table 2.6d Age-standardized characteristics of the population by total vitamin B6 
intake at baseline: NHS2 PMS Sub-study, 1991-2001. 
  Total vitamin B6 intake in 1991, mg/d  
 
Q1 
(n=537) 
Q2 
(n=697) 
Q3 
(n=592) 
Q4 
(n=595) 
Q5 
(n=604)  
 Characteristics1 
Mean 
(SE) 
Mean 
(SE) 
Mean 
(SE) 
Mean 
(SE) 
Mean 
(SE) 
Pvalue4 
Age in years2 35.1 (4.1) 35.2 (4.1) 35.0 (3.9) 34.2 (4.2) 34.3 (3.9) <0.0001 
BMI (kg/m2)       
At baseline (1991) 24.3 (0.2) 24.3 (0.2) 23.7 (0.2) 23.7 (0.2) 24.1 (0.2) 0.06
At the age of 18 yrs 21.1 (0.1) 21.5 (0.1) 21.0 (0.1) 21.1 (0.1) 21.2 (0.1) 0.04
Age at menarche, years 12.6 (0.1) 12.4 (0.1) 12.5 (0.1) 12.4 (0.1) 12.5 (0.1) 0.15
Age at first birth, years3 25.6 (0.2) 25.6 (0.2) 25.6 (0.2) 26.4 (0.2) 26.8 (0.2) <0.0001 
Number of full-term 
pregnancies 1.7 (0.05) 1.8 (0.05) 1.8 (0.05) 1.6 (0.05) 1.5 (0.05) <0.0001 
MET of physical 
activity per week 17.5 (2.5) 21.8 (2.2) 22.7 (2.4) 25.9 (2.4) 27.3 (2.4) 0.04 
  % % % % % Pvalue5 
History of tubal ligation 20 19 20 17 13 0.003
Oral contraceptive use       
Current user 12 12 10 10 8 0.03
Ever user 83 80 82 77 82 0.14
Smoking Status       
Current smoker 12 10 6 7 8 0.002
Past smoker 16 20 26 21 22 <0.0001
Ever used 
antidepressants 9 6 8 7 7 0.24 
History of severe 
childhood trauma  11 9 11 11 10 0.67 
1 All characteristics, except for age,  standardized to the age distribution of participants in 1991. 
2 For age, the value in parentheses is the standard deviation instead of the standard error. 
3 Limited to parous women. 
4 Calculated using the t statistic. 
5 Calculated using the F statistic. 
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Table 2.6e Age-standardized characteristics of the population by total folate intake
at baseline: NHS2 PMS Sub-study, 1991-2001. 
  Total folate intake in 1991, µg/d  
 
Q1 
(n=556) 
Q2 
(n=621) 
Q3 
(n=585) 
Q4 
(n=604) 
Q5 
(n=659)  
 Characteristics1 
Mean 
(SE) 
Mean 
(SE) 
Mean 
(SE) 
Mean 
(SE) 
Mean 
(SE) 
Pvalue4 
Age in years2 34.8 (4.1) 35.3 (4.0) 35.2 (4.0) 34.6 (4.1) 34.0 (4.0) <0.0001 
BMI (kg/m2)       
At baseline (1991) 24.7 (0.2) 24.1 (0.2) 23.8 (0.2) 23.5 (0.2) 24.1 (0.2) 0.002
At the age of 18 yrs 21.4 (0.1) 21.3 (0.1) 21.2 (0.1) 20.9 (0.1) 21.3 (0.1) 0.13
Age at menarche, years 12.5 (0.1) 12.5 (0.1) 12.5 (0.1) 12.5 (0.1) 12.4 (0.1) 0.53
Age at first birth, years3 25.6 (0.2) 25.5 (0.2) 25.4 (0.2) 26.2 (0.2) 27.2 (0.2) <0.0001 
Number of full-term 
pregnancies 1.7 (0.05) 1.8 (0.05) 1.8 (0.05) 1.6 (0.05) 1.5 (0.05) <0.0001 
MET of physical 
activity per week 16.9 (2.5) 24.1 (2.3) 22.7 (2.4) 23.9 (2.4) 27.4 (2.3) 0.04 
  % % % % % Pvalue5 
History of tubal ligation 20 20 18 18 13 0.003
Oral contraceptive use       
Current user 11 12 10 12 8 0.02
Ever user 82 84 80 78 79 0.11
Smoking Status       
Current smoker 12 10 7 7 7 0.007
Past smoker 19 19 23 21 23 0.20
Ever used 
antidepressants 8 8 7 8 6 0.85 
History of severe 
childhood trauma  10 8 13 10 11 0.15 
1 All characteristics, except for age,  standardized to the age distribution of participants in 1991. 
2 For age, the value in parentheses is the standard deviation instead of the standard error. 
3 Limited to parous women. 
4 Calculated using the t statistic. 
5 Calculated using the F statistic. 
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Table 2.6f Age-standardized characteristics of the population by total vitamin B12 
intake at baseline: NHS2 PMS Sub-study, 1991-2001. 
  Total vitamin B12 intake in 1991, µg/d  
 
Q1 
(n=508) 
Q2 
(n=775) 
Q3 
(n=550) 
Q4 
(n=616) 
Q5 
(n=576)  
 Characteristics1 
Mean 
(SE) 
Mean 
(SE) 
Mean 
(SE) 
Mean 
(SE) 
Mean 
(SE) 
Pvalue4 
Age in years2 35.2(4.1) 35.0(4.0) 34.7(3.9) 34.5(4.0) 34.3(4.2) <0.0001 
BMI (kg/m2)       
At baseline (1991) 24.2(0.2) 24.0(0.2) 23.9(0.2) 23.7(0.2) 24.3(0.2) 0.24
At the age of 18 yrs 21.5(0.1) 21.3(0.1) 21.0(0.1) 21.0(3.0) 21.2(3.0) 0.15
Age at menarche, years 12.5(0.1) 12.5(0.1) 12.4(0.1) 12.5(0.1) 12.4(0.1) 0.16
Age at first birth, years3 25.7(0.2) 25.6(0.2) 25.8(0.2) 26.4(0.2) 26.7(0.2) <0.0001 
Number of full-term 
pregnancies 1.7(0.05) 1.8(0.04) 1.7(0.05) 1.7(0.05) 1.6(0.05) 0.01 
MET of physical 
activity per week 20.8(2.6) 21.6(2.1) 24.7(2.5) 26.1(2.3) 22.8(2.4) 0.49 
  % % % % % Pvalue5 
History of tubal ligation 18 19 17 20 14 0.05
Oral contraceptive use       
Current user 11 11 11 11 9 0.50
Ever user 80 82 79 81 80 0.70
Smoking Status       
Current smoker 12 9 6 8 8 0.03
Past smoker 20 21 23 22 20 0.76
Ever used 
antidepressants 7 8 7 8 7 0.83 
History of severe 
childhood trauma  12 10 10 11 10 0.89 
1 All characteristics, except for age,  standardized to the age distribution of participants in 1991. 
2 For age, the value in parentheses is the standard deviation instead of the standard error. 
3 Limited to parous women. 
4 Calculated using the t statistic. 
5 Calculated using the F statistic. 
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Table 2.7 Spearman correlation coefficients1 for total intake of B vitamins: 
NHS2 PMS Sub-study, 1991-2001. 
  Thiamin Riboflavin Niacin B6 Folate B12 
Thiamin 1.00 
Riboflavin 0.91 1.00 
Niacin 0.86 0.81 1.00 
B6 0.85 0.84 0.86 1.00 
Folate 0.82 0.79 0.76 0.80 1.00 
B12 0.70 0.80 0.69 0.70 0.68 1.00 
1All correlations are statistically significant at <0.0001 
 
 
 
Table 2.8 Spearman Correlation Coefficients1 for intake of B vitamins from 
food sources: NHS2 PMS Sub-study, 1991-2001. 
  Thiamin Riboflavin Niacin B6 Folate B12 
Thiamin 1.00 
Riboflavin 0.57 1.00 
Niacin 0.46 0.26 1.00 
B6 0.54 0.49 0.64 1.00 
Folate 0.61 0.48 0.36 0.60 1.00 
B12 0.20 0.54 0.23 0.30 0.16 1.00 
1All correlations are statistically significant at <0.0001
 
 
 
Table 2.9 Spearman Correlation Coefficients1 for intake of B vitamins from 
supplement sources: NHS2 PMS Sub-study, 1991-2001. 
  Thiamin Riboflavin Niacin B6 Folate B12 
Thiamin 1.00 
Riboflavin 0.99 1.00 
Niacin 0.98 0.98 1.00 
B6 0.89 0.89 0.88 1.00 
Folate 0.90 0.90 0.90 0.83 1.00 
B12 0.90 0.90 0.89 0.81 0.88 1.00 
1All correlations are statistically significant at <0.0001
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Table 2.10 Age-adjusted relative risks (RR) and 95% confidence intervals (CI) for 
total intake of B vitamins 2 to 4  years before reference year and risk of 
premenstrual syndrome: NHS2 PMS Sub-study, 1991-2001. 
  Q1 Q2 Q3 Q4 Q5 Ptrend 
Thiamin (mg/d) 
Median 1.27 1.53 1.84 2.73 5.06 
Case:Control Ratio 186:342 218:395 204:462 226:405 221:360 
RR 1.00 1.01 0.81 1.00 1.10 0.16
95% CI   (0.80-1.29) (0.64-1.04) (0.79-1.28) (0.86-1.40)  
Riboflavin (mg/d) 
Median 1.45 1.83 2.33 3.28 6.09 
Case:Control Ratio 195:356 197:390 226:440 218:424 219:354 
RR 1.00 0.90 0.92 0.90 1.08 0.24
95% CI   (0.70-1.15) (0.73-1.17) (0.71-1.14) (0.84-1.37)  
Niacin (mg/d) 
Median 19.4 23.6 28.0 37.7 56.4 
Case:Control Ratio 180:356 234:422 194:377 221:396 226:354 
RR 1.00 1.27 1.19 1.24 1.45 0.01
95% CI   (1.00-1.61) (0.93-1.53) (0.98-1.58) (1.14-1.85)  
Vitamin B6 (mg/d) 
Median 1.63 2.00 2.54 3.90 9.10 
Case:Control Ratio 173:369 227:464 218:402 197:392 240:337 
RR 1.00 1.04 1.16 1.05 1.48 0.001
95% CI   (0.82-1.33) (0.91-1.48) (0.82-1.34) (1.16-1.90)  
Folate (µg/d) 
Median 219.9 293.0 371.0 551.0 846.5 
Case:Control Ratio 180:382 208:403 213:380 243:380 211:419 
RR 1.00 1.11 1.21 1.36 1.03 0.92
95% CI   (0.87-1.41) (0.95-1.54) (1.07-1.72) (0.81-1.31)  
Vitamin B12 (µg/d) 
Median 4.0 5.0 7.0 10.0 17.0 
Case:Control Ratio 194:358 251:533 172:335 238:411 200:327 
RR 1.00 0.87 0.94 1.05 1.10 0.10
95% CI   (0.69-1.10) (0.73-1.21) (0.83-1.33) (0.85-1.40)  
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Table 2.11 Age-adjusted relative risks (RR) and 95% confidence intervals (CI) for 
intake of B vitamins from food sources 2 to 4  years before reference year and risk 
of premenstrual syndrome: NHS2 PMS Sub-study, 1991-2001. 
  Q1 Q2 Q3 Q4 Q5 Ptrend
Thiamin (mg/d) 
Median 1.20 1.39 1.53 1.67 1.93 
Case:Control Ratio 185:314 214:364 227:400 218:417 211:469 
RR 1.00 1.01 0.97 0.89 0.76 0.01
95% CI   (0.79-1.29) (0.76-1.23) (0.70-1.14) (0.60-0.97)  
Riboflavin (mg/d) 
Median 1.38 1.63 1.86 2.12 2.52 
Case:Control Ratio 195:318 198:382 241:396 220:405 201:463 
RR 1.00 0.84 0.97 0.87 0.68 0.004
95% CI   (0.66-1.08) (0.76-1.23) (0.69-1.11) (0.53-0.87)  
Niacin (mg/d) 
Median 18.1 21.2 23.5 25.8 29.9 
Case:Control Ratio 203:397 212:425 239:382 188:406 213:354 
RR 1.00 0.99 1.23 0.91 1.20 0.23
95% CI   (0.78-1.25) (0.97-1.55) (0.72-1.16) (0.95-1.53)  
Vitamin B6 (mg/d) 
Median 1.56 1.83 2.05 2.28 2.71 
Case:Control Ratio 178:380 245:414 217:426 231:372 184:372 
RR 1.00 1.27 1.09 1.33 1.07 0.69
95% CI   (1.00-1.61) (0.86-1.39) (1.04-1.69) (0.83-1.38)  
Folate (µg/d) 
Median 206.0 256.0 299.1 347.0 434.4 
Case:Control Ratio 198:348 207:403 223:399 231:398 196:416 
RR 1.00 0.90 1.01 1.04 0.85 0.34
95% CI   (0.71-1.15) (0.79-1.28) (0.82-1.32) (0.66-1.08)  
Vitamin B12 (µg/d) 
Median 3.3 4.6 5.5 6.6 9.0 
Case:Control Ratio 224:384 225:396 202:454 213:370 191:357 
RR 1.00 0.97 0.77 0.98 0.92 0.60
95% CI   (0.77-1.23) (0.61-0.97) (0.78-1.25) (0.72-1.17)  
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Table 2.12 Age-adjusted relative risks (RR) and 95% confidence intervals 
(CI) of B vitamins from supplements 2 to 4 years before reference year and 
risk of premenstrual syndrome: NHS2 PMS Sub-study, 1991-2001. 
Supplement Users
  Non-Users T1 T2 T3 Ptrend1 
Thiamin (mg/d) 
Median 0.9 1.5 5.7
Case:Control Ratio 538:1080 163:287 178:328 178:273 
RR 1.00 1.12 1.05 1.28 0.16
95% CI   (0.90-1.39) (0.85-1.30) (1.03-1.59)   
Riboflavin (mg/d) 
Median 1.0 1.7 5.7
Case:Control Ratio 540:1081 179:310 158:290 180:287 
RR 1.00 1.14 1.04 1.22 0.38
95% CI   (0.93-1.41) (0.84-1.30) (0.99-1.52)   
Niacin (mg/d) 
Median 6 20 50
Case:Control Ratio 535:1077 154:294 220:372 148:225 
RR 1.00 1.04 1.13 1.32 0.09
95% CI   (0.83-1.30) (0.93-1.38) (1.05-1.66)   
Vitamin B6 (mg/d) 
Median 0.03 1.2 5.0
Case:Control Ratio 288:626 242:460 234:463 293:419 
RR 1.00 1.16 1.08 1.48 0.01
95% CI   (0.94-1.43) (0.88-1.34) (1.21-1.82)   
Folate (µg/d) 
Median 228 400 800 
Case:Control Ratio 553:1115 220:359 196:317 88:177 
RR 1.00 1.22 1.22 0.90 0.05
95% CI   (1.00-1.49) (0.99-1.50) (0.68-1.19)   
Vitamin B12 
(µg/d) 
Median 0.3 3.2 6.5
Case:Control Ratio 295:647 260:462 258:411 244:448 
RR 1.00 1.25 1.35 1.16 0.41
95% CI   (1.02-1.53) (1.10-1.67) (0.94-1.43)   
1Test for trend was conducted among users of supplements only. 
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Table 2.13 Multivariable adjusted RR1 and 95% CI for total B vitamin intake 
2 to 4 years before reference year and PMS: NHS2 PMS Sub-study 1991-2001. 
  Q1 Q2 Q3 Q4 Q5 Ptrend 
Thiamin 
RR 1.00 0.91 0.76 1.08 1.30 0.02
95% CI   (0.69-1.21) (0.57-1.01) (0.78-1.51) (0.92-1.84)  
Riboflavin 
RR 1.00 0.97 0.94 0.93 1.23 0.06
95% CI   (0.71-1.32) (0.66-1.34) (0.62-1.39) (0.82-1.86)  
Niacin 
RR 1.00 1.17 1.03 1.42 1.71 0.002
95% CI   (0.90-1.53) (0.78-1.37) (1.04-1.95) (1.23-2.39)  
Vitamin B6  
RR 1.00 0.99 1.09 1.25 1.77 <0.001
95% CI   (0.75-1.30) (0.81-1.47) (0.88-1.75) (1.26-2.48)  
Folate 
RR 1.00 1.24 1.24 1.48 1.32 0.23
95% CI   (0.93-1.63) (0.92-1.66) (1.07-2.04) (0.90-1.95)  
Vitamin B12  
RR 1.00 0.81 0.90 1.16 1.29 0.02
95% CI   (0.62-1.06) (0.66-1.24) (0.83-1.63) (0.90-1.86)  
1Adjusted for age (<30, 30-34, 35-39 or ≥40 years), year of diagnosis (1993, 1994-1995, 1996-1997, 1998-1999 or 2000-
2001), number of full-term pregnancies (0. 1-2, 3-4 or ≥5 pregnancies lasting at least 6 months), body mass index (<20.0, 
20.0-22.4, 22.5-24.9, 25.0-27.4, 27.5-29.9 or ≥30.0 kg/m2), pack-years of smoking (quintiles), tubal ligation (no vs. yes), 
duration or oral contraceptive use (never, 1-23, 24-71, 72-119 or ≥120 months), antidepressant use (never vs. ever), history of 
childhood trauma score (5, 6-10, 11-15, ≥16), intake of alcohol, potassium, calcium and vitamin D (quintiles) at 2 to 4 years 
before reference year. 
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Table 2.14 Multivariable adjusted RR1 and 95% CI for  B vitamin intake from 
food sources 2 to 4 years before reference year and risk of PMS: NHS2 PMS Sub-
study, 1991-2001. 
  Q1 Q2 Q3 Q4 Q5 Ptrend 
Thiamin  
Model 1 1.00 0.94 0.91 0.89 0.75 0.04
95% CI (0.71-1.25) (0.68-1.21) (0.67-1.19) (0.56-1.00) 
Model 2 1.00 0.90 0.87 0.87 0.78 0.22
95% CI   (0.67-1.21) (0.64-1.19) (0.62-1.21) (0.53-1.14)  
Riboflavin 
Model 1 1.00 0.81 1.00 0.99 0.65 0.02 
95% CI (0.60-1.09) (0.74-1.37) (0.64-1.25) (0.46-0.93) 
Model 2 1.00 0.85 1.04 0.94 0.67 0.09 
95% CI   (0.62-1.16) (0.74-1.47) (0.64-1.39) (0.43-1.05)   
Niacin  
Model 1 1.00 1.01 1.18 0.84 1.10 0.87 
95% CI (0.77-1.31) (0.91-1.54) (0.64-1.10) (0.83-1.45) 
Model 2 1.00 1.02 1.21 0.89 1.27 0.28 
95% CI   (0.77-1.34) (0.91-1.62) (0.65-1.23) (0.90-1.80)   
Vitamin B6 
Model 1 1.00 1.20 1.04 1.16 0.97 0.57 
95% CI (0.91-1.58) (0.78-1.38) (0.86-1.57) (0.70-1.33) 
Model 2 1.00 1.23 1.08 1.18 1.05 0.97 
95% CI   (0.92-1.65) (0.77-1.49) (0.82-1.70) (0.70-1.61)   
Folate 
Model 1 1.00 0.87 1.00 0.99 0.75 0.25 
95% CI (0.66-1.14) (0.76-1.33) (0.69-1.26) (0.55-1.03) 
Model 2 1.00 0.92 1.11 1.09 0.98 0.91 
95% CI   (0.69-1.24) (0.81-1.53) (0.77-1.54) (0.66-1.45)   
Vitamin B12 
Model 1 1.00 0.97 0.79 0.93 0.89 0.50 
95% CI (0.74-1.26) (0.60-1.03) (0.70-1.23) (0.67-1.19) 
Model 2 1.00 0.93 0.77 0.92 0.98 0.93 
95% CI   (0.71-1.22) (0.58-1.02) (0.69-1.24) (0.71-1.35)   
Model 1. Adjusted for age (<30, 30-34, 35-39 or ≥40 years), year of diagnosis (1993, 1994-1995, 1996-1997, 1998-1999 or 
2000-2001), number of full-term pregnancies (0. 1-2, 3-4 or ≥5 pregnancies lasting at least 6 months), body mass index (<20.0, 
20.0-22.4, 22.5-24.9, 25.0-27.4, 27.5-29.9 or ≥30.0 kg/m2), pack-years of smoking (quintiles), tubal ligation, duration or oral 
contraceptive use, antidepressant use (never vs. ever), history of childhood trauma score (5, 6-10, 11-15, >=16), intake of alcohol, 
potassium, calcium and vitamin D (quintiles) at 2 to 4 years before reference year and respective intake from supplemental 
sources. 
Model 2. Model 1 additionally adjusted for food intake of other B vitamins in table. 
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Table 2.15 Multivariable adjusted RR1 and 95% CI of intake of B vitamins from 
food sources at baseline and PMS: NHS2 PMS Sub-study, 1991-2001. 
  Q1 Q2 Q3 Q4 Q5 Ptrend
Thiamin (mg/d) 
Median 1.2 1.4 1.5 1.7 1.9 
Case:Control Ratio 203:308 221:356 222:415 192:420 219:469
RR 1.00 0.98 0.83 0.73 0.76 0.02
95% CI   (0.74-1.30) (0.63-1.10) (0.54-0.97) (0.57-1.01)  
Riboflavin (mg/d) 
Median 1.4 1.6 1.9 2.1 2.5 
Case:Control Ratio 201:315 202:370 222:365 212:454 220:464
RR 1.00 0.92 0.99 0.85 0.84 0.28
95% CI   (0.68-1.24) (0.72-1.36) (0.61-1.19) (0.58-1.20)  
Niacin (mg/d) 
Median 17.9 21.2 23.4 25.9 30.4
Case:Control Ratio 199:422 219:429 240:378 196:376 203:363
RR 1.00 1.19 1.35 1.14 1.18 0.39
95% CI   (0.92-1.55) (1.04-1.76) (0.87-1.51) (0.89-1.57)  
Vitamin B6 (mg/d) 
Median 1.6 1.8 2.1 2.3 2.8 
Case:Control Ratio 183:381 238:395 218:428 234:367 184:397
RR 1.00 1.18 1.02 1.28 0.94 0.56
95% CI   (0.89-1.56) (0.76-1.37) (0.94-1.73) (0.68-1.30)  
Folate (µg/d) 
Median 210 261 303 350 438
Case:Control Ratio 207:373 235:404 209:414 209:399 196:378
RR 1.00 0.84 1.12 1.04 0.75 0.16
95% CI   (0.64-1.11) (0.84-1.49) (0.77-1.41) (0.55-1.04)  
Vitamin B12 (µg/d) 
Median 3.5 4.7 5.6 6.8 9.2 
Case:Control Ratio 208:373 235:404 209:414 209:399 196:378
RR 1.00 1.00 0.97 0.99 1.01 0.89
95% CI   (0.76-1.29) (0.73-1.27) (0.74-1.31) (0.76-1.35)   
1Adjusted for age (<30, 30-34, 35-39 or ≥40 years), year of diagnosis (1993, 1994-1995, 1996-1997, 1998-1999 or 2000-2001), 
number of full-term pregnancies (0. 1-2, 3-4 or ≥5 pregnancies lasting at least 6 months), body mass index (<20.0, 20.0-22.4, 22.5-
24.9, 25.0-27.4, 27.5-29.9 or ≥30.0 kg/m2), pack-years of smoking (quintiles), tubal ligation (no vs. yes), duration or oral contraceptive 
use, antidepressant use (never vs. ever), history of childhood trauma score (5, 6-10, 11-15, >=16), intake of alcohol, potassium, 
calcium and vitamin D (quintiles) at baseline (1991) and respective intake from supplemental sources. 
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Table 2.16 Multivariate relative risks (RR)1 of  B vitamin intakes from 
supplemental sources at different times and risk of PMS: NHS2 PMS Sub-study, 
1991-2001. 
Supplement Users 
  Non-Users T1 T2 T3 
RR RR 
(95% CI) 
RR 
(95% CI) 
RR 
(95% CI) Ptrend
1 
Thiamin (mg/d) 
Median3 0 0.85 1.5 5.7 
Case:Control Ratio3 538:1080 163:287 178:328 178:273 
Baseline (1991)  1.00 1.44 
(1.09,1.88) 
1.45 
(1.03,2.04) 
1.50 
(1.10,2.06) 0.68 
Baseline excluding cases with 
symptoms before 19914 1 
1.16 
(0.76,1.77) 
1.00 
(0.58,1.70) 
0.91 
(0.55,1.51) 0.62 
2-4 years before reference 1 1.41 
(1.08,1.85) 
1.54 
(1.11,2.14) 
1.66 
(1.23,2.26) 0.22 
0-2 years before reference 1 1.35 
(1.04,1.75) 
1.44 
(1.05,1.97) 
1.77 
(1.33,2.36) 0.07 
Riboflavin (mg/d) 
Median3 0 0.96 1.7 5.7 
Case:Control Ratio3 540:1081 179:310 158:290 180:287 
Baseline (1991)  1 1.42 
(1.07,1.86) 
1.51 
(1.06,2.14) 
1.43 
(1.03,1.98) 0.98 
Baseline excluding cases with 
symptoms before 19914 1 
1.17 
(0.76,1.80) 
1.14 
(0.65,1.98) 
0.98 
(0.58,1.65) 0.82 
2-4 years before reference 1 1.38 
(1.05,1.81) 
1.42 
(1.00,2.01) 
1.44 
(1.05,1.97) 0.65 
0-2 years before reference 1 1.24 
(0.95,1.62) 
1.39 
(1.01,1.91) 
1.71 
(1.28,2.30) 0.05 
Niacin (mg/d) 
Median3 0 5.7 20 50 
Case:Control Ratio3 535:1077 154:294 220:372 148:225 
Baseline (1991)  1 1.34 
(1.02,1.76) 
1.69 
(1.23,2.33) 
1.77 
(1.26,2.48) 0.22 
Baseline excluding cases with 
symptoms before 19914 1 
1.06 
(0.69,1.62) 
1.14 
(0.69,1.87) 
1.02 
(0.59,1.78) 0.99 
2-4 years before reference 1 1.33 
(1.01,1.74) 
1.81 
(1.32,2.47) 
2.07 
(1.49,2.87) 0.01 
0-2 years before reference 1 1.29 
(1.00,1.67) 
1.44 
(1.05,1.94) 
2.11 
(1.56,2.85) 0.002 
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Table 2.16, continued.      
Vitamin B6 (mg/day) 
Median3 0 0.03 1.15 4.98 
Case:Control Ratio3 288:626 242:460 234:463 293:419 
Baseline (1991)  1 0.93 
(0.74,1.17) 
1.37 
(1.04,1.79) 
1.79 
(1.34,2.41) 0.0004
Baseline excluding cases with 
symptoms before 19914 1 
0.74 
(0.51,1.07) 
1.03 
(0.68,1.55) 
1.12 
(0.70,1.77) 0.35 
2-4 years before reference 1 1.09 
(0.86,1.37) 
1.45 
(1.00,1.92) 
2.08 
(1.56,2.78) <0.0001
0-2 years before reference 1 1.05 
(0.83,1.33) 
1.43 
(1.08,1.90) 
2.10 
(1.58,2.79) <0.0001
Folate (ug/day) 
Median3 0 228 400 800 
Case:Control Ratio3 553:1115 220:359 196:317 88:177 
Baseline (1991)  1 1.53 
(1.19,1.98) 
1.69 
(1.19,2.41) 
1.11 
(0.74,1.66) 0.05 
Baseline excluding cases with 
symptoms before 19914 1 
1.15 
(0.76,1.72) 
1.30 
(0.74,2.26) 
0.92 
(0.51,1.66) 0.68 
2-4 years before reference 1 1.57 
(1.22,2.03) 
2.05 
(1.46,2.87) 
1.43 
(0.96,2.13) 0.25 
0-2 years before reference 1 1.29 
(0.99,1.67) 
1.90 
(1.40,2.58) 
1.61 
(1.15,2.25) 0.15 
Vitamin B12 (ug/day) 
Median3 0 0.3 3.2 6.5 
Case:Control Ratio3 295:647 260:462 258:411 244:448 
Baseline (1991)  1 1.00 
(0.79,1.26) 
1.41 
(1.09,1.83) 
1.59 
(1.13,2.23) 0.02 
Baseline excluding cases with 
symptoms before 19914 1 
1.25 
(0.88,1.78) 
1.17 
(0.77,1.78) 
1.20 
(0.71,2.04) 0.72 
2-4 years before reference 1 1.25 
(1.00,1.58) 
1.65 
(1.25,2.16) 
1.68 
(1.19,2.35) 0.13 
0-2 years before reference 1 1.25 
(0.91,1.71) 
1.75 
(1.20,2.55) 
1.45 
(0.97,2.17) 0.26 
1Adjusted for age (<30, 30-34, 35-39 or ≥40 years), year of diagnosis (1993, 1994-1995, 1996-1997, 1998-1999 or 2000-2001), 
number of full-term pregnancies (0. 1-2, 3-4 or ≥5 pregnancies lasting at least 6 months), body mass index (<20.0, 20.0-22.4, 
22.5-24.9, 25.0-27.4, 27.5-29.9 or ≥30.0 kg/m2), pack-years of smoking (quintiles), tubal ligation (no vs. yes), duration or oral 
contraceptive use (never, 1-23, 24-71, 72-119 or ≥120 months), antidepressant use (never vs. ever), history of childhood trauma 
score (5, 6-10, 11-15, ≥16), intake of alcohol, potassium, calcium and vitamin D (quintiles) at 2 to 4 years before reference time. 
Intake of each vitamin from supplement sources is also adjusted for  intake of that vitamin from food sources. 
2Test for trend among users of supplements only. 
3Medians and case-control ratios from 2-4 years before reference data. 
4Analysis includes 329 cases and 1968 controls. 
/ 
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Table 2.17 Stratified RR1 and 95% CI for total B vitamin intake 2 to 4 years before 
reference year and PMS by age at diagnosis: NHS2 PMS Sub-study, 1991-2001. 
  Q1 Q2 Q3 Q4 Q5 Pvalue2
Thiamin Case:Control 90:112 103:151 85:180 115:182 114:157 0.16
Age < 40 RR 1.00 0.77 0.55 0.89 1.03  
(n=1289) 95% CI  (0.49-1.20) (0.35-0.87) (0.54-1.50) (0.59-1.79)  
Age ≥ 40 Case:Control 96:230 115:244 119:282 111:223 107:203  
(n=1735) RR 1.00 1.00 1.01 1.17 1.40  
  95% CI  (0.69-1.44) (0.70-1.45) (0.74-1.82) (0.88-2.22)  
Riboflavin Case:Control 90:111 96:156 98:170 108:188 115:157 0.29
Age < 40 RR 1.00 0.93 0.77 0.81 1.13  
  95% CI  (0.56-1.54) (0.43-1.37) (0.43-1.54) (0.58-2.21)  
Age ≥ 40 Case:Control 105:245 101:234 128:270 110:236 104:197  
 RR 1.00 1.03 1.12 1.02 1.26  
  95% CI  (0.68-1.53) (0.71-1.77) (0.60-1.75) (0.74-2.14)  
Niacin Case:Control 85:160 121:153 78:143 111:185 112:141 0.32
Age < 40 RR 1.00 1.50 1.03 1.34 1.82  
  95% CI   (1.00-2.26) (0.66-1.60) (0.82-2.19) (1.08-3.07)  
Age ≥ 40 Case:Control 95:255 113:269 116:234 110:211 114:213  
 RR 1.00 0.04 0.13 1.44 1.66  
  95% CI  (0.73-1.49) (0.79-1.63) (0.95-2.19) (1.06-2.59)  
Vitamin B6 Case:Control 91:143 102:168 96:147 97:181 121:143 0.25
Age < 40 RR 1.00 0.90 1.00 1.13 1.65  
  95%CI  (0.59-1.38) (0.63-1.58) (0.68-1.89) (0.99-2.76)  
Age ≥ 40 Case:Control 82:226 125:296 122:255 100:211 119:194  
 RR 1.00 1.09 1.21 0.14 1.89  
  95%CI  (0.75-1.59) (0.81-1.81) (0.87-2.23) (1.19-3.00)  
Folate Case:Control 100:135 85:151 90:138 117:159 115:199 0.08
Age < 40 RR 1.00 0.86 0.87 1.14 0.91  
  95%CI  (0.56-1.33) (0.55-1.37) (0.71-1.85) (0.51-1.60)  
Age ≥ 40 Case:Control 80:247 123:252 123:242 126:221 96:220  
 RR 1.00 1.55 1.54 1.64 1.53  
  95%CI  (1.07-2.25) (1.03-2.30) (1.05-2.57) (0.89-2.61)  
VitaminB12 Case:Control 96:123 114:195 77:142 115:179 105:143 0.13
Age < 40 RR 1.00 0.65 0.61 0.85 0.99  
  95%CI  (0.43-1.00) (0.37-1.00) (0.50-1.43) (0.57-1.72)  
Age ≥ 40 Case:Control 98:235 137:338 95:193 123:232 95:184  
 RR 1.00 0.96 1.18 1.43 1.45  
  95%CI  (0.67-1.36) (0.77-1.80) (0.90-2.27) (0.88-2.39)  
1  Adjusted for age (continuous), year of diagnosis, number of full-term pregnancies, BMI, pack-years of smoking, tubal ligation, 
duration of oral contraceptive use, antidepressant use, history of childhood trauma score, intake of alcohol, potassium, calcium 
and vitamin D at 2 to 4 years before reference year. 
2  P-value for likelihood ratio test of the interaction terms of age (<40 or ≥40 years) by quintiles of each  mineral. 
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Table 2.18 Stratified RR1 and 95% CI for total B vitamin intake 2 to 4 years before 
reference year and PMS by BMI: NHS2 PMS Sub-study, 1991-2001. 
 Q1 Q2 Q3 Q4 Q5 Pvalue2
Thiamin Case:Control 107:209 122:238 114:302 138:283 141:233 0.35
BMI<25 RR 1.00 0.84 0.65 0.94 1.27  
(n=1890) 95% CI  (0.58-1.20) (0.45-0.94) (0.62-1.42) (0.82-1.97)  
BMI≥25 Case:Control 75:117 82:142 81:151 84:115 79:119  
(n=1048) RR 1.00 0.82 0.81 1.18 1.26  
 95% CI  (0.51-1.32) (0.50-1.32) (0.67-2.09) (0.69-2.30)  
Riboflavin Case:Control 111:213 113:255 127:287 128:278 143:232 0.65
BMI<25 RR 1.00 0.80 0.79 0.83 1.23  
  95% CI  (0.54-1.20) (0.50-1.24) (0.50-1.39) (0.74-2.06)  
BMI≥25 Case:Control 77:131 75:121 89:141 85:135 75:116  
 RR 1.00 1.27 1.26 1.04 1.28  
  95% CI  (0.74-2.18) (0.68-2.33) (0.52-2.10) (0.62-2.62)  
Niacin Case:Control 108:283 133:246 112:236 129:280 140:220 0.29
BMI<25 RR 1.00 1.37 1.15 1.25 1.93  
  95% CI  (0.98-1.93) (0.81-1.63) (0.84-1.87) (1.27-2.93)  
BMI≥25 Case:Control 60:115 93:163 75:130 89:108 84:128  
 RR 1.00 1.08 1.05 1.89 1.66  
  95% CI  (0.68-1.73) (0.64-1.72) (1.09-3.27) (0.92-3.01)  
Vitamin B6 Case:Control 104:230 121:284 125:267 116:263 156:221 0.59
BMI<25 RR 1.00 0.89 0.96 1.18 1.75  
  95% CI  (0.62-1.26) (0.66-1.39) (0.77-1.82) (1.16-2.65)  
BMI≥25 Case:Control 64:125 93:165 85:124 76:119 83:111  
 RR 1.00 1.10 1.29 1.20 1.74  
  95% CI  (0.69-1.76) (0.77-2.17) (0.65-2.20) (0.95-3.20)  
Folate Case:Control 99:233 116:241 130:247 142:268 135:276 0.42
BMI<25 RR 1.00 1.37 1.34 1.34 1.53  
 95% CI  (0.95-1.98) (0.92-1.97) (0.88-2.03) (0.94-2.48)  
BMI≥25 Case:Control 75:139 80:148 75:119 96:101 75:137  
RR 1.00 1.00 1.08 1.81 0.96  
 95% CI  (0.63-1.60) (0.65-1.79) (1.04-3.15) (0.48-1.90)  
Vitamin B12 Case:Control 117:227 154:335 98:225 131:285 122:193 0.41
BMI<25 RR 1.00 0.79 0.68 0.82 1.20  
 95% CI  (0.56-1.11) (0.45-1.03) (0.53-1.27) (0.76-1.90)  
BMI≥25 Case:Control 72:114 88:180 65:105 103:115 73:130  
 RR 1.00 0.74 1.09 1.68 1.09  
  95% CI  (0.47-1.18) (0.64-1.87) (0.94-3.01) (0.58-2.05)  
1  Adjusted for age, year of diagnosis, number of full-term pregnancies, BMI (continuous), pack-years of smoking, tubal ligation, 
duration of oral contraceptive use, antidepressant use, history of childhood trauma score, intake of alcohol, potassium, calcium and 
vitamin D at 2 to 4 years before reference year. 
2  P-value for likelihood ratio test of the interaction terms of BMI (<25 or ≥25 years) by quintiles of each  mineral. 
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Table 2.19 Stratified RR1 and 95% CI for total B vitamin intake 2 to 4 years 
before reference year and PMS by smoking: NHS2 PMS Sub-study, 1991-2001. 
  Q1 Q2 Q3 Q4 Q5 Pvalue2
Thiamin Case:Control 75:85 82:107 84:105 85:91 80:103 0.59
Ever smoker RR 1.00 0.68 0.66 0.77 0.85  
(n=897) 95%CI  (0.41-1.12) (0.39-1.12) (0.41-1.44) (0.45-1.62)  
Never smoker Case:Control 111:256 134:287 120:355 141:314 141:255  
(n=2120) RR 1.00 1.03 0.79 1.24 1.63  
 95%CI  (0.73-1.46) (0.55-1.12) (0.83-1.85) (1.06-2.49)  
Riboflavin Case:Control 76:91 77:101 84:107 92:89 77:103 0.76
Ever smoker RR 1.00 0.85 0.60 0.75 0.68  
 95%CI  (0.48-1.49) (0.32-1.15) (0.35-1.60) (0.32-1.44)  
Never smoker Case:Control 119:263 119:289 141:331 126:335 142:249  
RR 1.00 1.01 1.12 1.00 1.67  
 95%CI  (0.69-1.48) (0.73-1.73) (0.62-1.64) (1.01-2.73)  
Niacin Case:Control 59:79 91:107 85:115 83:88 88:102 0.44
Ever smoker RR 1.00 1.18 0.83 1.22 1.30  
  95%CI  (0.71-1.97) (0.49-1.40) (0.65-2.30) (0.68-2.47)  
Never smoker Case:Control 121:335 142:314 108:260 138:308 138:250  
 RR 1.00 1.13 1.09 1.50 2.01  
  95%CI  (0.82-1.55) (0.77-1.52) (1.03-2.18) (1.34-3.00)  
Vitamin B6 Case:Control 67:87 92:105 88:109 79:89 80:101 0.11
Ever smoker RR 1.00 0.94 0.67 0.80 0.89  
  95%CI  (0.57-1.57) (0.39-1.17) (0.42-1.53) (0.47-1.69)  
Never smoker Case:Control 106:282 134:358 129:290 118:303 160:234  
 RR 1.00 0.93 1.24 1.40 2.31  
  95%CI  (0.67-1.31) (0.86-1.78) (0.92-2.13) (1.54-3.47)  
Folate Case:Control 69:99 81:96 88:100 85:92 83:104 0.87
Ever smoker RR 1.00 1.32 1.17 1.07 1.10  
 95%CI  (0.79-2.19) (0.69-1.98) (0.58-1.98) (0.53-2.27)  
Never smoker Case:Control 111:282 127:307 123:278 158:287 128:313  
RR 1.00 1.13 1.18 1.57 1.38  
 95%CI  (0.80-1.59) (0.82-1.71) (1.06-2.32) (0.87-2.20)  
Vitamin B12 Case:Control 70:103 104:126 60:78 101:89 71:95 0.84
Ever smoker RR 1.00 1.10 0.87 1.55 1.10  
 95%CI  (0.67-1.80) (0.48-1.59) (0.83-2.90) (0.56-2.15)  
Never smoker Case:Control 123:253 147:405 111:257 137:322 129:230  
RR 1.00 0.70 0.87 1.00 1.40  
 95%CI  (0.51-0.97) (0.60-1.28) (0.66-1.51) (0.90-2.17)  
1  Adjusted for age, year of diagnosis, number of full-term pregnancies, BMI, tubal ligation, duration of oral contraceptive use, 
antidepressant use, history of childhood trauma score, intake of alcohol, potassium, calcium and vitamin D at 2 to 4 years before 
reference year. 
2  P-value for likelihood ratio test of the interaction terms of smoking (ever vs. never) by quintiles of each  mineral. 
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Table 2.20 Stratified RR1 and 95% CI for total B vitamin intake 2 to 4 years before 
reference year and PMS by alcohol intake: NHS2 PMS Sub-study, 1991-2001. 
 Q1 Q2 Q3 Q4 Q5 Pvalue2
Thiamin Case:Control 117:190 132:240 110:254 143:256 125:197 0.52
Drinker RR 1.00 0.74 0.61 0.83 1.00  
(n=1764) 95% CI  (0.51-1.06) (0.41-0.90) (0.54-1.28) (0.64-1.59)  
Non-drinker Case:Control 69:152 86:155 94:208 83:149 96:163  
(n=1255) RR 1.00 1.24 0.99 1.48 1.79  
95% CI  (0.79-1.95) (0.63-1.55) (0.86-2.54) (1.02-3.15)  
Riboflavin Case:Control 119:210 112:232 141:243 131:254 124:198 0.44
Drinker RR 1.00 0.83 0.90 0.75 0.97  
 95% CI  (0.55-1.25) (0.57-1.42) (0.45-1.26) (0.57-1.65)  
Non-drinker Case:Control 76:146 85:158 85:197 87:170 95:156  
RR 1.00 1.24 1.03 1.24 1.70  
 95% CI  (0.76-2.05) (0.58-1.85) (0.64-2.41) (0.87-3.32)  
Niacin Case:Control 103:213 129:242 121:232 143:245 131:205 0.67
Drinker RR 1.00 1.07 0.98 1.31 1.47  
  95% CI  (0.75-1.52) (0.68-1.41) (0.86-1.98) (0.95-2.29)  
Non-drinker Case:Control 77:202 105:180 73:145 78:151 95:149  
 RR 1.00 1.30 1.06 1.56 2.05  
  95% CI  (0.86-1.95) (0.68-1.66) (0.94-2.58) (1.20-3.50)  
Vitamin B6 Case:Control 109:203 123:265 137:239 119:234 139:196 0.45
Drinker RR 1.00 0.71 0.97 0.97 1.33  
  95%CI  (0.49-1.02) (0.66-1.44) (0.62-1.52) (0.86-2.06)  
Non-drinker Case:Control 64:166 104:199 81:163 78:158 101:141  
 RR 1.00 1.55 1.28 1.80 2.84  
  95%CI  (1.00-2.41) (0.79-2.08) (1.03-3.15) (1.64-4.92)  
Folate Case:Control 100:207 126:235 133:226 151:229 117:240 0.63
Drinker RR 1.00 1.25 1.23 1.37 1.03  
 95%CI  (0.86-1.83) (0.83-1.82) (0.89-2.11) (0.62-1.72)  
Non-drinker Case:Control 80:175 82:168 80:154 92:151 94:179  
RR 1.00 1.22 1.22 1.55 1.77  
 95%CI  (0.79-1.88) (0.76-1.96) (0.93-2.58) (0.96-3.29)  
VitaminB12 Case:Control 112:216 157:309 102:181 143:246 113:185 0.97
Drinker RR 1.00 0.87 0.97 1.09 1.13  
 95%CI  (0.61-1.24) (0.63-1.47) (0.69-1.70) (0.70-1.82)  
Non-drinker Case:Control 82:142 94:224 70:154 95:165 87:142  
RR 1.00 0.74 0.85 1.30 1.51  
95%CI  (0.48-1.14) (0.52-1.40) (0.76-2.24) (0.85-2.68)  
1  Adjusted for age, year of diagnosis, number of full-term pregnancies, BMI, pack-years of smoking, tubal ligation, duration of oral 
contraceptive use, antidepressant use, history of childhood trauma score, intake of potassium, calcium and vitamin D at 2 to 4 
years before reference year. 
2  P-value for likelihood ratio test of the interaction terms of drinking (yes vs. no) by quintiles of each  mineral. 
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CHAPTER 3 
DIETARY INTAKE OF SELECTED MINERALS 
AND PREMENSTRUAL SYDROME 
 
3.1 Background 
 
3.1.1 Introduction 
Premenstrual syndrome (PMS) affects 8 to 15% of women of reproductive age in 
the US (1). Most frequently reported PMS symptoms are irritability, depression, fatigue, 
bloating, breast tenderness and headaches (2). Presence of these symptoms is restricted to 
the luteal phase of the menstrual cycle, and has effects on social life, interpersonal 
relationships and work activities (1). 
Because of the wide variety of symptoms and timing during the menstrual cycle, 
the pathophysiology of PMS likely involves multiple systems affected by hormonal 
variations during the menstrual cycle. The neurotransmitters gamma-amino butyric acid 
(GABA) and serotonin are the most widely studied (3, 4). However, other 
neurotransmitters like melatonin (5) and systems like the renin-angiotensin-aldosterone 
system(6, 7) may be involved.  Moreover, potential cyclic variations in serum mineral 
levels may reflect an interaction between ovarian hormones and mineral metabolism that 
contributes to symptom occurrence and severity. 
Although overt micronutrient deficiencies are not common in the US, it has been 
suggested that women with affective disorders have low levels of magnesium (8), zinc 
(9), and iron (10, 11). Increased intake of minerals and vitamins has been recommended 
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for prevention and treatment of affective disorders such as PMS (1, 12). The 
identification of a modifiable risk factor, such as dietary mineral intake, could contribute 
to the prevention of PMS.  
To date, only supplemental magnesium, manganese and potassium have been 
studied in relation to PMS. Zinc has been studied as a potential treatment for depression 
and as an adjunct treatment in cases of treatment resistant depression (13). No previous 
studies have evaluated the effect of dietary intake of these minerals on the development 
of PMS. Therefore, we propose to study the effects of magnesium, zinc, copper, 
manganese, potassium, sodium, and iron in the development of incident PMS among a 
sub-group of women participating in the Nurses’ Health Study II.   
3.1.2 Physiologic Mechanisms 
 
a) Magnesium 
Magnesium (chemical symbol: Mg) is the fourth most abundant cation in the 
body, and it acts as a cofactor for enzymatic reactions involved in muscle contraction, 
neurotransmitter release and regulation of ion channels (14). The recommended dietary 
allowance (RDA) is 320 mg/day for adult women (15). However, deficiency is relatively 
common. Although there are many food sources of magnesium, according to the 1999-
2000 U.S. National Health and Nutrition Examination Survey (NHANES) the median 
magnesium dietary intake in Caucasian women was 237 mg/day (16), which was 
substantially lower than the RDA. In addition, many other dietary factors interfere with 
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Mg absorption and elimination, such as coffee, ethanol, phosphoric acid, and selenium 
(17). 
Magnesium may be associated with PMS through its association with melatonin 
deficiency, which may contribute to PMS. Additionally, magnesium is an antagonist to 
glutamate, which has been associated with depression, and like serotonin and GABA, 
may also be associated with PMS.  
• Magnesium and melatonin 
Melatonin is synthesized in the pineal gland from serotonin (18). Magnesium is a 
cofactor for N-acetyl-transferase, the enzyme responsible for the conversion of serotonin 
into melatonin(18). Premenstrual syndrome, as well as other affective disorders, might be 
associated with abnormal melatonin secretion. In 1990, Parry et al.(19) conducted a study 
among 8 women with a diagnosis of PMS and 8 women without PMS, matched 
according to cycle phase. Participants provided plasma samples every 30 minutes from 6 
pm to 9 am during the early follicular (day 8 ± 2), late follicular (day 12 ± 2), mid-luteal 
(day 7 ± 2 after luteinizing hormone (LH) surge) and late-luteal phases (day 12 ± 2 after 
LH surge) of the menstrual cycle. Throughout the menstrual cycle, women with PMS had 
an overall lower secretion of melatonin, with a lower area under the curve (Mean area 
under the curve, 10,000 nmol/L melatonin among PMS cases, compared to 22,000 
nmol/L melatonin among controls, during the late luteal phase, p< 0.001), lower 
melatonin half life (1 hour average in PMS cases vs. 8 hours average in controls, during 
late luteal phase, p = 0.03) and an earlier cessation of melatonin secretion (5 am among 
PMS cases vs. 7 am among controls, during late luteal phase; p = 0.03) as compared to 
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controls. Although the sample size for this study is small, it suggests that women with 
PMS have an abnormal melatonin secretion compared to women without PMS (19).   
Magnesium may play a role in the abnormal secretion of melatonin. In 2006, 
Billyard et al. (20) conducted studied young male rats to evaluate the effects of a Mg-
deficient (150 ppm, n=20) or a Mg-adequate (1000 ppm, n=19) diet on plasma melatonin 
levels. After four weeks, the authors found that mean plasma melatonin levels decreased 
significantly among animals with the Mg deficient diet (mean=50 pg/mL) as compared to 
those with the Mg-adequate diet (mean=75 pg/mL, p=0.01).  Although this was a pilot 
study, the results show that magnesium can negatively influence plasma melatonin levels 
in rats. If this is the case in humans, magnesium could be associated to PMS through its 
interaction with melatonin (20). 
• Magnesium and glutamate receptor NMDA 
Glutamate is an excitatory neurotransmitter inhibited by GABA and also 
associated with fast pain conduction. The glutamate receptor N-methyl-d-aspartate 
(NMDA) binds to membrane sodium–calcium channels, leading to an influx of 
extracellular calcium after activation by glutamate. The actions of the NMDA receptor 
are associated with learning, memory and depression (21, 22). Magnesium is a natural 
antagonist of the NMDA receptor and blocks the entrance of glutamate to the post-
synaptic cells (22).  
Several lines of evidence support a relationship between glutamate and PMS, in 
which magnesium may play a role. Batra et al.(23) used proton magnetic resonance 
spectroscopy to evaluate glutamate levels in the prefrontal cortex during the follicular and 
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luteal phases of 12 women with a diagnosis of PMDD and 13 women without PMD, and  
found that glutamate levels were lower during the luteal phase as compared to the 
follicular phase in both cases and controls (Mean (±SD) glutamate/creatinine  levels 
during follicular phase were 5.86 (2.3) in controls and 6.14 (1.5) in cases, compared to 
levels during luteal phase of  4.85 (1.3) and 4.51 (1.2),  respectively, p=0.014).  Even 
though the differences in glutamate levels were the same in cases vs. controls, this study 
suggests that there is an association of glutamate levels with hormonal fluctuations of the 
menstrual cycle. Other studies (24, 25) have suggested that glutamate levels in the brain 
are associated with major depression, a disorder that could have a similar underlying 
mechanisms to PMS. Finally, PMS has been successfully treated with selective serotonin 
reuptake inhibitors (1, 26, 27)  which, in addition to inhibiting serotonin reuptake, may 
act as antagonists of the glutamate NMDA receptor (28). Other NMDA antagonists such 
as ketamine may have antidepressant effects (29). Magnesium may play a role in PMS by 
blocking the NMDA receptor and thereby acting as an antidepressant. 
 
b) Zinc 
Zinc (chemical symbol: Zn) is highly concentrated in the brain, particularly in the 
hippocampus and the amygdala, and it is believed to be involved in neuronal growth and 
function (14). The RDA for zinc in adult women is 8mg/day, and best food sources of 
zinc are red meats, liver and shellfish (14, 15).  Because zinc transport between the 
plasma and the brain is strictly regulated by the blood-brain barrier, brain zinc 
homeostasis is not easily disrupted by dietary zinc deficiency. However, chronic zinc 
deficiency may reduce zinc concentrations in the hippocampus, induce abnormal 
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glucocorticoid secretion, and elicit neuropsychological symptoms such as isolation and 
depression. Zinc deficiency can also aggravate glutamate excitotoxicity in the presence of 
neurological diseases (30). 
In presynaptic neurons in the brain, free zinc is translocated to glutamate vesicles, 
and co-released with glutamate after depolarization of the membrane. Free zinc and 
glutamate bind to allosteric sites on the subunits of the NMDA receptor.  Zinc binding to 
the NMDA receptor inhibits its activity (31, 32). Like magnesium, zinc may have an 
antidepressant effect by blocking the NMDA receptor. Certain subtypes of NMDA 
receptors (NR1/NR2A) have a higher affinity for zinc than others (NR1/NR2B) which 
suggests that the role of zinc is specific to some neurons (33). 
 
c) Manganese 
Manganese (chemical symbol: Mn) is an essential trace element required for 
many enzymatic and redox reactions. It is involved in a variety of cellular functions 
including brain energy metabolism, cartilage formation and reproduction.  Food sources 
include unrefined cereals, nuts, tea and leafy vegetables (14). After ingestion, dietary 
manganese is transported to the liver, and then crosses the blood-cerebrospinal fluid 
barrier bound with transferrin. Brain permeability to manganese is higher than to iron and 
zinc (30). Though uncommon in humans, manganese deficiency in animals is associated 
with poor growth, impaired glucose tolerance, reduced reproduction and malformation of 
offspring.(34) Low levels of manganese in humans may be associated with epilepsy.(35) 
There is no recommended dietary intake (RDA) for manganese but the adequate intake 
(AI) is 2.3 mg/day for adult women. The upper tolerable level (UL) for manganese is 11 
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mg/day.(15) This level may be reached by individuals consuming western vegetarian 
diets.(34)  High manganese exposure through parenteral nutrition and toxic pollutants is 
associated with neurotoxicity (36). Manganese toxicity is called manganism, and 
symptoms include fatigue, headaches, sleep disturbances, reduced coordination, 
hallucinations and mental irritability (36). 
Manganese is present in the substantia nigra and striatum in the brain, where most 
GABAergic neurons are also present. The vast majority of brain manganese is present in 
astrocytes associated to glutamine synthetase. This enzyme catalyzes the conversion of 
glutamate into glutamine, thereby removing the excitatory neurotransmitter from the 
extracellular space. In addition, manganese is present in presynaptic cells inside the 
glutamate vesicules. Manganese possibly activates the voltage dependent calcium 
channels, leading to release of glutamate and GABA from the presynaptic cells (30). As 
mentioned before, the GABA system may be associated with PMS, as neurosteroids 
generated by the corpus luteum interact with GABA receptors and women with PMS may 
have a lower sensibility to them (37).  
 
 
d) Potassium and sodium 
Potassium (chemical symbol: K) is a mineral widely distributed in fruits and 
vegetables. It is a mainly intracellular cation, and it is required for many cellular 
functions, such as protein synthesis and the control of intracellular fluid volume (14). The 
adequate intake (AI) is 4700 mg/day for adults (15). To date, there is no evidence that 
high levels of potassium from foods have adverse effects. 
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Sodium (chemical symbol: Na) is mainly consumed as sodium chloride (table 
salt). Sodium is the main determinant of extracellular fluid volume (14). The AI for adult 
women is 1.5 g/day (65 mmol/day), equivalent to 3.8 g of table salt per day (15). 
Potassium and sodium may play a role in PMS symptoms like swelling and 
bloating though their interaction with aldosterone, a mineralocorticoid shown to fluctuate 
across the menstrual cycle (6, 38, 39). A potassium channel called TREK-1 has been 
identified as a potential target for antidepressant drugs (40), which are recommended for 
PMS treatment. To date, the effects of dietary intake of potassium and sodium on PMS 
are still unclear.   
 
• Potassium and TREK-1 in depression 
TREK-1 is a potassium two-pore channel that acts as an outward rectifier of the 
membrane potential contributing to repolarization of the cell by moving potassium 
cations from the intracellular space to the extracellular space (41). TREK-1 is abundant in 
GABA neurons in the caudate nucleus and putamen and in serotoneric neurons of the 
dorsal raphe nuclei.(41, 42) TREK-1 regulation is still under study but it may be blocked 
after phosphorilation by protein kinase A (PKA). In the raphe nuclei cells, activation of 
the serotonin receptor 5-HTA1 leads to decreased activity of PKA and increased activity 
of TREK-1. In consequence, there is hyperpolarization of the cell and decreased 
serotonin release. SSRIs may inhibit TREK-1, and therefore not only reduce serotonin 
reuptake but also increase serotonin release (41). In 2006, Hearteaux (42) conducted a 
study in TREK-1 -/- knockout mice and normal mice (wild type). Using the forced swim 
test to measure depression, the authors found that the TREK-1 -/- mice demonstrated less 
138 
 
depressive behavior than the wild type mice. The authors concluded that deletion of the 
TREK-1 gene led to increased efficiency of serotonin transmission and resistance to 
depression (42). 
Serotonin levels may be lower during the luteal phase of women with PMS (43), and 
SSRIs have shown to be efficient in reducing PMS symptoms (1, 26, 27). Although the 
potassium channel TREK-1 in the brain may play a role in the metabolism of serotonin 
and in the pharmacologic mechanisms of SSRIs, the effects of dietary potassium on this 
receptor have not been studied to date.  
 
• Potassium, sodium and aldosterone 
Potassium and sodium balance is regulated by the renin-angiotensin-aldosterone 
system (RAAS).  Renin is secreted and released by the kidneys in response to low arterial 
pressure. In the liver, renin stimulates the conversion of angiotensinogen into angiotensin 
I and angiotensin II. Release of these hormones leads to vasoconstriction and increased 
blood pressure. In the adrenal glands, angiotensin II stimulates the secretion of 
aldosterone, a mineralocorticoid that increases sodium and water reabsorption and 
stimulates potassium secretion in the kidneys.  Excess potassium intake leads to higher 
levels of aldosterone and therefore to a higher urinary potassium excretion (14, 18). 
Some studies have found that aldosterone levels are higher during the luteal than 
during the follicular phases of normal premenopausal women.(6, 38, 39) For example, in 
a study by Fommei et al.(2009) (39), 26 women aged 21 to 55 years with mild 
hypertension and low renin levels provided plasma samples on the 7th, 14th, 21st, and 28th 
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day of their cycles. The authors found that aldosterone levels increased from 11.2 ng/100 
ml at day 7 (follicular phase) to 17.8 ng/100 ml at day 21 (luteal phase, p=0.004). 
Because aldosterone is associated with water and sodium retention, high secretion of 
aldosterone during the luteal phase has been postulated as a contributor for symptoms of 
PMS such as swelling of extremities and abdominal bloating (3). 
High dietary intake of potassium, and to a lesser extent sodium, increases the 
levels of aldosterone secretion (18) but the effect of these minerals may vary by 
menstrual cycle phase. For example, Szmuilowicz et al.(6) conducted a randomized 
clinical trial among 60 women aged 25 to 41 years receiving either a high sodium (200 
mEq) or a low sodium diet (10 mEq) for 7 days. The authors found that among women 
with the high sodium diet, urinary and serum aldosterone were significantly greater 
among those who were in the luteal than to those who were in the follicular phases (Mean 
urinary aldosterone, 16.5 µg/24 hr during the luteal phase and 8.5 µg/24 hr during the 
follicular phase, p<0.05), and that progesterone levels were positively correlated with 
aldosterone levels (r=0.65, p <0.001). No differences were shown among those with a 
low sodium diet (Mean urinary aldosterone, 78 µg/24 hr during the luteal phase and 76 
µg/24 hr during the follicular phase, p<0.05).  
Spironolactone, an aldosterone agonist, has been shown to reduce PMS symptoms 
in some studies(44, 45), but not in all (46). In 1995, Wang et al.(44) conducted a cross-
sectional study among 35 women aged 25 to 45 years with a diagnosis of “late luteal 
phase dysphoric disorder” .(47) Participants received 100 mg spironolactone (n=17) or 
placebo (n-16) from day 14 of the cycle for 3 cycles, and then crossed over to the other 
group for another 3 cycles.  At the end of the first 3 cycles, women randomized with 
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spironolactone had a significant decrease in all premenstrual symptoms as compared to 
women assigned to placebo (Mean (SE) negative affective and somatic symptom scores 
were 11.1 (0.3) and 4.7 (0.2) for spironolactone group, while mean (SE) respective scores 
were 12.1 (0.4) and 6.2 (0.2) for the placebo group, p<0.001), and their symptoms did not 
worsen after changing to placebo. Women who crossed over from placebo to 
spironolactone reported a significant decrease in negative mood and somatic symptoms 
(F (5, 1526) = 7.12  and F (5,1514) = 4.97, for summarized negative and somatic 
symptom scores, p < 0.001) after three months.  
In conclusion, potassium and sodium may play a role on PMS through their 
interactions with the TREK-1 receptor and the RAAS system. The potassium TREK-1 
channel has been associated with depression, and TREK-1 agonists have been used as 
antidepressants but the effects of dietary potassium on this receptor are unknown.  
Aldosterone may be increased during the luteal phase, which leads to water and sodium 
retention and potassium secretion. Aldosterone antagonists, such as spironolactone, may 
reduce PMS symptoms. Potassium and sodium from the diet may act as aldosterone 
agonists, but their particular role in PMS remains unknown. 
 
 
e) Copper 
Copper (chemical symbol: Cu) is a transition metal that is a cofactor in a variety 
of reactions. It is the third most abundant metal in the body after iron and zinc. Copper is 
required for immune cell differentiation, iron metabolism, collagen formation, and the 
synthesis of dopamine and melanin.(11)  The RDA for copper is 0.9 mg/day for adult 
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women, and the UL is 10 mg/day.(12)  Food sources of copper include shellfish, nuts, 
legumes and the bran portions of grains. Copper interacts with the absorption of iron and 
manganese.(11) 
Patients with Wilson’s disease, a genetic disorder where copper is accumulated in 
the liver, cornea and brain, have symptoms of depression, anxiety and personality 
changes, which suggest a disruption of the serotonergic system.  In a study by Jones et 
al.(2007),(48) rat pheochromocytoma cells (PC12) were used as model neuronal cells to 
evaluate  the interactions between copper and serotonin in vitro.  The authors found that 
copper addition caused a 32% reduction in the survival of serotonin-cultured 
undifferentiated cells, possibly due to oxidation of serotonin molecules. In differentiated 
cells, there was no reduction in the survival of cells by the interaction of copper with 
serotonin. 
 
f) Iron 
Iron (chemical symbol: Fe) is required for oxygen transport and metabolism, and 
is a cofactor for the enzyme tryptophan hydroxylase, required in the synthesis of 
serotonin from tryptophan.(49) Many areas in the brain are rich in iron, but particularly in 
the cells that receive input from the GABA system, suggesting a functional association 
(50). Rodents fed with iron deficient diets have shown altered GABA metabolism (51, 
52). Nevertheless, the role of iron deficiency in serotonin and GABA metabolism in 
humans is still under study (49). 
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In 2008, Anderson et al.(52) evaluated the effects of dietary iron (Fe) and 
manganese (Mn) on the GABA system. Fourty-one male rats were treated with one of 
four diets: 1) Iron deficient diet ( 6 mg Fe/kg), 2) Iron adequate diet (35 mg Fe/kg), 3) 
Iron deficient diet + manganese (1g Mn/l of drinking water), and 4) Iron adequate diet + 
manganese. The authors found that animals in the ‘iron deficient diet + manganese diet’ 
exhibited increased concentrations of extracellular GABA and a decrease in GABA-B 
receptor expression as compared to those on the other diets. This study shows that there is 
an interaction between manganese intake, iron and the neurotransmitter GABA, which 
has been previously associated with the pathophysiology of PMS.  
Iron deficiency is the most common single-nutrient deficiencies, and as many as 
50% of women of reproductive age in the entire world may suffer from it (50). The RDA 
for iron among women aged 18 to 50 years is 18 mg/day, but the median intake of 
women of reproductive age in the U.S from 1999 to 2000 was 11.6 mg/day (53). 
Symptoms of iron deficiency include impaired physical work performance, depressed 
immune function and cognitive impairment (49, 54). 
 
g) Summary 
Because PMS is characterized by a variety of symptoms, many systems may be 
involved in its pathophysiology.  Magnesium, zinc, copper, manganese, iron and 
potassium are important cofactors in many reactions associated to neurotransmitter 
metabolism involved in PMS pathophysiology such as GABA, melatonin and serotonin. 
Additionally magnesium and zinc interact with the glutamate receptor NMDA, associated 
with depression. Potassium and sodium are involved in the regulation of extracellular and 
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intracellular fluid balance and may therefore be associated with symptoms related to 
water retention. Nevertheless, the pathophysiology of PMS is still under study, and the 
role of these minerals on PMS development is unclear.  
 
3.1.3 Epidemiologic Research  
To date, only magnesium(55-59), manganese (60), and potassium(61)  have been 
studied as potential treatments for PMS. Zinc has been studied in relation to depression 
and affective symptoms (9, 13, 32, 62). Copper and iron have been studied in relation to 
post-partum depression (PPD) (11, 63), which is characterized by the presence of 
depression symptoms such as sleep disturbances, lack of appetite, lack of energy, 
depressed mood, during most of the day every days for two weeks or more beginning 
within 4 weeks of delivery (64). The underlying causes of PPD are under study, but onset 
is likely triggered by the rapid decline in reproductive hormones levels after delivery 
(65). As premenstrual syndrome is also associated to changes in reproductive hormones, 
these two disorders may share the same underlying risk factors. Moreover, some studies 
(66) have found that premenstrual dysphoric disorder is a risk factor for PPD . 
a) Magnesium 
To date, there are no prospective studies on the effects of magnesium on 
prevention of incident PMS. One cross-sectional study (8) but not another one (56) found 
that magnesium levels are lower in women with PMS compared to those without PMS.  
Other clinical trials have evaluated the effects of magnesium supplementation on PMS 
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symptoms, with beneficial (55, 59) or null results (56, 58), though one study found that 
placebo is better than magnesium in relieving PMS symptoms (57). 
The most recent clinical trial of magnesium supplementation in PMS was 
conducted by Quaranta et al.(55) among 40 Italian women aged 18 to 45 years. All 
participants had PMS, defined by a score higher or equal to 25 on the Moos’ Modified 
Menstrual Distress Questionnaire (MMDQ).  After 3 months of observation, participants 
were instructed to take 250 mg of magnesium beginning 20 days after the start of the last 
menstruation and continuing until the start of the next menstrual period for the next 3 
months. During the observation and treatment periods participants completed a daily 
symptom diary, and at the end of each treatment period, participants compared their 
symptoms to the MMDQ rating scale (self-assessed MMDQ). Participants also completed 
interviewer-administered MMDQ questionnaires at screening visits before and after the 
treatment period. At the end of the treatment period, there was a 35% reduction in the 
mean total interviewer-assessed MMDQ score (mean ± standard deviation (SD) = 19.7 ± 
7.6) compared to baseline (mean ± SD = 30.5 ±4.5, p<0.0001).  In addition, there was a 
43.5% decrease in mean total self-assessed MMDQ score (mean ± SD = 17.9 ± 7.3) 
compared to baseline (mean ± SD= 31.8 ± 6.4 respectively, p <0.0001). Side effects were 
low, though one patient reported vertigo as a side effect for treatment.  Although the 
authors found that magnesium decreased the number and severity of PMS symptoms, this 
study has several limitations. The study had no control group, as all women received 
magnesium. Neither participants nor interviewers were blinded to treatment status.  
In 2005, Khine et al.(56) studied the relationship of magnesium and PMS in three 
ways. First, the authors conducted a cross-sectional study of magnesium levels in serum, 
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red blood cells (RBC) and mononuclear cells (MBC) of women with and without PMDD. 
Participants were 17 women aged 27 to 43 years prospectively diagnosed with 
premenstrual dysphoric disorder (PMDD) and 14 women aged 20 to 37 years without 
PMDD.  PMDD was assessed with a completion of a daily visual analogue symptom 
rating scale for at least 3 months before entering the study and DSM-IV diagnostic 
criteria. Women met criteria for PMDD if they reported an increase of more than 30% in 
mean negative mood symptoms in the week before menses compared to the week 
following cessation of menses during at least 2 menstrual cycles. The authors measured 
serum, RBC and MBC magnesium content at baseline. Both cases and controls had 
normal serum total magnesium levels (0.79 mmol/L among cases, 0.75 mmol/L among 
controls) and there was no statistically significant difference between serum, RBC or 
MBC total magnesium levels between both groups.  
The authors then conducted a magnesium loading test to further assess 
magnesium status.  After the 3 months of the screening period, women of both groups 
received magnesium sulfate at a dose of 0.1mmol/kg body infused over 4 hours in 5% 
dextrose during the luteal phase of the menstrual cycle. Participants collected 24hour 
urine samples before and after each infusion for measurements of total Mg, calcium and 
creatinine. Deficiency was assessed by calculating how much of the administered Mg 
load was retained, based on the criteria that people in Mg balance should excrete 100% of 
the Mg load. Mg deficiency was defined as the retention of more than 30% of the Mg 
load.  After the Mg infusion, the authors found no statistically significant difference in % 
urinary Mg retention between cases (mean± SD =31.5± 25) and controls (mean± SD  
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=27.5± 19).  These results did not provide evidence of Mg deficiency among PMDD 
cases compared to controls (56).  
Finally, the authors conducted a cross-over study to assess changes in mood and 
behavioral ratings among a sub-group of 10 women with PMDD after magnesium 
infusion. Participants were randomized to receive a 4-hour infusion of magnesium sulfate 
(dose of 0.1 mmol/kg body in 5% dextrose) or placebo (5% dextrose) during the 8 to 12 
days following LH surge and crossed over the other treatment (placebo or magnesium) 
for the next cycle. Before and immediately following each infusion, as well as the 
morning after, participants completed a variety of mood and behavior questionnaires 
including a Premenstrual Tension Scale-Self Rated (PMTS-S) and Premenstrual Tension 
Scale-Objective Rated. There was no statistically significant effect of magnesium 
treatment on any of the mood symptom measures compared to placebo. For example, for 
the PMTS-S questionnaire, participants reported a mean (SD) score of 21.6 (5.4) before 
treatment and 13.5 (7.6) after treatment vs. 21.0 (5.5) before placebo and 15.3 (7.5) after 
placebo. Overall, in this study the authors found no evidence of magnesium deficiency in 
women with PMDD compared to controls, and no beneficial effect of magnesium 
infusion on premenstrual symptoms compared to placebo. However, this study has 
several limitations. Power in this study was limited for finding differences between 
placebo and magnesium infusions given the small sample size. Additionally, magnesium 
and placebo supplementation was provided without a washout period in between. The 
effects of magnesium acutely infused may be different to long term oral magnesium 
intake (56). 
147 
 
In contrast to these studies,  Walker et al. (57) conducted a crossover trial to 
evaluate the effect of different doses of daily Mg supplementation on premenstrual 
symptoms and had unexpected results. Participants were 85 women with a mean age of 
35 years who reported premenstrual symptoms.  After one month of observation, 
participants were randomized into four groups:  three treatment groups receiving different 
doses of magnesium (200, 350 or 500 mg of Mg per day, containing 1050, 830 and 717 
mg of sorbitol as excipients respectively) and a placebo group (sorbitol  1305 mg).  
Participants received one of four potential treatments for two cycles, followed by a 
washout period of one cycle without treatment. Then, participants were randomized again 
into one of the other treatment or placebo groups for another 2 months. Throughout the 
study period, women completed a daily 20-item menstrual diary where they scored daily 
symptoms on a 5-point scale (0=none to 4=very severe).  Symptoms were classified into 
four categories: anxiety, craving, depression and hydration. For each category, symptom 
scores during the luteal phase (7 days before menstruation) were compared to scores 
during the postmenstrual phase (days 8-14 of the cycle). The authors found that after two 
months of supplementation, participants who took placebo had a significant reduction in 
anxiety-related and total symptoms as compared to women taking any dose of 
magnesium after adjustment for baseline scores. Total scores after the second month were 
6.9 for placebo and 10.8, 9.8 and 10.8 for those receiving magnesium a different doses 
(p=0.0006). Anxiety scores were 1.7 for placebo and 3.6, 2.8 and 3.2 for magnesium 
treatment (p=0.006).  The authors suggest that this counterintuitive result may be related 
to an influence of sorbitol on magnesium homeostasis in women suffering from 
premenstrual symptoms.  
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Overall, these three studies reported different effects of magnesium on PMS. 
Although Quaranta et al. observed a beneficial effect of magnesium on PMS symptoms, 
there was no placebo group and participants were thus unblinded. As suggested by the 
results observed by Walker et al., the placebo effect can be substantial. In the crossover 
study by Khine et al. magnesium infusion was no better than placebo in ameliorating 
mood and behavioral symptoms in women with PMDD. However, this study had a very 
small sample size (10 women). Therefore, the effects of magnesium supplementation on 
premenstrual symptoms remain unclear. 
  
b) Manganese 
To date, only one study has evaluated the effects of manganese on PMS. In this 
study conducted by Penland et al. in 1992.(60) ten women who reported the presence of 
premenstrual and menstrual symptoms were randomly assigned to one of four diets: 1) 
587 mg of calcium and 1.0 mg of manganese/day, 2) 587 mg of calcium and 5.6 mg of 
manganese/day, 3) 1336 mg of calcium and 1.0 mg of manganese/day, and 4) 1336 mg of 
calcium and 5.6 mg of manganese/day. The duration of the intervention was 39 days. 
After the menstrual phase of each cycle, participants completed a ‘Menstrual Distress 
Questionnaire’ (MDQ) assessing the presence of 47 symptoms during the premenstrual (7 
days before menses), inter-menstrual, and menstrual phases of the most recent cycle.  
Symptoms were grouped into eight categories: autonomic reactions, behavior change, 
concentration, negative affect, pain, water retention, arousal, and a control group of 
symptoms not associated with PMS but found in perimenopausal women.  During the 
premenstrual phase, women assigned to the low calcium diets reported significant 
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worsening of behavior, concentration, negative affect, and water retention symptom 
scores, as compared to when they were treated with high calcium diets.  There was no 
significant difference based on manganese intake, but women consuming the high 
calcium low manganese diets had worsening in negative affect scores during the 
premenstrual phase (mean MDQ score = 17.6, standard error (SE) = 1.9) compared to 
when they consumed the high calcium-high manganese diet (mean MDQ score = 11.5, 
SE = 1.8, p < 0.05). There was significant interaction of calcium and manganese for 
negative affect symptoms (p = 0.04).  Although the authors observed a role of calcium 
and manganese on premenstrual affective symptoms, they did not find a beneficial effect 
of manganese alone. However, as the authors report, absorption of manganese may have 
been blunted due to high iron intakes of the diets (32 mg iron/day) and poor solubility of 
the form of manganese selected for the study.  Moreover, the intervention periods were of 
longer duration than menstrual cycles, with no supplementation-free diet period in 
between, which could have led to a carry-over effect from one diet to the others.  
Although it is possible that manganese plays a role in PMS, potentially due to its 
interaction with other micronutrients, its effects on PMS development remain unstudied.  
 
c) Potassium and sodium 
The only study of potassium supplementation and premenstrual symptoms dates 
from 1971. In this cross-over study conducted by Reeves et al.(61), 10 women with a 
diagnosis of premenstrual tension and 10 women with only mild menstrual ‘complaints’ 
or no symptoms received 1 mg of potassium chloride or placebo (glucose) for 2 
consecutive cycles, and then crossed over to the other treatment. Each day throughout the 
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study period, participants recorded their weight and symptoms common in PMS such as 
swollen ankles, breast tenderness, bloating, headache, and irritability. Overall, study 
participants had an average weight gain of 0.22 lb (standard error (SE) = 0.06) during the 
last 5 days of the cycle (p < 0.001). Treatment with potassium produced no substantial 
difference in weight gain (mean = 0.21, SE = 0.09) as compared to placebo (mean = 0.19, 
SE = 0.09) although no statistical test was conducted to evaluate the differences between 
these groups.  Furthermore, potassium treatment was not associated with fewer symptoms 
after treatment (mean number of symptoms = 12.6) vs. before treatment (mean = 12.3). 
Participants receiving placebo reported fewer symptoms (mean = 9.5), but no statistical 
test was conducted to evaluate the differences between these groups.  The results of this 
study are unclear because of the lack of appropriate statistical testing. Therefore, it is 
necessary to further evaluate the role of potassium in premenstrual symptoms. 
One additional study has tested the effects of potassium along with sodium and 
calcium in overall mood.  Torres et al.(67) conducted a crossover study among 38 women 
and 56 men with average age 56.3 years. The authors tested the effects of four diets: 1) a 
high-potassium, high-calcium, moderate-sodium diet based on the Dietary Approaches to 
Stop Hypertension diet (OD);  2) a high-potassium diet with lower sodium and potassium 
than the OD diet (LNAHK); and 3) a high calcium diet (HC). At baseline all participants 
received a control diet (CD) low in potassium, magnesium and calcium for 2 weeks. 
Then, participants were randomized to one of the three diets for four weeks, followed by 
a washout period of 2 weeks with the CD diet. After this period, participants were 
randomized again into one of the remaining test diets. Mood was assessed weekly using 
the ‘Profile of Mood States’ (POMS) questionnaire, which rated 37 items on a 5 point 
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scale (0 = not at all, 4 = extremely). Every two weeks, 24-hr urinary samples were 
collected to assess diet compliance and electrolyte balance. Compared to the control diet, 
there was a significant reduction of POMS global scores for the LNAHK diet (POMS 
score difference = -3.9, p = 0.02) and for the HC diet (POMS score difference = -2.5, p = 
0.04), but no significant difference with the OD diet. Compared to the OD diet, there was 
a significant reduction of the POMS global score for participants taking the LNAHK diet 
(POMS score difference = -5.4 p < 0.05), but no significant differences with the HC diet.  
Additionally, the authors found that urinary sodium excretion was positively associated 
with anger and vigor symptoms (r = 0.13 and 0.16 respectively, p < 0.01). Higher urinary 
potassium excretion was associated with lower fatigue symptoms (r = -0.17, p < 0.0001).  
Overall, the results suggest that a diet high in potassium (LNAHK) improves mood 
symptoms as compared to a diet low in potassium (CD), and high potassium intake 
reflected in high urinary potassium excretion may lead to lower fatigue. With regard to 
sodium, a diet low in sodium (LNAHK) improves mood symptoms as compared to diets 
with moderate sodium (OC and CD), and high sodium intake, reflected in high sodium 
urinary excretion, is positively correlated with anger and vigor. Overall this study 
supports the hypothesis of a beneficial role of potassium and an adverse effect of sodium 
on symptoms associated to PMS such as depression, vigor and fatigue.  
 
d) Zinc 
Few studies have suggested that women with PMS may have lower levels of zinc 
(68) and that zinc serum levels fluctuate during the menstrual cycle (69). However, 
several studies have found that people with major depression have lower zinc levels as 
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compared to people without depression (9, 70). The effects of zinc supplementation on 
mood have been studied recently (62). In addition, zinc has also been considered for 
treatment augmentation in treatment resistant depression (13).  
One of the most complete studies of zinc status and PMS throughout the 
menstrual cycle was conducted by Chuong et al.(68). Cases were 10 women diagnosed 
with PMS using prospective charting of presence and severity of 18 symptoms. Controls 
were 10 women as controls who reported absence of significant symptoms. Participants 
were required to not consume vitamin, mineral or herbal supplements two months before 
the study period. Since the day 1 of the cycle, and every 2 to 3 days, blood samples were 
collected from all participants for 3 menstrual cycles. Luteinizing hormone (LH) was 
measured to estimate timing of the luteal and follicular phases. Samples from 14 to 3 
days before the surge of LH were considered as follicular phase samples, and their 
average values for the 3 cycles were calculated for each woman.  Luteal phase values 
were an average between days 3 to 14 after the LH surge. In cases, serum zinc levels 
during the luteal phase were significantly lower than during the follicular phase (mean ± 
SE = 90.3 ± 4.1 µg/dL vs. 100.2 ± 3.6 µg/dL, p < 0.05), and significantly lower than 
serum zinc luteal phase levels in controls (mean ± SE = 107.8 ± 7.8 µg/dL, p < 0.05). 
Follicular zinc levels in controls were not significantly different from the luteal phase 
levels (mean ± SE = 102.6 ± 7.1 µg/dL). Additionally during the luteal phase, copper 
levels were significantly higher in cases compared to controls (mean ± SE = 106.3 ± 3.3 
µg/dL vs. 96.2 ± 2.1 µg/dL, p < 0.05), but there was no significant difference with the 
respective follicular phases.  Although this study had a very small sample size, it suggests 
that zinc levels are lower in women with PMS during the luteal phase. Moreover, serum 
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copper levels are elevated during the luteal phase (68) and may have affected zinc status, 
as copper is known to interfere with zinc absorption.(14) Nevertheless, it is possible that 
during the luteal phase women with PMS may have different dietary intakes of certain 
foods because of their symptoms, which include cravings.  
A most recent cross-sectional study was conducted by Amani et al. (2009)(9) 
among Iranian female university students aged 20 to 25 years to the correlation of serum 
zinc concentrations and dietary zinc intake with depression scores. First, 308 students 
were screened for major depressive disorder (MDD) using Beck’s Depression Inventory 
(BDI).  From this group, 23 students were identified as having moderate to severe 
depression (BDI score > 19) and were selected as cases. Controls were 23 students 
matched by age, who reported no history of depressed mood.  All participants completed 
a 12-item FFQ and a 24 hr diet recall to assess daily and weekly consumption of zinc 
from food sources. Additionally, participants provided blood samples for measurement of 
serum zinc concentrations.  The authors found that women with MDD had significantly 
lower serum zinc concentrations (mean ± SD = 79.6 ± 30.7 µg/dL) as compared to 
controls (mean ± SD = 111.6 ± 21.9 µg/dL, p < 0.001). There was a statistically 
significant inverse linear correlation between BDI scores and zinc serum levels among all 
participants (r = -0.65, p < 0.001), which was stronger among cases (r = -0.71, p < 0.001). 
Moreover, 23% of cases but no controls had serum zinc concentrations < 70 µg/dL and 
were classified as having zinc deficiency.  Dietary zinc intake was also substantially 
lower among cases (mean ± SD=1.97 ±0.5 mg/day) as compared to controls (mean ± SD 
= 2.93 ± 0.9 mg/day, p < 0.001). Specific zinc-rich foods that were less commonly 
consumed by cases as compared to controls were red meat and chicken (p < 0.0001). 
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However, because of the cross-sectional nature of this study, it is not possible to 
determine whether zinc deficiency contributed to the development of depression, or 
whether it was a consequence of decreased appetite, a common symptom of depression.  
Recently, Sawada et al. (2010) (62) conducted a small clinical trial of Zn 
supplementation among healthy Japanese women aged 18-21 years old. Participants were 
randomized to receive multivitamin capsules alone (n=16) or multivitamins and 7 mg of 
zinc (n=15) for 10 weeks.  The multivitamins contained vitamins A, D, B6, B12, thiamin, 
riboflavin, niacin and folic acid in concentrations that were 50% of the Japanese 
recommended dietary allowance.  Psychological tests included the Japanese versions of 
the Cornell Medical Index (CMI) and the Profile of Moods State (POMS).  After the 
intervention, serum Zn levels were significantly increased among those who received 
zinc and multivitamins (0.92 µg/ml compared to 0.84 µg/ml at baseline, p = 0.01), 
whereas those who received only multivitamins did not change their serum zinc levels 
significantly. Among women who received zinc and multivitamins, the CMI assessment 
suggested an improvement of somatic symptoms (19.1 post-intervention compared to 
25.5 at baseline, p = 0.07), but no improvement of psychological symptoms.  Using the 
POMS assessment, there was a significant improvement of depression-dejection 
symptoms (15.1 post-intervention compared to 19.6 at baseline, p < 0.01) and an 
improvement of anger-hostility symptoms (8.4 post-intervention compared to 11.7 at 
baseline, p = 0.01) but no improvement of vigor, fatigue, confusion, and tension-anxiety 
symptoms.  Using Mann-Whitney tests to compare changes from baseline among both 
groups, the authors found no statistically significant difference between scores in both 
groups. To our knowledge, this is the first study to evaluate the effects of zinc 
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supplementation on mood of healthy premenopausal women.  Although the authors did 
not report a statistically significant improvement of mood symptoms as compared to 
placebo, they found a significant effect of zinc supplementation on somatic, depression 
and anger symptoms as compared to baseline (62). The use of multivitamins containing 
vitamin B6, folate and vitamin B12 as a placebo could explain the lack of statistically 
significant differences between both groups.   
Siwek et al.(13) conducted a randomized clinical trial among 60 men and women 
aged 18 to 55 years diagnosed as having unipolar major depression according to the 
DSM-IV criteria.   Participants were randomized to receive either placebo (n = 30) or 
supplements with 25 mg of Zinc (n = 30) daily for 12 weeks.  During the study period, 
both groups were treated with 100-200 mg of imipramine, a tricyclic antidepressant.  
Depression status was evaluated before  treatment and at weeks 2, 6 and 12 of treatment 
using the ‘Hamilton Depression Rating Scale’ (HDRS), Beck Depression Inventory 
(BDI), Clinical Global Impression (CGI) and Montogomery-Asberg Depression Rating 
Scale (MADRS).  Based on reaction to prior depression treatments, participants in both 
groups were sub-classified as ‘treatment resistant’ and ‘non-resistant’. The authors found 
that treatment with imipramine and zinc resulted in improvements HDRS, BDI, CGI and 
MADRS scores as compared to imipramine and placebo. All groups had a significant 
improvement in scores by week 2. Treatment-resistant patients who received imipramine 
and zinc (n = 12) had lower depression scores (mean BDI for weeks 2, 6 and 12 were 25, 
17 and 10)  than those who received imipramine and placebo (n = 10, mean BDI scores 
were 31, 30 and 18, for respective weeks, p < 0.05 at any given point). Furthermore, 
treatment-resistant patients receiving imipramine and zinc had scores similar to those 
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who were not treatment resistant.  Among non treatment-resistant patients, there were no 
significant differences in any scores between zinc- or placebo- supplemented therapy.  
Overall, this study suggests that zinc supplementation in addition to imipramine improves 
depression symptoms among treatment-resistant patients.  
These studies show that there is a potential role of zinc in mood and affective 
symptoms, though the effects of zinc supplementation in PMS remains unknown.   
 
e) Copper 
Copper levels may be higher in women with PMS as detailed previously in the 
study by Chuong et al. (68). Copper levels have also been studied in women with 
PPD,(54) which likely has a similar pathophysiology to PMS, as both disorders are 
related to changes in reproductive hormone levels (65, 66).  
 In 2007, Crayton et al. (63) conducted a cross-sectional study among patients of 
the Pfeiffer Treatment Center. Cases were 226 women diagnosed with depression. Of this 
group, 78 had history of PPD and 148 had no history of PPD. Controls were 28 women 
without history of psychiatric problems who were participating in a wellness program at 
the clinic. Blood samples were collected from all study participants to assess copper and 
zinc levels.  The authors found that women with a prior history of PPD had higher serum 
copper levels (mean = 131 µg/dL) than non depressed women (mean = 106 µg/dL, p < 
0.001) and higher levels than depressed women without history of PPD (mean = 111 
µg/dL, p < 0.001). There was no significant difference between zinc levels in any group.  
A particular limitation of this study is that women participating in this study may have 
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had PPD months or years prior to the collection of blood samples.  The time range 
between PPD and sample collection was not taken into account for the analyses. Because 
samples were collected after PPD diagnosis, copper elevation could be a result of 
treatment instead of cause of disease. Another limitation is that free copper measured in 
this group may not reflect copper status (71). 
Although copper levels have a potential correlation with PMS and PPD, the role 
of copper in PMS development remains unknown.  
 
f) Iron 
To date, there are no studies of dietary iron intake and PMS. In a study by 
Shamberger et al.(1996) (10) among 46 women with PMS diagnosis and 50 women 
without PMS as controls, iron levels in hair were significantly lower in PMS patients than 
in controls (mean ± SD = 5.5 ± 3.8 ppm among cases and 8.4 ± 5.7 ppm among controls, 
p-value < 0.03), but no statistically significant differences were observed in red blood cell 
levels (mean ± SD = 692 ± 134 ppm among cases and 696 ± 107 ppm among controls). 
However, this was a cross-sectional study and iron measurements in hair are not as 
representative of iron levels in the body as ferritin. 
Some studies have evaluated the association between ferritin levels and post-
partum depression (11, 72). In a recent study conducted by Alcabar et al. (11) in Spain, 
729 women were followed from childbirth for two years. Several iron status markers 
were measured 40 hours after delivery, and participants replied to depressive 
questionnaires 48 hours, 8 weeks and 32 weeks after delivery. From this sample, 9% of 
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women developed PPD during the 32 week postpartum period, and had lower serum 
ferritin concentrations (mean (SD) = 15.4 (12.7) µg/L)  compared to the rest of the 
participants (mean (SD) = 21.6 (13.5) µg/L, p=0.002) . This study shows that iron 
deficiency may play a role in depressive disorders associated with hormonal changes. 
Nevertheless, the role of iron in PMS remains unstudied. 
 
g) Summary 
To date, the effects of dietary intake of manganese, magnesium, potassium, 
sodium, zinc and copper on incident PMS are unknown.  Magnesium is the mineral most 
studied with regards of PMS. Although it has been suggested that magnesium levels are 
lower in women with PMS, a magnesium load test found no differences in magnesium 
levels between women with PMDD and women without PMDD (56). Several randomized 
clinical trials (55-59) have evaluated magnesium as a treatment for symptoms with mixed 
results. One study evaluated the effects of manganese and calcium supplementation on 
PMS symptoms, and although it did not find significant improvement of symptoms with 
manganese, it found a significant interaction between manganese and calcium (60). A 
study evaluating the effects of potassium on PMS symptoms and weight gain did not 
observe a significant benefit (61).  A study of dietary intakes of different combination of 
electrolyte levels found that diets high in potassium and low in sodium resulted in 
improved depression symptoms, less fatigue and higher vigor compared to diets low in 
potassium and moderate in sodium  (67). Women with PMS may have higher copper and 
lower zinc serum levels during the luteal phase as compared to women without PMS 
(68). One study found that copper levels were elevated in women with PPD, and in 
159 
 
consequence may be associated as well with PMS symptoms (63). The roles of these 
minerals in incident PMS remain to be studied.  
 
3.1.4 Summary 
Although PMS affects a substantial number of women of reproductive age, there 
is no clear understanding of its pathophysiology and effective treatments are still under 
study. Current recommended pharmaceutical treatments are associated with substantial 
side effects, and certain micronutrient supplements have been studied as alternative 
treatments. Moreover, because mineral deficiency has been associated with PMS, 
minerals from dietary and supplementary sources could prevent PMS in some women.  
Magnesium and zinc are antagonists of the NMDA receptor of glutamate. 
Glutamate is an excitatory amino acid, but its receptor activity has been associated with 
depression (33). Magnesium and zinc may have the same mechanism of action as many 
antidepressants, through inhibition of the NMDA (31, 73). Additionally, magnesium is 
required for the formation of melatonin from serotonin. Women with PMS may have 
altered melatonin metabolism leading to an earlier ‘phase’ secretion and overall lower 
serotonin levels (19).  Manganese and iron deficiency has been associated with lower 
GABA levels and decreased expression of the GABA-B receptor (52).  Copper has been 
associated with serotonin oxidation (48). 
Potassium and sodium are associated with PMS through their interaction with the 
renin-angiotensin-aldosterone system. Women with PMS may have higher levels of 
aldosterone during the luteal phase than women without PMS (6). High potassium intakes 
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from diet are controlled by increased aldosterone levels, which lead to increased sodium 
reabsorption and potassium secretion in urine.  Sodium reabsorption leads to extracellular 
water retention, and is associated with edema and bloating, which are common PMS 
symptoms (18). Additionally, the action of potassium channels influences serotoninergic 
function, but the role of dietary potassium on these is unknown (42). 
To date, there are no prospective studies of the effects of these minerals in the 
development of PMS. Some studies(8, 56, 68, 69) have found that magnesium, zinc, and 
copper blood levels vary throughout the menstrual cycle in women with PMS. 
Magnesium supplements have been studied as potential treatments, with mixed results 
(55-57, 59). Manganese has shown no direct effect on PMS but potentially an interaction 
with calcium to reduce symptoms (60). Only one study evaluated the effects of potassium 
chloride in PMS, with no significant difference in PMS symptoms compared to placebo 
(61). Copper and iron have been studied in post-partum depression (PPD), a disorder also 
associated with increased sensitivity to gonadal hormones changes, suggesting an 
association with copper levels(63) and an inverse association with ferritin levels (11). In 
normal women, zinc supplements did not show improvement of mood compared to 
multivitamins only. However, zinc supplementation has shown beneficial effects in 
patients with treatment resistant-depression when given in conjunction with imipramine, 
a tricyclic antidepressant (13). 
Overall, the role of minerals in PMS is still unknown but because of all the 
potential role of  magnesium, zinc, copper, manganese, potassium, sodium, and iron in 
PMS, it is important to evaluate whether intake of these minerals affect PMS 
development in the following years.  
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3.1.5 Specific Aims and Hypotheses 
Specific Aim: 
To examine the relationship between magnesium, zinc, copper, manganese, potassium, 
sodium, and iron intake and the development of premenstrual syndrome among a subset 
of women participating in the Nurses’ Health Study II. 
 
Secondary Aims: 
1) To evaluate the effects of magnesium, zinc, copper, manganese, potassium, 
sodium and iron intake from food sources 2 to 4 years before reference time on 
the development of PMS. 
2) To evaluate the effects of magnesium, zinc, copper, manganese, potassium, 
sodium and iron intake from supplement sources 2 to 4 years before reference 
time on the development of PMS. 
3) To evaluate effect modification of the association between these minerals and 
PMS by age, body mass index (BMI), alcohol and smoking.  
 
 
Hypotheses: 
There is an inverse relationship between dietary intake of magnesium, manganese, 
potassium and zinc and the risk of developing premenstrual syndrome. High intakes of 
sodium and copper are associated with increased risk of developing premenstrual 
syndrome. 
162 
 
Age, BMI, alcohol and smoking status do not modify the relationship between 
magnesium, manganese, potassium and zinc and the risk of developing premenstrual 
syndrome. 
 
3.2 Methods 
 
3.2.1 Study Design and Population 
The Nurses’ Health Study II (NHS II) is a prospective cohort of 116,678 female 
US registered nurses, who replied to a mailed questionnaire in 1989 when they were 25 to 
42 years old. Information regarding various lifestyle factors and medical conditions has 
been collected by mailed questionnaire every 2 years.  The response rate for each 
questionnaire cycle has been ≥89%. 
The establishment of the NHS II PMS Sub-study has been described in detail in 
chapter 2. From among all NHS II participants who had not reported a diagnosis of PMS 
in 1989 or 1991, 3,430 women reported a new clinician-made diagnosis of PMS on an 
NHSII questionnaire between 1993 and 2001. The diagnosis year was assigned as the 
‘reference year’ and it was used to determine eligibility for the study, as well as to assess 
menstrual symptom experience and diet. The authors then identified 2,570 women who 
did not report a diagnosis of PMS at any time between 1989 and 2001 to serve as 
potential controls. For these women, a randomly chosen year between 1993 and 2001 was 
assigned as their reference year.   
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To prevent the inclusion of women with menstrual symptoms attributed to causes 
other than PMS, women with a diagnosis of cancer, endometriosis, usual irregular 
menstrual cycles or infertility before their reference year were excluded from the initial 
selection of participants. Women who had a hysterectomy or who had reported 
menopause were excluded to ensure participation of only premenopausal women.  
Because the study was designed to focus on dietary factors and PMS, participants who 
did not complete the food frequency questionnaires (FFQs) in 1991 and 1995 or who 
reported an implausible total calorie intake (<500 and ≥ 3500 cal/day on their FFQ) were 
also excluded from the study.  
 
3.2.2 Exposure Assessment 
To evaluate individual intake of selected nutrients, NHS2 participants completed 
a semi quantitative food frequency questionnaire (FFQ) in 1991, 1995 and 1999.  
The FFQs included 133 items, with a standard portion size for each, which aimed 
to reflect natural portion sizes whenever possible (e.g. a slice of bread, an egg, a fruit).  
Participants were asked how often they consume the specific food item, on average, with 
9 response options: ">6  per day", "4 to 6 per day", "2 to 3 per day", "1 per day", "5 to 6 
per week", "2 to 4 per week", "1 per week", "1 to 3 per month" and "never or less than 
once per month". 
Additionally, the FFQ included questions about types of fat used, brand and type 
of cold cereal consumed, and supplements used. For supplement use, participants were 
asked to report whether they currently took multivitamins, how many they took per week 
164 
 
(<2, 3-5, 6-9, ≥10 tablets) and the specific brand used.  Additional questions on regular 
use of supplements or multivitamins (yes/no) were also included.  Specific use of 
magnesium and potassium supplements was measured on all questionnaires.  A question 
about zinc use and dosage (<25, 25–74, 75-100, ≥101 mg/day) was included on the 
questionnaires of 1991, 1995 and 1999. Iron use and dosage was included on 
questionnaires in 1991 (<51, 51–200, 201-400, ≥401 mg/day) and in 1995 (<41, 41–80, 
81–150, ≥151 mg/day). 
The total intake of each mineral was calculated multiplying the relative frequency 
of consumption of each food item (converted to number of servings per day) by the 
nutrient content of the specified portion size, according to the United States Department 
of Agriculture database and manufacturers sources as needed. Finally, adjustment for 
total calorie intake was performed using the residual method (74).  
 
Validity and Reproducibility of Exposure Assessment: 
The validity and reproducibility of the FFQ designed by Willett et al. has been 
widely studied before (75, 76).  In 1992, Rimm et al.(75) conducted a validation study of 
this FFQ among 127 men, members of the Health Professionals Follow-up study cohort. 
Participants completed two FFQS between 1996 and 1988, separated by one year. Two 
one-week diet records were collected between those years, separated by 6 to 7 months to 
capture seasonal variability. Participants were given a dietetic scale and trained by a 
dietitian for weighing and recording all foods consumed during 7 days.  Diet records 
were used as a "gold" standard because they are minimally dependent on memory and 
allow direct measurement of food quantities.  Nutrient scores were calculated for each 
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questionnaire and for the diet records and were adjusted for total calorie intake based on 
the residual method.  
Reproducibility was measured by comparing nutrient scores from both 
questionnaires. Intraclass correlation coefficients were 0.72 for magnesium, 0.53 for 
sodium, 0.60 for potassium, and 0.64 for zinc. Validity was measured by comparing 
nutrient intake assessed by the FFQ to the nutrient intake assessed by the average nutrient 
score of the one-week diet records.  Correlation coefficients for the second FFQ corrected 
for within-person variability assessed by the diet records were 0.71 for magnesium, 0.60 
for sodium, 0.73 for potassium and 0.71 for zinc.  
Participants’ nutrient scores from the questionnaire and the mean of the two one-
week diet records were categorized into quintiles to evaluate the degree of 
misclassification. Among participants classified in the lowest quintile of magnesium 
according diet records, 48% of them were also in the lowest quintile according to the 
questionnaire, and 72% were in the two lowest quintiles. Among the participants 
classified in the highest quintile of magnesium intake according to diet records, 44% 
were in the highest quintile and 68% in the two highest quintiles according to the 
questionnaire.  Results were similar for sodium, potassium and magnesium.  
In conclusion, the reproducibility and validity of nutrient scores for 
micronutrients calculated from the food frequency questionnaire were found to be 
acceptable (75). The validity and reproducibility of this questionnaire is likely to be 
similar in our population of U.S. female nurses. 
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3.2.3 Outcome Assessment 
Case and control status was ascertained in 2002 using information from a 
supplementary menstrual symptom questionnaire based on the Calendar of Premenstrual 
Experiences designed by Mortola et al.(77) as detailed in the previous chapter. Briefly, 
sub-study participants (i.e., 3430 women who reported a diagnosis of PMS made by a 
clinician between 1993 and 2001 and 2570 women who did not report a diagnosis of 
PMS) reported the presence of any of 26 specific symptoms for at least several days each 
month, most months of the year in the specific 2 years before their individual reference 
year. The questionnaire included questions about the age at which symptoms started, 
timing of symptom onset and cessation during an average menstrual cycle, as well as the 
severity of the symptoms and their interference on personal relationships, social 
functioning and work-related activities. This questionnaire was completed by 86.5% of 
the potential cases (n=2966) and 97.4% of the potential controls (n=2504). 
Validated PMS cases were self-reported cases who met the following criteria 
based on those proposed by Mortola in 1990 (77).  
1) Occurrence of at least 1 physical and 1 affective menstrual symptom; 
2) Overall symptom severity moderate or severe, or the effect of symptoms of life 
and social relationships classified as moderate or severe;  
3) Symptoms beginning within 14 days of the onset of menstruation;  
4) Symptoms ending within 4 days of the onset of menstruation; and  
5) Symptoms absent in the week after end of menses.  
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From the 2966 potential cases who replied to the questionnaire, 1057 women (35.6%) 
met these criteria. 
 
Validated controls were women not reporting PMS during the follow-up who met the 
following criteria: 
1) Complete absence of symptoms or only mild symptoms 
2) Mild overall symptom severity 
3) No substantial effect on life activities and interpersonal relationships  
4) Confirmed no diagnosis of PMS. 
From the 2540 potential controls who replied to the questionnaire, 1968 women (78.6%) 
met these criteria. 
 
Validity of outcome assessment 
The validity of this approach for assessing PMS symptoms was evaluated 
previously by Bertone-Johnson et al.(78) and detailed in the previous chapter. Briefly, the 
validation study included only those participants from the PMS Sub-study who reported a 
diagnosis of PMS for the first time in 2001 (n=138) and controls whose reference year 
was 2001 (n=377). They concluded that women who did not report prospective symptom 
charting as part of their diagnosis but who met the Mortola criteria for PMS (77) were 
essentially identical to those who both reported prospective charting and who met the 
Mortola criteria (78).  
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3.2.4 Covariate assessment 
We collected information on several factors potentially associated with PMS and 
mineral intake, such as age, smoking status, body weight, pregnancy history, tubal 
ligation, oral contraceptive use, and other micronutrient intakes on biennial 
questionnaires throughout the study period.   
Age may be inversely associated with PMS prevalence (79). For this study, age 
was calculated using information on date of birth collected at the baseline questionnaire. 
High BMI has been associated with PMS (79, 80). BMI for all participants will be 
calculated as the weight reported in the reference year questionnaire in kilograms divided 
by the square of the height in meters reported in the baseline questionnaire (1989).  
Some reproductive factors may be potential confounders of the association 
between minerals and PMS. For instance, tubal ligation has been associated with 
premenstrual syndrome (3, 81). Oral contraceptives  (OCs) are recommended as 
treatment for PMS (82), but also may be associated to symptoms such as depression and 
anxiety (83). Oral contraceptive use has been associated with lower levels of zinc (84), 
potassium (85), magnesium (86), and higher levels of sodium (85). Parity is directly 
related to PMS via progesterone sensitization, and will be assessed as the number of 
pregnancies that lasted more than 6 months. These variables have been assessed on the 
main NHS II questionnaires. 
Cigarette smoking and alcohol use may be associated with PMS through an 
association with levels of sex steroids (87, 88) and neurotransmitters (89, 90). In this 
population, Bertone-Johnson et al.(91) found that there was a dose-response relationship 
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for pack-years of smoking and PMS (p trend = 0.03). Current smokers had relative risk of 
2.10 (95% CI = 1.56 - 2.83) of developing PMS over the next 2 to 4 years as compared to 
never smokers. There was no overall association between alcohol intake and PMS in this 
population (92), but among leaner women (BMI <25 kg/m2), those in the highest quintile 
of drinking-years of alcohol had a RR of 1.74 (95% CI = 1.11 - 2.72) compared to never 
drinkers. Additionally, smoking and alcohol are related with mineral intake. Smokers 
may have less healthful diets than non smokers (93). Alcohol interferes with zinc and 
magnesium absorption (94). Smoking information was collected in the biannual NHS2 
questionnaires and alcohol information was collected in the FFQs of 1991, 1995 and 
1999.  
Other micronutrients such as calcium, vitamin D, and iron are known to interact 
with magnesium and zinc absorption, and excretion. Intakes of calcium and vitamin D 
have been associated with incidence of PMS in this population (95) and thus will be 
evaluated as confounders.  
 
 
3.2.5 Data Analysis  
Univariate Analysis: 
The number and percentages of women who fulfilled the validation criteria and 
who were validated as cases and controls was already presented in chapter 2 (Table 2.1). 
For magnesium, zinc, copper, manganese, and iron, we presented the recommended 
dietary allowance (RDA) for women aged 20 to 40 years. Because there is no RDA 
information available on potassium and sodium intakes, the adequate intake (AI) was 
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presented instead (15).  Using the Statistical Analysis System (SAS Institute, Cary, NC) 
for Unix, version 9.1, we calculated means, standard deviations (SD), medians and 
interquartile ranges (IQR) of total intakes (Table 3.1), intakes from food sources only 
(Table 3.2) and intakes from supplement sources only (Table 3.3).   
Bivariate Analysis: 
We examined the relationship between mineral intake and potential confounders 
by cross-tabulation of age-standardized covariates at baseline by quintiles of mineral 
intake (Tables 3.4a to 3.4g). We used t-tests to compare the distribution of continuous 
covariates: age, BMI at baseline and at age 18, age at menarche, physical activity, and 
age at first birth and number of full term pregnancies among parous women. For 
dichotomous covariates, which included history of tubal ligation, use of oral 
contraceptives, smoking, use of antidepressants and history of severe childhood trauma, 
we used chi-square tests. Covariates were cross-tabulated with PMS in chapter 2 (Table 
2.5). 
To examine the interrelationships among minerals, we calculated Spearman 
correlation coefficients for mineral total intake (Table 3.5), for food sources (Table 3.6) 
and for supplement sources (Table 3.7). 
For each selected mineral, we used logistic regression to calculate age-adjusted 
relative risks (RR) and 95% confidence intervals (CIs) for women in the highest quintiles 
of total and foods only intakes using the lowest quintile as the reference. For 
supplemental intakes, supplement-users were categorized in tertiles and we selected non-
users of supplements as the reference group. To assess dose-response relationships, we 
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calculated p-values for trend by including the median of mineral intakes in each category 
as a continuous variable in the regression model. For supplemental intakes we calculated 
the p for trend among supplement users only. Medians, case to control ratios, age-
adjusted RRs, 95% CIs and p for trends were reported in tables 3.8, 3.9 and 3.10 for total, 
food and supplement intakes respectively. 
Multivariable Analysis: 
Using logistic regression, we calculated multivariable-adjusted RRs by including 
covariates whose addition to the model changed the relative risks by more than 10%, as 
well as those covariates identified as important predictors of PMS risk.  The final models 
were adjusted for age (<30, 30-34, 35-39 or ≥ 40 years), year of diagnosis (1993, 1994-
1995, 1996-1997, 1998-1999 or 2000-2001), BMI (<20.0, 20.0-22.4, 22.5-24.9, 25.0-
27.4, 27.5-29.9 or ≥ 30.0 kg/m2),  number of full term pregnancies (pregnancies that 
lasted more than 6 months), tubal ligation (no vs. yes), duration of oral contraceptive use 
(never, 1-23, 24-71, 72-119, or ≥ 120 months), antidepressant use (never vs. ever), pack-
years of smoking (quintiles), history of severe childhood trauma score (5, 6-10, 11-15, or 
≥ 16), and intake of alcohol, vitamin D, calcium and vitamin B6 in quintiles. 
Additionally, for each mineral from food sources, we adjusted relative risks for the same 
specific mineral intake from supplements and vice versa.  For food mineral intake, we 
estimated a second model that included additional adjustment of each mineral for the 
effects of the others. P for trends for all models were calculated using the medians of 
each category as a continuous variable. Relative risks, 95% CIs and p-values are reported 
in tables 3.11, 3.12 and 3.13 for total, food, and supplemental intake respectively. 
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Post-hoc Analysis: 
After our initial analyses, we decided to evaluate the effects of potassium in 
symptoms of PMS. We used logistic regression to calculate relative risks and 95% CIs of 
physical and emotional symptoms, presented in tables 3.14a and 3.14b. 
Additionally, we evaluated the effects of zinc to copper and calcium to 
magnesium ratios in PMS. First, we divided total and food intakes of zinc, copper, 
calcium and magnesium by their molecular weight (65.41, 63.55, 40.10, and 24.31 
respectively). Then we divided the results of zinc by copper and calcium by magnesium 
intake. After categorization by quintiles, we used logistic regression to calculate relative 
risks and 95% CIs using the lowest category as the reference. P for trends were calculated 
in the same manner as detailed above. We summarized the results in table 3.15.  
Effect Modification: 
We stratified mineral intakes from food sources into two categories of age ( < 40 
years, n= 1289; and ≥ 40 years, n = 1735), two categories of BMI ( < 25 kg/m2, n = 1890; 
and  ≥ 25 kg/m2, n = 1048), ever smokers (n = 897) vs. never smokers (n = 2120), and 
alcohol intake (drinker, n = 1764; vs. non-drinkers, n = 1255). Using logistic regression, 
we calculated stratified RRs and  95% CIs for each mineral. We created interaction terms 
by multiplying mineral intakes in quintiles by the potential effect modifiers, and used 
likelihood ratio tests to test multiplicative interaction. Results for the potential effect 
modifiers: age, BMI, smoking and alcohol are reported in tables 3.16, 3.17, 3.18, and 
3.19. 
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3.3 Results 
The NHS2 PMS Sub-study had a total of 3025 participants. The distribution of 
their total intakes of minerals, as well as intakes from food and supplement sources 
separately are summarized in tables 2.1, 2.2 and 2.3. Mean total dietary intake of 
minerals was in general higher than the recommended dietary intakes (RDA, Table 3.1). 
For example,  the mean (SD) dietary intake of zinc was 16.2 (0.8) mg/day, twice the 
RDA for women aged 20 to 40 years (RDA=8 mg/day), and the mean intake of 
magnesium was 320 (72) mg/day, slightly higher than the RDA of 310 mg/day. Mean 
dietary intakes of zinc and magnesium from food sources were 11.9 (3.2) and 305 (59) 
mg/day respectively (Table 3.2). For iron, the mean (mean=14.4 mg/day, SD=5.4 
mg/day) and median (median=13.4 mg/day) intakes from food sources were not as high 
as the RDA (RDA=18 mg/d, Table 2.2). Among multivitamin and individual supplement 
users, intakes of zinc and magnesium from supplemental sources were 16.1 (14.3) and 70 
(52) mg/day (Table 3.3).  
We evaluated the characteristics of the population by quintiles of mineral intake  
(Tables 3.4a to 3.4g). Overall, women with higher mineral intakes were older, except for 
women with high iron and zinc intakes who were younger (p<0.0001 for all). Women 
with high intakes of zinc and sodium had higher BMI at baseline and at age 18 
(p<0.0001) than those with low intakes. Among parous women, those with higher intakes 
of zinc, magnesium, copper, manganese and iron had a higher age at first birth and lower 
number of pregnancies (p=0.04 to <0.0001). The opposite was observed for women with 
high sodium intakes (p=0.01). With the exception of zinc and sodium, women with high 
intakes of minerals had higher physical activity (p=0.04 to <0.0001). Women with high 
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intakes of zinc, magnesium, manganese, and iron were less likely to report tubal ligation 
(p=0.05 to 0.002). Overall, dietary intakes of minerals were not associated with ever use 
of oral contraceptives (OCs), but women in the highest quintiles of zinc, copper, 
potassium and iron were more likely to be current users of OCs (p=0.05 to 0.01). High 
zinc, manganese and iron intakes were inversely associated with current smoking (p = 
0.0003, 0.01 and p <0.0001 respectively). On the other hand, high potassium intake was 
positively associated with current smoking (p= 0.01). Except for zinc, women with high 
mineral intakes were more likely to be past smokers (p=0.03 to <0.0001). There was no 
association between use of antidepressants and mineral intakes.  
We evaluated the correlations between total mineral intake (Table 3.5), mineral 
intakes from food sources only (Table 3.6), and mineral intakes from supplement sources 
only (Table 3.7). Magnesium and potassium had the highest correlation for total and 
foods only intakes  (Spearman correlation coefficient, r=0.72 and 0.80, respectively, 
p<0.0001 for both,). There were high correlations between intakes of magnesium and 
copper, magnesium and manganese, and manganese and copper (range of Spearman 
coefficients: 0.62 to 0.65 for total intakes, and 0.61 to 0.56 for foods only intakes). 
Sodium had the lowest correlation coefficients with other minerals. Among intakes from 
supplements, the highest correlation was observed between manganese and potassium 
(r=0.86) but overall correlation coefficients were high and significant for all minerals 
(range: 0.86 to 0.49) except for calcium, which had the lowest correlation coefficients.  
In age-adjusted analysis, we observed no significant association between total 
intakes of zinc, magnesium, and iron and PMS (Table 3.8). Women in the highest 
quintiles of copper, potassium and manganese intakes had higher significant risks of PMS 
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(RR=1.43, 1.37, and 1.32 respectively), with a significant linear trend across quintiles (p 
trend=0.004, 0.009, and 0,03 respectively).  Women with high sodium intake had a 
significant trend of increased risk (p=0.04), but the relative risks for the highest quintiles 
were not significant (RR for the highest quintile=1.18, 95% CI=0.93-1.49).  
When we studied the association between mineral intakes only from food sources 
and PMS, adjusting only for age, we found no significant associations between potassium 
and manganese and PMS (Table 3.9). Copper was associated with increased risk of PMS; 
women in the highest quintiles of copper intake from foods only had 47% higher risk of 
developing PMS as compared to women in the lowest quintile (95%CI=1.51-1.87, p 
trend=0.002).  Food intakes from other minerals were not associated with PMS.  
When we evaluated mineral intake from supplements and PMS, adjusting only for 
age, we observed a significant inverse trend between supplemental intake of zinc and 
PMS (p trend=0.03, Table 3.10). There was no significant association between intakes of 
magnesium, zinc, copper, potassium, manganese, and iron, and PMS.  
In the multivariable analysis of total intakes of minerals, we adjusted relative risks 
for age, year of diagnosis, number of full-term pregnancies, body mass index, smoking, 
tubal ligation, duration of oral contraceptive use, antidepressant use, childhood trauma 
score, antidepressant use and intakes of alcohol, vitamin B6, calcium and vitamin D 
(Table 3.11). After adjustment, we no longer observed an increased risk of PMS among 
women with high intakes of copper, manganese, and sodium. However, women in the 
highest quintile of potassium intake had a higher risk of developing PMS as compared to 
women in the lowest quintile (RR = 1.53, 95% CI = 1.14 - 2.04, p trend = 0.004). In 
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contrast, we observed an inverse association with iron intake; women in the highest 
quintile of total iron intake had a 31% lower risk of developing PMS as compared to 
women in the lowest quintile (95% CI=0.50-0.95, p trend=0.03).  There was no 
association between total intakes of zinc, and magnesium and PMS.  
In table 3.12, we presented the results for the multivariable analysis of mineral 
intakes from foods and PMS. After adjustment for the selected covariates, including 
respective supplement use (model 1) as well as further adjustment for the effect of the 
other minerals (model 2), there was no association between zinc, magnesium, copper, 
manganese and iron intakes from food sources and PMS. We observed that women in the 
highest quintile of potassium intake from food sources had a higher risk of PMS as 
compared to women with the lowest intake (RR=1.42, 95%CI=1.05-1.92). After further 
adjustment of each mineral for the effect of the others, the association between potassium 
and PMS was no longer significant. In the multivariable analysis of mineral intakes from 
supplement sources only, we found no association between any of the selected minerals 
and PMS (Table 3.13). 
To further investigate the observed positive association of PMS risk with 
potassium, we evaluated potassium intake from foods and risk of specific physical (Table 
3.14a) and emotional (Table 3.14b) symptoms. High potassium intake was associated 
with a significant increased risk of all symptoms except diarrhea, acne, anger, confusion 
and anxiety.  
Additionally, we evaluated the association between the zinc to copper and 
calcium to magnesium molar ratios and PMS (Table 3.15). For mineral intake from food 
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sources only, we observed that women with the highest zinc to copper and calcium to 
magnesium ratios had lower risks of PMS. For example, women in the highest quintile of 
calcium to magnesium ratio of intakes from food sources had a multivariable adjusted RR 
of 0.74 compared to women in the lowest quintile (95%CI=0.54-1.00, p trend=0.02). 
Women in the highest quintile of zinc to copper ratios of intakes from food sources had 
an adjusted RR of 0.69 compared to women in the lowest quintile (95%CI=0.52-0.90, p 
trend=0.02). For total intakes, the association between zinc to copper ratio and PMS was 
marginally significant (RR for the highest quintile vs. the lowest = 0.76, 95% CI = 0.58 - 
1.00, p trend = 0.05). 
Finally, we tested whether the association between minerals and PMS was 
modified by age (<40 vs. ≥40, Table 3.16), BMI (<25 vs. ≥25 kg/m2, Table 3.17), 
smoking (ever vs. never, Table 2.18) and alcohol (drinker vs. non-drinker, Table 2.19). 
We found no significant interaction of the mineral-PMS relationship by any of these 
factors. 
3.4 Discussion 
This is the first study to evaluate the association between dietary intakes of zinc, 
magnesium, copper, potassium, manganese, iron, and sodium and PMS incidence. We 
observed that total iron intake was associated with a lower risk of PMS. However there 
was no association between iron intake from foods and from supplements separately and 
PMS. In addition, we found that total potassium intake and potassium intake from food 
sources only was associated with higher risk of PMS, as well as with risk of most 
physical and emotional risk factors. There was no association between other mineral 
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intakes from foods or supplements and PMS. When we evaluated the zinc to copper and 
calcium to magnesium ratios, we found that women with higher zinc to copper ratios had 
lower risks of developing PMS as compared to women with lower zinc to copper ratios. 
The same was observed for the calcium to magnesium ratio.  The relationship between 
mineral intakes and PMS was not modified by age, BMI, smoking and alcohol. 
There have been few previous studies of minerals and PMS, some of which have 
found significant associations.  Women with PMS may have lower blood levels of 
magnesium,(8) zinc,(68) and higher levels of copper(68) during the luteal phase as 
compared to women without PMS. Some randomized clinical trials(55)but not all(56, 57) 
have found that  magnesium supplementation could effectively reduce PMS symptoms. 
In a randomized clinical trial conducted by Khine (2005) among ten women aged 27 to 
43 years old diagnosed with PMDD, 1 hour infusion with 0.1 mmol/kg of magnesium 
was not different than infusion of 5% dextrose alone for one cycle.(56) Only one 
previous study has evaluated the effect of dietary manganese on PMS, in combination 
with calcium.(60) In the study by Penland, ten women with reported PMS were assigned 
to one of four diets combining high and low levels of manganese and calcium for 39 
days.  The authors observed that women with diets high in calcium but low in manganese 
had worsening of premenstrual affective symptoms (interaction test for calcium and 
manganese=0.04). (60)  
Contrary to our main hypothesis that potassium could exert a protective effect on 
PMS, we found that higher total potassium intakes and potassium intakes from foods only 
was associated with increased risk of PMS. A study more than 30 years old evaluated the 
effects of a very low potassium supplementation (1 mg/day for two cycles) among 10 
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women with PMS symptoms and did not observe a significant difference with placebo on 
symptom occurrence and weight gain.(61) However, a  study of dietary intakes of a 
different combination of electrolytes found that diets high in potassium and low in 
sodium resulted in improvement of affective symptoms and higher vigor compared to 
diets low in potassium and with moderate sodium levels.(67)  
Potassium levels are regulated by aldosterone, and high potassium intakes lead to 
higher levels of aldosterone secretion.(18) In normal premenopausal women, aldosterone 
levels may be higher during the luteal phase than during the follicular phase.(6, 38, 39) 
High aldosterone levels have been proposed as contributors to PMS symptoms of 
bloating and edema. In fact, an aldosterone agonist and diuretic, spironolactone, has been 
shown to reduce PMS symptoms.(44, 45) The association of potassium with increased 
risk of PMS in our study could be related to induction of higher levels of aldosterone. We 
observed that high potassium intakes were associated with increased risk of not only 
bloating and edema symptoms, but of several other symptoms of PMS including mood 
and behavioral symptoms.  Nevertheless, mood and behavioral symptoms may be highly 
correlated with physical symptoms. The role of potassium in PMS is still unclear and 
needs to be further studied.  
Iron is a cofactor for the enzyme tryptophan hydroxylase which catalyzes the 
conversion of tryptophan into 5-hydroxytryptophan, a precursor of serotonin; yet it is 
unclear whether iron deficiency affects this enzyme.(49)  Dietary iron intakes and PMS 
have not been studied before. However, some studies have evaluated the association 
between ferritin levels and post-partum depression,(11, 72) which may have a similar 
pathophysiology and shares some of the same risk factors as premenstrual syndrome. In 
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the study conducted by Alcabar in Spain,(11) 729 women were followed from childbirth 
for two years. During the postpartum period, 9% of participants developed PPD, and had 
lower serum ferritin concentrations (mean (SD) = 15.4 (12.7) µg/L)  compared to the rest 
of the participants (mean (SD) = 21.6 (13.5) µg/L, p=0.002) . Although in our study  we 
did not have information on ferritin status, participants in the lowest three quintiles of 
iron intake had medians below the RDA of 18 mg/day for women aged 30-40 years of 
age. 
Although there are no previous studies of zinc to copper ratios in PMS, we 
hypothesized a possible association given the potential protective effect of zinc in PMS 
and the potential increased risk of PMS in women with high intakes of copper (observed 
in age-adjusted analysis only). Zinc and copper can compete with each other for binding 
sites at the intestine,(96) but the interaction of their dietary intakes in their absorption 
levels remains unclear.(97) Average zinc to copper molar ratios are 5 to 14 in the U.S., 
(98) and a ratio of no more than 15 has been suggested due to risk of decreasing copper 
absorption.(99). In our population, ratios of zinc to copper intakes from foods only, as 
well as total intakes were between 6.6 to 13.9. The observed protective effects of high 
zinc low copper ratios on PMS observed in this population should be further studied.  
Calcium and magnesium have been both associated with PMS(12, 100) A 
previous study in our population observed an inverse association between calcium intakes 
from food sources and PMS risk.(95) Some studies have evaluated the effects of calcium 
to magnesium ratios in serum(101) and in cerebral spinal fluid(25) and their association 
with depressive syndromes with inconsistent results. We decided to further evaluated the 
role of calcium to magnesium ratios and PMS risk. We observed that high intakes of 
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calcium from food sources were associated with lower PMS risk, possibly regardless of 
magnesium status as the RR is very similar as for calcium alone (RR = 0.74, 95% CI - 
0.54 - 1.00, and p trend =0.02 for highest quintile of calcium to magnesium ratio, vs. RR 
= 0.70, 95% CI = 0.50 - 0.97, p trend = 0.02 for the highest quintile of calcium intake 
from food sources as reported by Bertone-Johnson in 2005 (95) ). 
 
Study limitations 
We used self-reported FFQs to estimate mineral intake from foods and from 
supplemental sources. Specific portion sizes were included for each item, in order to 
minimize within person variability in reporting. Nevertheless, it may be difficult to 
accurately recall dietary intake over the past year, therefore some misclassification is 
likely. We excluded from the analysis women who reported intakes below 500 or above 
3500 calories per day, because of such small and large intakes are likely to be due to 
misreport. Misclassification is more likely between adjacent quintiles than distant 
quintiles, thus we focused our analysis on comparisons between the highest versus the 
lowest quintile (reference) and the trend over quintiles. Additionally, because the dietary 
assessment was conducted independently from the outcome assessment, misclassification 
would be non-differential with respect of PMS status. This type of misclassification could 
have attenuated relative risks observed in this study.  
The gold standard for PMS assessment in clinical studies requires prospective 
recording of daily symptoms for  two to three menstrual cycles, which was not feasible 
with our study size. However, we used validated established criteria to retrospectively 
identify PMS cases and symptom-free controls and thus to compare women at the two 
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extremes of the spectrum of menstrual symptom experience, thereby decreasing the 
likelihood of misclassification of PMS cases or controls. In the validation study of our 
method,(78) the authors found that women who reported prospective charting and who 
met PMS criteria based on those defined by Mortola et al.(77) were essentially identical 
to those who did not report prospective charting but who met the Mortola criteria 
assessed in the retrospective questionnaire. Because PMS assessment was conducted 
independently of diet assessment, any misclassification of PMS status would be non-
differential and could have attenuated our results.  
Information on many lifestyle and dietary variables that are potential confounders 
of the association between minerals and PMS was collected by questionnaires throughout 
the follow-up. However, because risk factors for PMS are still under study, and the 
pathophysiology of the disorder is still unclear, it is possible that there are confounders of 
the association of minerals and PMS yet unknown. Although we  tried to minimize 
confounding by including all known risk factors for PMS as potential confounders, some 
residual confounding it is still possible.  
Clinical indication could also be confounder with regard to use of mineral 
supplements. Although use of specific mineral supplements in the treatment of menstrual 
symptoms is less common than specific vitamin supplement use, minerals are part of 
multivitamin/mineral supplements sold over the counter and used commonly. Some 
physicians may recommend magnesium supplements or multivitamins to women 
complaining of premenstrual symptoms, and this could bias the relative risk from an 
inverse association to a positive association as we observed in Chapter 2 for B vitamin 
supplements. However in the case of mineral intakes, we did not observe an association 
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between supplement intakes 2-4 years before reference and PMS risk, thus suggesting 
that self-medication with supplements was an unlikely explanation for our findings.  
Participants in this study are members of the NHS2 cohort and are mostly white 
women and more educated than the general population. It is possible that they have a 
better diet quality than the general population, even though some of them had iron intakes 
below the RDA. We have no reason to believe that mineral intake physiologically affects 
PMS in women from this cohort differently than less educated women and women from 
other races. Therefore, we can generalize these results to other premenopausal women 
with the same range of intakes of minerals.  
Conclusion 
In  this population, high intake of iron was associated with lower risk of 
developing PMS. In contrast, high intake of potassium was associated with an increased 
risk of PMS. There was no association between dietary intakes of magnesium, zinc, 
copper, manganese and sodium and PMS. To our knowledge, this is the first study to 
evaluate the association between dietary intakes of these specific minerals and 
development of PMS.  
 
3.5 Significance 
Premenstrual syndrome has high prevalence and substantial impact on quality of 
life but many currently recommended treatments have significant side effects and limited 
efficacy. Potential effects of diet modification, particularly of mineral intakes, on PMS 
prevention are important to be studied.   
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The results of this study suggest a possible benefit of high intakes of iron and a 
possible adverse effect of high potassium intakes on PMS incidence. Because this is the 
first study to evaluate the effects or iron and other mineral intakes in PMS development, 
further studies are needed to evaluate these associations, particularly randomized clinical 
trials of the efficacy of iron supplementation for the prevention and treatment of PMS.  
 
3.6 Human Subject Protection 
This study has been approved by the University of Massachusetts, Amherst and 
the Brigham and Women’s Hospital (BWH) institutional review boards.  
Participants in the NHS2 are identified through a confidential identification 
number only. Documents containing the names corresponding to each ID as well as the 
questionnaires are kept separately in the Channing Laboratory in locked fire-proof 
cabinets.  
There are no invasive procedures involved in this sub-study. There are no known 
risks involved in filling in questionnaires, except for the consequences of potential 
disclosure of confidential data. Women will not benefit directly from participating in this 
study. 
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Table 3.1 Distribution of total intake of selected minerals 2 to 4  years before 
reference year: NHS2 PMS Sub-study, 1991-2001. 
  
Dietary 
Reference 
Intake1 
Mean Standard 
Deviation Median 
Interquartile 
Range 
Zinc (mg/d) 8 16.2 11.8 12.3 10.5 - 16.8
Magnesium (mg/d) 310 320 72 310 273 - 358
Copper (mg/d) 0.9 1.6 0.8 1.3 1.1 - 1.6
Potassium (mg/d) 4700 2967 528 2928 2613 - 3289
Manganese (mg/d) 1.8 3.8 1.6 3.5 2.8 - 4.4
Iron (mg/d) 18 24.7 24.4 15.1 12.1 - 26.7
Sodium (mg/d) 1500 2130.4 367.5 2116.0 1886 - 2359 
1Dietary reference intake is the recommended dietary allowance (RDA) for women aged 20 to 40 years for all minerals, 
except for potassium and sodium where the adequate intake (AI) was used instead. 
 
 
 
Table 3.2 Distribution of  intake of selected minerals from food sources 2 
to 4  years before reference year: NHS2 PMS Sub-study, 1991-2001. 
  Mean 
Standard 
Deviation Median 
Interquartile 
Range 
Zinc (mg/d) 11.9 3.2 11.4 10.1 - 12.9 
Magnesium (mg/d) 305 59 301 266 - 340 
Copper (mg/d) 1.3 0.3 1.2 1.1 - 1.4 
Potassium (mg/d) 2962 527 2925 2609 - 3284 
Manganese (mg/d) 3.4 1.1 3.3 2.7 - 4.0 
Iron (mg/d) 14.4 5.4 13.1 11.4 - 15.7 
 
 
 
Table 3.3 Distribution of  intake of selected minerals from supplement 
sources1 2 to 4  years before reference year: NHS2 PMS Sub-study, 
1991-2001. 
  Mean 
Standard 
Deviation Median 
Interquartile 
Range 
Zinc (mg/d) 16.1 14.3 15.0 8.5 - 20.0 
Magnesium (mg/d) 70 52 57 30 - 100 
Copper (mg/d) 1.5 0.8 1.9 1.1 -2.0 
Potassium (mg/d) 35 85 23 7 - 40 
Manganese (mg/d) 2.4 2.0 2.5 1.4 - 2.8 
Iron (mg/d) 31.6 31.6 18.0 10.3 - 43.0 
1Includes multivitamin and individual supplement users. 
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Table 3.4a Age-standardized characteristics of the population by zinc intake at 
baseline: NHS2 PMS Sub-study, 1991-2001. 
  Total zinc intake in 1991, mg/d  
 
Q1 
(n=594) 
Q2 
(n=564) 
Q3 
(n=645) 
Q4 
(n=560) 
Q5 
(n=662)  
 Characteristics1 
Mean 
(SE) 
Mean 
(SE) 
Mean 
(SE) 
Mean 
(SE) 
Mean 
(SE) 
Pvalue4 
Age in years2 35.0 (4.0) 34.9 (4.1) 35.1 (4.1) 35.0(4.0) 33.8 (3.9) <0.0001
BMI (kg/m2)       
At baseline (1991) 23.5 (5.2) 23.6 (4.5) 24.4 (5.1) 24.4 (5.0) 24.2 (4.7) 0.0001
At the age of 18 yrs 20.8 (3.3) 21.1 (3.1) 21.6 (3.5) 21.3 (3.1) 21.2 (2.9) 0.001
Age at menarche, years 12.6 (0.1) 12.5 (0.1) 12.4 (0.1) 12.5 (0.1) 12.4 (0.1) 0.01
Age at first birth, years3 26.1 (0.2) 25.9 (0.2) 25.7 (0.2) 25.4 (0.2) 26.8 (0.2) <0.0001
Number of full-term 
pregnancies 1.5 (0.1) 1.8 (0.1) 1.8 (0.1) 1.8 (0.1) 1.5 (0.1) <0.0001
MET of physical 
activity per week 21.8 (2.4) 24.6 (2.4) 20.7 (2.5) 23.0 (2.9) 25.6 (2.2) 0.49 
  % % % % % Pvalue5 
History of tubal ligation 16 20 19 21 13 0.002
Oral contraceptive use       
Current user 13 9 12 11 8 0.01
Ever user 80 79 81 82 79 0.68
Smoking Status       
Current smoker 12 9 9 5 8 0.0003
Past smoker 19 20 21 22 23 0.45
Ever used 
antidepressants 7 6 8 8 7 0.61 
History of severe 
childhood trauma  12 8 10 11 10 0.18 
1 All characteristics, except for age,  standardized to the age distribution of participants in 1991. 
2 For age, the value in parentheses is the standard deviation instead of the standard error. 
3 Limited to parous women. 
4 Calculated using the t statistic. 
5 Calculated using the F statistic. 
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Table 3.4b Age-standardized characteristics of the population by total 
magnesium intake at baseline: NHS2 PMS Sub-study, 1991-2001. 
  Total magnesium intake in 1991, mg/d  
 
Q1 
(n=579) 
Q2 
(n=589) 
Q3 
(n=662) 
Q4 
(n=609) 
Q5 
(n=586)  
 Characteristics1 
Mean 
(SE) 
Mean 
(SE) 
Mean 
(SE) 
Mean 
(SE) 
Mean 
(SE) 
Pvalue4 
Age in years2 34.3 (4.2) 34.7 (4.1) 34.9 (4.1) 34.9 (3.9) 34.9 (4.0) <0.0001 
BMI (kg/m2)       
At baseline (1991) 24.3 (0.2) 24.2 (0.2) 24.1 (0.2) 23.9 (0.2) 23.6 (0.2) 0.16
At the age of 18 yrs 20.9 (0.1) 21.1 (0.1) 21.2 (0.1) 21.5 (0.1) 21.3 (0.1) 0.04
Age at menarche, years 12.6 (0.1) 12.5 (0.1) 12.4 (0.1) 12.4 (0.1) 12.5 (0.1) 0.21
Age at first birth, years3 25.6 (0.2) 25.6 (0.2) 26.2 (0.2) 25.9 (0.2) 26.7 (0.2) <0.0001 
Number of full-term 
pregnancies 1.8 (0.1) 1.8 (0.1) 1.8 (0.1) 1.6 (0.1) 1.4 (0.1) <0.0001 
MET of physical 
activity per week 17.7 (2.4) 19.0 (2.4) 21.7 (2.3) 25.7 (2.4) 31.7(2.4) <0.0001 
  % % % % % Pvalue5 
History of tubal ligation 20 20 18 18 13 0.02
Oral contraceptive use       
Current user 12 11 10 9 9 0.28
Ever user 82 79 80 80 81 0.77
Smoking Status       
Current smoker 8 10 8 9 7 0.40
Past smoker 13 20 21 22 28 <0.0001
Ever used 
antidepressants 8 7 7 6 8 0.85 
History of severe 
childhood trauma  10 9 9 14 10 0.04 
1 All characteristics, except for age,  standardized to the age distribution of participants in 1991. 
2 For age, the value in parentheses is the standard deviation instead of the standard error. 
3 Limited to parous women. 
4 Calculated using the t statistic. 
5 Calculated using the F statistic. 
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Table 3.4c Age-standardized characteristics of the population by total copper 
intake at baseline: NHS2 PMS Sub-study, 1991-2001. 
  Total copper intake in 1991, mg/d  
 
Q1 
(n=526) 
Q2 
(n=946) 
Q3 
(n=342) 
Q4 
(n=632) 
Q5 
(n=579)  
 Characteristics1 
Mean 
(SE) 
Mean 
(SE) 
Mean 
(SE) 
Mean 
(SE) 
Mean 
(SE) 
Pvalue4 
Age in years2 33.9 (4.2) 35.1 (4.0) 35.5 (4.0) 35.2 (3.9) 34.1 (4.1) <0.0001
BMI (kg/m2)       
At baseline (1991) 23.7 (0.2) 23.9 (0.2) 24.3 (0.3) 24.2 (0.2) 24.2 (0.2) 0.22
At the age of 18 yrs 20.9 (0.1) 21.0 (0.1) 21.3 (0.2) 21.7 (0.1) 21.2 (0.1) <0.0001
Age at menarche, years 12.6 (0.1) 12.5 (0.1) 12.4 (0.1) 12.4 (0.1) 12.4 (0.1) 0.04
Age at first birth, years3 26.0 (0.2) 25.9 (0.1) 25.8 (0.2) 25.5 (0.2) 26.8 (0.2) <0.0001
Number of full-term 
pregnancies 1.8 (0.1) 1.9 (0.1) 1.7 (0.1) 1.5 (0.1) 1.5 (0.1) <0.0001
MET of physical 
activity per week 18.4 (0.1) 20.8 (0.1) 20.0 (0.1) 25.3 (0.1) 29.8 (0.1) 0.003 
  % % % % % Pvalue5 
History of tubal ligation 18 19 16 19 15 0.24
Oral contraceptive use       
Current user 12 9 11 12 8 0.02
Ever user 79 80 81 82 81 0.83
Smoking Status       
Current smoker 8 9 5 10 9 0.11
Past smoker 18 20 21 24 24 0.03
Ever used 
antidepressants 7 7 8 8 7 0.73 
History of severe 
childhood trauma  11 9 9 11 11 0.57 
1 All characteristics, except for age,  standardized to the age distribution of participants in 1991. 
2 For age, the value in parentheses is the standard deviation instead of the standard error. 
3 Limited to parous women. 
4 Calculated using the t statistic. 
5 Calculated using the F statistic. 
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Table 3.4d Age-standardized characteristics of the population by total potassium 
intake at baseline: NHS2 PMS Sub-study, 1991-2001. 
  Total potassium intake in 1991, mg/d  
 
Q1 
(n=598) 
Q2 
(n=650) 
Q3 
(n=658) 
Q4 
(n=626) 
Q5 
(n=493)  
 Characteristics1 
Mean 
(SE) 
Mean 
(SE) 
Mean 
(SE) 
Mean 
(SE) 
Mean 
(SE) 
Pvalue4 
Age in years2 34.1(4.2) 34.2(4.0) 34.8(4.0) 35.0(4.0) 35.9(3.8) <0.0001
BMI (kg/m2)       
At baseline (1991) 24.4 (0.2) 24.0 (0.2) 23.9 (0.2) 24.0 (0.2) 23.9 (0.2) 0.46
At the age of 18 yrs 20.9 (0.1) 21.1 (0.1) 21.2 (0.1) 21.1 (0.1) 21.8 (0.1) 0.0004
Age at menarche, years 12.5 (0.1) 12.5 (0.1) 12.4 (0.1) 12.5 (0.1) 12.4 (0.1) 0.37
Age at first birth, years3 25.9 (0.2) 26.1 (0.2) 26.2 (0.2) 25.7 (0.2) 26.3 (0.2) 0.14 
Number of full-term 
pregnancies 1.7 (0.1) 1.7 (0.1) 1.8 (0.1) 1.7 (0.1) 1.4 (0.1) <0.0001
MET of physical 
activity per week 18.8 (0.1) 19.8 (0.1) 22.4 (0.1) 24.7 (0.1) 33.0 (0.1) 0.001 
  % % % % % Pvalue5 
History of tubal ligation 19 18 16 19 16 0.387
Oral contraceptive use       
Current user 13 9 10 10 9 0.05
Ever user 83 80 79 80 81 0.39
Smoking Status       
Current smoker 7 7 7 10 12 0.01
Past smoker 16 18 22 21 30 <0.0001
Ever used 
antidepressants 9 8 7 6 6 0.33 
History of severe 
childhood trauma  10 9 11 9 13 0.16 
1 All characteristics, except for age,  standardized to the age distribution of participants in 1991. 
2 For age, the value in parentheses is the standard deviation instead of the standard error. 
3 Limited to parous women. 
4 Calculated using the t statistic. 
5 Calculated using the F statistic. 
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Table 3.4e Age-standardized characteristics of the population by total manganese 
intake at baseline: NHS2 PMS Sub-study, 1991-2001. 
  Total manganese intake in 1991, mg/d  
 
Q1 
(n=583) 
Q2 
(n=576) 
Q3 
(n=680) 
Q4 
(n=592) 
Q5 
(n=594)  
 Characteristics1 
Mean 
(SE) 
Mean 
(SE) 
Mean 
(SE) 
Mean 
(SE) 
Mean 
(SE) 
Pvalue4 
Age in years2 34.2(4.2) 34.8(4.1) 34.9(4.0) 35.1(4.0) 34.7(4.0) <0.0001
BMI (kg/m2)       
At baseline (1991) 24.2 (0.2) 24.1 (0.2) 24.0 (0.2) 23.9 (0.2) 23.8 (0.2) 0.61
At the age of 18 yrs 21.0 (0.1) 21.1 (0.1) 21.2 (0.1) 21.2 (0.1) 
21.4( 
(0.1) 0.36 
Age at menarche, years 12.5 (0.1) 12.5 (0.1) 12.4 (0.1) 12.5 (0.1) 12.3 (0.1) 0.13
Age at first birth, years3 25.7 (0.2) 25.9 (0.2) 25.9 (0.2) 26.1 (0.2) 26.5 (0.2) 0.02 
Number of full-term 
pregnancies 1.8 (0.1) 1.8 (0.1) 1.7( (0.1) 1.6 (0.1) 1.5 (0.1) <0.0001
MET of physical 
activity per week 17.1 (0.1) 21.7 (0.1) 22.2 (0.1) 28.4 (0.1) 26.0 (0.1) 0.01 
  % % % % % Pvalue5 
History of tubal ligation 22 17 18 14 17 0.01
Oral contraceptive use       
Current user 11 10 10 9 11 0.96
Ever user 83 78 79 82 80 0.17
Smoking Status       
Current smoker 10 12 6 9 7 0.005
Past smoker 17 18 23 23 23 0.01
Ever used 
antidepressants 7 6 7 7 8 0.45 
History of severe 
childhood trauma  10 8 11 12 11 0.09 
1 All characteristics, except for age,  standardized to the age distribution of participants in 1991. 
2 For age, the value in parentheses is the standard deviation instead of the standard error. 
3 Limited to parous women. 
4 Calculated using the t statistic. 
5 Calculated using the F statistic. 
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Table 3.4f Age-standardized characteristics of the population by total iron intake 
at baseline: NHS2 PMS Sub-study, 1991-2001. 
  Total iron intake in 1991, mg/d  
 
Q1 
(n=546) 
Q2 
(n=576) 
Q3 
(n=600) 
Q4 
(n=625) 
Q5 
(n=678)  
 Characteristics1 
Mean 
(SE) 
Mean 
(SE) 
Mean 
(SE) 
Mean 
(SE) 
Mean 
(SE) 
Pvalue4 
Age in years2 34.8(4.1) 35.2(4.1) 35.1(4.0) 34.9(4.0) 33.9(4.1) <0.0001
BMI (kg/m2)       
At baseline (1991) 24.2 (0.2) 24.1 (0.2) 23.9 (0.2) 23.8 (0.2) 24.0 (0.2) 0.60
At the age of 18 yrs 21.1 (0.1) 21.6 (0.1) 21.1 (0.1) 21.1 (0.1) 21.1 (0.1) 0.03
Age at menarche, years 12.5 (0.1) 12.4 (0.1) 12.4 (0.1) 12.5 (0.1) 12.4 (0.1) 0.50
Age at first birth, years3 25.6 (0.2) 25.8 (0.2) 25.6 (0.2) 25.9 (0.2) 26.9 (0.2) <0.0001
Number of full-term 
pregnancies 1.7 (0.1) 1.7 (0.1) 1.8 (0.1) 1.7 (0.1) 1.6 (0.1) 0.03 
MET of physical 
activity per week 17.5 (2.5) 21.4 (2.4) 26.8 (2.4) 23.6 (2.3) 25.6 (2.3) 0.04 
  % % % % % Pvalue5 
History of tubal ligation 20 19 20 17 15 0.05
Oral contraceptive use       
Current user 12 11 11 12 7 0.01
Ever user 82 82 80 77 81 0.16
Smoking Status       
Current smoker 13 9 8 6 6 <0.0001
Past smoker 17 20 24 23 20 0.02
Ever used 
antidepressants 9 7 6 8 7 0.42 
History of severe 
childhood trauma  10 10 11 11 10 0.99 
1 All characteristics, except for age,  standardized to the age distribution of participants in 1991. 
2 For age, the value in parentheses is the standard deviation instead of the standard error. 
3 Limited to parous women. 
4 Calculated using the t statistic. 
5 Calculated using the F statistic. 
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Table 3.4g Age-standardized characteristics of the population by total sodium 
intake at baseline: NHS2 PMS Sub-study, 1991-2001. 
  Total sodium intake in 1991, mg/d  
 
Q1 
(n=579) 
Q2 
(n=589) 
Q3 
(n=662) 
Q4 
(n=609) 
Q5  
(n=)  
 Characteristics1 
Mean 
(SE) 
Mean 
(SE) 
Mean 
(SE) 
Mean 
(SE) 
Mean 
(SE) 
Pvalue4 
Age in years2 34.6(4.1) 34.7(4.2) 34.5(4.0) 35.0(4.0) 35.0(4.0) <0.0001 
BMI (kg/m2)       
At baseline (1991) 23.7 (0.2) 23.7 (0.2) 23.7 (0.2) 24.2 (0.2) 24.8 (0.2) 0.0001
At the age of 18 yrs 21.0 (0.1) 21.0 (0.1) 21.2 (0.1) 21.2 (0.1) 21.5 (0.1) 0.04
Age at menarche, years 12.4 (0.1) 12.6 (0.1) 12.5 (0.1) 12.5 (0.1) 12.4 (0.1) 0.24
Age at first birth, years3 26.3 (0.2) 26.4 (0.2) 26.0 (0.2) 25.9 (0.2) 25.5 (0.2) 0.01 
Number of full-term 
pregnancies 1.4 (0.1) 1.6 (0.1) 1.8 (0.1) 1.8 (0.1) 1.8 (0.1) <0.0001 
MET of physical 
activity per week 24.8 (2.4) 23.2 (2.4) 28.0 (2.4) 18.8 (2.4) 20.1 (2.4) 0.03 
  % % % % % Pvalue5 
History of tubal ligation 16 17 18 19 18 0.70
Oral contraceptive use       
Current user 9 11 11 7 12 0.02
Ever user 80 83 78 82 80 0.17
Smoking Status       
Current smoker 9 9 7 7 10 0.18
Past smoker 22 20 22 22 19 0.83
Ever used 
antidepressants 7 6 8 7 8 0.46 
History of severe 
childhood trauma  13 12 11 8 8 0.04 
1 All characteristics, except for age,  standardized to the age distribution of participants in 1991. 
2 For age, the value in parentheses is the standard deviation instead of the standard error. 
3 Limited to parous women. 
4 Calculated using the t statistic. 
5 Calculated using the F statistic. 
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Table 3.5 Spearman correlation coefficients1 for total intake of selected 
minerals: NHS2 PMS Sub-study, 1991-2001. 
  Zinc Magnesium Copper Potassium Manganese Iron Sodium
Zinc 1.00       
Magnesium 0.40 1.00      
Copper 0.49 0.64 1.00     
Potassium 0.18 0.72 0.42 1.00    
Manganese 0.29 0.65 0.62 0.37 1.00   
Iron 0.58 0.46 0.51 0.17 0.45 1.00  
Sodium 0.05 0.10 0.14 0.06 0.12 0.11 1.00
Calcium 0.37 0.47 0.23 0.33 0.14 0.29 0.13
1All correlations are statistically significant at <0.0001, except for the correlation between sodium and zinc, which was 
significant at 0.004 
 
 
Table 3.6 Spearman correlation coefficients1 for  intake of selected 
minerals from food sources: NHS2 PMS Sub-study, 1991-2001. 
  Zinc Magnesium Copper Potassium Manganese Iron 
Zinc 1.00      
Magnesium 0.25 1.00     
Copper 0.19 0.61 1.00    
Potassium 0.23 0.80 0.55 1.00   
Manganese 0.04 0.61 0.56 0.41 1.00  
Iron 0.36 0.44 0.38 0.27 0.50 1.00 
Calcium 0.25 0.44 0.03 0.37 -0.01 0.07 
1  Correlations between calcium and copper, and between calcium and manganese were not statistically 
significant. The correlation between zinc and manganese was significant at 0.05. All the other correlations 
were statistically significant at <0.0001. 
 
 
Table 3.7 Spearman correlation coefficients1 for intake of selected 
minerals from supplements: NHS2 PMS Sub-study, 1991-2001. 
  Zinc Magnesium Copper Potassium Manganese Iron 
Zinc 1.00      
Magnesium 0.77 1.00     
Copper 0.82 0.83 1.00    
Potassium 0.63 0.78 0.73 1.00   
Manganese 0.70 0.84 0.83 0.86 1.00  
Iron 0.75 0.64 0.68 0.49 0.55 1.00 
Calcium 0.10 0.09 0.09 0.01 0.03 0.12 
1  The correlation between calcium and potassium was not statistically significant. The correlation between 
calcium and manganese was significant at 0.03. All the other correlations were statistically significant at 
<0.0001. 
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Table 3.8 Age-adjusted relative risks (RR) and 95% confidence intervals (CI) 
for total intake of selected minerals 2-4  years before reference year and risk of 
premenstrual syndrome: NHS2 PMS Sub study, 1991-2001. 
  Q1 Q2 Q3 Q4 Q5 Ptrend 
Zinc (mg/d)   
Median 9.2 10.8 12.2 14.9 27.9  
Case:Control Ratio 206:405 182:386 227:417 203:352 237:401  
RR 1.00 0.92 1.07 1.13 1.11 0.24
95% CI   (0.72-1.17) (0.84-1.34) (0.89-1.44) (0.88-1.41)  
Magnesium (mg/d)   
Median 237 280 311 350 415  
Case:Control Ratio 191:370 223:418 216:435 213:397 212:344  
RR 1.00 1.04 0.98 1.07 1.232 0.09
95% CI   (0.82-1.33) (0.77-1.25) (0.84-1.36) (0.96-1.57)  
Copper (mg/d)   
Median 1.0 1.2 1.3 1.5 2.9  
Case:Control Ratio 182:395 268:515 138:321 245:397 222:336  
RR 1.00 1.17 0.98 1.39 1.43 0.004
95% CI   (0.93-1.48) (0.75-1.27) (1.09-1.76) (1.12-1.83)  
Potassium (mg/d)   
Median 2319 2684 2952 3248 3717  
Case:Control Ratio 203:391 221:430 212:437 209:393 210:313  
RR 1.00 0.981 0.956 1.063 1.37 0.009
95% CI   (0.78-1.24) (0.76-1.21) (0.84-1.35) (1.07-1.75)  
Manganese (mg/d)   
Median 2.3 2.8 3.4 4.2 5.8  
Case:Control Ratio 193:383 204:376 216:446 219:407 223:352  
RR 1.00 1.106 0.994 1.09 1.32 0.03
95% CI   (0.87-1.41) (0.78-1.26) (0.86-1.39) (1.03-1.68)  
Iron (mg/d)   
Median 10.4 12.4 14.8 21.7 49.2  
Case:Control Ratio 192:346 202:396 229:396 220:409 212:417  
RR 1.00 0.93 1.04 0.97 0.89 0.28
95% CI   (0.73-1.19) (0.82-1.32) (0.77-1.24) (0.70-1.13)  
Sodium(mg/d)   
Median 1684 1932 2116 2308 2586  
Case:Control Ratio 201:402 192:412 213:392 226:375 223:383  
RR 1.00 0.93 1.10 1.23 1.18 0.04
95% CI   (0.73-1.18) (0.87-1.39) (0.97-1.56) (0.93-1.49)  
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Table 3.9 Age-adjusted relative risks (RR) and 95% confidence intervals (CI) 
for intake of selected minerals from food sources 2-4  years before reference 
year and risk of premenstrual syndrome: NHS2 PMS Sub study, 1991-2001. 
  Q1 Q2 Q3 Q4 Q5 Ptrend
Zinc (mg/d)     
Median 8.9 10.3 11.4 12.6 14.9  
Case:Control Ratio 203:363 202:419 230:412 218:373 202:397  
RR 1.00 0.86 0.99 1.03 0.89 0.74
95% CI   (0.67-1.09) (0.78-1.25) (0.81-1.31) (0.70-1.14)  
Magnesium (mg/d)    
Median 233 273 301 332 379  
Case:Control Ratio 195:368 214:399 234:421 197:414 215:362  
RR 1.00 1.04 1.07 0.94 1.19 0.34
95% CI   (0.82-1.32) (0.85-1.36) (0.73-1.19) (0.93-1.51)  
Copper (mg/d)    
Median 1.0 1.1 1.2 1.4 1.6  
Case:Control Ratio 234:477 186:381 195:363 244:454 196:289  
RR 1.00 1.03 1.15 1.151 1.47 0.002
95% CI   (0.82-1.31) (0.92-1.45) (0.92-1.44) (1.51-1.87)  
Potassium (mg/d)    
Median 2316 2681 2951 3241 3700  
Case:Control Ratio 204:387 218:432 222:440 205:379 206:326  
RR 1.00 0.95 0.98 1.07 1.27 0.03
95% CI   (0.75-1.21) (0.78-1.24) (0.84-1.36) (0.99-1.62)  
Manganese (mg/d)    
Median 2.2 2.8 3.2 3.8 4.8  
Case:Control Ratio 180:358 226:400 212:363 224:422 213:391  
RR 1.00 1.15 1.11 1.08 1.14 0.53
95% CI   (0.88-1.50) (0.88-1.51) (0.89-1.52) (0.96-1.66)  
Iron (mg/d)     
Median 10.1 11.6 12.9 14.8 19.3  
Case:Control Ratio 190:371 207:371 213:382 242:404 203:436  
RR 1.00 1.11 1.09 1.18 0.92 0.31
95% CI   (0.87-1.41) (0.86-1.40) (0.93-1.50) (0.72-1.17)  
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Table 3.10 Age-adjusted relative risks (RR) and 95% confidence intervals 
(CI) for intake of selected minerals from supplement sources 2-4  years 
before reference year and risk of premenstrual syndrome: NHS2 PMS Sub 
study, 1991-2001. 
  Supplement Users 
  Non-Users T1 T2 T3 Ptrend1 
Zinc (mg/d)      
Median 0.0 5.9 15.0 25.0  
Case:Control Ratio 755:1477 109:161 112:157 81:173  
RR 1.00 1.31 1.33 0.87 0.03
95% CI   (1.01-1.69) (1.03-1.73) (0.66-1.15)  
Magnesium (mg/d)     
Median 0.0 14.0 57.0 100.0  
Case:Control Ratio 806:1594 93:114 57:98 101:162  
RR 1.00 1.59 1.13 1.19 0.14
95% CI   (1.19-2.12) (0.81-1.58) (0.91-1.55)  
Copper (mg/d)     
Median 0.0 0.5 1.5 2.0  
Case:Control Ratio 827:1594 88:127 48:88 94:159  
RR 1.00 1.31 1.00 1.08 0.28
95% CI   (0.99-1.75) (0.70-1.44) (0.83-1.42)  
Potassium (mg/d)     
Median 0.0 6.00 23.0 40.0  
Case:Control Ratio 891:1715 59:80 45:65 62:108  
RR 1.00 1.42 1.34 1.09 0.25
95% CI   (1.01-2.01) (0.91-1.98) (0.79-1.51)  
Manganese (mg/d)     
Median 0.0 0.6 2.5 5.0  
Case:Control Ratio 870:1672 64:94 75:112 48:90  
RR 1.00 1.31 1.25 1.02 0.26
95% CI   (0.94-1.82) (0.92-1.69) (0.71-1.46)  
Iron (mg/d)      
Median 0.0 10.0 18.0 60.0  
Case:Control Ratio 705:1350 122:202 114:208 116:208  
RR 1.00 1.15 1.03 1.00 0.43
95% CI  (0.90-1.46) (0.80-1.32) (0.78-1.28)  
1Test for trend was conducted among users of supplements only. 
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Table 3.11 Multivariable adjusted RR1 and  95% CI  for total mineral intake 
2 to 4 years before reference year and PMS: NHS2 PMS Sub-study, 1991-
2001. 
  Q1 Q2 Q3 Q4 Q5 Ptrend 
Zinc        
RR 1.00 0.97 0.99 0.99 0.95 0.75
95% CI   (0.73-1.27) (0.76-1.30) (0.74-1.32) (0.69-1.30)  
Magnesium      
RR 1.00 1.10 1.13 1.08 1.30 0.16
95% CI   (0.83-1.45) (0.80-1.47) (0.80-1.47) (0.94-1.81)  
Copper       
RR 1.00 1.20 1.01 1.30 1.34 0.12
95% CI   (0.92-1.55) (0.75-1.38) (0.98-1.73) (0.98-1.82)  
Potassium      
RR 1.00 1.06 1.08 1.16 1.53 0.004
95% CI   (0.82-1.38) (0.83-1.41) (0.88-1.52) (1.14-2.04)  
Manganese      
RR 1.00 1.08 0.97 1.06 1.31 0.06
95% CI   (0.82-1.42) (0.74-1.26) (0.80-1.39) (0.98-1.74)  
Iron       
RR 1.00 0.88 0.92 0.78 0.69 0.03
95% CI   (0.67-1.16) (0.69-1.21) (0.58-1.05) (0.50-0.95)  
Sodium       
RR 1.00 0.91 0.99 1.51 1.06 0.28
95% CI   (0.69-1.19) (0.76-1.30) (0.88-1.51) (0.81-1.39)  
1Adjusted for age (<30, 30-34, 35-39 or ≥ 40 years), year of diagnosis (1993, 1994-1995, 1996-1996, 1998-1999 or 2000-
2001), number of full-term pregnancies (0. 1-2, 3-4 or ≥ 5 pregnancies lasting at least 6 months), body mass index (<20.0, 
20.0-22.4, 22.5-24.9, 25.0-27.4, 27.5-29.9 or ≥ 30.0 kg/m2), pack-years of smoking (quintiles), tubal ligation (no vs. yes), 
duration or oral contraceptive use (never, 1-23, 24-71, 72-119 or ≥ 120 months), antidepressant use (never vs. ever), history 
of childhood trauma score (5, 6-10, 11-15, ≥ 16), intake of alcohol, vitamin B6, calcium and vitamin D (quintiles) at 2 to 4 
years before reference year. 
/ 
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Table  3.12 Multivariable adjusted RR1 and  95% CI  for mineral intake 
from food sources 2 to 4 years before reference year and PMS: NHS2 PMS 
Sub-study, 1991-2001. 
  Q1 Q2 Q3 Q4 Q5 Ptrend 
Zinc      
Model 1: RR 1.00 0.91 0.97 0.98 0.83 0.26
95% CI  (0.69-1.19) (0.74-1.27) (0.74-1.30) (0.62-1.10)  
Model 2: RR 1.00 0.89 0.94 0.95 0.86 0.48
95% CI   (0.68-1.18) (0.71-1.24) (0.72-1.27) (0.64-1.17)  
Magnesium      
Model 1: RR 1.00 1.13 1.24 1.05 1.29 0.21
95% CI  (0.86-1.49) (0.94-1.64) (0.78-1.41) (0.94-1.76)  
Model 2: RR 1.00 1.09 1.13 0.89 0.99 0.72
95% CI   (0.79-1.50) (0.78-1.65) (0.58-1.37) (0.60-1.63)  
Copper      
Model 1: RR 1.00 1.13 1.13 1.12 1.28 0.14
95% CI  (0.86-1.47) (0.87-1.47) (0.87-1.45) (0.97-1.69)  
Model 2: RR 1.00 1.08 1.08 1.03 1.16 0.56
95% CI   (0.81-1.43) (0.80-1.46) (0.76-1.42) (0.82-1.65)  
Potassium      
Model 1: RR 1.00 1.02 1.10 1.14 1.42 0.02
95% CI  (0.79-1.34) (0.84-1.45) (0.87-1.52) (1.05-1.92)  
Model 2: RR 1.00 0.98 1.07 1.15 1.43 0.06
95% CI   (0.73-1.33) (0.76-1.51) (0.79-1.68) (0.94-2.17)  
Manganese      
Model 1: RR 1.00 1.13 1.10 1.10 1.18 0.36
95% CI  (0.86-1.48) (0.84-1.45) (0.83-1.45) (0.89-1.56)  
Model 2: RR 1.00 1.09 1.05 1.06 1.11 0.66
95% CI   (0.81-1.45) (0.77-1.43) (0.76-1.48) (0.77-1.60)  
Iron      
Model 1: RR 1.00 1.04 1.08 1.09 0.85 0.16
95% CI  (0.79-1.37) (0.82-1.42) (0.83-1.44) (0.64-1.13)  
Model 2: RR 1.00 0.99 1.01 1.01 0.80 0.13
95% CI  (0.74-1.32) (0.75-1.36) 0.74-1.37) (0.57-1.13)   
1Model 1. Adjusted for age (<30, 30-34, 35-39 or ≥ 40 years), year of diagnosis (1993, 1994-1995, 1996-1996, 1998-1999 
or 2000-2001), number of full-term pregnancies (0. 1-2, 3-4 or ≥ 5 pregnancies lasting at least 6 months), body mass 
index (<20.0, 20.0-22.4, 22.5-24.9, 25.0-27.4, 27.5-29.9 or ≥ 30.0 kg/m2), pack-years of smoking (quintiles), tubal ligation 
(no vs. yes), duration or oral contraceptive use (never, 1-23, 24-71, 72-119 or ≥ 120 months), antidepressant use (never vs. 
ever), history of childhood trauma score (5, 6-10, 11-15, ≥ 16), intake of alcohol, vitamin B6, calcium and vitamin D 
(quintiles) at 2 to 4 years before reference year. 
Model 2. Model 1 additionally adjusted for the effect of the other minerals from food sources in quintiles.  
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Table 3.13 Multivariable adjusted RR1 and  95% CI for mineral intake 
from supplement sources 2 to 4 years before reference year and PMS: 
NHS2 PMS Sub-study, 1991-2001. 
  Supplement users  
  Non-Users T1 T2 T3 Ptrend2 
Zinc      
RR 1.00 1.31 1.32 0.75 0.07 
95% CI  (0.97-1.77) (0.95-1.85) (0.52-1.10)   
Magnesium     
RR 1.00 1.66 0.96 1.35 0.80 
95% CI  (1.18-2.32) (0.65-1.42) (0.97-1.89)   
Copper      
RR 1.00 1.28 1.12 0.98 0.80 
95% CI  (0.92-1.78) (0.74-1.72) (0.69-1.38)   
Potassium     
RR 1.00 1.38 1.37 1.38 0.83 
95% CI  (0.93-2.05) (0.88-2.14) (0.93-2.05)   
Manganese     
RR 1.00 1.44 1.35 1.14 0.46 
95% CI  (0.99-2.08) (0.95-1.92) (0.75-1.73)   
Iron      
RR 1.00 1.07 1.03 0.81 0.23 
95% CI  (0.80-1.43) (0.75-1.41) (0.58-1.11)   
1Adjusted for age (<30, 30-34, 35-39 or ≥ 40 years), year of diagnosis (1993, 1994-1995, 1996-1996, 1998-1999 
or 2000-2001), number of full-term pregnancies (0. 1-2, 3-4 or ≥ 5 pregnancies lasting at least 6 months), body 
mass index (<20.0, 20.0-22.4, 22.5-24.9, 25.0-27.4, 27.5-29.9 or ≥ 30.0 kg/m2), pack-years of smoking (quintiles), 
tubal ligation (no vs. yes), duration or oral contraceptive use (never, 1-23, 24-71, 72-119 or ≥ 120 months), 
antidepressant use (never vs. ever), history of childhood trauma score (5, 6-10, 11-15, ≥ 16), intake of alcohol, 
vitamin B6, calcium and vitamin D (quintiles) at 2 to 4 years before reference year and  food intake of the 
respective mineral. 
2Test for trend among users of supplements only. 
/ 
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Table 3.14a Age and multivariable adjusted RR1 and 95% CI for potassium 
intake from foods 2 to 4 years before reference and premenstrual physical 
premenstrual symptoms: NHS2 PMS Sub-study, 1991-2001. 
  Q1 Q2 Q3 Q4 Q5 Ptrend 
Bloating       
Case-Control Ratio 129:243 131:279 144:261 132:231 138:196  
Age adjusted RR 1.00 0.89 1.10 1.13 1.45 0.005 
95% CI  (0.66-1.19) (0.82-1.48) (0.84-1.34) (1.07-1.98)  
Multivariable RR1 1.00 0.98 1.36 1.28 1.81 0.001 
95% CI   (0.69-1.38) (0.95-1.94) (0.88-1.87) (1.21-2.71)   
Swelling       
Case-Control Ratio 35:361 45:397 56:398 41:343 55:297  
Age adjusted RR 1.00 1.13 1.47 1.26 1.99 0.002 
95% CI  (0.71-1.80) (0.94-2.29) (0.79-2.03) (1.27-3.12)  
Multivariable RR1 1.00 1.56 2.27 2.11 4.06 <.0001
95% CI   (0.91-2.68) (1.31-3.93) (1.16-3.84) (2.21-7.47)   
Breast Tenderness      
Case-Control Ratio 139:167 159:193 165:186 163:159   
Age adjusted RR 1.00 0.99 1.10 1.29 1.44 0.008 
95% CI  (0.73-1.35) (0.81-1.50) (0.94-1.77) (1.04-2.00)  
Multivariable RR1 1.00 1.05 1.22 1.29 1.52 0.032 
95% CI   (0.73-1.50) (0.84-1.77) (0.87-1.92) (1.00-2.33)   
Cramping       
Case-Control Ratio 61:318 76:359 65:364 74:315 73:281  
Age adjusted RR 1.00 1.08 0.94 1.25 1.39 0.06 
95% CI  (0.75-1.56) (0.65-1.38) (0.86-1.81) (0.95-2.02)  
Multivariable RR1 1.00 1.30 1.23 1.74 2.10 0.002 
95% CI   (0.85-2.00) (0.78-1.93) (1.09-2.77) (1.29-3.43)   
Diarrhea       
Case-Control Ratio 85:316 67:359 89:350 83:310 82:268  
Age adjusted RR 1.00 0.68 0.96 1.03 1.19 0.08 
95% CI  (0.48-1.73) (0.67-1.34) (0.73-1.44) (0.84-1.68)  
Multivariable RR1 1.00 0.73 1.13 1.25 1.50 0.01 
95% CI   (0.49-1.09) (0.76-1.69) (0.82-1.91) (0.96-2.35)   
Fatigue       
Case-Control Ratio 118:321 100:351 128:343 114:306 109:264  
Age adjusted RR 1.00 0.77 1.04 1.06 1.20 0.06 
95% CI  (0.56-1.04) (0.78-1.40) (0.78-1.44) (0.88-1.64)  
Multivariable RR1 1.00 0.82 1.18 1.23 1.47 0.013 
95% CI   (0.58-1.16) (0.83-1.68) (0.85-1.79) (0.99-2.19)   
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Table 3.14a, continued. 
  Q1 Q2 Q3 Q4 Q5 Ptrend 
Appetite      
Case-Control Ratio 120:302 120:312 125:307 112:266 139:220  
Age adjusted RR 1.00 0.93 1.03 1.09 1.67 0.0004 
95% CI  (0.69-1.26) (0.77-1.39) (0.80-1.49) (1.23-2.26)  
Multivariable RR1 1.00 0.98 1.17 1.15 1.85 0.001 
95% CI   (0.69-1.38) (0.82-1.68) (0.78-1.68) (1.25-2.76)   
Insomnia       
Case-Control Ratio 38:367 35:404 42:412 50:353 49:301  
Age adjusted RR 1.00 0.82 0.99 1.38 1.63 0.004 
95% CI  (0.50-1.33) (0.62-1.57) (0.88-2.16) (1.04-2.56)  
Multivariable RR1 1.00 1.03 1.33 1.96 3.00 <0.001 
95% CI   (0.61-1.74) (0.78-2.25) (1.15-3.34) (1.70-5.30)   
Acne       
Case-Control Ratio 82:306 81:342 78:334 67:304 66:259  
Age adjusted RR 1.00 0.85 0.91 0.89 1.08 0.68 
95% CI  (0.60-1.20) (0.64-1.30) (0.61-2.28) (0.74-1.56)  
Multivariable RR1 1.00 1.02 1.20 1.14 1.52 0.09 
95% CI   (0.68-1.54) (0.78-1.84) (0.72-1.80) (0.94-2.47)   
Back pain       
Case-Control Ratio 77:314 80:361 82:353 84:303 92:270  
Age adjusted RR 1.00 0.87 0.95 1.15 1.43 0.01 
95% CI  (0.62-1.24) (0.67-1.34) (0.81-1.62) (1.02-2.02)  
Multivariable RR1 1.00 1.02 1.21 1.61 2.09 0.0002 
95% CI   (0.68-1.53) (0.80-1.84) (1.04-2.48) (1.34-3.28)   
1Adjusted for age (<30, 30-34, 35-39 or ≥ 40 years), year of diagnosis (1993, 1994-1995, 1996-1996, 1998-1999 or 2000-
2001), number of full-term pregnancies (0. 1-2, 3-4 or ≥ 5 pregnancies lasting at least 6 months), body mass index (<20.0, 
20.0-22.4, 22.5-24.9, 25.0-27.4, 27.5-29.9 or ≥ 30.0 kg/m2), pack-years of smoking (quintiles), tubal ligation (no vs. yes), 
duration or oral contraceptive use (never, 1-23, 24-71, 72-119 or ≥ 120 months), antidepressant use (never vs. ever), history of 
childhood trauma score (5, 6-10, 11-15, ≥ 16), intake of alcohol, vitamin B6, calcium and vitamin D (quintiles) and potassium 
intake from supplements, at 2 to 4 years before reference year. 
/ 
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Table 3.14b Age and multivariable adjusted RR1 and 95% CI for potassium 
intake from foods 2 to 4 years before reference and premenstrual psychological 
premenstrual symptoms: NHS2 PMS Sub-study, 1991-2001. 
  Q1 Q2 Q3 Q4 Q5 Ptrend 
Depression        
Case-Control Ratio 89:354 96:407 84:415 92:357 101:301  
Age adjusted RR 1.00 0.93 0.83 1.06 1.40 0.023
95% CI  (0.68-1.29) (0.60-1.15) (0.77-1.47) (1.01-1.93)  
Multivariable RR1 1.00 1.06 1.00 1.27 1.60 0.013
95% CI   (0.74-1.53) (0.68-1.48) (0.85-1.89) (1.06-2.43)  
Irritability       
Case-Control Ratio 188:244 178:256 184:265 172:224 181:197  
Age adjusted RR 1.00 0.90 0.93 1.05 1.29 0.038
95% CI  (0.68-1.17) (0.71-1.21) (0.79-1.38) (0.98-1.71)  
Multivariable RR1 1.00 0.99 1.12 1.17 1.61 0.006
95% CI   (0.72-1.37) (0.81-1.55) (0.83-2.33) (1.12-2.33)  
Mood       
Case-Control Ratio 131:317 152:367 152:366 127:320 160:268  
Age adjusted RR 1.00 0.99 1.03 1.01 1.55 0.003
95% CI  (0.75-1.30) (0.78-1.37) (0.75-1.35) (1.16-2.06)  
Multivariable RR1 1.00 1.13 1.15 1.15 1.92 0.001
95% CI   (0.82-1.56) (0.82-1.60) (0.80-1.64) (1.33-2.78)  
Angry       
Case-Control Ratio 130:332 130:381 134:388 116:343 121:291  
Age adjusted RR 1.00 0.85 0.92 0.92 1.17 0.23
95% CI  (0.64-1.13) (0.69-1.22) (0.68-1.24) (0.87-1.58)  
Multivariable RR1 1.00 0.91 0.99 0.95 1.31 0.15
95% CI   (0.66-1.26) (0.71-1.39) (0.66-1.35) (0.89-1.91)  
Confusion       
Case-Control Ratio 19:384 20:428 23:426 21:375 20:322  
Age adjusted RR 1.00 0.88 1.03 1.11 1.25 0.30
95% CI  (0.47-1.67) (0.56-1.91) (0.59-2.08) (0.66-2.37)  
Multivariable RR1 1.00 1.05 1.42 1.53 1.93 0.07
95% CI   (0.51-2.16) (0.68-2.96) (0.71-3.29) (0.85-4.37)  
Cry       
Case-Control Ratio 102:315 110:356 114:356 112:310 127:255  
Age adjusted RR 1.00 0.94 1.01 1.15 1.61 0.001
95% CI  (0.69-1.28) (0.74-1.37) (0.84-1.57) (1.18-2.20)  
Multivariable RR1 1.00 1.04 1.14 1.26 1.86 0.001
95% CI   (0.73-1.48) (0.80-1.64) (0.86-1.84) (1.25-2.75)  
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Table 3.14b, continued. 
  Q1 Q2 Q3 Q4 Q5 Ptrend 
Alone      
Case-Control Ratio 79:360 82:404 79:412 64:359 87:305  
Age adjusted RR 1.00 0.89 0.90 0.85 1.41 0.07
95% CI  (0.64-1.26) (0.64-1.27) (0.59-1.22) (1.00-1.99)  
Multivariable RR1 1.00 0.96 1.00 0.95 1.58 0.04
95% CI   (0.65-1.43) (0.66-1.50) (0.61-1.48) (1.01-2.45)  
Forgetfulness       
Case-Control Ratio 40:379 35:415 47:429 38:367 47:312  
Age adjusted RR 1.00 0.77 1.05 1.00 1.48 0.04
95% CI  (0.48-1.24) (0.67-1.63) (0.63-1.59) (0.95-2.31)  
Multivariable RR1 1.00 0.88 1.33 1.22 1.93 0.01
95% CI   (0.51-1.51) (0.78-2.25) (0.70-2.16) (1.09-3.44)  
Anxiety       
Case-Control Ratio 72:364 67:411 72:418 59:365 73:314  
Age adjusted RR 1.00 0.80 0.89 0.84 1.23 0.20
95% CI  (0.56-1.15) (0.62-1.27) (0.58-1.22) (0.86-1.76)  
Multivariable RR1 1.00 0.98 1.08 1.04 1.63 0.04
95% CI   (0.65-1.47) (0.71-1.66) (0.71-1.66) (0.66-1.64)  
Sensibility       
Case-Control Ratio 73:355 65:380 82:400 64:344 95:291  
Age adjusted RR 1.00 0.81 1.01 0.93 1.69 0.001
95% CI  (0.56-1.17) (0.72-1.44) (0.65-1.35) (1.19-2.38)  
Multivariable RR1 1.00 0.90 1.14 1.04 1.88 0.003
95% CI   (0.60-1.36) (0.75-1.71) (0.67-1.62) (1.20-2.95)  
1Adjusted for age (<30, 30-34, 35-39 or ≥ 40 years), year of diagnosis (1993, 1994-1995, 1996-1996, 1998-1999 or 2000-
2001), number of full-term pregnancies (0. 1-2, 3-4 or ≥ 5 pregnancies lasting at least 6 months), body mass index (<20.0, 
20.0-22.4, 22.5-24.9, 25.0-27.4, 27.5-29.9 or ≥ 30.0 kg/m2), pack-years of smoking (quintiles), tubal ligation (no vs. yes), 
duration or oral contraceptive use (never, 1-23, 24-71, 72-119 or ≥ 120 months), antidepressant use (never vs. ever), history of 
childhood trauma score (5, 6-10, 11-15, ≥ 16), intake of alcohol, vitamin B6, calcium and vitamin D (quintiles) and potassium 
intake from supplements, at 2 to 4 years before reference year. 
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Table 3.15 Age and multivariate adjusted RR and 95% CI  for zinc/copper and 
calcium/magnesium molar ratios: NHS2 PMS Sub-study, 1991-2001 
  Q1 Q2 Q3 Q4 Q5 Ptrend 
Total Intakes1  
 Calcium/Magnesium molar ratio 
Median 1.21 1.56 1.87 2.23 2.89 
Case-Control Ratio 211:392 236:368 202:402 216:388 190:414 
Age-adjusted RR 1.00 1.18 0.91 0.99 0.83 0.03 
95% CI (0.94-1.49) (0.71-1.15) (0.78-1.26) (0.65-1.05) 
Multivariate  RR 1.00 1.38 0.97 1.01 0.92 0.15 
95% CI (1.06-1.80) (0.74-1.28) (0.77-1.34) (0.69-1.23) 
Zinc/Copper molar ratio
Median 6.8 8 9 10.3 13.9 
Case-Control Ratio 220:384 217:386 219:382 191:418 208:394 
Age-adjusted RR 1.00 0.98 0.99 0.78 0.88 0.15 
95% CI (0.77-1.24) (0.78-1.26) (0.62-0.99) (0.70-1.12) 
Multivariate  RR 1.00 0.84 0.92 0.71 0.76 0.05 
95% CI   (0.64-1.09) (0.71-1.20) (0.54-0.93) (0.58-1.00)  
Food intake only2  
 Calcium/Magnesium molar ratio 
Median 1.15 1.48 1.73 2.04 2.52 
Case-Control Ratio 211:392 221:383 238:366 204:400 181:423 
Age-adjusted RR 1.00 1.06 1.17 0.91 0.74 0.004
95% CI (0.84-1.34) (0.93-1.48) (0.71-1.15) (0.58-0.95) 
Multivariate  RR 1.00 1.09 1.26 0.9 0.74 0.02 
95% CI (0.83-1.42) (0.96-1.66) (0.67-1.19) (0.54-1.00) 
Zinc/Copper molar ratio
Median 6.6 7.9 9 10.2 12.4 
Case-Control Ratio 228:372 208:396 219:290 199:402 201:404 
Age-adjusted RR 1.00 0.86 0.9 0.79 0.77 0.03 
95% CI (0.68-1.08) (0.72-1.14) (0.62-1.00) (0.61-0.98) 
Multivariate  RR 1.00 0.71 0.83 0.72 0.69 0.02 
95% CI   (0.55-0.93) (0.64-1.08) (0.54-0.94) (0.53-0.90)  
1 Multivariable RR were adjusted for age, year of diagnosis, number of full-term pregnancies (lasting at least 6 months), body 
mass index, pack-years of smoking, tubal ligation, duration or oral contraceptive use, antidepressant use,  history of 
childhood trauma score , intake of alcohol, vitamin B6, and vitamin D 2 to 4 years before reference year. For zinc/copper 
ratios, RR were additionally adjusted for total calcium intakes in quintiles 
2 Multivariable RR were additionally adjusted for the corresponding molar ratios from supplemental sources. 
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Table 3.16 Stratified RR1 and 95% CI for total mineral intake 2 to 4 years before 
reference year and PMS by age at diagnosis: NHS2 PMS Sub-study, 1991-2001. 
  Q1 Q2 Q3 Q4 Q5 Pvalue2
Zinc Case:Control 92:152 91:146 102:159 89:136 133:189 0.79 
Age < 40 RR 1.00 1.00 1.03 1.09 0.97  
(n=1289) 95% CI   (0.66-1.53) (0.68-1.58) (0.70-1.72) (0.60-1.57)  
Age ≥ 40 Case:Control 114:253 91:243 125:258 114:216 104:212  
(n=1735) RR 1.00 1.12 0.99 1.01 1.25  
  95% CI   (0.78-1.62) (0.70-1.42) (0.70-1.47) (0.28-1.92)  
Magnesium Case:Control 106:157 114:177 89:173 96:144 102:131 0.72 
Age < 40 RR 1.00 0.94 0.88 0.82 0.57  
  95% CI   (0.63-1.41) (0.56-1.38) (0.51-1.32) (0.34-0.94)  
Age ≥ 40 Case:Control 85:213 109:241 127:262 117:253 110:213  
 RR 1.00 0.86 0.9 0.94 0.9  
  95% CI   (0.59-1.25) (0.61-1.33) (0.62-1.41) (0.58-1.40)  
Copper Case:Control 98:178 124:212 56:93 109:150 120:149 0.63 
Age < 40 RR 1.00 0.79 0.80 0.7 0.59  
  95% CI   (0.54-1.16) (0.50-1.29) (0.46-1.07) (0.38-0.92)  
Age ≥ 40 Case:Control 84:217 144:303 82:228 136:247 102:187  
 RR 1.00 0.88 1.12 0.77 0.88  
  95% CI   (0.61-1.26) (0.74-1.69) (0.52-1.14) (0.57-1.37)  
Potassium Case:Control 116:161 124:205 99:178 91:139 77:99 0.43 
Age < 40 RR 1.00 1.05 1.03 0.89 0.64  
  95%CI   (0.72-1.53) (0.68-1.56) (0.58-1.38) (0.40-1.03)  
Age ≥ 40 Case:Control 87:230 97:225 113:259 118:254 133:214  
 RR 1.00 0.79 0.82 0.74 0.58  
  95%CI   (0.54-1.15) (0.56-1.20) (0.50-1.09) (0.39-0.87)  
Manganese Case:Control 99:171 95:146 104:163 100:162 109:140 0.72 
Age < 40 RR 1.00 0.86 0.79 0.86 0.56  
  95%CI   (0.57-1.30) (0.53-1.18) (0.57-1.31) (0.36-0.86)  
Age ≥ 40 Case:Control 94:212 109:230 112:283 119:245 114:212  
 RR 1.00 1.02 1.35 1.02 1.08  
  95%CI   (0.70-1.48) (0.93-1.95) (0.70-1.49) (0.72-1.60)  
Iron Case:Control 91:139 86:140 104:155 110:160 116:188 0.61 
Age < 40 RR 1.00 1.19 1.08 0.94 1.16  
  95%CI   (0.77-1.85) (0.70-1.66) (0.59-1.48) (0.71-1.90)  
Age ≥ 40 Case:Control 101:207 116:256 125:241 110:249 96:229  
 RR 1.00 1.12 1.10 1.70 1.76  
  95%CI   (0.78-1.61) (0.76-1.60) (1.14-2.54) (1.14-2.71)  
1  Adjusted for age (continuous), year of diagnosis, number of full-term pregnancies, BMI, pack-years of smoking, tubal ligation, 
duration of oral contraceptive use, antidepressant use, history of childhood trauma score, intake of alcohol, vitamin B6, calcium 
and vitamin D at 2 to 4 years before reference year. 
2  P-value for likelihood ratio test of the interaction terms of age (<40 or ≥40 years) by quintiles of each  mineral. 
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Table 3.17 Stratified RR1 and 95% CI for total mineral intake 2 to 4 years before 
reference year and PMS by BMI: NHS2 PMS Sub-study, 1991-2001. 
 Q1 Q2 Q3 Q4 Q5 Pvalue2
Zinc Case:Control 132:279 117:257 122:254 106:209 145:266 0.12 
BMI<25 RR 1.00 0.98 0.94 0.91 0.88  
(n=1890) 95% CI   (0.70-1.38) (0.67-1.32) (0.63-1.31) (0.59-1.30)  
BMI≥25 Case:Control 68:109 56:122 95:155 91:128 91:130  
(n=1048) RR 1.00 0.77 0.96 1.12 1.06  
  95% CI   (0.50-1.27) (0.60-1.54) (0.68-1.83) (0.59-1.88)   
MagnesiumCase:Control 111:230 127:268 123:277 127:259 134:231 0.90 
BMI<25 RR 1.00 0.98 1.01 1.05 1.21  
  95% CI   (0.69-1.40) (0.69-1.46) (0.71-1.55) (0.80-1.82)  
BMI≥25 Case:Control 76:133 90:138 85:144 81:126 69:103  
 RR 1.00 1.30 1.32 1.40 1.62  
  95% CI   (0.82-2.06) (0.81-2.15) (0.83-2.34) (0.91-2.91)   
Copper Case:Control 113:266 156:350 77:194 141:232 135:223 0.42 
BMI<25 RR 1.00 1.13 1.06 1.41 1.42  
  95% CI   (0.82-1.57) (0.72-1.56) (0.98-2.02) (0.96-2.09)  
BMI≥25 Case:Control 63:117 106:150 56:112 93:158 83:107  
 RR 1.00 1.47 1.03 1.16 1.38  
  95% CI   (0.93-2.32) (0.61-1.74) (0.72-1.88) (0.80-2.37)   
Potassium Case:Control 121:232 126:295 127:275 127:254 121:209 0.98 
BMI<25 RR 1.00 0.81 0.90 1.04 1.19  
  95%CI   (0.58-1.13) (0.63-1.28) (0.73-1.50) (0.82-1.74)  
BMI≥25 Case:Control 64:125 79:145 91:129 74:148 78:124  
 RR 1.00 1.54 1.20 1.45 2.27  
  95%CI   (0.98-2.43) (0.75-1.93) (0.89-2.35) (1.34-3.83)   
Manganese Case:Control 107:235 109:245 126:292 137:255 143:238 0.45 
BMI<25 RR 1.00 1.04 0.93 1.12 1.37  
  95%CI   (0.72-1.49) (0.65-1.31) (0.79-1.59) (0.95-1.98)  
BMI≥25 Case:Control 80:138 89:118 85:144 72:140 75:104  
 RR 1.00 1.26 1.06 0.98 1.25  
  95%CI   (0.81-1.95) (0.69-1.65) (0.62-1.57) (0.76-2.05)   
Iron Case:Control 107:224 123:253 126:239 136:267 130:282 0.42 
BMI<25 RR 1.00 1.02 1.08 0.93 0.71  
  95%CI   (0.72-1.50) (0.75-1.56) (0.63-1.36) (0.47-1.07)  
BMI≥25 Case:Control 76:111 74:134 94:135 77:134 80:130  
RR 1.00 0.77 0.82 0.65 0.68  
 95%CI   (0.48-1.22) (0.51-1.30) (0.39-1.08) (0.39-1.19)   
1  Adjusted for age, year of diagnosis, number of full-term pregnancies, BMI (continuous), pack-years of smoking, tubal ligation, 
duration of oral contraceptive use, antidepressant use, history of childhood trauma score, intake of alcohol, vitamin B6, calcium 
and vitamin D at 2 to 4 years before reference year. 
2  P-value for likelihood ratio test of the interaction terms of BMI (<25 or ≥25 years) by quintiles of each  mineral. 
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Table 3.18 Stratified RR1 and 95% CI for total mineral intake 2 to 4 years before 
reference year and PMS by smoking: NHS2 PMS Sub-study, 1991-2001. 
  Q1 Q2 Q3 Q4 Q5 Pvalue2
Zinc Case:Control 79:116 71:84 91:101 69:95 96:95 0.71
Ever smoker RR 1.00 1.25 1.17 0.78 1.39  
(n=897) 95%CI   (0.76-2.06) (0.72-1.89) (0.46-1.31) (0.78-2.46)  
Never smoker Case:Control 126:289 111:303 136:314 133:257 141:304  
(n=2120) RR 1.00 0.88 0.94 1.03 0.78  
 95%CI   (0.63-1.23) (0.67-1.31) (0.73-1.47) (0.53-1.16)   
Magnesium Case:Control 56:71 80:96 81:114 96:106 93:104 0.37
Ever smoker RR 1.00 1.19 1.41 1.49 1.63  
 95%CI   (0.69-2.05) (0.80-2.49) (0.83-2.68) (0.87-3.06)  
Never smoker Case:Control 135:298 143:320 134:321 117:290 118:238  
RR 1.00 1.07 1.03 0.95 1.21  
 95%CI   (0.77-1.47) (0.73-1.45) (0.66-1.38) (0.82-1.80)   
Copper Case:Control 59:87 106:111 52:81 99:122 90:90 0.93
Ever smoker RR 1.00 1.45 1.17 1.44 1.62  
  95%CI   (0.87-2.41) (0.65-2.09) (0.84-2.47) (0.90-2.93)  
Never smoker Case:Control 123:308 162:402 86:237 144:275 132:245  
 RR 1.00 1.06 0.91 1.23 1.20  
  95%CI   (0.78-1.45) (0.63-1.32) (0.87-1.72) (0.82-1.75)   
Potassium Case:Control 62:80 75:93 75:106 100:102 94:110 0.59
Ever smoker RR 1.00 1.03 1.41 1.89 1.53  
  95%CI   (0.71-2.04) (0.83-2.40) (1.10-3.22) (0.89-2.65)  
Never smoker Case:Control 141:311 146:336 137:329 108:290 115:201  
 RR 1.00 1.08 1.00 0.94 1.67  
  95%CI   (0.79-1.48) (0.72-1.39) (0.66-1.33) (1.15-2.43)   
Manganese Case:Control 23:33 31:22 31:23 27:24 21:20 0.20
Ever smoker RR 1.00 1.87 1.67 1.53 2.00  
 95%CI   (0.73-4.81) (0.64-4.36) (0.57-4.09) (0.69-5.75)  
Never smoker Case:Control 170:349 173:353 184:423 191:381 202:330  
RR 1.00 1.02 0.91 1.07 1.31  
 95%CI   (0.77-1.34) (0.69-1.19) (0.81-1.41) (0.98-1.75)   
Iron Case:Control 33:33 26:27 29:18 19:21 26:23 0.77
Ever smoker RR 1.00 1.00 1.10 0.44 0.85  
 95%CI   (0.40-2.50) (0.41-2.98) (0.12-1.53) (0.25-2.93)  
Never smoker Case:Control 159:312 175:368 199:377 201:386 186:939  
RR 1.00 1.00 1.00 0.91 0.70  
 95%CI   (0.76-1.33) (0.75-1.33) (0.68-1.24) (0.51-0.97)   
1  Adjusted for age, year of diagnosis, number of full-term pregnancies, BMI, tubal ligation, duration of oral contraceptive use, 
antidepressant use, history of childhood trauma score, intake of alcohol, vitamin B6, calcium and vitamin D at 2 to 4 years before 
reference year. 
2  P-value for likelihood ratio test of the interaction terms of smoking (ever vs. never) by quintiles of each  mineral. 
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Table 3.19 Stratified RR1 and 95% CI for total mineral intake 2 to 4 years before 
reference year and PMS by alcohol intake: NHS2 PMS Sub-study, 1991-2001. 
 Q1 Q2 Q3 Q4 Q5 Pvalue2
Zinc Case:Control 131:237 108:238 137:237 114:199 137:226 0.97
Drinker RR 1.00 0.80 0.95 0.90 0.92  
(n=1764) 95% CI   (0.57-1.12) (0.68-1.34) (0.63-1.29) (0.62-1.37)  
Non-drinker Case:Control 75:168 74:151 90:180 89:153 100:175  
(n=1255) RR 1.00 1.19 1.15 1.16 1.04  
95% CI   (0.78-1.83) (0.76-1.75) (0.75-1.80) (0.63-1.71)   
Magnesium Case:Control 97:166 128:240 137:278 136:234 129:219 0.57
Drinker RR 1.00 1.04 0.98 1.13 1.22  
 95% CI   (0.72-1.51) (0.67-1.43) (0.76-1.67) (0.79-1.87)  
Non-drinker Case:Control 94:204 95:178 79:157 77:163 83:125  
RR 1.00 1.16 1.12 1.21 1.59  
 95% CI   (0.78-1.73) (0.73-1.74) (0.77-1.92) (0.98-2.60)   
Copper Case:Control 93:193 161:298 79:202 164:253 130:191 0.22
Drinker RR 1.00 1.23 0.90 1.38 1.52  
  95% CI   (0.87-1.73) (0.61-1.34) (0.96-1.98) (1.01-2.30)  
Non-drinker Case:Control 89:202 107:217 59:119 81:144 92:145  
 RR 1.00 1.08 1.19 1.26 1.40  
  95% CI   (0.74-1.58) (0.75-1.88) (0.82-1.93) (0.89-2.20)   
Potassium Case:Control 103:187 133:229 123:272 135:245 133:204 0.18 
Drinker RR 1.00 1.14 0.92 1.20 1.56  
  95%CI   (0.80-1.62) (0.64-1.31) (0.83-1.73) (1.06-2.30)  
Non-drinker Case:Control 100:204 88:201 89:165 74:148 77:109  
 RR 1.00 0.95 1.25 1.21 1.91  
  95%CI   (0.64-1.39) (0.83-1.88) (0.78-1.86) (1.21-3.02)   
Manganese Case:Control 96:171 126:214 135:276 141:266 129:210 0.05
Drinker RR 1.00 1.09 0.93 0.99 1.19  
 95%CI   (0.76-1.57) (0.65-1.32) (0.69-1.42) (0.80-1.76)  
Non-drinker Case:Control 97:212 78:162 81:170 78:141 94:142  
RR 1.00 1.00 0.96 1.21 1.49  
 95%CI   (0.67-1.49) (0.65-1.43) (0.81-1.83) (0.98-2.25)   
Iron Case:Control 116:200 126:233 138:238 133:239 114:227 0.92
Drinker RR 1.00 1.06 0.96 0.91 0.71  
 95%CI   (0.75-1.50) (0.68-1.36) (0.63-1.32) (0.47-1.06)  
Non-drinker Case:Control 76:146 76:163 91:158 87:170 98:190  
RR 1.00 0.87 0.97 0.78 0.69  
95%CI   (0.56-1.35) (0.63-1.49) (0.49-1.24) (0.42-1.12)   
1  Adjusted for age, year of diagnosis, number of full-term pregnancies, BMI, pack-years of smoking, tubal ligation, duration of 
oral contraceptive use, antidepressant use, history of childhood trauma score, intake of vitamin B6, calcium and vitamin D at 2 
to 4 years before reference year. 
2  P-value for likelihood ratio test of the interaction terms of drinking (yes vs. no) by quintiles of each  mineral. 
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CHAPTER 4 
DIETARY INTAKE AND BLOOD LEVELS OF SELECTED 
MICRONUTRIENTS AND PREMENSTRUAL SYNDROME  
IN A COLLEGE-AGED POPULATION 
 
4.1 Background 
 
4.1.1 Introduction 
Premenstrual syndrome (PMS) is a disorder that can affect women at any age 
between menarche and menopause.  It is characterized by the presence of at least one 
physical and one psychological symptom, restricted to the luteal phase, that adversely 
affect life activities and social relationships. Although the true prevalence of PMS is 
currently unknown, it has been estimated that 15% of women of reproductive age in the 
USA meet established clinical criteria for PMS. Current treatments for PMS include oral 
contraceptives, gonadotropin-releasing hormone agonists, and antidepressants, all of 
which have significant side effects (1).  
The pathophysiology of PMS remains unclear, but it is suspected that diet may 
play a role in the development of this disorder. Dietary intakes of some micronutrients 
like calcium and vitamin D have been already identified as potential risk factors (2). We 
propose to evaluate the association between dietary intakes of vitamin B6, riboflavin, 
folate, vitamin B12, magnesium, zinc, sodium and potassium and premenstrual syndrome 
among young adult women.  
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4.1.2 Physiology of the relationship between micronutrients and premenstrual 
syndrome 
Because of the variety of symptoms present in PMS, many systems may be 
involved in its pathophysiology. Neurotransmitters, such as serotonin, gamma-amino 
butyric acid (GABA), and melatonin are associated with symptoms of anxiety, depression 
and fatigue, and may be affected by cyclical ovarian hormonal changes (3, 4).  Some 
studies have suggested that women with PMS have lower levels of serotonin (5, 6), 
melatonin (7), and GABA (8, 9) compared to women without PMS, but other studies (10, 
11) have not observed these associations. 
Micronutrients may play a role in the development of PMS through their 
involvement in the metabolism of neurotransmitters and hormones. For example, 
riboflavin is needed to activate vitamin B6, which is a cofactor in the generation of 
serotonin from the amino acid tryptophan (12). Vitamins B12, B6, and folate are 
associated with the formation of S-adenosyl-methionine and tetrahydrobiopterin, both of 
which are required for the metabolism of serotonin and dopamine (13, 14). Magnesium is 
required for the conversion of serotonin into melatonin (15). Magnesium and zinc interact 
with the glutamate receptor NMDA, which is associated with depression (16-18). The 
potassium brain pore, TREK-1, has been also associated with depression (19, 20). 
Potassium and sodium intakes are regulators of the extracellular and intracellular fluid 
balance through the renin-angiotensin-aldosterone system, thereby potentially associated 
to symptoms of bloating and edema (21). Nevertheless, the role of these micronutrients in 
PMS development is still unclear.  
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4.1.3 Epidemiologic evidence for the association between micronutrients and 
premenstrual syndrome 
The epidemiologic studies of vitamin B6, riboflavin, folate, and vitamin B12 and 
PMS have been described before in chapter 2. Studies of mineral intakes have been 
described in chapter 3. Briefly, we are going to summarize the findings of the most 
relevant studies.  
a) Micronutrient supplementation and PMS 
Vitamin B6 and magnesium are the most studied micronutrient supplements in the 
treatment of PMS. Several randomized clinical trials of vitamin B6 supplementation (22-
27) have found an improvement in PMS symptoms with doses ranging from 50 to 500 
mg/day, but others have not found beneficial effects (28-30). Randomized clinical trials 
of magnesium supplementation have found beneficial (31, 32) or null (33-35) effects on 
the treatment of PMS symptoms. 
A study evaluating the effects of potassium on PMS symptoms and weight gain 
did not observe a significant benefit of potassium supplementation (36).  In a randomized 
cross-over study of four diets with different combinations of electrolyte contents, the 
authors found that diets high in potassium and low in sodium resulted in reduced 
depression symptoms, less fatigue and higher vigor compared to diets low in potassium 
and moderate in sodium (37).   
Other randomized clinical trials have evaluated the effects of supplements 
containing multiple micronutrients such as B6, riboflavin, and magnesium on symptoms 
of PMS, and observed significant improvement of symptoms (38-40).  
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Limited evidence also suggests that folate, vitamin B12 and zinc supplements 
may be effective in treatment of depression (13, 14, 41-44). This association is relevant 
for research on PMS because depression potentially shares some etiologic features with 
PMS.  
 
b) Micronutrient status and PMS 
Although micronutrient deficiencies in the US are uncommon, it has been 
suggested that women with PMS have lower levels of vitamin B6, magnesium and zinc. 
Very few studies have evaluated these relationships and results have been inconsistent 
with regard to the assessment methods used.   
Few studies (45-47) have evaluated plasma levels of pyridoxal 5’-phosphate 
(PLP), the active form of vitamin B6, in women with and without PMS, but no significant 
differences were reported. In a cross-sectional study conducted by Ritchie et al. (46) 
blood samples were collected from 41 women with moderate to severe PMS and 95 
women with none or only mild symptoms. The authors found that mean plasma PLP was 
similar in both groups (mean ± standard deviation (SD)=39.6 ± 23.0 nmol/l in cases, and 
40.6 ± 23.3 nmol/l in controls). 
Magnesium levels in serum and blood cells have been evaluated in women with 
PMS with inconclusive results (47, 48). Khine et al.(33) used a magnesium loading test 
for measuring magnesium deficiency in 17 women with premenstrual dysphoric disorder 
(PMDD) and 14 women without PMDD . The authors found that the magnesium 
retention after infusion was similar in cases and in controls (mean ± SD = 31.5 ± 25 % 
urinary magnesium retention in cases vs. 27.9± 19 % urinary magnesium retention 
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controls) and concluded that there was no evidence of a magnesium deficiency in women 
with PMDD.  
In a study conducted by Shamberger et al. (49) magnesium, zinc, copper, and 
potassium levels were evaluated in hair samples of women diagnosed with PMS (n = 46) 
and compared to women without PMS (n = 50) . The authors found that women with 
PMS had significantly lower potassium levels in hair as compared to women without 
PMS (potassium = 15.7 ± 15.2 parts per million (ppm) in cases vs. 31.3 ± 28.4 parts per 
million (ppm)  in controls; p < 0.05). There were no significant differences in 
concentrations of copper, sodium, zinc and magnesium (magnesium= 104 ± 85.1 ppm in 
cases, and 111.7 ± 66 ppm in controls). 
Blood levels of micronutrients may fluctuate across the menstrual cycle 
differently in women with PMS and in women without PMS.(50, 51) Das et al.(50) 
conducted a study among 20 healthy women aged 25 to 35 years old with regular 
menstrual cycles and reportedly not suffering from PMS. Using basal body temperature 
as the reference, blood samples were collected at four different points of their menstrual 
cycle: follicular, ovulatory and luteal phases, and the first day of menses. Blood levels of 
zinc, magnesium, selenium and manganese were assessed. Compared to the ovulatory 
phase, during the luteal phase participants had lower levels of zinc (85 ± 0.6 µg/ml vs. 80 
± 0.6 µg/ml; p<0.01) and higher levels of magnesium (1.54 ± 0.06 mEq/L vs. 1.65 ± 0.07 
mEq/L; p<0.01).  
Although only few studies have evaluated the relationships of micronutrients and 
PMS, there is some evidence that blood levels of certain micronutrients may be different 
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during the luteal phase in women suffering from PMS compared to women without PMS 
and that some micronutrient supplements may help in relieving PMS symptoms. The role 
of dietary intakes of vitamin B6, riboflavin, folate, vitamin B12, magnesium, zinc, 
potassium, and sodium and premenstrual syndrome remains unknown.  
 
4.1.4 Summary 
Many systems may be involved in the pathophysiology of this PMS, including 
neurotransmitters such as serotonin, GABA, glutamate and melatonin, as well as other 
systems like the renin-angiotensin-aldosterone system (3).Vitamin B6, riboflavin, folate, 
vitamin B12, magnesium, zinc, potassium and sodium are involved in the metabolical 
pathways of these neurotransmitters and hormones.  Therefore, they may play a role in 
the development of premenstrual syndrome.  
To date, few studies have evaluated micronutrient status in women with PMS 
using blood (45-47, 50, 51), blood cells (48, 49),  hair samples (49), or functional tests 
(33), but results remain controversial.  Vitamin B6 and magnesium supplements are the 
best studied for treatment of premenstrual symptoms, and although some studies have 
found that supplements of B6 (22-26) or magnesium (31, 32) may reduce PMS 
symptoms, other studies have not found beneficial effects (28-30, 33-35). Potassium 
supplementation had no significant effects on premenstrual symptoms, but diets with high 
potassium may be associated to lower fatigue and a decrease in depressive symptoms. 
Folate, B12, and zinc have not been directly studied in relation to PMS, but they may be 
associated with depression (13, 14, 41-43) 
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Therefore, the role of micronutrients and PMS deserves further investigation. In 
this study, we evaluated the association between dietary intakes of vitamin B6, riboflavin, 
folate, vitamin B12, magnesium, zinc, potassium, sodium, and iron, and PMS among 
young adult women.  
 
4.1.5 Specific Aims and Hypotheses 
Specific aim: 
To evaluate the association between dietary intakes and blood levels of vitamin B6, 
riboflavin, folate, vitamin B12, magnesium, zinc, sodium, potassium, and iron, and PMS 
among young adult women. 
Secondary aims:  
- To examine the relationship between dietary intakes of vitamin B6, riboflavin, 
folate, vitamin B12, magnesium, zinc, sodium, potassium, and iron, and PMS. 
- To evaluate the association between blood levels of vitamin B6, folate, vitamin 
B12, magnesium, and ferritin, and PMS. 
Hypotheses: 
There is an inverse relationship between dietary intakes of vitamin B6, riboflavin, folate, 
vitamin B12 magnesium, zinc, potassium, and iron and premenstrual syndrome. High 
dietary intakes of sodium are associated with increased risk of having PMS. Blood levels 
of vitamin B6, folate, vitamin B12 and magnesium are inversely associated with PMS. 
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4.2 Methods 
 
4.2.1 Study design and population 
To examine the association between micronutrient intake and premenstrual 
symptoms and PMS we conducted a cross-sectional study among participants in the 
University of Massachusetts Vitamin D Status Study (UMass Vitamin D Study). 
The UMass Vitamin D Study was conducted from March 2006 to June 2008 
(Phase 1) and from January 2010 to May 2010 (Phase 2) at the University of 
Massachusetts. We recruited 186 women during phase one and 51 during phase two 
through advertisements and fliers posted in area colleges.  
Women were ineligible for the study if they had one or more of the following 
characteristics: 
- Pregnant or not currently menstruating 
- Experiencing untreated depression 
- Reported history of high blood pressure, elevated cholesterol, kidney, liver, digestive, 
rheumatologic, thyroid or bone diseases, hyperparathyroidism, cancer, type 1 or type 
2 diabetes; or polycystic ovaries 
- Taking currently corticosteroids, anabolic steroids, anticonvulsants, cimetidine or 
propanolol.  
Participants had a single clinic visit scheduled on a morning during the 5 to 7 days 
before anticipated start of next menses (late luteal phase). At this visit, a trained research 
assistant measured anthropometric factors and blood pressure of each participant. 
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Participants completed a food frequency questionnaire, a questionnaire on menstrual 
symptom experience, and a questionnaire on lifestyle and demographic factors.  After 
this, participants had blood samples taken at the University Health Services by a trained 
phlebotomist and a DXA scan to evaluate their body composition and bone mineral 
density. 
 
4.2.2 Exposure assessment 
Dietary micronutrient intake: 
To obtain information on dietary intakes of micronutrients, participants completed 
a modified version of the Harvard Food Frequency Questionnaire (FFQ).  Each food item 
had specific portion sizes according to the natural portions or standard weight and 
volumes commonly consumed in the U.S. Participants were asked how often, on average, 
they consumed foods of that specified amount during the previous 2 months with 9 
response options: "6 + per day", "4 to 6 per day", "2 to 3 per day", "1 per day", "5 to 6 per 
week", "2 to 4 per week", "1 per week", "1 to 3 per month" and "never or less than once 
per month". 
The FFQ included additional questions about vitamin and mineral supplements 
used. Participants were asked to report whether they currently took multivitamins, how 
many they took per week (<2, 3-5, 6-9, ≥10 tablets) and the specific brand used.  Use of 
vitamin B6 and dosage (<50, 50 – 99, 100 – 149, ≥150 mg/day) and zinc use and dosage 
(<25, 25–74, 75-100, ≥101 mg/day) were also queried. Additional questions on regular 
use of folate, B complex, magnesium and potassium supplements were included. 
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FFQs were analyzed at Harvard University. For each nutrient, total intake was 
calculated by multiplying the frequency of intake of a specific portion size of each food 
and supplement by its nutrient contents and then summing across all items. Finally, 
adjustment for total calorie intake was performed using the residual method (52). 
 
Validity and Reproducibility of Exposure Assessment: 
The validity and reproducibility of the FFQ has been  studied before.(53-56)  In 
1985, Willett et al.(53) conducted a validation study among 194 members of the Nurses’ 
Health Study. A 61-item semi quantitative FFQ was administered twice with an interval 
of one year (1980 to 1981). During that period four 1-week diet records were also 
collected to serve as a ‘gold’ standard because they are minimally dependent on memory 
and allow direct measurement of food quantities. Participants were instructed by a trained 
dietitian on how to record detailed information on food and beverages consumed for a 
one-week period, using a provided dietetic scale.  
Reproducibility was measured by comparing nutrient scores from both 
questionnaires. Intraclass correlation coefficients ranged from 0.49 for vitamin A without 
supplements to 0.71 for sucrose. Validity was calculated by comparing nutrient intake 
assessed by the FFQ to nutrient intake assessed by the average nutrient score of the four 
one-week diet records.  Correlation coefficients between the second FFQ and the mean 
nutrient intake from the four diet records were high, and ranged from 0.36 for vitamin A 
without supplements to 0.75 for total vitamin C. Overall the food frequency questionnaire 
has high validity and reproducibility.(53) 
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Blood levels of vitamin B6, folate, vitamin B12, magnesium and iron:  
Vitamin B6 was measured as pyridoxal-5’phosphate (PLP) in plasma. For plasma, 
fasting venous blood samples were collected for each participant into heparin-treated 
vacutainers (Becton Dickinson) for plasma and kept in ice for no more than 1 to 2 hours. 
Plasma was then separated by centrifugation at 3000 x g for 15 minutes, aliquoted into 
cryotubes, and stored at -80˚C until needed for biomarker assessment.  
For vitamin B6 analyses, frozen samples were transferred on dry ice to the 
laboratory of Dr. Jacob Selhub, at Tufts University, where plasma PLP concentration was 
measured using a radioactive assay described by  Shin et al. in 1983 (57). In this method, 
radioactive tyrosine is decarboxylated to tyramine by the PLP-dependent enzyme, 
tyrosine decarboxylase. The activity of this enzyme is linearly dependent on PLP 
concentration. The coefficient of variation (CV) for this assay in Dr. Selhub’s laboratory 
is 10%.   
Folate, vitamin B12, magnesium, and ferritin were measured in serum. For serum, 
fasting venous blood was collected into serum-separator vacutainers (Becton Dickinson) 
and kept on ice for one to two hours, which allowed time for a clot to form.  Serum was 
then separated by centrifugation at 3000 x g for 15 minutes, aliquoted into cryotubes, and 
stored at -80˚C until needed for biomarker assessment. 
Folate and vitamin B12 concentrations were determined using a commercially 
available radioimmunoassay kit (SimulTRAC B12 /FOLATE - SNB 57Co/125I, MP 
Biomedicals (06B257117, Orangeburg, NY). Samples were assayed in duplicate for each 
subject; duplicates with greater than 8% difference in either folate or vitamin B12 
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radioactive counts were re-run to improve precision.  Counts were plotted on a log-
normal curve of standards to ascertain serum concentrations. 
Magnesium concentrations were measured using a AAS-Graphite Furnace (AAS-
GF) (Perkin-Elmer 4100 ZL, Perkin-Elmer, Norwalk, CT). The Perkin-Elmer 4100 ZL 
AAS was equipped with a longitudinal Zeeman background correction and a pyrolytically 
coated transversely heated graphite atomizer with an integrated L’vov platform. 
Serum ferritin levels were determined using a commercially available enzyme 
immunoassay (EIA) kit (RAMCO Laboratories, TX). The absorbance was read at 490 nm 
and a background correction wavelength of 630 nm using a 96-well plate reader (Dynex 
Technologies, Chantilly, VA). Absorbance values were entered into the Spectro Ferritin 
MT- calculation program provided by RAMCO laboratories for calculation of ferritin 
concentrations.  
 
Validity of blood level measurements: 
We used standard methods for measurements of vitamin B6, folate, vitamin B12, 
magnesium, and ferritin. PLP is the active form of vitamin B6, and it comprises over half 
the total body pool. PLP levels reflect short-term intake better than long-term intake.(52) 
In 1984, Schuster et al. conducted a study among 19 men and women in a metabolic unit, 
where they received a controlled diet and vitamin B6 supplements. Plasma PLP levels 
had a correlation of r=0.61 with vitamin B6 intake from the previous day.(58) Serum 
folate levels also reflect short-term intake, compared to red blood cell levels.(52) In a 
study conducted by Selhub et al. among 385 members of the Framingham Heart Study 
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cohort, serum folate levels (determined using a radioassay kit from Ciba-Corning) had a 
correlation of r=0.43 with dietary folate intakes.(59) Magnesium serum levels are 
homeostatically controlled, and therefore weakly correlated with dietary intakes (12, 52). 
 
4.2.3 Outcome assessment 
Participants self-reported current menstrual symptom experience on a 
questionnaire based on the “Calendar of Premenstrual Experiences” (COPE) designed by 
Mortola et al.(60). The questionnaire included a list of 26 menstrual symptoms including 
abdominal bloating, breast tenderness, fatigue, tendency to cry easily among others. 
Participants were asked to indicate which symptoms they experienced “most months of 
the year, for at least several days before their menstrual period begins”, and the severity 
of each symptom (not at all, mild, moderate, and severe). Women were asked to report 
when during the cycle their symptoms usually began, when they ended, and to indicate it 
they were present in the week after menses ended. The questionnaire also inquired about 
overall symptom severity, with response options of “minimal” (no effect on normal 
activities), “mild” (some but not that troublesome), “moderate (interferes with normal 
activities’) and “severe” (intolerable, prevents normal activities). Additionally, 
participants were asked whether or not the symptoms resulted in them experiencing 
“relationship discord with spouse or partner”, “difficulties in parenting”, “poor work 
performance/attendance” and “social isolation”, and if so, the severity of the problem (not 
a problem mild, moderate, or severe). 
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Participants were classified as PMS cases if met the following criteria based on 
those established by Mortola et al.(60). 
1. At least one physical and one affective symptom 
2. Overall symptom severity “moderate” or “severe” OR 
Impact of symptoms on life activities “moderate” or “severe” OR 
3. One or more individual symptoms rated as “severe” 
4. Symptoms begins within 14 days of start of menstruation and ends within 4 days 
of start of menses 
5. Symptoms absent in the week after menstruation 
From the 237 women participating in the first two phases, 56 (23.6 %) met these criteria. 
We also used menstrual symptom questionnaire information to identify a 
comparison group of women to serve as controls if they met the following criteria: 
1. Individual symptom severity “none” or “mild” for all symptoms 
2. Overall symptoms severity rated as “none”, “minimal” or “mild” 
3. Impact of symptoms on life activities and relationships of “not a problem” or 
“mild” for all items 
4. Confirmed no previous clinical diagnosis of PMS 
Among women participating in the study, 60 (25.3 %) met these criteria 
 
Validity of outcome assessment 
The validity of this approach for assessing PMS symptoms was evaluated 
previously by Bertone-Johnson et al.(61) among participants from the Nurses’ Health 
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Study II PMS Sub-study. Women who reported a diagnosis of PMS for the first time in 
2001 (n=138) and controls whose reference year was 2001 (n = 377) completed a 
retrospective questionnaire about premenstrual symptoms and PMS diagnosis during the 
2-years prior to diagnosis or reference year. Potential cases were classified into four 
groups: 1) women who met  the Mortola criteria and kept prospective symptom charts as 
part of their diagnosis  (Chart/Mortola cases = 36) ; 2) women who kept prospective 
charts as part of their diagnosis but did not meet the Mortola criteria (Chart cases = 31); 
3) women who met the Mortola criteria but did not keep prospective symptom charts as 
part of their diagnosis (Mortola cases = 30); and 4) women who neither met Mortola 
criteria, nor kept prospective charts (self-report-only cases = 38). The first group was 
considered the most accurate diagnostic group and was used as an “alloyed gold 
standard” for comparisons with the other groups. Potential controls were classified in 
“confirmed controls” if they met the control criteria detailed before (no symptoms or only 
mild symptoms with no interference on normal life activities) and “unconfirmed 
controls” otherwise. The authors found that both “Chart/Mortola cases” and “Mortola 
cases” were similar with regard to symptom timing and severity, as well as to the 
presence of physical symptoms. The groups only differed in the number of affective 
symptoms reported (5.3 for the “Chart/Mortola cases” and 4.3 for the “Mortola cases”, 
p=0.04).  In contrast, the other 2 case groups (“Chart cases” and “Self-report-only” cases) 
differed in multiple ways from the alloyed gold standard “Chart/Mortola cases”. The 
authors concluded that women who did not report prospective symptom charting as part 
of their diagnosis but who met the Mortola criteria were essentially identical to those who 
reported prospective charting and who met the modified Mortola criteria for PMS (61).  
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4.2.4 Covariate assessment  
We collected information on several demographic and lifestyle factors on a self-
reported questionnaire, such as date of birth, current and past use of oral contraceptives, 
use of antidepressants, smoking and alcohol use. 
Age was calculated from the date of birth reported in the questionnaire. At the 
study visit, weight and height were measured by a trained research assistant using a 
calibrated scale and a stadiometer. Participants were required to wear minimal clothing 
and to remove shoes. BMI was calculated by dividing the weight in kilograms by the 
height in meters squared.   
Aspects of reproductive history such as use of oral contraceptives (OCs) are also 
potential confounders of the association between micronutrients and PMS. In the lifestyle 
questionnaire, participants reported whether they ever used OCs, how many years they 
used them, if they were currently taken OCs and the type or formula used. Additionally, 
participants reported whether they had ever been pregnant and if they currently use 
contraceptive implants, injectable contraceptives, or intrauterine devices.  
Cigarette smoking and alcohol use may also be associated with PMS(62, 63). 
Participants were asked in the questionnaire whether they smoke currently, the frequency 
and type of cigarettes currently smoked, the age at which they started smoking, if they no 
longer smoked, the age at which they quit. Additional information on environmental 
tobacco exposure was also collected.  Information on alcohol intake, frequency and type 
of alcohol ingested was also collected in the FFQs.  
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Participants also completed detailed information regarding their physical activity 
including the time they spent each week walking, jogging, running, bicycling, swimming, 
participating in aerobics/dancing, tennis/racket sport, yoga/Pilates and weight training in 
the previous two months. We calculated total MET-hours per week of activity. 
Other micronutrients such as calcium and vitamin D were measured in the FFQ 
and were considered as potential confounders. For example, calcium and vitamin D  and 
are known to interact with magnesium and zinc absorption and excretion (12) and been 
associated with a decreased risk of developing PMS (2).  
 
4.2.5   Data Analysis 
Univariate analyses: 
We presented the total number of participants as well as the number and 
percentage of women who fulfilled the criteria for becoming cases and controls in table 
4.1. For all participants, we described the distribution of intakes of all selected 
micronutrients by reporting the mean, standard deviation (SD), median and interquartile 
range of the total dietary intakes (Table 4.2) as well as for dietary intakes from food 
sources only (Table 4.3). Additionally, we reported the mean, SD, median and 
interquartile ranges of blood levels of vitamin B6, folate, vitamin B12, magnesium, zinc, 
and ferritin for the 182 participants for which we have information available (Table 4.4).  
Bivariate analyses: 
The covariates age, age at menarche, BMI, physical activity, smoking ever vs. 
never, current oral contraceptive use, and current antidepressant use were cross-tabulated 
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with PMS status (Table 4.5). For the continuous covariates we reported means and SDs 
for each category and compared their distributions using t-tests. For the categorical 
covariates we reported the frequency and percentage of women in each category and used 
chi-square tests for comparisons. We also compared the distribution of covariates by 
tertiles of selected micronutrient intakes using generalized linear models (Tables 4.6a to 
4.6k). 
We assessed the degree of correlation among the total intake of micronutrients 
using Spearman correlation coefficients (Table 4.7) as well the correlation among intakes 
from food sources only (Table 4.8).  Additionally, we assessed the correlations between 
blood levels and total dietary intakes of vitamin B6, folate, vitamin B12, magnesium, and 
iron (Table 4.9a) as well as the correlations among each other (Table 4.9b).  
Using logistic regression, we calculated age-adjusted odds ratios (OR) and 95% 
confidence intervals (CI) for prevalent PMS and total micronutrient intake by tertiles 
using the lowest tertile as the reference (Table 4.10). To assess dose-response 
relationships, we calculated p for trends by including the median intake in each category 
as a continuous variable in the regression model. Additionally, we calculated age-
adjusted odds ratios, 95% CIs and p for trends for dietary intakes from food sources only 
(Table 4.11) and for blood levels of selected micronutrients (Table 4.12).  
 
Multivariable analyses: 
We further adjusted the logistic regression models for age, smoking (ever vs. 
never), use of multivitamins (yes vs. no) and total vitamin D intake (<100 vs. ≥100 
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IU/day). Multivariate adjusted odds ratios, 95% CIs and p-values for total intakes, food 
intakes and blood samples are presented in tables 4.13, 4.14, and 4.15, respectively.  
Also, we evaluated the association between PMS and continuous total 
micronutrient intake. Age and multivariable adjusted odds ratios and 95% CIs are 
presented in table 3.16. 
 
Continuous PMS symptom score: 
To evaluate PMS symptom presence and severity in all participants, we calculated 
a symptom score by adding the severity of the 26 symptoms reported ("none"=0, 
"mild"=1, "moderate"=2, or "severe"=3). Participants were categorized in three groups 
according to their total PMS symptom scores. We evaluated the association between 
PMS symptoms and total micronutrient intakes using linear regression. Regression 
coefficients, standard errors and p-values were reported in table 3.17. The same analysis 
was conducted for micronutrient intakes from food sources only and blood levels of 
selected micronutrients (Tables 3.18 and 3.19).  
 
4.3 Results 
The total number of participants in the UMass Vitamin D Study were 237 (Table 
4.1). From these women, 211 reported the presence of at least one physical and one 
affective symptom. After applying other criteria for PMS definition, we identified 56 
women as PMS cases.  From the remaining women, 60 of them were identified as 
controls according to our control criteria. 
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The mean total intakes of thiamin, riboflavin, niacin, vitamin B6, folate, vitamin 
B12, magnesium, zinc, and iron were above the recommended dietary intakes for women 
aged 20 to 40 years ( Table 4.2).  For example,  the mean total thiamin intake was 3.0 
mg/d and the RDA was 1.1 mg/d. Mean total potassium intakes were below the AI (mean 
= 3551 mg/d vs. AI = 4700 mg/d) whereas mean sodium intake was above the AI (mean 
= 2170 mg/d, AI for sodium = 1500 mg/d).  For micronutrient intakes from food sources 
only, all participants had mean intakes above the recommended levels, except for iron, 
which was slightly below the RDA (mean iron intake from foods=17.1 mg/day vs. 
RDA=18 mg/day, Table 4.3)  
For 182 participants from phase 1 of the study, blood concentrations of vitamin 
B6, folate, vitamin B12, magnesium, zinc and ferritin were assessed (Table 4.4). Mean 
levels of vitamin B6, folate and vitamin B12 were 73 pmol/L, 33.1 nmol/L, and 709.2 
pmol/L, respectively. Mean levels of magnesium, zinc and ferritin were 21.7 mg/L, 0.06 
mg/ml, and 26.9 ng/ml, respectively.  
We compared baseline characteristics of the 56 cases and 60 controls (Table 4.5). 
Overall, cases and controls were similar with regard to age, age at menarche, body mass 
index (BMI), physical activity, alcohol intake, total vitamin D intake, use of multivitamin 
supplements, oral contraceptives and selective serotonin reuptake inhibitors. Cases were 
more likely than controls  to be current smokers (12.5% vs. 3.3%; p=0.09) or to have ever 
smoked (33.9% vs. 6.7%; p<0.001).  
We then compared the characteristics of the participants by tertiles of total intakes 
of B vitamin, magnesium, zinc, potassium, sodium and iron (Tables 4.6a to 4.6k). 
237 
 
Overall, women with high intakes of the selected micronutrients had higher intakes of 
vitamin D and higher use of multivitamins (range of p=0.04 to <0.0001) than women 
with lower intakes. Women with higher intakes or thiamin, riboflavin, folate, zinc, and 
iron had lower intakes of alcohol (p=0.07 to <0.0001) than women with lower 
micronutrient intakes. Women with higher intakes of vitamin B6, magnesium and zinc 
had higher physical activity (p=0.03 to 0.0001) than women with lower intakes.  
We also evaluated the correlations between total micronutrients (Table 4.7). The 
highest correlation was observed between total niacin and total vitamin B6 intakes 
(Spearman correlation coefficient (r) = 0.82, p<0.0001). Thiamin had high correlations 
with riboflavin, vitamin B6 and folate (r = 0.79, 0.79 and 0.81 respectively, p<0.0001). In 
general, sodium and potassium intakes were not highly correlated with intakes of other 
micronutrients, though the correlation of potassium and magnesium was high (r = 0.77, 
p<0.0001). The lowest correlation was observed between sodium and zinc (r=0.07, not 
significant), and sodium and vitamin B12 (r= 0.12, not significant).  
Correlations were also high for micronutrient intakes from foods sources only 
(Table 4.8). The highest correlations were observed among potassium and magnesium, 
and among iron and folate (r = 80, p<0.0001 for both).  Food intake of thiamin was 
highly correlated with folate intake (r=0.77, p<0.0001) and with iron intake (r=0.78, 
p<0.0001). Food intake of vitamin B12 were not significantly correlated with thiamin (r 
=0.13), folate (r=0.01), and magnesium (r=-0.02) intakes.  
Dietary intakes of vitamin B6, folate and vitamin B12 were highly correlated with 
their respective blood levels (r=0.40, 0.51, and 0.32, respectively, p<0.0001; Table 4.9a). 
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There were no statistically significant correlations between dietary intakes of magnesium, 
zinc, and iron and their respective blood levels. Blood levels of vitamin B12 were highly 
correlated with blood levels of folate (r = 0.87, p<0.0001; Table 4.9b) and moderately 
correlated with vitamin B6 (r=0.49, p<0.0001). There was an inverse correlation between 
blood levels of magnesium and blood levels of zinc (r=-0.20, p=0.01). 
In age-adjusted logistic regression analyses, we found no association between 
total intakes of thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, magnesium, 
sodium, and potassium and prevalence of PMS (Table 4.10). Women in the highest tertile 
of zinc intake (median = 22.2 mg/day) had a lower risk of having PMS (OR=0.39, 
95%CI=0.16-0.94, p trend = 0.07) as compared to women in the lowest tertile (median = 
10.7 mg/day). In age-adjusted analyses of micronutrients from food sources only, we 
found no association between any of these micronutrients and PMS (Table 4.11). 
Although the odds ratios for the highest tertile of zinc intake from foods only was only 
marginally significant (OR=0.41, 95%CI = 0.16, 1.01), there was a significant trend of 
lower prevalence with increased zinc intake (p trend = 0.04).  
Blood levels of vitamin B6, folate, vitamin B12, zinc, and ferritin were not 
associated with PMS prevalence in age-adjusted analysis (Table 4.12). However, women 
with the highest levels of magnesium in blood (n=26, median=25.6 mg/L) had a higher 
prevalence of PMS (OR = 3.21, 95% CI = 1.09 - 9.41) as compared to women with the 
lowest levels (median=16.7 mg/L).  
After additional adjustment for smoking status (ever vs. never), use of 
multivitamins (yes vs. no) and total vitamin D intake (<100 vs. ≥100 IU/day), we 
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observed no significant association between total intake of any selected micronutrients 
and PMS prevalence (Table 4.13). In the multivariable-adjusted analyses restricted to 
food sources only, we observed a non-significant reduced prevalence of PMS in women 
with high intakes of zinc (OR = 0.40, 95% CI = 0.15 - 1.09) with a marginally significant 
trend (p trend = 0.06, Table 4.14). In the multivariable-adjusted analyses of blood levels 
and PMS, we observed no significant association between vitamin B6, folate, vitamin 
B12, zinc, and ferritin levels and PMS prevalence (Table 4.15). Similarly to the age-
adjusted analyses, we observed that women with high levels of magnesium in blood had a 
higher prevalence of PMS (OR = 4.20, 95% = 1.24 - 14.23, p trend = 0.01) as compared 
to women with the lowest levels.  
We did not find that intakes of selected micronutrients assessed continuously 
were associated with PMS risk in age and multivariable adjusted analyses (Table 4.16).  
In addition, we used linear regression to evaluate the association between dietary 
intakes and blood levels of selected micronutrients and PMS symptoms among all study 
participants. We observed that total intakes thiamin and riboflavin were significantly 
associated with a higher PMS symptom score in multivariable analyses (p=0.01 for both, 
Table 4.17). In age and multivariable analyses restricted to food sources only, we 
observed no significant associations between thiamin, riboflavin, niacin, folate, vitamin 
B12, magnesium, potassium, and iron intakes and PMS prevalence (Table 4.18). An 
increase of 1 mg/day of vitamin B6 from foods was associated with a lower PMS 
symptom score (age-adjusted β ± SE = -1.89 ± 0.86, p-value = 0.03; multivariable-
adjusted β ± SE = -1.65 ± 0.84, p-value = 0.05). Similarly, an increase of 1 mg/day of 
zinc from foods was associated with a lower PMS symptom score ( age-adjusted β ± SE 
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= -0.41 ± 0.16, p-value = 0.01; multivariable-adjusted β ± SE = -0.31 ± 0.16, p-value = 
0.05).  
Among women who had information on blood levels of selected micronutrients, 
there was no association between vitamin B6, folate, vitamin B12, zinc, and ferritin blood 
levels and PMS prevalence (Table 4.19). Blood levels of magnesium (mg/L)  were 
associated with increased prevalence of PMS in age and multivariable adjusted models 
(age-adjusted β ± SE = 0.43 ± 0.19, p-value = 0.02; multivariable-adjusted β ± SE = 0.48 
± 0.18, p-value = 0.01). 
 
4.4 Discussion 
In this cross-sectional study, we found that total zinc intake, and zinc intake from 
foods was marginally associated with lower prevalence of PMS. In addition, each 1 
mg/day increase in  vitamin B6 from foods was associated with a modestly lower PMS 
symptom score. Contrary to our main hypothesis, we found that each 1 mg/day increase 
in thiamin and riboflavin intakes was associated with 32% and 30% higher prevalence of 
PMS, respectively. Although we found no association between vitamin B6, folate, 
vitamin B12, zinc, and ferritin blood levels and PMS, we observed that higher 
magnesium blood levels were associated with higher prevalence of PMS. 
Previous studies have suggested that women with PMS may have lower levels of 
zinc(51) and that zinc serum levels fluctuate during the menstrual cycle (50). Zinc may 
interact with neurotransmitters involved in mood regulation(41, 43). In a recent study, 
zinc supplements did not show improvement of mood compared to multivitamins only 
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among normal women (42). However, zinc supplementation has shown beneficial effects 
in patients with treatment resistant-depression when given in conjunction with 
imipramine, a tricyclic antidepressant (44).  The results of our study suggest that zinc 
intake may be associated with lower PMS risk.   
Vitamin B6 supplements have been suggested as potential treatments for 
PMS(24), and some studies(22, 26, 34) have found that vitamin B6 supplements up to 
100 mg/day are effective in treating PMS symptoms. Although we did not find a 
significant association between dietary vitamin B6 intakes by tertiles and PMS, we 
observed a significant protective effect of vitamin B6 consumption on premenstrual 
symptoms in our linear regression analysis among all study participants.  
In 1997, Das et al.(50) conducted a study among 20 healthy women reportedly not 
suffering from PMS.  Blood levels of zinc, magnesium, selenium and manganese were 
evaluated at four different points of their cycle according to their basal body temperature: 
follicular, ovulatory and luteal phases, and the first day of menses. Compared to the 
ovulatory phase, during the luteal phase participants had lower levels of zinc (85 ± 0.6 
µg/ml vs. 80 ± 0.6 µg/ml; p<0.01) and higher levels of magnesium (1.54 ± 0.06 mEq/L 
vs. 1.65 ± 0.07 mEq/L; p<0.01)(50).  Similartly, Chuong (51) observed that women with 
PMS had lower serum levels of zinc during the luteal phase compared to the follicular 
phase (90.3 ± 4.1 µg/dL vs. 100.2 ± 3.6µg/dL; p < 0.05)  and to serum zinc levels during 
the luteal phase of women without PMS (107.8 ± 7.8 µg/dL, p < 0.05). In our study, we 
found a positive association between magnesium blood levels and PMS prevalence 
during the luteal phase. Because we did not have blood samples from other times during 
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the menstrual cycle of the participants, we cannot compare the observed blood levels with 
blood levels during other phases of the menstrual cycle.  
 Chocolate is a significant source of magnesium (100 mg of magnesium by 100 g 
of chocolate, and 520 mg of magnesium by 100 g of cocoa powder)(64). The increased 
magnesium blood levels observed among participants with PMS could reflect increased 
intake of chocolate among women with PMS. Cravings is one of the several symptoms of 
PMS(65) and women with premenstrual disorders may have a higher reward sensitivity 
from high-fat high-sugar foods like chocolate than women without PMS (66). 
Additionally, chocolate consumption could be motivated in part by magnesium 
deficiency (64). 
Study Limitations 
We assessed dietary intakes based on self-report using a modified version of the 
Harvard FFQ and on blood levels of certain micronutrients. In this study, we selected a 
period of 2 months of previous intake to reflect recent micronutrient intake and to reflect 
micronutrient blood levels. The Harvard FFQ has been validated before in a population of 
female nurses (52, 53), which may be similar to college-students with regard of certain 
characteristics like high education and social status.  Dietary intakes based on self-report 
may be affected by recall.  Although a period of 2 months may lead to better recall than 
the usual 1 year period, it could be affected by temporal events like exam periods during 
the school year. Although some misclassification of self-reported dietary intakes, 
misclassification is usually not extensive enough to misclassify participants in the highest 
tertile to the lowest. Micronutrient intakes were assessed at Harvard University, and 
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independently of the outcome status. Nevertheless, because of the cross-sectional nature 
of the study, outcome status might have influenced dietary choices, as food cravings is 
one of the symptoms of PMS. Cravings of high-fat high-sugar foods like chocolate, 
which is rich in magnesium and other micronutrients, is reported to be higher among 
women with premenstrual disorders than among women without them (66). This could 
have bias the results against the null value. 
Blood samples were collected during the late luteal phase at the University Health 
Services. Procedures for biomarker assessment were standard and previously validated. 
For all biomarkers, laboratory staff at the Department of Nutrition was blinded to PMS 
status. In our study we found a moderately high correlation between reported intakes and 
blood samples of vitamin B6 (r = 0.40, p <0.0001), folate (r = 0.51, p <0.0001) and 
vitamin B12 (r = 0.32, p < 0.0001), but no significant correlations between magnesium, 
zinc and iron blood levels and reported intakes. In a study conducted among 385 
members of the Framingham Heart Study cohort, serum folate levels had a correlation of 
r=0.43 with dietary folate intakes (59). Plasma magnesium levels are under homeostatic 
control and represent only a small proportion of the body magnesium pools (12, 52). 
Other measures such a magnesium loading test and intracellular magnesium are 
recommended for better assessment of magnesium status, but were not feasible for this 
study. Misclassification due to measurement error would not be associated with the 
outcome therefore leading to underestimation of the results. Nevertheless, because of the 
cross-sectional nature of the study, blood levels may be affected by PMS treatments, like 
oral contraceptives and antidepressants. Women taking oral contraceptives may have 
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lower levels of vitamin B6 and other B vitamins(67, 68). Further adjustment of our 
results by oral contraceptive use did not change the odds ratios substantially.  
For this study, we did not use prospective charting of symptoms, as recommended 
by the American College of Obstetricians (ACOG) for clinical diagnosis of PMS.(1) 
Instead, premenstrual syndrome was assessed using a retrospective questionnaire that has 
been validated before in a sub-group of women participating in the NHS2 PMS Sub-
study, who may be similar to college students with regard to socio economic status and 
education. Although women in the NHS2 PMS Sub-study who participated in the 
validation study were older than the UMass Vitamin D Study population, it is unlikely 
that the small age difference affects the reports on PMS symptoms. Additionally, to 
minimize misclassification we used standard criteria by Mortola et al.(60) for case 
selection and we selected only women with mild or no symptoms as the controls, thereby 
selecting women in the extreme ends of the range of menstrual symptom experience. 
Because outcome assessment was conducted separately from micronutrient assessment, 
any misclassification would be non-differential and would lead to an underestimation of 
the results.   
Our study questionnaires measured a variety of variables that could be associated 
with both PMS and micronutrient intake.  Although we selected as covariates those 
factors that were strongly associated with PMS and that substantially changed the odds 
ratios when added to the regression models, it is possible that residual confounding 
occurs due to unknown risk factors.  
245 
 
Because most of the participants were students at the School of Public Health, it is 
possible that participants in this study have a higher diet quality than the general 
population. Nevertheless, we have no reason to believe that the associations of 
micronutrients and PMS would be different in other populations of the same age. The 
results from this study can be generalized to young, premenopausal women with 
micronutrient intakes within the same range. 
In summary, we found a marginal association between zinc intake and lower 
prevalence of PMS. Additionally, we observed that blood magnesium levels were higher 
in women with PMS compared to women without PMS, potentially because of increased 
intakes of high-fat high-sugar foods like chocolate, which are rich in magnesium. Further 
studies are needed to evaluate the association between these micronutrients and PMS. 
 
4.5 Significance 
Premenstrual symptoms have a high prevalence in women of reproductive age 
and may be associated with micronutrient intakes. Assessment of micronutrient intakes 
and status and premenstrual symptoms in a college age population contributes to a better 
understanding of PMS in how dietary factors relate to PMS in young adulthood. 
 
4.6 Human Subject Protection 
This research has been approved by the University of Massachusetts, Amherst. 
Participants were informed on a written consent statement about the project title, the 
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principal investigators, the sponsors of the project, the purpose of the study and 
procedures involved and the risks associated with them. After reading this statement, 
participants signed the informed consent.   
Participants were allowed to drop the study at any point of the clinic visit, and 
later if they decide that their samples should not be used for future research, they may 
contact the principal investigator and samples will be discarded in immediately. 
To provide confidentiality, study participants were identified on all study 
materials by a confidential identification number (ID) only. Documents containing the 
names corresponding to each ID as well as the questionnaires are kept separately in the 
School of Public Health in locked fire-proof cabinets. Nutritional, demographic and 
lifestyle data by ID is stored in the J-drives of the computers of the School of Public 
Health and may be accessed only by authorized research assistants with a password.  
The collection of blood was an invasive procedure used in this study. For having 
blood drawn, risks include pain at the site of needle entry, occasional bruising at the site, 
and rarely, fainting. Risk of infection is minimal since only sterile one-time-use 
equipment was used.  Other procedures involved blood pressure assessment, urine 
collection, undergoing studies of genetic factors and a DXA scan.  
Participants had  no direct benefit from participating in this study besides 
receiving information on their blood sugar levels, the results of the dietary assessment 
and their body composition by the DXA scan.  
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Table 4.1 Criteria for selection of premenstrual syndrome (PMS) cases and controls: 
The UMass Vitamin D Study, 2006 - 2010. 
  N % 
Total number of participants  237   
1) Participants with at least one physical and one affective symptoms 211 89.03%
2)       -  Overall symptom severity ‘moderate’ or ‘severe’; or 39 16.46%
  -  Impact of symptoms on life activities ‘moderate’ or severe’ ; or 25 10.55%
  -  One or more individual symptoms rated as ‘severe’ 48 20.25%
3) Symptoms begins within 14 days of start of menstruation and ends within 4 
days of start of menses 
197 85.28%
4) Symptoms absent in the week after menstruation 213 92.21%
PMS cases1 56 23.63%
1) Participants with individual symptom severity ‘none’ or ‘mild’ for all 
symptoms 
64 27.71%
2) Overall symptoms severity rated as ‘none’, ‘minimal’ or ‘mild’ 198 83.54%
3) Impact of symptoms on life activities and relationships of ‘not a problem’ or 
‘mild’ for all items 
212 89.45%
4) Confirmed no previous clinical diagnosis of PMS 229 96.62%
PMS controls2 60 25.32%
1Participants must meet all four criteria for being considered as PMS cases. 
2Participants must meet all four criteria for being considered as PMS controls 
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Table 4.2 Distribution of total micronutrient intake (n=237): The UMass Vitamin 
D Study 2006-2010. 
  
Dietary Reference 
Intake1 Mean 
Standard 
Deviation
Median Interquartile 
Range 
Thiamin (mg/d) 1.1 3.0 5.3 2.0 1.6 - 2.9
Riboflavin (mg/d) 1.1 3.8 5.4 2.9 2.2 - 3.7
Niacin (mg/d) 14 32.4 13.4 28.7 23.3 - 38.1
Vitamin B6 (mg/d) 1.3 4.6 9.1 2.7 2.2 - 4.1
Folate (µg/d) 400 760 336 692 505 - 945
Vitamin B12 (µg/d) 2.4 12.6 44.0 7.4 4.9 - 10.7
Magnesium (mg/d) 310 404 115 389 334 - 457
Zinc (mg/d) 8 17.4 12.7 13.8 11.8 - 18.6
Potassium (mg/d) 4700 3551 950 3447 2967 - 4039
Iron (mg/d) 18 23.2 15.2 18.3 14.3 - 26.0
Sodium (mg/d) 1500 2170 477 2129 1917 - 2455
1Dietary reference intake is the recommended dietary allowance (RDA) for women aged 20 to 40 years for all 
nutrients, except for potassium and sodium where the adequate intake (AI) was used instead. 
 
 
 
Table 4.3 Distribution of micronutrient intake from food sources (n=237): 
The UMass Vitamin D Study, 2006-2010. 
  Mean 
Standard 
Deviation Median 
Interquartile 
Range 
Thiamin (mg/d) 1.8 0.6 1.7 1.5 -2.0 
Riboflavin (mg/d) 2.5 0.8 2.4 2.0 - 2.8 
Niacin (mg/d) 25.8 7.8 24.6 21.1 - 29.1 
Vitamin B6 (mg/d) 2.4 0.8 2.3 2.0 - 2.7 
Folate (µg/d) 626 259 562 325 - 716 
Vitamin B12 (µg/d) 6.0 3.4 5.4 3.9 - 7.3 
Magnesium (mg/d) 389 103 371 325 - 444 
Zinc (mg/d) 12.9 4.1 12.1 10.7 - 14.2 
Potassium (mg/d) 3525 955 3443 2940 - 4020
Iron (mg/d) 17.1 5.9 15.3 13.4 - 19.5 
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Table 4.4 Distribution of selected micronutrient levels in blood (n=182): 
The UMass Vitamin D Study, 2006-2010. 
  Mean 
Standard 
Deviation Median 
Interquartile 
Range 
Vitamin B6 (nmol/L) 91.8 52.1 91.8 44.2-136.6 
Folate (nmol/L) 33.1 26.0 29.0 23.1 - 35.3 
Vitamin B12 (pmol/L) 709.2 222.2 658.2 554.3 - 823.8 
Magnesium (mg/L) 21.7 4.2 22.4 18.0 - 25.2 
Zinc (mg/ml) 0.06 0.02 0.06 0.05-0.07 
Ferritin (ng/ml) 26.9 21.4 22.0 11.4 - 34.5 
 
 
 
Table 4.5 Selected characteristics of participants by PMS case/control 
status: The UMass Vitamin D Study, 2006 - 2010. 
 Cases Controls  
  Mean (SD) Mean (SD) Pvalue1 
Age (years) 21.3 (2.9) 21.8 (3.1) 0.36 
Age at menarche 12.4 (1.4) 12.6 (1.3) 0.40 
BMI (kg/m2) 22.7 (3.0) 22.6 (3.4) 0.90 
MET hours/week of physical 
activity 173.6 (64.4) 170.5 (68.7) 0.84 
Total alcohol intake (g/day) 7.4 (7.0) 5.4 (7.7) 0.15 
Total vitamin D intake (IU/day) 360 (275) 433 (335) 0.20 
  N (%) N (%) Pvalue2 
Multivitamin supplement use 25 (45.2%) 34 (56.8%) 0.22 
Smoking status    
Ever smoker 19 (33.9%) 4 (6.7%) <0.001 
Current smoker 7 (12.5%) 2 (3.3%) 0.09 
Oral contraceptive use    
Ever used 35 (62.5%) 35 (59.3%) 0.83 
Current user 24 (44.4%) 24 (42.3%) 0.72 
Current use of antidepressants 3 (5.9%) 2 (3.5%) 0.67 
1 Calculated using the t statistic. 
2 Calculated using the chi-square statistic, except for smoking variables and use of antidepressants, where 
the Fisher exact test was used instead. 
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Table 4.6a Characteristics of participants by total thiamin intake in tertiles: The 
UMass Vitamin D Study, 2006 - 2010. 
 Thiamin intake, mg/d  
 T1 T2 T3  
  Mean (SD) Mean (SD) Mean (SD) Pvalue1 
Age (years) 21.7 (3.3) 21.1 (2.4) 21.9 (3.4) 0.29
Age at menarche 12.3 (1.4) 12.7 (1.3) 12.4 (1.4) 0.16
BMI (kg/m2) 23.1 (3.2) 23.3 (2.9) 22.7 (3.3) 0.44
MET (hr/week) of physical 
activity 168.3 (66.8) 184.1 (78.1) 177.5 (62.5) 0.36 
Total alcohol intake (g/day) 8.6 (11.1) 6.1 (6.4) 4.9 (6.1) 0.01 
Total vitamin D intake 
(IU/day) 235.3 (170.4) 303.6 (232.8) 596.0 (334.9) <0.0001 
  N (%) N (%) N (%) Pvalue2
Multivitamin supplement 
use 10 (12.7) 26 (33.3) 70 (88.6) <0.0001 
Smoking status    
Ever smoker 12 (15.2) 15 (19.0) 8 (10.1) 0.29 
Current smoker 4 (5.1) 4 (5.1) 3 (3.8) 0.91 
Oral contraceptive use    
Ever used 42 (53.2) 41 (52.6) 48 (60.8) 0.52 
Current user 32 (42.1) 29 (39.7) 37 (47.4) 0.62 
Current use of 
antidepressants 3 (4.0) 1 (1.4) 6 (7.9) 0.16 
1 Calculated using the F statistic. 
2 Calculated using the chi-square statistic, except for smoking variables and use of antidepressants, where the Fisher 
exact test was used instead. 
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Table 4.6b Characteristics of participants by total tiboflavin intake in tertiles: 
The UMass Vitamin D Study, 2006 - 2010. 
 Riboflavin intake, mg/d  
 T1 T2 T3  
  Mean (SD) Mean (SD) Mean (SD) Pvalue1 
Age (years) 21.2 (2.7) 21.8 (3.1) 21.7 (3.4) 0.47
Age at menarche 12.4 (1.4) 12.6 (1.2) 12.5 (1.4) 0.58
BMI (kg/m2) 23.2 (3.2) 23.1 (3.1) 22.8 (3.3) 0.65
MET (hr/week) of physical 
activity 165.9 (66.2) 186.0 (73.6) 178.0 (67.7) 0.19 
Total alcohol intake (g/day) 7.8 (10.7) 7.0 (7.4) 4.8 (6.0) 0.07 
Total vitamin D intake 
(IU/day) 187.8 (143.9) 322.9 (217.4) 624.2 (317.3) <0.0001 
  N (%) N (%) N (%) Pvalue2
Multivitamin supplement 
use 11 (13.9) 32 (41.0) 63 (79.7) <0.0001 
Smoking status      
Ever smoker 12 (15.2) 14 (17.7) 9 (11.4) 0.53 
Current smoker 4 (5.1) 4 (5.1) 3 (3.8) 0.91 
Oral contraceptive use      
Ever used 37 (47.4) 47 (59.5) 47 (59.5) 0.22 
Current user 29 (39.7) 30 (39.5) 39 (50.0) 0.33 
Current use of 
antidepressants 3 (4.1) 2 (2.7) 5 (6.8) 0.48 
1 Calculated using the F statistic. 
2 Calculated using the chi-square statistic, except for smoking variables and use of antidepressants, where the Fisher 
exact test was used instead. 
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Table 4.6c Characteristics of participants by total niacin intake in tertiles: The 
UMass Vitamin D Study, 2006 - 2010. 
 Niacin intake, mg/d  
 T1 T2 T3  
  Mean (SD) Mean (SD) Mean (SD) Pvalue1 
Age (years) 21.8 (3.0) 21.3 (2.9) 21.6 (3.3) 0.59
Age at menarche 12.3 (1.4) 12.7 (1.2) 12.5 (1.5) 0.17
BMI (kg/m2) 23.2 (3.0) 23.0 (2.9) 22.9 (3.6) 0.83
MET (hr/week) of physical 
activity 
169.0 (67.5) 182.0 (72.1) 178.4 (68.7) 0.49 
Total alcohol intake (g/day) 6.5 (7.1) 7.7 (10.6) 5.5 (6.5) 0.25 
Total vitamin D intake 
(IU/day) 
217.6 (156.1) 333.3 (272.3) 584.1 (316.5) <0.0001 
  N (%) N (%) N (%) Pvalue2
Multivitamin supplement 
use 14 (17.9) 26 (32.9) 66 (83.5) <0.0001 
Smoking status     
Ever smoker 17 (21.5) 11 (13.9) 7 (8.9) 0.08
Current smoker 4 (5.1) 4 (5.1) 3 (3.8) 0.91
Oral contraceptive use     
Ever used 40 (51.3) 46 (58.2) 45 (57.0) 0.65
Current user 25 (35.2) 37 (47.4) 36 (46.2) 0.26
Current use of 
antidepressants 2 (2.7) 3 (4.2) 5 (6.5) 0.57 
1 Calculated using the F statistic. 
2 Calculated using the chi-square statistic, except for smoking variables and use of antidepressants, where the Fisher 
exact test was used instead. 
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Table 4.6d Characteristics of participants by total vitamin B6 intake in tertiles: 
The UMass Vitamin D Study, 2006 - 2010. 
 Vitamin B6 intake, mg/d  
 T1 T2 T3  
  Mean (SD) Mean (SD) Mean (SD) Pvalue1 
Age (years) 21.5 (2.9) 21.4 (2.9) 21.8 (3.3) 0.68
Age at menarche 12.4 (1.3) 12.5 (1.4) 12.5 (1.4) 0.66
BMI (kg/m2) 22.9 (2.6) 23.0 (3.4) 23.2 (3.4) 0.81
MET (hr/week) of physical 
activity 
178.4 (72.0) 161.0 (61.4) 190.3 (71.9) 0.03 
Total alcohol intake (g/day) 7.1 (10.0) 6.5 (7.8) 6.0 (6.8) 0.67 
Total vitamin D intake 
(IU/day) 
214.1 (147.7) 302.8 (191.7) 618.1 (346.2) <0.0001 
  N (%) N (%) N (%) Pvalue2
Multivitamin supplement 
use 13 (16.5) 27 (34.6) 66 (83.5) <0.0001 
Smoking status     
Ever smoker 15 (19.0) 12 (15.2) 8 (10.1) 0.29
Current smoker 4 (5.1) 4 (5.1) 3 (3.8) 0.91
Oral contraceptive use     
Ever used 38 (48.1) 43 (55.1) 50 (63.3) 0.16
Current user 27 (37.0) 33 (43.4) 38 (48.7) 0.35
Current use of 
antidepressants 1 (1.3) 4 (5.7) 5 (6.6) 0.25 
1 Calculated using the F statistic. 
2 Calculated using the chi-square statistic, except for smoking variables and use of antidepressants, where the Fisher 
exact test was used instead. 
 
  
254 
 
Table 4.6e Characteristics of participants by total folate intake in tertiles: The 
UMass Vitamin D Study, 2006 - 2010. 
 Folate intake, µg/d  
 T1 T2 T3  
  Mean (SD) Mean (SD) Mean (SD) Pvalue1 
Age (years) 21.2 (2.8) 21.7 (3.0) 21.8 (3.4) 0.40
Age at menarche 12.5 (1.3) 12.5 (1.5) 12.5 (1.3) 0.95
BMI (kg/m2) 22.6 (3.0) 23.7 (3.3) 22.8 (3.1) 0.09
MET (hr/week) of physical 
activity 
170.9 (73.1) 171.8 (66.7) 186.8 (67.9) 0.27 
Total alcohol intake (g/day) 7.2 (10.7) 7.7 (7.7) 4.6 (5.4) 0.04 
Total vitamin D intake 
(IU/day) 
263.1 (164.4) 349.5 (309.2) 522.3 (334.4) <0.0001 
  N (%) N (%) N (%) Pvalue2
Multivitamin supplement 
use 13 (16.5) 36 (46.2) 57 (72.2) <0.0001 
Smoking status     
Ever smoker 9 (11.4) 10 (12.7) 16 (20.3) 0.24
Current smoker 3 (3.8) 2 (2.5) 6 (7.6) 0.40
Oral contraceptive use     
Ever used 40 (50.6) 45 (57.7) 46 (58.2) 0.57
Current user 35 (46.7) 32 (42.1) 31 (40.8) 0.75
Current use of 
antidepressants 3 (4.0) 2 (2.8) 5 (6.6) 0.61 
1 Calculated using the F statistic. 
2 Calculated using the chi-square statistic, except for smoking variables and use of antidepressants, where the Fisher 
exact test was used instead. 
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Table 4.6f Characteristics of participants by total vitamin B12 intake in tertiles: 
The UMass Vitamin D Study, 2006 - 2010. 
 Vitamin B12 intake, µg/d  
 T1 T2 T3  
  Mean (SD) Mean (SD) Mean (SD) Pvalue1 
Age (years) 21.5 (3.0) 21.3 (2.6) 21.9 (3.5) 0.43 
Age at menarche 12.4 (1.4) 12.6 (1.2) 12.4 (1.5) 0.45 
BMI (kg/m2) 22.7 (3.0) 23.4 (3.1) 23.0 (3.4) 0.33 
MET (hr/week) of physical 
activity 163.9 (64.1) 177.4 (70.2) 188.3 (72.3) 0.09 
Total alcohol intake (g/day) 6.8 (7.4) 7.7 (10.6) 5.1 (6.2) 0.14 
Total vitamin D intake 
(IU/day) 159.1 (123.3) 356.7 (204.6) 619.2 (323.8) <0.0001 
  N (%) N (%) N (%) Pvalue2
Multivitamin supplement 
use 10 (12.8) 36 (45.6) 60 (75.9) <0.0001
Smoking status     
Ever smoker 15 (19.0) 10 (12.7) 10 (12.7) 0.44
Current smoker 5 (6.3) 3 (3.8) 3 (3.8) 0.80
Oral contraceptive use     
Ever used 41 (52.6) 39 (49.4) 51 (64.6) 0.13
Current user 24 (33.8) 33 (42.3) 41 (52.6) 0.07
Current use of 
antidepressants 1 (1.4) 5 (6.7) 4 (5.3) 0.35
1 Calculated using the F statistic. 
2 Calculated using the chi-square statistic, except for smoking variables and use of antidepressants, where the Fisher 
exact test was used instead. 
 
  
256 
 
Table 4.6g Characteristics of participants by total magnesium intake in tertiles: 
The UMass Vitamin D Study, 2006 - 2010. 
 Magnesium intake, mg/d  
 T1 T2 T3  
  Mean (SD) Mean (SD) Mean (SD) Pvalue1 
Age (years) 20.6 (2.2) 22.3 (3.5) 21.8 (3.1) 0.002
Age at menarche 12.5 (1.5) 12.4 (1.3) 12.5 (1.2) 0.83
BMI (kg/m2) 23.3 (3.4) 23.2 (3.0) 22.7 (3.0) 0.43
MET (hr/week) of physical 
activity 
158.5 (70.0) 183.5 (68.9) 188.2 (66.3) 0.02 
Total alcohol intake (g/day) 6.8 (10.6) 6.4 (7.2) 6.4 (6.8) 0.93 
Total vitamin D intake 
(IU/day) 
279.0 (235.0) 396.0 (268.1) 460.0 (354.4) 0.0005 
  N (%) N (%) N (%) Pvalue2
Multivitamin supplement 
use 26 (32.9) 37 (46.8) 43 (55.1) 0.02 
Smoking status     
Ever smoker 9 (11.4) 9 (11.4) 17 (21.5) 0.12
Current smoker 5 (6.3) 1 (1.3) 5 (6.3) 0.24
Oral contraceptive use     
Ever used 40 (50.6) 45 (57.0) 46 (59.0) 0.55
Current user 35 (46.7) 36 (46.8) 27 (36.0) 0.31
Current use of 
antidepressants 6 (7.9) 3 (4.1) 1 (1.4) 0.17 
1 Calculated using the F statistic. 
2 Calculated using the chi-square statistic, except for smoking variables and use of antidepressants, where the Fisher 
exact test was used instead. 
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Table 4.6h Characteristics of participants by total zinc intake in tertiles: The 
UMass Vitamin D Study, 2006 - 2010. 
 Zinc intake, mg/d  
 T1 T2 T3  
  Mean (SD) Mean (SD) Mean (SD) Pvalue1 
Age (years) 21.6 (2.9) 21.4 (3.0) 21.7 (3.3) 0.83
Age at menarche 12.3 (1.4) 12.6 (1.1) 12.5 (1.6) 0.25
BMI (kg/m2) 22.9 (3.2) 23.2 (2.8) 22.9 (3.5) 0.78
MET (hr/week) of physical 
activity 
153.4 (57.5) 199.9 (75.3) 176.1 (67.0) 0.0001 
Total alcohol intake (g/day) 6.7 (6.5) 8.4 (11.4) 4.5 (5.3) 0.01 
Total vitamin D intake 
(IU/day) 
255.8 (239.7) 318.9 (197.6) 560.3 (347.8) <0.0001 
  N (%) N (%) N (%) Pvalue2
Multivitamin supplement 
use 21 (26.6) 24 (30.4) 61 (78.2) <0.0001 
Smoking status      
Ever smoker 16 (20.3) 12 (15.2) 7 (8.9) 0.13
Current smoker 7 (8.9) 2 (2.5) 2 (2.5) 0.12
Oral contraceptive use      
Ever used 39 (49.4) 46 (59.0) 46 (58.2) 0.41
Current user 24 (34.3) 40 (51.3) 34 (43.0) 0.11
Current use of 
antidepressants 2 (2.7) 2 (2.8) 6 (7.9) 0.33 
1 Calculated using the F statistic. 
2 Calculated using the chi-square statistic, except for smoking variables and use of antidepressants, where the 
Fisher exact test was used instead. 
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Table 4.6i Characteristics of participants by total potassium intake in tertiles: 
The UMass Vitamin D Study, 2006 - 2010. 
 Potassium intake, mg/d  
 T1 T2 T3  
  Mean (SD) Mean (SD) Mean (SD) Pvalue1 
Age (years) 21.3 (2.8) 21.7 (2.9) 21.7 (3.4) 0.72
Age at menarche 12.7 (1.6) 12.3 (1.2) 12.4 (1.2) 0.09
BMI (kg/m2) 23.5 (3.1) 22.7 (3.4) 22.9 (3.0) 0.28
MET (hr/week) of physical 
activity 
163.9 (65.6) 179.5 (76.0) 186.3 (65.2) 0.12 
Total alcohol intake (g/day) 8.0 (11.1) 6.5 (6.7) 5.1 (6.0) 0.09 
Total vitamin D intake 
(IU/day) 
314.3 (294.8) 388.6
(288.4
) 
432.1 (304.1) 0.04 
  N (%) N (%) N (%) Pvalue2
Multivitamin supplement 
use 30 (38.0) 40 (50.6) 36 (46.2) 0.27 
Smoking status      
Ever smoker 9 (11.4) 10 (12.7) 16 (20.3) 0.24
Current smoker 4 (5.1) 2 (2.5) 5 (6.3) 0.63
Oral contraceptive use      
Ever used 41 (51.9) 43 (55.1) 47 (59.5) 0.63
Current user 33 (44.6) 38 (50.0) 27 (35.1) 0.17
Current use of 
antidepressants 5 (6.8) 4 (5.3) 1 (1.4) 0.33 
1 Calculated using the F statistic. 
2 Calculated using the chi-square statistic, except for smoking variables and use of antidepressants, where the 
Fisher exact test was used instead. 
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Table 4.6j Characteristics of participants by total sodium intake in tertiles: The 
UMass Vitamin D Study, 2006 - 2010. 
 Sodium intake, mg/d  
 T1 T2 T3  
  Mean (SD) Mean (SD) Mean (SD) Pvalue1 
Age (years) 21.3 (3.0) 21.5 (3.0) 21.9 (3.2) 0.37
Age at menarche 12.6 (1.6) 12.5 (1.3) 12.4 (1.2) 0.70
BMI (kg/m2) 23.3 (3.2) 22.9 (3.2) 23.0 (3.1) 0.73
MET (hr/week) of physical 
activity 
180.7 (67.2) 177.3 (70.5) 171.7 (71.1) 0.72 
Total alcohol intake (g/day) 6.0 (10.3) 7.4 (7.3) 6.2 (7.0) 0.53 
Total vitamin D intake 
(IU/day) 
350.5 (265.1) 431.2 (345.6) 353.3 (275.3) 0.16 
  N (%) N (%) N (%) Pvalue2
Multivitamin supplement 
use 35 (44.9) 34 (43.0) 37 (46.8) 0.89 
Smoking status      
Ever smoker 6 (7.6) 13 (16.5) 16 (20.3) 0.07
Current smoker 3 (3.8) 4 (5.1) 4 (5.1) 0.91
Oral contraceptive use      
Ever used 39 (49.4) 48 (61.5) 44 (55.7) 0.31
Current user 31 (41.3) 39 (52.7) 28 (35.9) 0.10
Current use of 
antidepressants 5 (6.8) 3 (4.1) 2 (2.7) 0.48 
1 Calculated using the F statistic. 
2 Calculated using the chi-square statistic, except for smoking variables and use of antidepressants, where the 
Fisher exact test was used instead. 
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Table 4.6j Characteristics of participants by total iron intake in tertiles: The 
UMass Vitamin D Study, 2006 - 2010. 
 Iron intake, mg/d  
 T1 T2 T3  
  Mean (SD) Mean (SD) Mean (SD) Pvalue1 
Age (years) 21.1 (2.9) 21.8 (3.1) 21.7 (3.2) 0.24
Age at menarche 12.5 (1.2) 12.4 (1.5) 12.6 (1.4) 0.63
BMI (kg/m2) 23.0 (3.3) 23.4 (2.9) 22.8 (3.2) 0.52
MET (hr/week) of physical 
activity 
165.2 (70.0) 182.7 (66.2) 182.0 (71.3) 0.21 
Total alcohol intake (g/day) 8.2 (11.2) 6.6 (6.9) 4.8 (5.4) 0.04 
Total vitamin D intake 
(IU/day) 
318.8 (244.3) 314.8 (272.0) 501.3 (336.2) <0.0001 
  N (%) N (%) N (%) Pvalue2
Multivitamin supplement 
use 22 (27.8) 25 (32.1) 59 (74.7) <0.0001 
Smoking status      
Ever smoker 15 (19.0) 12 (15.2) 8 (10.1) 0.29
Current smoker 7 (8.9) 3 (3.8) 1 (1.3) 0.09
Oral contraceptive use      
Ever used 48 (60.8) 43 (55.1) 40 (50.6) 0.44
Current user 37 (48.7) 30 (41.1) 31 (39.7) 0.49
Current use of 
antidepressants 2 (2.7) 2 (2.7) 6 (8.2) 0.18 
1 Calculated using the F statistic. 
2 Calculated using the chi-square statistic, except for smoking variables and use of antidepressants, where the 
Fisher exact test was used instead. 
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Table 4.7 Spearman correlation coefficients for total micronutrient intake: The 
UMass Vitamin D Study,  2006-2010. 
  Thiamin 
Ribo-
flavin Niacin
Vitamin 
B6 Folate
Vitamin 
B12 Mg Zinc Na K 
Thiamin 1.00          
Riboflavin 0.79 1.00         
Niacin 0.67 0.68 1.00        
Vitamin B6 0.79 0.76 0.82 1.00       
Folate 0.81 0.64 0.57 0.72 1.00      
Vitamin B12 0.56 0.74 0.64 0.74 0.41 1.00     
Magnesium 
(Mg) 0.47 0.38 0.23
† 0.38 0.60 0.13‡ 1.00    
Zinc 0.52 0.62 0.61 0.62 0.44 0.59 0.27 1.00   
Sodium (Na) 0.22† 0.25 0.16‡ 0.13‡ 0.34 0.12§ 0.25† 0.07§ 1.00  
Potassium 
(K) 0.29 0.35 0.13
‡ 0.30 0.45 0.15‡ 0.77 0.18‡ 0.24† 1.00
Iron 0.61 0.47 0.46 0.54 0.66 0.34 0.40 0.58 0.25† 0.22†
‡ Statistically significant at p<0.05 
§ Not significant 
Otherwise, all correlations are statistically significant at <0.0001   
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Table 4.8 Spearman correlation coefficients for micronutrient intake from 
food sources: The UMass Vitamin D Study, 2006-2010. 
  Thiamin 
Ribo-
flavin Niacin
Vitamin 
B6 Folate
Vitamin 
B12 Mg Zinc K 
Thiamin 1.00         
Riboflavin 0.53 1.00        
Niacin 0.34 0.33 1.00       
Vitamin B6 0.57 0.48 0.66 1.00      
Folate 0.77 0.42 0.28 0.55 1.00     
Vitamin 
B12 0.13§ 0.48 0.38 0.46 0.01§ 1.00    
Magnesium 
(Mg) 0.56 0.39 0.22‡ 0.42 0.64 -0.02§ 1.00   
Zinc 0.28 0.52 0.59 0.58 0.18‡ 0.65 0.21 1.00  
Potassium 
(K) 0.42 0.49 0.18‡ 0.46 0.52 0.15‡ 0.80 0.26 1.00 
Iron 0.78 0.46 0.49 0.61 0.80 0.16‡ 0.53 0.37 0.38
‡ p-value statistically significant at <0.05 
§ Not significant 
Otherwise all correlations are statistically significant at <0.0001 
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Table 4.9a Spearman correlation coefficients for vitamin B6, folate, vitamin 
B12, magnesium, zinc, and iron dietary intakes with respective blood levels: 
The UMass Vitamin D Study, 2006-2010. 
 Dietary Intake 
Biomarker Vitamin B6 Folate Vitamin B12 Magnesium Zinc Iron 
Vitamin B6 0.40†      
Folate  0.51†     
Vitamin 
B12   0.32†    
Magnesium    0.12   
Zinc     -0.02  
Ferritin       0.06 
†p-value statistically significant at <0.0001 
 
 
Table 4.9b Spearman correlation coefficients for vitamin B6, folate, vitamin 
B12, magnesium, zinc, and ferritin blood levels: The UMass Vitamin D Study, 
2006-2010. 
Biomarker Vitamin B6 Folate Vitamin B12 Magnesium Zinc Ferritin 
Vitamin B6 1.00      
Folate 0.42† 1.00     
Vitamin B12 0.49† 0.87† 1.00    
Magnesium 0.17‡ 0.16‡ 0.19‡ 1.00   
Zinc 0.17‡ 0.25‡ 0.13 -0.20‡ 1.00  
Ferritin 0.08 0.09 0.08 -0.01 0.11 1.00
‡ p-value statistically significant at <0.05 
†p-value statistically significant at <0.0001 
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Table 4.10 Case control ratios, age-adjusted odds ratios (OR) and 95% 
confidence intervals (CI) for total micronutrient intake and PMS: The UMass 
Vitamin D Study, 2006-2010. 
  1st Tertile 2nd Tertile 3rd Tertile Ptrend
Thiamin (mg/d)     
Median 1.4 1.7 2.2  
Case-Control Ratio 20:20 19:17 17:23 0.38
OR 1.00 1.13 0.70  
95% CI  (0.46-2.79) (0.29-1.72)   
Riboflavin (mg/d)     
Median 1.8 2.4 3  
Case-Control Ratio 20:19 24:15 12:26 0.36
OR 1.00 1.09 0.65  
95% CI  (0.43-2.73) (0.27-1.60)   
Niacin (mg/d)     
Median 19.1 24.6 32  
Case-Control Ratio 23:16 16:22 17:22 0.07
OR 1.00 1.46 0.44  
95% CI  (0.59-3.64) (0.17-1.12)   
Vitamin B6 (mg/d)     
Median 1.9 2.2 2.9  
Case-Control Ratio 23:16 16:22 17:22 0.26
OR 1.00 0.49 0.55  
95% CI  (0.20-1.23) (0.22-1.36)   
Folate (µg/d)     
Median 428.2 562.4 839.7  
Case-Control Ratio 16:21 19:18 21:21 0.75
OR 1.00 1.32 1.22  
95% CI  (0.53-3.33) (0.49-3.02)   
Vitamin B12 (µg/d)     
Median 3.2 5.4 8.4  
Case-Control Ratio 18:20 19:19 19:21 0.92
OR 1.00 1.17 1.06  
95% CI  (0.47-2.92) (0.43-2.62)   
Magnesium (mg/d)     
Median 297.7 371.3 487.2  
Case-Control Ratio 17:16 17:24 22:30 0.98
OR 1.00 0.60 0.89  
95% CI  (0.23-1.54) (0.34-2.32)   
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Table 4.10, continued.     
Zinc (mg/d)     
Median 10.1 12.1 15.1  
Case-Control Ratio 21:18 22:14 13:28 0.04
OR 1.00 1.35 0.41  
95% CI  (0.54-3.40) (0.16-1.01)   
Potassium (mg/d)     
Median 2685.9 3443 4271.20  
Case-Control Ratio 16:17 22:20 18:23 0.56
OR 1.00 1.12 0.78  
95% CI  (0.45-2.81) (0.30-1.98)   
Iron (mg/d)     
Median 12.6 15.3 21.9  
Case-Control Ratio 15:17 21:23 20:20 0.79
OR 1.00 0.95 1.09  
95% CI  (0.37-2.42) (0.43-2.79)   
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Table 4.11 Case control ratios, age-adjusted odds ratios (OR) and 95% 
confidence intervals (CI) for micronutrient intake from food sources and PMS: 
The UMass Vitamin D Study, 2006-2010. 
  1st Tertile 2nd Tertile 3rd Tertile Ptrend
Thiamin (mg/d)     
Median 1.4 1.7 2.2  
Case-Control Ratio 20:20 19:17 17:23 0.38
OR 1.00 1.13 0.70  
95% CI  (0.46-2.79) (0.29-1.72)   
Riboflavin (mg/d)     
Median 1.8 2.4 3  
Case-Control Ratio 20:19 24:15 12:26 0.36
OR 1.00 1.09 0.65  
95% CI  (0.43-2.73) (0.27-1.60)   
Niacin (mg/d)     
Median 19.1 24.6 32  
Case-Control Ratio 23:16 16:22 17:22 0.07
OR 1.00 1.46 0.44  
95% CI  (0.59-3.64) (0.17-1.12)   
Vitamin B6 (mg/d)     
Median 1.9 2.2 2.9  
Case-Control Ratio 23:16 16:22 17:22 0.26
OR 1.00 0.49 0.55  
95% CI  (0.20-1.23) (0.22-1.36)   
Folate (µg/d)     
Median 428.2 562.4 839.7  
Case-Control Ratio 16:21 19:18 21:21 0.75
OR 1.00 1.32 1.22  
95% CI  (0.53-3.33) (0.49-3.02)   
Vitamin B12 (µg/d)     
Median 3.2 5.4 8.4  
Case-Control Ratio 18:20 19:19 19:21 0.92
OR 1.00 1.17 1.06  
95% CI  (0.47-2.92) (0.43-2.62)   
Magnesium (mg/d)     
Median 297.7 371.3 487.2  
Case-Control Ratio 17:16 17:24 22:30 0.98
OR 1.00 0.60 0.89  
95% CI  (0.23-1.54) (0.34-2.32)   
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Table 4.11, continued.     
Zinc (mg/d)     
Median 10.1 12.1 15.1  
Case-Control Ratio 21:18 22:14 13:28 0.04
OR 1.00 1.35 0.41  
95% CI  (0.54-3.40) (0.16-1.01)   
Potassium (mg/d)     
Median 2685.9 3443 4271.20  
Case-Control Ratio 16:17 22:20 18:23 0.56
OR 1.00 1.12 0.78  
95% CI  (0.45-2.81) (0.30-1.98)   
Iron (mg/d)     
Median 12.6 15.3 21.9  
Case-Control Ratio 15:17 21:23 20:20 0.79
OR 1.00 0.95 1.09  
95% CI  (0.37-2.42) (0.43-2.79)   
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Table 4.12 Case control ratios, age-adjusted odds ratios and 95% confidence 
intervals (CI) for vitamin B6, folate, B12, magnesium, zinc, and ferritin blood 
levels and PMS: The UMass Vitamin D Study, 2006-2010. 
  1st Tertile 2nd Tertile 3rd Tertile Ptrend
Vitamin B6 (nmol/L)    
Median 33.2 54.1 95.1 0.55
Case:control ratio 15:14 10:16 16:12  
OR 1.00 0.59 1.23  
95% CI   (0.20-1.74) (0.43-3.51)  
Folate (nmol/L)    
Median 21.8 29.0 39.8 0.32
Case:control ratio 13:11 16:14 12:16  
OR 1.00 0.93 0.59  
95% CI   (0.31-2.74) (0.19-1.80)  
Vitamin B12 (pmol/L)    
Median 503.4 658.2 931.3 0.14
Case:control ratio 14:12 16:13 12:19  
OR 1.00 0.96 0.48  
95% CI   (0.32-2.83) (0.16-1.42)  
Magnesium (mg/L)    
Median 16.7 22.3 25.6 0.02
Case:control ratio 11:23 17:12 16:10  
OR 1.00 2.89 3.21  
95% CI   (1.02-8.13) (1.09-9.41)  
Zinc (mg/ml)    
Median 0.05 0.06 0.07 0.62
Case:control ratio 12:10 17:16 15:16  
OR 1.00 0.84 0.76  
95% CI   (0.28-2.51) (0.25-2.28)  
Ferritin (ng/ml)    
Median 8.5 22.4 41.0 0.85
Case:control ratio 16:14 9:16 19:15  
OR 1.00 0.48 1.01  
95% CI   (0.16-1.42) (0.37-2.78)  
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Table 4.13 Multivariate adjusted odds ratios1 and 95% CI for total 
micronutrient intake and PMS: The UMass Vitamin D Study, 2006-2010. 
  1st Tertile 2nd Tertile 3rd Tertile Ptrend 
Thiamin     
OR 1.00 0.73 1.12 0.73 
95% CI   (0.25-2.13) (0.32-3.92)   
Riboflavin     
OR 1.00 0.67 1.29 0.52 
95% CI   (0.22-1.99) (0.38-4.33)   
Niacin     
OR 1.00 0.74 0.81 0.79 
95% CI   (0.26-2.10) (0.25-2.61)   
Vitamin B6     
OR 1.00 0.53 0.87 0.88 
95% CI   (0.19-1.50) (0.28-2.72)   
Folate     
OR 1.00 1.25 1.15 0.87 
95% CI   (0.42-3.72) (0.38-3.46)   
Vitamin B12      
OR 1.00 0.73 1.43 0.41 
95% CI   (0.23-2.25) (0.43-4.76)   
Magnesium      
OR 1.00 0.97 0.67 0.39 
95% CI   (0.34-2.75) (0.24-1.89)   
Zinc     
OR 1.00 0.45 0.49 0.23 
95% CI   (0.16-1.27) (0.17-1.40)   
Sodium      
OR 1.00 1.35 1.21 0.92 
95% CI   (0.48-3.77) (0.48-3.19)   
Potassium      
OR 1.00 1.40 0.69 0.39 
95% CI   (0.51-3.85) (0.24-1.97)   
Iron     
OR 1.00 1.82 1.82 0.65 
95% CI   (0.63-5.26) (0.49-4.11)   
1 Adjusted for age, smoking (ever vs. never), use of multivitamins (yes vs. no) and total vitamin D intake 
(<100 vs. ≥100 IU). 
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Table 4.14 Multivariate adjusted odds ratios1 and 95% CI for 
micronutrient intake from food sources and PMS: The UMass Vitamin 
D Study, 2006-2010. 
  1st Tertile 2nd Tertile 3rd Tertile Ptrend 
Thiamin     
OR 1.00 0.92 0.57 0.24 
95% CI   (0.34-2.46) (0.21-1.52)   
Riboflavin     
OR 1.00 0.95 0.66 0.42 
95% CI   (0.35-2.61) (0.24-1.84)   
Niacin     
OR 1.00 1.66 0.51 0.17 
95% CI   (0.61-4.51) (0.18-1.42)   
Vitamin B6     
OR 1.00 0.39 0.40 0.11 
95% CI   (0.14-1.08) (0.14-1.12)   
Folate     
OR 1.00 0.99 0.65 0.37 
95% CI   (0.36-2.71) (0.23-1.84)   
Vitamin B12      
OR 1.00 2.32 1.96 0.42 
95% CI   (0.69-7.80) (0.59-6.46)   
Magnesium      
OR 1.00 0.81 0.68 0.48 
95% CI   (0.29-2.27) (0.23-1.97)   
Zinc     
OR 1.00 1.08 0.40 0.06 
95% CI   (0.38-3.02) (0.15-1.09)   
Potassium      
OR 1.00 1.47 0.66 0.38 
95% CI   (0.53-4.06) (0.23-1.88)   
Iron     
OR 1.00 0.56 0.79 0.92 
95% CI   (0.20-1.61) (0.29-2.19)   
1 Adjusted for age, smoking (ever vs. never), use of multivitamins (yes vs. no) and total vitamin D 
intake (<100 vs. ≥100 IU). 
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Table 4.15 Multivariate adjusted odds ratios1 and 95% CI for vitamin B6, 
folate, vitamin B12, magnesium, zinc, and ferritin blood levels and PMS: 
The UMass Vitamin D Study, 2006-2010. 
  1st Tertile 2nd Tertile 3rd Tertile Ptrend
Vitamin B6      
OR 1.00 0.79 1.64 0.32 
95% CI   (0.24-2.61) (0.51-5.30)   
Folate     
OR 1.00 1.41 0.94 0.81 
95% CI   (0.40-4.94) (0.27-3.27)   
Vitamin B12     
OR 1.00 1.51 0.92 0.71 
95% CI   (0.43-5.32) (0.27-3.15)   
Magnesium    
OR 1.00 3.31 4.20 0.01 
95% CI   (1.03-10.72) (1.24-14.23)   
Zinc     
OR 1.00 1.00 0.97 0.96 
95% CI   (0.30-3.30) (0.28-3.30)   
Ferritin     
OR 1.00 0.37 0.96 0.92 
95% CI   (0.11-1.26) (0.32-2.89)   
1 Adjusted for age, smoking (ever vs. never), and total vitamin D intake (<100 vs ≥100 UI). 
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Table 4.16 Age and multivariate estimates for the association of total intake of 
micronutrients (continuous) and PMS: The UMass Vitamin D Study, 2006-
2010. 
 Age-adjusted Multivariate adjusted1 
  OR 95% CI OR 95% CI
Thiamin (1 mg/day) 1.14 (0.88-1.48) 1.25 (0.92-1.68)
Riboflavin (1 mg/day) 1.08 (0.90-1.68) 1.18 (0.90-1.55)
Niacin (1 mg/day) 0.98 (0.95-1.01) 1.00 (0.97-1.03)
Vitamin B6 (1 mg/day) 1.04 (0.97-1.11) 1.05 (0.98-1.11)
Folate (100 µg/day) 1.00 (0.90-1.10) 1.00 (0.90-1.11)
Vitamin B12 (1 µg/day) 1.02 (0.96-1.08) 1.05 (0.97-1.13)
Magnesium (10 mg/day) 1.01 (0.98-1.04) 1.01 (0.97-1.04)
Zinc (1 mg/day) 0.99 (0.96-1.02) 1.00 (0.97-1.03)
Potassium (1000 mg/day) 1.04 (0.72-1.50) 0.99 (0.66-1.49)
Iron (1 mg/day) 1.01 (0.99-1.03) 1.01 (0.99-1.04)
Sodium (100 mg/day) 1.02 (0.95-1.09) 1.03 (0.96-1.11)
1 Adjusted for age, smoking (ever vs. never) and total vitamin D intake (<100 vs. ≥100 IU). 
 
 
 
Table 4.17 Age and multivariate estimates for the association between total 
micronutrient intake (continuous) and PMS symptom score (continuous): The 
UMass Vitamin D Study, 2006-2010. 
 Age-adjusted Multivariate adjusted1 
  β SE Pvalue β SE Pvalue 
Thiamin (1 mg/day) 0.22 0.12 0.07 0.32 0.12 0.01
Riboflavin (1 mg/day) 0.20 0.12 0.11 0.30 0.12 0.01
Niacin (1 mg/day) -0.04 0.05 0.47 0.05 0.06 0.35
Vitamin B6 (1 mg/day) 0.06 0.07 0.41 0.09 0.07 0.23
Folate (100 µg/day) -0.04 0.20 0.83 0.14 0.22 0.53
Vitamin B12 (1 µg/day) 0.002 0.01 0.90 0.003 0.01 0.83
Magnesium (10 mg/day) -0.02 0.06 0.78 -0.01 0.06 0.82
Zinc (1 mg/day) -0.03 0.05 0.52 0.02 0.05 0.68
Potassium (1000 mg/day) -0.43 0.69 0.54 -0.60 0.69 0.39
Iron (1 mg/day) 0.03 0.04 0.48 0.08 0.04 0.09
Sodium (100 mg/day) -0.05 0.14 0.73 -0.01 0.14 0.92
1 Adjusted for age, smoking (ever vs. never), use of multivitamins (yes vs. no) and total vitamin D intake (<100 vs. 
≥100 IU). 
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Table 4.18 Age and multivariate estimates for the association between 
micronutrient intake from food sources (continuous) and PMS symptom score 
(continuous): The UMass Vitamin D Study, 2006-2010. 
 Age-adjusted Multivariate adjusted1 
  β SE Pvalue β SE Pvalue 
Thiamin (1 mg/d) -0.68 1.14 0.55 -0.56 1.11 0.62
Riboflavin (1 mg/d) -1.20 0.83 0.15 -0.79 0.83 0.34
Niacin (1 mg/d) -0.16 0.08 0.06 -0.12 0.08 0.16
Vitamin B6 (1 mg/d) -1.89 0.86 0.03 -1.65 0.84 0.05
Folate (100 µg/d) -0.17 0.25 0.50 -0.26 0.25 0.29
Vitamin B12 (1 µg/d) -0.30 0.19 0.12 -0.18 0.20 0.37
Magnesium (10 mg/d) -0.05 0.06 0.42 -0.07 0.06 0.28
Zinc (1 mg/d) -0.41 0.16 0.01 -0.31 0.16 0.05
Potassium (1000 mg/d) -0.70 0.68 0.30 -0.82 0.68 0.23
Iron (1 mg/d) -0.13 0.11 0.24 -0.10 0.11 0.35
1 Adjusted for age, smoking (ever vs. never),  use of multivitamins (yes vs. no) and total vitamin D intake (<100 
vs. ≥100 IU). 
 
 
 
Table 4.19 Age and multivariate estimates for the association between blood levels 
of vitamin B6, folate, vitamin B12, magnesium, zinc, and ferritin, and PMS 
symptom score (continuous): The UMass Vitamin D Study, 2006-2010. 
 Age-adjusted Multivariate adjusted1 
  β SE Pvalue β SE Pvalue
Vitamin B6 (nmol/L) -0.01 0.01 0.62 -0.001 0.01 0.95
Folate (nmol/L) -0.01 0.03 0.63 -0.02 0.03 0.42
Vitamin B12 (pmol/L) -0.004 0.004 0.22 -0.003 0.004 0.43
Magnesium (mg/L) 0.43 0.19 0.02 0.48 0.18 0.01
Zinc (mg/ml) -62.00 47.36 0.19 -54.55 46.87 0.25
Ferritin (ng/ml) -0.03 0.04 0.51 -0.03 0.04 0.47
1 Adjusted for age, smoking (ever vs. never)  and total vitamin D intake (<100 vs .≥100 IU). 
 
  
274 
 
References  
1. American College of Obstetrics and Gynecology Practice Bulletin. Clinical 
management guidelines for obstetricians-gynecologists. Obstet Gynecol 2000;95:1-9.  
2. Bertone-Johnson ER, Hankinson SE, Bendich A, Johnson SR, Willett WC, Manson JE. 
Calcium and vitamin D intake and risk of incident premenstrual syndrome. Arch Intern 
Med 2005;165:1246-52.  
3. Halbreich U. The etiology, biology, and evolving pathology of premenstrual 
syndromes. Psychoneuroendocrinology 2003;28 Suppl 3:55-99.  
4. Maguire J, Mody I. Steroid hormone fluctuations and GABA(A)R plasticity. 
Psychoneuroendocrinology 2009;34 Suppl 1:S84.  
5. Rapkin AJ, Edelmuth E, Chang LC, Reading AE, McGuire MT, Su TP. Whole-blood 
serotonin in premenstrual syndrome. Obstet Gynecol 1987;70:533-7.  
6. Taylor DL, Mathew RJ, Ho BT, Weinman ML. Serotonin levels and platelet uptake 
during premenstrual tension. Neuropsychobiology 1984;12:16-8.  
7. Parry BL, Berga SL, Kripke DF, et al. Altered waveform of plasma nocturnal 
melatonin secretion in premenstrual depression. Arch Gen Psychiatry 1990;47:1139-46.  
8. Epperson CN, Haga K, Mason GF, et al. Cortical gamma-aminobutyric acid levels 
across the menstrual cycle in healthy women and those with premenstrual dysphoric 
disorder: a proton magnetic resonance spectroscopy study. Arch Gen Psychiatry 
2002;59:851-8.  
9. Halbreich U, Petty F, Yonkers K, Kramer GL, Rush AJ, Bibi KW. Low plasma 
gamma-aminobutyric acid levels during the late luteal phase of women with premenstrual 
dysphoric disorder. Am J Psychiatry 1996;153:718-20.  
10. Eriksson E, Alling C, Andersch B, Andersson K, Berggren U. Cerebrospinal fluid 
levels of monoamine metabolites. A preliminary study of their relation to menstrual cycle 
phase, sex steroids, and pituitary hormones in healthy women and in women with 
premenstrual syndrome. Neuropsychopharmacology 1994;11:201-13.  
11. Malmgren R, Collins A, Nilsson CG. Platelet serotonin uptake and effects of vitamin 
B6-treatment in premenstrual tension. Neuropsychobiology 1987;18:83-6.  
12. Stipanuk MH. Biochemical, physiological, & molecular aspects of human nutrition. 
2nd ed. St. Louis: Saunders Elsevier, 2006.  
13. Coppen A, Bolander-Gouaille C. Treatment of depression: time to consider folic acid 
and vitamin B12. J Psychopharmacol 2005;19:59-65.  
275 
 
14. Miller A. The methylation, neurotransmitter, and antioxidant connections between 
folate and depression. Alternative medicine review 2008;13:216.  
15. Billyard AJ, Eggett DL, Franz KB. Dietary magnesium deficiency decreases plasma 
melatonin in rats. Magnesium research 2006;19:157-61.  
16. Maeng S, Zarate C. The role of glutamate in mood disorders: results from the 
ketamine in major depression study and the presumed cellular mechanism underlying its 
antidepressant effects. Curr Psychiatry Rep 2007;9:467-74.  
17. Levenson C. Regulation of the NMDA receptor: implications for neuropsychological 
development. Nutr Rev 2006;64:428-32.  
18. Sanacora G, Zarate C, Krystal J, Manji H. Targeting the glutamatergic system to 
develop novel, improved therapeutics for mood disorders. Nature Reviews.Drug 
Discovery 2008;7:426-37.  
19. Honor E. The neuronal background K2P channels: focus on TREK1. Nature 
Reviews.Neuroscience 2007;8:251-61.  
20. Heurteaux C, Lucas G, Guy N, et al. Deletion of the background potassium channel 
TREK-1 results in a depression-resistant phenotype. Nat Neurosci 2006;9:1134-41.  
21. Guyton AC, Hall JE. Textbook of medical physiology. 11th ed. Philadelphia: Elsevier 
Saunders, 2006.  
22. Sharma P, Kulshreshtha S, Singh GM, Bhagoliwal A. Role of bromocriptine and 
pyridoxine in premenstrual tension syndrome. Indian J Physiol Pharmacol 2007;51:368-
74.  
23. Williams MJ, Harris RI, Dean BC. Controlled trial of pyridoxine in the premenstrual 
syndrome. J Int Med Res 1985;13:174-9.  
24. Wyatt KM, Dimmock PW, Jones PW, Shaughn O'Brien PM. Efficacy of vitamin B-6 
in the treatment of premenstrual syndrome: systematic review. BMJ 1999;318:1375-81.  
25. Doll H, Brown S, Thurston A, Vessey M. Pyridoxine (vitamin B6) and the 
premenstrual syndrome: a randomized crossover trial. J R Coll Gen Pract 1989;39:364-8.  
26. Kashanian M, Mazinani R, Jalalmanesh S. Pyridoxine (vitamin B6) therapy for 
premenstrual syndrome. Int J Gynaecol Obstet 2007;96:43-4.  
27. Colin C. Controlled studies on the oral administration of progestagens, an 
antiestrogen and vitamin B6 in the treatment of mastodynias. Rev Med Brux 1982;3:605-
9.  
276 
 
28. Berman MK, Taylor ML, Freeman E. Vitamin B-6 in premenstrual syndrome. J Am 
Diet Assoc 1990;90:859-61.  
29. Hagen I, Nesheim BI, Tuntland T. No effect of vitamin B-6 against premenstrual 
tension. A controlled clinical study. Acta Obstet Gynecol Scand 1985;64:667-70.  
30. Smallwood J, Ah-Kye D, Taylor I. Vitamin B6 in the treatment of pre-menstrual 
mastalgia. Br J Clin Pract 1986;40:532-3.  
31. Quaranta S, Buscaglia MA, Meroni MG, Colombo E, Cella S. Pilot study of the 
efficacy and safety of a modified-release magnesium 250 mg tablet (Sincromag) for the 
treatment of premenstrual syndrome. Clinical Drug Investigation 2007;27:51-8.  
32. Facchinetti F, Borella P, Sances G, Fioroni L, Nappi RE, Genazzani AR. Oral 
magnesium successfully relieves premenstrual mood changes. Obstet Gynecol 
1991;78:177-81.  
33. Khine K, Rosenstein D, Elin R, Niemela J, Schmidt P, Rubinow D. Magnesium (mg) 
retention and mood effects after intravenous mg infusion in premenstrual dysphoric 
disorder. Biol Psychiatry 2006;59:327-33.  
34. De Souza MC, Walker AF, Robinson PA, Bolland K. A synergistic effect of a daily 
supplement for 1 month of 200 mg magnesium plus 50 mg vitamin B6 for the relief of 
anxiety-related premenstrual symptoms: a randomized, double-blind, crossover study. J 
Womens Health Gend Based Med 2000;9:131-9.  
35. Walker A, De Souza MC, Marakis G, Robinson PA, Morris AP, Bolland KM. 
Unexpected benefit of sorbitol placebo in Mg intervention study of premenstrual 
symptoms: implications for choice of placebo in RCTs. Med Hypotheses 2002;58:213-
20.  
36. Reeves BD, Garvin JE, McElin TW. Premenstrual tension: symptoms and weight 
changes related to potassium therapy. Obstet Gynecol 1971;109:1036-41.  
37. Torres S, Nowson C, Worsley A. Dietary electrolytes are related to mood. Br J Nutr 
2008;100:1038-45.  
38. Facchinetti F, Nappi RE, Sances MG, Neri I, Grandinetti G, Genazzani A. Effects of 
a yeast-based dietary supplementation on premenstrual syndrome. A double-blind 
placebo-controlled study. Gynecol Obstet Invest 1997;43:120-4.  
39. London RS, Bradley L, Chiamori NY. Effect of a nutritional supplement on 
premenstrual symptomatology in women with premenstrual syndrome: a double-blind 
longitudinal study. J Am Coll Nutr 1991;10:494-9.  
277 
 
40. Goei GS, Abraham GE. Effect of a nutritional supplement, optivite, on symptoms of 
premenstrual tension. J Reprod Med 1983;28:527-31.  
41. Szewczyk B, Kubera M, Nowak G. The role of zinc in neurodegenerative and 
inflammatory pathways in depression. Progress in neuro-psychopharmacology biological 
psychiatry 2011.35(3):693-701. 
42. Sawada T, Yokoi K. Effect of zinc supplementation on mood states in young women: 
a pilot study. Eur J Clin Nutr 2010;64(3):331-3. 
43. Sowa-Kućma M, Legutko B, Szewczyk B, et al. Antidepressant-like activity of zinc: 
further behavioral and molecular evidence. J Neural Transm 2008;115:1621.  
44. Siwek M, Dudek D, Paul I, et al. Zinc supplementation augments efficacy of 
imipramine in treatment resistant patients: a double blind, placebo-controlled study. J 
Affect Disord 2009;118:187-95.  
45. van den Berg H, Louwerse ES, Bruinse HW, Thissen JT, Schrijver J. Vitamin B6 
status of women suffering from premenstrual syndrome. Hum Nutr Clin Nutr 
1986;40:441-50.  
46. Ritchie CD, Singkamani R. Plasma pyridoxal 5'-phosphate in women with the 
premenstrual syndrome. Hum Nutr Clin Nutr 1986;40:75-80.  
47. Mira M, Stewart PM, Abraham SF. Vitamin and trace element status in premenstrual 
syndrome. Am J Clin Nutr 1988;47:636-41.  
48. Rosenstein DL, Elin RJ, Hosseini JM, Grover G, Rubinow DR. Magnesium measures 
across the menstrual cycle in premenstrual syndrome. Biol Psychiatry 1994;35:557-61.  
49. Shamberger R. Calcium, magnesium, and other elements in the red blood cells and 
hair of normals and patients with premenstrual syndrome. Biol Trace Elem Res 
2003;94:123-9.  
50. Das K, Chowdhury AR. Metallic ion concentration during menstrual cycle in 
normally menstruating women. Indian J Med Sci 1997;51:52-4.  
51. Chuong CJ, Dawson EB. Zinc and copper levels in premenstrual syndrome. Fertil 
Steril 1994;62:313-20.  
52. Willett WC. Nutritional Epidemiology. Second Edition ed. New York, Oxford: 
Oxford University Press, 1998.  
53. Willett WC, Sampson L, Stampfer MJ, et al. Reproducibility and validity of a 
semiquantitative food frequency questionnaire. Am J Epidemiol 1985;122:51-65.  
278 
 
54. Salvini S, Hunter DJ, Sampson L, et al. Food-based validation of a dietary 
questionnaire: the effects of week-to-week variation in food consumption. Int J 
Epidemiol 1989;18:858-67.  
55. Rimm EB, Giovannucci EL, Stampfer MJ, Colditz GA, Litin LB, Willett WC. 
Reproducibility and validity of an expanded self-administered semiquantitative food 
frequency questionnaire among male health professionals. Am J Epidemiol 
1992;135:1114,26; discussion 1127-36.  
56. Feskanich D, Rimm EB, Giovannucci EL, et al. Reproducibility and validity of food 
intake measurements from a semiquantitative food frequency questionnaire. J Am Diet 
Assoc 1993;93:790-6.  
57. Shin YS, Rasshofer R, Friedrich B, Endres W. Pyridoxal-5'-phosphate determination 
by a sensitive micromethod in human blood, urine and tissues its relation to 
cystathioninuria in neuroblastoma and biliary atresia. Clinica chimica acta 1983;127:77-
85.  
58. Schuster K, Bailey LB, Cerda JJ, Gregory JF. Urinary 4-pyridoxic acid excretion in 
24-hour versus random urine samples as a measurement of vitamin B6 status in humans. 
Am J Clin Nutr 1984;39:466-70.  
59. Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin status and intake 
as primary determinants of homocysteinemia in an elderly population. JAMA 
1993;270:2693-8.  
60. Mortola JF, Girton L, Beck L, Yen SS. Diagnosis of premenstrual syndrome by a 
simple, prospective, and reliable instrument: the calendar of premenstrual experiences. 
Obstet Gynecol 1990;76:302-7.  
61. Bertone-Johnson ER, Hankinson SE, Johnson SR, Manson JE. A simple method of 
assessing premenstrual syndrome in large prospective studies. J Reprod Med 
2007;52:779-86.  
62. Bertone-Johnson ER, Hankinson SE, Johnson SR, Manson JE. Cigarette Smoking and 
the Development of Premenstrual Syndrome. Am J Epidemiol 2008; 168(8):938-45. 
63. Bertone-Johnson E, Hankinson S, Johnson S, Manson J. Timing of alcohol use and 
the incidence of premenstrual syndrome and probable premenstrual dysphoric disorder. 
Journal of women's health 2009;18:1945.  
64. Bruinsma K, Taren DL. Chocolate: food or drug? J Am Diet Assoc 1999;99:1249-56.  
65. Mortola JF. Issues in the diagnosis and research of premenstrual syndrome. Clin 
Obstet Gynecol 1992;35:587-98.  
279 
 
66. Yen J, Chang S, Ko C, et al. The high-sweet-fat food craving among women with 
premenstrual dysphoric disorder: emotional response, implicit attitude and rewards 
sensitivity. Psychoneuroendocrinology 2010;35:1203-12.  
67. Lussana F, Zighetti M, Bucciarelli P, Cugno M, Cattaneo M. Blood levels of 
homocysteine, folate, vitamin B6 and B12 in women using oral contraceptives compared 
to non-users. Thromb Res 2003;112:37-41.  
68. Bielenberg J. [Folic acid and vitamin deficiency caused by oral contraceptives]. 
Medizinische Monatsschrift für Pharmazeuten 1991;14:244-7.  
 
  
280 
 
BIBLIOGRAPHY 
ACOG Practice Bulletin no. 110: Noncontraceptive uses of hormonal contraceptives. 
2010. Obstetrics and Gynecology 115 (1): 206-18.  
Abraham, G. E. 1983. Nutritional factors in the etiology of the premenstrual tension 
syndromes. The Journal of Reproductive Medicine 28 (7) (Jul): 446-64.  
Albacar, G., T. Sans, R. Martin-Santos, L. Garcia-Esteve, R. Guillamat, J. Sanjuan, F. 
Caellas, et al. 2010. An association between plasma ferritin concentrations measured 
48h after delivery and postpartum depression. Journal of Affective Disorders.  
Amani, R., Somaye S., Z. Nazari, and S. Nematpour. 2009. Correlation between dietary 
zinc intakes and its serum levels with depression scales in young female students. 
Biological Trace Element Research 137(2):150-8. 
American College of Obstetrics and Gynecology Practice Bulletin. 2000. Clinical 
management guidelines for obstetricians-gynecologists. Obstetrics and Gynecology 
95 (15): 1-9.  
American Psychiatric Association. 2000. Diagnostic and statistical manual of mental 
disorders-IV-TR. 4th edition ed. American Psychiatric Publishing, Inc.  
———. 1987. Diagnostic and statistical manual of mental disorders-III-R. 3rd edition 
(revised) ed. Washington, DC.: American Psychiatric Publishing, Inc.  
Anderson, J., S. Fordahl, P. Cooney, T. Weaver, C. Colyer, and K. Erikson. 2008. 
Manganese exposure alters extracellular GABA, GABA receptor and transporter 
protein and mRNA levels in the developing rat brain. Neurotoxicology 29 (6): 1044-
53.  
Andren, L., S. Nyberg, S. Turkmen, G. van Wingen, G. Fernndez, and T. Backstrom. 
2009. Sex steroid induced negative mood may be explained by the paradoxical effect 
mediated by GABAA modulators. Psychoneuroendocrinology 34 (8): 1121.  
Ashby, C. R., L. A. Carr, C. L. Cook, M. M. Steptoe, and D. D. Franks. 1988. Alteration 
of platelet serotonergic mechanisms and monoamine oxidase activity in 
premenstrual syndrome. Biological Psychiatry 24 (2): 225-33.  
Backstrom, T., L. Andreen, V. Birzniece, I. Bjorn, I. M. Johansson, M. Nordenstam-
Haghjo, S. Nyberg, et al. 2003. The role of hormones and hormonal treatments in 
premenstrual syndrome. CNS Drugs 17 (5): 325-42.  
Ball, D. M., P. Glue, S. Wilson, and D. J. Nutt. 1991. Pharmacology of saccadic eye 
movements in man. 1. effects of the benzodiazepine receptor ligands midazolam and 
flumazenil. Psychopharmacology 105 (3): 361-7.  
281 
 
Batra, N., J. Seres-Mailo, C. Hanstock, P. Seres, J. Khudabux, F.  Bellavance, G. Baker, 
et al. 2008. Proton magnetic resonance spectroscopy measurement of brain 
glutamate levels in premenstrual dysphoric disorder. Biological Psychiatry 63 (12): 
1178-84.  
Beard, J., and J.Connor. 2003. Iron status and neural functioning. Annual Review of 
Nutrition 23 : 41-58.  
Beard, John, Michael Hendricks, Eva Perez, Laura Murray Kolb, Astrid Berg, Lynne 
Vernon Feagans, James Irlam, Washiefa Isaacs, Alan Sive, and Mark Tomlinson. 
2005. Maternal iron deficiency anemia affects postpartum emotions and cognition. 
The Journal of Nutrition 135 (2): 267-72.  
Bendich, A. 2000. The potential for dietary supplements to reduce premenstrual 
syndrome (PMS) symptoms. Journal of the American College of Nutrition 19 (1) 
(Feb): 3-12.  
Benton, D., and R. T. Donohoe. 1999. The effects of nutrients on mood. Public Health 
Nutrition 2 (3A) (Sep): 403-9.  
Berger, C. P., and B. Presser. 1994. Alprazolam in the treatment of two subsamples of 
patients with late luteal phase dysphoric disorder: A double-blind, placebo-
controlled crossover study. Obstetrics and Gynecology 84 (3) (Sep): 379-85.  
Berger, D., W. Schaffner, E. Schrader, B. Meier, and A. Brattstrm. 2000. Efficacy of 
vitex agnus castus L. extract ze 440 in patients with pre-menstrual syndrome (PMS). 
Archives of Gynecology and Obstetrics 264 (3): 150-3.  
Berman, M. K., M. L. Taylor, and E. Freeman. 1990. Vitamin B-6 in premenstrual 
syndrome. Journal of the American Dietetic Association 90 (6) (Jun): 859-61.  
Bermond, P. 1982. Therapy of side effects of oral contraceptive agents with vitamin B6. 
Acta Vitaminologica Et Enzymologica 4 (1-2): 45-54.  
Bertone-Johnson, E. R., S. E. Hankinson, A. Bendich, S. R. Johnson, W. C. Willett, and 
J. E. Manson. 2010. Adiposity and the development of premenstrual syndrome. 
Journal of Women's Health 19 (11): 1955.  
Bertone-Johnson, E. R., S. E. Hankinson, A. Bendich, S. R. Johnson, W. C. Willett, and 
J. E. Manson. 2005. Calcium and vitamin D intake and risk of incident premenstrual 
syndrome. Archives of Internal Medicine 165 (11) (Jun 13): 1246-52.  
Bertone-Johnson, E. R., S. E. Hankinson, S. R. Johnson, and J. E. Manson. 2008. 
Cigarette smoking and the development of premenstrual syndrome. American 
Journal of Epidemiology (Aug 13).  
282 
 
———. 2007. A simple method of assessing premenstrual syndrome in large prospective 
studies. The Journal of Reproductive Medicine 52 (9) (Sep): 779-86.  
Bertone-Johnson, E. R., S.E. Hankinson, S.R. Johnson, and J.E. Manson. 2009. Timing of 
alcohol use and the incidence of premenstrual syndrome and probable premenstrual 
dysphoric disorder. Journal of Women's Health 18 (12): 1945.  
Beydoun, M., M.T. F. Kuczmarski, H. Beydoun, M.Shroff, M. Mason, M. Evans, and A. 
Zonderman. 2010. The sex-specific role of plasma folate in mediating the 
association of dietary quality with depressive symptoms. The Journal of Nutrition 
140 (2): 338-47.  
Bielenberg, J. 1991. [Folic acid and vitamin deficiency caused by oral contraceptives]. 
Medizinische Monatsschrift fur Pharmazeuten 14 (8): 244-7.  
Billyard, A. J., D. L. Eggett, and K. B. Franz. 2006. Dietary magnesium deficiency 
decreases plasma melatonin in rats. Magnesium Research 19 (3): 157-61.  
Birdsall, T. C. 1998. 5-hydroxytryptophan: A clinically-effective serotonin precursor. 
Alternative Medicine Review : A Journal of Clinical Therapeutic 3 (4) (Aug): 271-
80.  
Bloch, M., N. Rotenberg, D. Koren, and E. Klein. 2005. Risk factors associated with the 
development of postpartum mood disorders. Journal of Affective Disorders 88 (1): 9-
18.  
Blumenthal, Mark, and Bundesinstitut fur Arzneimittel und Medizinprodukte . 
Commission E. 2000. Herbal medicine : Expanded commission E monographs. 1st 
ed. Newton, MA: Integrative Medicine Communications.  
Borenstein, J., C. F. Chiou, B. Dean, J. Wong, and S. Wade. 2005. Estimating direct and 
indirect costs of premenstrual syndrome. Journal of Occupational and 
Environmental Medicine / American College of Occupational and Environmental 
Medicine 47 (1) (Jan): 26-33.  
Bourre, J. M. 2006. Effects of nutrients (in food) on the structure and function of the 
nervous system: Update on dietary requirements for brain. part 1: Micronutrients. 
The Journal of Nutrition, Health & Aging 10 (5) (Sep-Oct): 377-85.  
Braverman, P. K. 2007. Premenstrual syndrome and premenstrual dysphoric disorder. 
Journal of Pediatric and Adolescent Gynecology 20 (1) (Feb): 3-12.  
Brown, K. H., S. E. Wuehler, and J. M. Peerson. 2001. The importance of zinc in human 
nutrition and estimation of the global prevalence of zinc deficiency. Food and 
Nutrition Bulletin 22 (2): 113.  
283 
 
Bruinsma, K., and D. L. Taren. 1999. Chocolate: Food or drug? Journal of the American 
Dietetic Association 99 (10): 1249-56.  
Brush, M. G. 1984. Abnormal essential fatty acid levels in plasma of women with 
premenstrual syndrome. American Journal of Obstetrics and Gynecology 150, (4).  
Budeiri, D., A. Li Wan Po, and J. C. Dornan. 1996. Is evening primrose oil of value in 
the treatment of premenstrual syndrome? Controlled Clinical Trials 17 (1) (Feb): 60-
8.  
Busse, J. W., V. M. Montori, C. Krasnik, I. Patelis-Siotis, and G. H. Guyatt. 2008. 
Psychological intervention for premenstrual syndrome: A meta-analysis of 
randomized controlled trials. Psychotherapy and Psychosomatics 78 (1) (Oct 14): 6-
15.  
Caminiti, F., M. De Murtas, G. Parodo, U. Lecca, and A. Nasi. 1980. Decrease in human 
plasma prolactin levels by oral prostaglandin E2 in early puerperium. The Journal of 
Endocrinology 87 (3): 333-7.  
Chidambaram, M., J.Duncan, V. Lai, D. Cattran, J. Floras, J. Scholey, and J. Miller. 
2002. Variation in the renin angiotensin system throughout the normal menstrual 
cycle. Journal of the American Society of Nephrology 13 (2): 446-52.  
Chuong, C. J., and E. B. Dawson. 1994. Zinc and copper levels in premenstrual 
syndrome. Fertility and Sterility 62 (2): 313-20.  
Clayton, A. H. 2008. Symptoms related to the menstrual cycle: Diagnosis, prevalence, 
and treatment. Journal of Psychiatric Practice 14 (1) (Jan): 13-21.  
Cohen, L., C. Miner, E. Brown, E. Freeman, U. Halbreich, K. Sundell, and S.McCray. 
2002. Premenstrual daily fluoxetine for premenstrual dysphoric disorder: A placebo-
controlled, clinical trial using computerized diaries. Obstetrics and Gynecology 100 
(3): 435-44.  
Cohen, L., C. Soares, K. Yonkers, K. Bellew, I. Bridges, and M. Steiner. 2004. 
Paroxetine controlled release for premenstrual dysphoric disorder: A double-blind, 
placebo-controlled trial. Psychosomatic Medicine 66 (5): 707-13.  
Colin, C. 1982. Controlled studies on the oral administration of progestagens, an 
antiestrogen and vitamin B6 in the treatment of mastodynias. Revue Medicale De 
Bruxelles 3 (9) (Nov): 605-9.  
Collins, A. 1993. Essential fatty acids in the treatment of premenstrual syndrome. 
Obstetrics and Gynecology 81, (1).  
284 
 
Compagnone, N. A., and S. H. Mellon. 2000. Neurosteroids: Biosynthesis and function of 
these novel neuromodulators. Frontiers in Neuroendocrinology 21 (1): 1-56.  
Coppen, A., and C. Bolander-Gouaille. 2005. Treatment of depression: Time to consider 
folic acid and vitamin B12. Journal of Psychopharmacology (Oxford, England) 19 
(1) (Jan): 59-65.  
Crayton, John, and William Walsh. 2007. Elevated serum copper levels in women with a 
history of post-partum depression. Journal of Trace Elements in Medicine and 
Biology 21 (1): 17-21.  
Cressent, M., C. Elie, J. Taboulet, M. S. Moukhtar, and G. Milhaud. 1983. Calcium 
regulating hormones during the estrous cycle of the rat. Proceedings of the Society 
for Experimental Biology and Medicine.Society for Experimental Biology and 
Medicine (New York, N.Y.) 172 (2) (Feb): 158-62.  
Dalton, K. 1985. Pyridoxine overdose in premenstrual syndrome. The Lancet 1 (8438): 
1168-9.  
Das, K., and A. R. Chowdhury. 1997. Metallic ion concentration during menstrual cycle 
in normally menstruating women. Indian Journal of Medical Sciences 51 (2) (Feb): 
52-4.  
De Souza, M. C., A. F. Walker, P. A. Robinson, and K. Bolland. 2000. A synergistic 
effect of a daily supplement for 1 month of 200 mg magnesium plus 50 mg vitamin 
B6 for the relief of anxiety-related premenstrual symptoms: A randomized, double-
blind, crossover study. Journal of Women's Health & Gender-Based Medicine 9 (2) 
(Mar): 131-9.  
Dean, B. B., and J. E. Borenstein. 2004. A prospective assessment investigating the 
relationship between work productivity and impairment with premenstrual 
syndrome. Journal of Occupational and Environmental Medicine / American 
College of Occupational and Environmental Medicine 46 (7) (Jul): 649-56.  
Dennehy, C. E. 2006. The use of herbs and dietary supplements in gynecology: An 
evidence-based review. Journal of Midwifery & Women's Health 51 (6) (Nov-Dec): 
402-9.  
Deuster, P. A., T. Adera, and J. South-Paul. 1999. Biological, social, and behavioral 
factors associated with premenstrual syndrome. Archives of Family Medicine 8 (2) 
(Mar-Apr): 122-8.  
Dimmock, P. W., K. M. Wyatt, P. W. Jones, and P. M. O'Brien. 2000. Efficacy of 
selective serotonin-reuptake inhibitors in premenstrual syndrome: A systematic 
review. Lancet 356 (9236) (Sep 30): 1131-6.  
285 
 
Doll, H., S. Brown, A. Thurston, and M. Vessey. 1989. Pyridoxine (vitamin B6) and the 
premenstrual syndrome: A randomized crossover trial. The Journal of the Royal 
College of General Practitioners 39 (326) (Sep): 364-8.  
Dyer, A. R., P. Elliott, J. Stamler, Q. Chan, H. Ueshima, and B. F. Zhou. 2003. Dietary 
intake in male and female smokers, ex-smokers, and never smokers: The 
INTERMAP study. Journal of Human Hypertension 17 (9): 641-54.  
Eby, George, and Karen Eby. 2009. Magnesium for treatment-resistant depression: A 
review and hypothesis. Medical Hypotheses.  
Endicott, J., J. Amsterdam, E. Eriksson, E. Frank, E. Freeman, R. Hirschfeld, F. Ling, et 
al. 1999. Is premenstrual dysphoric disorder a distinct clinical entity? Journal of 
Women's Health & Gender-Based Medicine 8 (5) (Jun): 663-79.  
Epperson, C. N., K. Haga, G. F. Mason, E. Sellers, R. Gueorguieva, W. Zhang, E. Weiss, 
D. L. Rothman, and J. H. Krystal. 2002. Cortical gamma-aminobutyric acid levels 
across the menstrual cycle in healthy women and those with premenstrual dysphoric 
disorder: A proton magnetic resonance spectroscopy study. Archives of General 
Psychiatry 59 (9) (Sep): 851-8.  
Erikson, Keith, Zakariya Shihabi, Judy Aschner, and Michael Aschner. 2002. Manganese 
accumulates in iron-deficient rat brain regions in a heterogeneous fashion and is 
associated with neurochemical alterations. Biological Trace Element Research 87 (1-
3): 143-56.  
Eriksson, E., C. Alling, B. Andersch, K. Andersson, and U. Berggren. 1994. 
Cerebrospinal fluid levels of monoamine metabolites. A preliminary study of their 
relation to menstrual cycle phase, sex steroids, and pituitary hormones in healthy 
women and in women with premenstrual syndrome. Neuropsychopharmacology 11 
(3): 201-13.  
Eriksson, E., M. A. Hedberg, B. Andersch, and C. Sundblad. 1995. The serotonin 
reuptake inhibitor paroxetin is superior to the noradrenaline reuptake inhibitor 
maprotiline in the treatment of premenstrual syndrome. Neuropsychopharmacology 
12 (2): 167-76.  
Ervin, R. B., Chia-Yih Wang, Jacqueline Wright, and Jocelyn Kennedy Stephenson. 
2004. Dietary intake of selected minerals for the united states population: 1999-
2000. Advance Data from Vital Health Statistics of the National Center for Health 
Statistics(341): 1-5.  
Evans, S. M., M. Haney, F. R. Levin, R. W. Foltin, and M. W. Fischman. 1998. Mood 
and performance changes in women with premenstrual dysphoric disorder: Acute 
effects of alprazolam. Neuropsychopharmacology : Official Publication of the 
American College of Neuropsychopharmacology 19 (6) (Dec): 499-516.  
286 
 
Facchinetti, F., P. Borella, G. Sances, L. Fioroni, R. E. Nappi, and A. R. Genazzani. 
1991. Oral magnesium successfully relieves premenstrual mood changes. Obstetrics 
and Gynecology 78 (2): 177-81.  
Facchinetti, F., R. E. Nappi, M. G. Sances, I. Neri, G. Grandinetti, and A. Genazzani. 
1997. Effects of a yeast-based dietary supplementation on premenstrual syndrome. A 
double-blind placebo-controlled study. Gynecologic and Obstetric Investigation 43 
(2): 120-4.  
Fallah, S., F. Sani, and M. Firoozrai. 2009. Effect of contraceptive pill on the selenium 
and zinc status of healthy subjects. Contraception 80 (1): 40-3.  
Feskanich, D., E. B. Rimm, E. L. Giovannucci, G. A. Colditz, M. J. Stampfer, L. B. Litin, 
and W. C. Willett. 1993. Reproducibility and validity of food intake measurements from 
a semiquantitative food frequency questionnaire. Journal of the American Dietetic 
Association 93 (7) (Jul): 790-6.  
Finley, J. W., and C. D. Davis. 1999. Manganese deficiency and toxicity: Are high or low 
dietary amounts of manganese cause for concern? BioFactors 10 (1): 15-24.  
Fommei, E., S. Ghione, A. Ripoli, S. Maffei, P. Di Cecco, A. Iervasi, and S. Turchi. 
2009. The ovarian cycle as a factor of variability in the laboratory screening for 
primary aldosteronism in women. Journal of Human Hypertension 23 (2): 130-5.  
Ford, Earl, and Ali Mokdad. 2003. Dietary magnesium intake in a national sample of US 
adults. The Journal of Nutrition 133 (9): 2879-82.  
Frank, R. 1931. The hormonal basis of premenstrual tension. Archives of Neurological 
Psychiatry 26 : 1053-1057.  
Frankenburg, Frances. 2007. The role of one-carbon metabolism in schizophrenia and 
depression. Harvard Review of Psychiatry 15 (4): 146.  
Freeman, E. W., R. J. DeRubeis, and K. Rickels. 1996. Reliability and validity of a daily 
diary for premenstrual syndrome. Psychiatry Research 65 (2) (Nov 15): 97-106.  
Freeman, E. W., K. Rickels, S. J. Sondheimer, and M. Polansky. 1995. A double-blind 
trial of oral progesterone, alprazolam, and placebo in treatment of severe 
premenstrual syndrome. JAMA : The Journal of the American Medical Association 
274 (1) (Jul 5): 51-7.  
French, Linda. 2005. Dysmenorrhea. American Family Physician 71 (2): 285-91.  
Fugh-Berman, A., and F. Kronenberg. 2003. Complementary and alternative medicine 
(CAM) in reproductive-age women: A review of randomized controlled trials. 
Reproductive Toxicology (Elmsford, N.Y.) 17 (2) (Mar-Apr): 137-52.  
287 
 
Gao, S.F., and A.M. Bao. 2010. Corticotropin-releasing hormone, glutamate, and 
{gamma}-aminobutyric acid in depression. The Neuroscientist.  
Gehlert, S., I. H. Song, C-H Chang, and S. A. Hartlage. 2009. The prevalence of 
premenstrual dysphoric disorder in a randomly selected group of urban and rural 
women. Psychological Medicine 39 (1): 129-36.  
Ghanbari, Zinat, Fedieh Haghollahi, Mamak Shariat, Abbas Foroshani, and Maryam 
Ashrafi. 2009. Effects of calcium supplement therapy in women with premenstrual 
syndrome. Taiwanese Journal of Obstetrics Gynecology 48 (2): 124.  
Gibson, A., J. V. Woodside, I. S. Young, P. C. Sharpe, C. Mercer, C. C. Patterson, M. C. 
McKinley, L. A. J. Kluijtmans, A. S. Whitehead, and A. Evans. 2008. Alcohol 
increases homocysteine and reduces B vitamin concentration in healthy male 
volunteers--a randomized, crossover intervention study. QJM 101 (11): 881-7.  
Goei, G. S., and G. E. Abraham. 1983. Effect of a nutritional supplement, optivite, on 
symptoms of premenstrual tension. The Journal of Reproductive Medicine 28 (8) 
(Aug): 527-31.  
Gokhale, L. B. 1996. Curative treatment of primary (spasmodic) dysmenorrhoea. The 
Indian Journal of Medical Research 103 (Apr): 227-31.  
Gold, E. B., Y. Bair, G. Block, G. A. Greendale, S. D. Harlow, S. Johnson, H. M. 
Kravitz, et al. 2007. Diet and lifestyle factors associated with premenstrual 
symptoms in a racially diverse community sample: Study of women's health across 
the nation (SWAN). Journal of Women's Health (2002) 16 (5) (Jun): 641-56.  
Goodale, I. L., A. D. Domar, and H. Benson. 1990. Alleviation of premenstrual syndrome 
symptoms with the relaxation response. Obstetrics and Gynecology 75 (4) (Apr): 
649-55.  
Gordon, J., and R. Hen. 2006. TREKing toward new antidepressants. Nature 
Neuroscience 9 (9): 1081-3.  
Graf, A., M. Kabysheva, E. Klimuk, L. Trofimova, T. Dunaeva, G. Zündorf, S. Kahlert, 
et al. 2009. Role of 2-oxoglutarate dehydrogenase in brain pathologies involving 
glutamate neurotoxicity. Journal of Molecular Catalysis B: Enzymatic 61 (1-2) (11): 
80-7.  
Grant, Ellen C. G. 2004. Epilepsy and manganese. The Lancet 363 (9408): 572-.  
Green, R., and K. Dalton. 1953. The premenstrual syndrome. British Medical Journal 1 
(4818): 1007-1014.  
288 
 
Guille, Constance, Susan Spencer, Idil Cavus, and C. N. Epperson. 2008. The role of sex 
steroids in catamenial epilepsy and premenstrual dysphoric disorder: Implications 
for diagnosis and treatment. Epilepsy Behavior 13 (1): 12-24.  
Guyton, Arthur C., and John E. Hall. 2006. Textbook of medical physiology. 11th ed. 
Philadelphia: Elsevier Saunders.  
Hagen, I., B. I. Nesheim, and T. Tuntland. 1985. No effect of vitamin B-6 against 
premenstrual tension. A controlled clinical study. Acta Obstetricia Et Gynecologica 
Scandinavica 64 (8): 667-70.  
Halbreich, U. 2008. Selective serotonin reuptake inhibitors and initial oral contraceptives 
for the treatment of PMDD: Effective but not enough. CNS Spectrums 13 (7) (Jul): 
566-72.  
———. 2005. Algorithm for treatment of premenstrual syndromes (PMS): Experts' 
recommendations and limitations. Gynecological Endocrinology : The Official 
Journal of the International Society of Gynecological Endocrinology 20 (1) (Jan): 
48-56.  
———. 2004. The diagnosis of premenstrual syndromes and premenstrual dysphoric 
disorder--clinical procedures and research perspectives. Gynecological 
Endocrinology : The Official Journal of the International Society of Gynecological 
Endocrinology 19 (6) (Dec): 320-34.  
———. 2003. The etiology, biology, and evolving pathology of premenstrual syndromes. 
Psychoneuroendocrinology 28 Suppl 3 (Aug): 55-99.  
Halbreich, U., J. Borenstein, T. Pearlstein, and L. S. Kahn. 2003. The prevalence, 
impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). 
Psychoneuroendocrinology 28 Suppl 3 (Aug): 1-23.  
Halbreich, U., F. Petty, K. Yonkers, G. L. Kramer, A. J. Rush, and K. W. Bibi. 1996. 
Low plasma gamma-aminobutyric acid levels during the late luteal phase of women 
with premenstrual dysphoric disorder. The American Journal of Psychiatry 153 (5): 
718-20.  
Halbreich, U., and H. Tworek. 1993. Altered serotonergic activity in women with 
dysphoric premenstrual syndromes. International Journal of Psychiatry in Medicine 
23 (1): 1-27.  
Halbreich, Uriel, Richard Bergeron, Kimberly Yonkers, Ellen Freeman, Anna Stout, and 
Lee Cohen. 2002. Efficacy of intermittent, luteal phase sertraline treatment of 
premenstrual dysphoric disorder. Obstetrics and Gynecology 100 (6): 1219-29.  
289 
 
Hameed, A., T. Majeed, S. Rauf, M. Ashraf, M. A. Jalil, M. Nasrullah, A. Hussan, and R. 
Noreen. 2001. Effect of oral and injectable contraceptives on serum calcium, 
magnesium and phosphorus in women. Journal of Ayub Medical College, 
Abbottabad 13 (3): 24-5.  
Hameed, A., T. Majeed, S. Rauf, Ashraf, and Nasrullah. 2001. Effect of oral and 
injectable contraceptives on serum electrolytes, weight and blood pressure. Journal 
of Ayub Medical College, Abbottabad 13 (4): 27-9.  
Hardy, M. L. 2000. Herbs of special interest to women. Journal of the American 
Pharmaceutical Association (Washington,D.C.: 1996) 40 (2) (Mar-Apr): 234,42; 
quiz 327-9.  
Hashimoto, Kenji, Akira Sawa, and Masaomi Iyo. 2007. Increased levels of glutamate in 
brains from patients with mood disorders. Biological Psychiatry 62 (11): 1310-6.  
Hawkins, Shannon M. 2008. The menstrual cycle: Basic biology. Annals of the New York 
Academy of Sciences 1135, .  
Hellberg, D., B. Claesson, and S. Nilsson. 1991. Premenstrual tension: A placebo-
controlled efficacy study with spironolactone and medroxyprogesterone acetate. 
International Journal of Gynecology and Obstetrics 34 (3): 243-8.  
Heurteaux, Catherine, Guillaume Lucas, Nicolas Guy, Malika El Yacoubi, Susanne 
Thmmler, Xiao-Dong Peng, Florence Noble, et al. 2006. Deletion of the background 
potassium channel TREK-1 results in a depression-resistant phenotype. Nature 
Neuroscience 9 (9): 1134-41.  
Honor, Eric. 2007. The neuronal background K2P channels: Focus on TREK1. Nature 
Reviews.Neuroscience 8 (4): 251-61.  
Horrobin, D. F. 1983. The role of essential fatty acids and prostaglandins in the 
premenstrual syndrome. Journal of Reproductive Medicine 28, (7).  
Hunter, M. S., J. M. Ussher, S. J. Browne, M. Cariss, R. Jelley, and M. Katz. 2002. A 
randomized comparison of psychological (cognitive behavior therapy), medical 
(fluoxetine) and combined treatment for women with premenstrual dysphoric 
disorder. Journal of Psychosomatic Obstetrics and Gynecology 23 (3): 193-9.  
Institute of Medicine . Standing Committee on the Scientific Evaluation of Dietary 
Reference Intakes, Institute of Medicine . Panel on Folate, Other B Vitamins, and 
Choline, and Institute of Medicine . Subcommittee on Upper Reference Levels of 
Nutrients. 1998. DRI, dietary reference intakes for thiamin, riboflavin, niacin, 
vitamin B₆, folate, vitamin B₁₂, pantothenic acid, biotin, and choline. Washington, 
D.C.: National Academy Press.  
290 
 
Jarry, H., B. Spengler, A. Porzel, J. Schmidt, W. Wuttke, and V. Christoffel. 2003. 
Evidence for estrogen receptor beta-selective activity of vitex agnus-castus and 
isolated flavones. Planta Medica 69 (10) (Oct): 945-7.  
Jarvis, C. I., A. M. Lynch, and A. K. Morin. 2008. Management strategies for 
premenstrual syndrome/premenstrual dysphoric disorder. The Annals of 
Pharmacotherapy 42 (7) (Jul): 967-78.  
Jermain, D. M., C. K. Preece, R. L. Sykes, T. J. Kuehl, and P. J. Sulak. 1999. Luteal 
phase sertraline treatment for premenstrual dysphoric disorder. results of a double-
blind, placebo-controlled, crossover study. Archives of Family Medicine 8 (4): 328-
32.  
Joffe, H., L. S. Cohen, and B. L. Harlow. 2003. Impact of oral contraceptive pill use on 
premenstrual mood: Predictors of improvement and deterioration. American Journal 
of Obstetrics and Gynecology 189 (6) (Dec): 1523-30.  
Johnson, S. 2001. The multifaceted and widespread pathology of magnesium deficiency. 
Medical Hypotheses 56 (2): 163-70.  
Johnson, S. R. 2004. Premenstrual syndrome, premenstrual dysphoric disorder, and 
beyond: A clinical primer for practitioners. Obstetrics and Gynecology 104 (4) 
(Oct): 845-59.  
Jones, Christopher, Clare Underwood, Elizabeth Coulson, and Paul Taylor. 2007. Copper 
induced oxidation of serotonin: Analysis of products and toxicity. Journal of 
Neurochemistry 102 (4): 1035-43.  
Jung, Kyu, Sun Ock, Ju Chung, and Chan Song. 2010. Associations of serum ca and mg 
levels with mental health in adult women without psychiatric disorders. Biological 
Trace Element Research 133 (2): 153-61.  
Kashanian, M., R. Mazinani, and S. Jalalmanesh. 2007. Pyridoxine (vitamin B6) therapy 
for premenstrual syndrome. International Journal of Gynaecology and Obstetrics: 
The Official Organ of the International Federation of Gynaecology and Obstetrics 
96 (1) (Jan): 43-4.  
Kaulhausen, H., G. Leyendecker, G. Benker, and H. Breuer. 1978. The relationship of the 
renin-angiotensin-aldosterone system to plasma gonadotropin, prolactin, and ovarian 
steroid patterns during the menstrual cycle. Archiv Für Gynäkologie 225 (3): 179-
200.  
Kelly, J., D. Kaufman, K. Kelley, L. Rosenberg, T. Anderson, and A. Mitchell. 2005. 
Recent trends in use of herbal and other natural products. Archives of Internal 
Medicine 165 (3): 281-6.  
291 
 
Khine, Khursheed, Donald Rosenstein, Ronald Elin, Julie Niemela, Peter Schmidt, and 
David Rubinow. 2006. Magnesium (mg) retention and mood effects after 
intravenous mg infusion in premenstrual dysphoric disorder. Biological Psychiatry 
59 (4): 327-33.  
Khoo, S. K., C. Munro, and D. Battistutta. 1990. Evening primrose oil and treatment of 
premenstrual syndrome. The Medical Journal of Australia 153 (4) (Aug 20): 189-92.  
Kleijnen, J., G. Ter Riet, and P. Knipschild. 1990. Vitamin B6 in the treatment of the 
premenstrual syndrome--a review. British Journal of Obstetrics and Gynaecology 97 
(9) (Sep): 847-52.  
Knaapen, L., and G. Weisz. 2008. The biomedical standardization of premenstrual 
syndrome. Studies in History and Philosophy of Biological and Biomedical Sciences 
39 (1) (Mar): 120-34.  
Kornstein, Susan, Teri Pearlstein, Rana Fayyad, Gail Farfel, and John Gillespie. 2006. 
Low-dose sertraline in the treatment of moderate-to-severe premenstrual syndrome: 
Efficacy of 3 dosing strategies. The Journal of Clinical Psychiatry 67 (10): 1624-32.  
Kroll, R., and A. J. Rapkin. 2006. Treatment of premenstrual disorders. The Journal of 
Reproductive Medicine 51 (4 Suppl) (Apr): 359-70.  
Levenson, Cathy. 2006. Regulation of the NMDA receptor: Implications for 
neuropsychological development. Nutrition Reviews 64 (9): 428-32.  
Levine, J., D. Stein, A. Rapoport, and L. Kurtzman. 1999. High serum and cerebrospinal 
fluid Ca/Mg ratio in recently hospitalized acutely depressed patients. 
Neuropsychobiology 39 (2): 63-70.  
Liedman, Ragner, Stefan Hansson, David Howe, Sarah Igidbashian, Alison McLeod, 
Rachel Russell, and Mats Akerlund. 2008. Reproductive hormones in plasma over 
the menstrual cycle in primary dysmenorrhea compared with healthy subjects. 
Gynecological Endocrinology 24 (9): 508-13.  
Lnnerdal, B. 2000. Dietary factors influencing zinc absorption. The Journal of Nutrition 
130 (5S Suppl): 1378-83S.  
London, R. S., L. Murphy, K. E. Kitlowski, and M. A. Reynolds. 1987. Efficacy of alpha-
tocopherol in the treatment of the premenstrual syndrome. Journal of Reproductive 
Medicine 32 (6): 400-4.  
London, R. S., L. Bradley, and N. Y. Chiamori. 1991. Effect of a nutritional supplement 
on premenstrual symptomatology in women with premenstrual syndrome: A double-
blind longitudinal study. Journal of the American College of Nutrition 10 (5) (Oct): 
494-9.  
292 
 
Lovick, T. A. 2008. GABA in the female brain -- oestrous cycle-related changes in 
GABAergic function in the periaqueductal grey matter. Pharmacology, 
Biochemistry, and Behavior 90 (1) (Jul): 43-50.  
Lussana, F., M. Zighetti, P. Bucciarelli, M. Cugno, and M. Cattaneo. 2003. Blood levels 
of homocysteine, folate, vitamin B6 and B12 in women using oral contraceptives 
compared to non-users. Thrombosis Research 112 (1-2): 37-41.  
Lustyk, M. K. B., W. Gerrish, S. Shaver, and S. Keys. 2009. Cognitive-behavioral 
therapy for premenstrual syndrome and premenstrual dysphoric disorder: A 
systematic review. Archives of Women's Mental Health 12 (2): 85-96.  
Maeng, S., and C. Zarate. 2007. The role of glutamate in mood disorders: Results from 
the ketamine in major depression study and the presumed cellular mechanism 
underlying its antidepressant effects. Current Psychiatry Reports 9 (6): 467-74.  
Maes, M., P. C. D'Haese, S. Scharp, P. D'Hondt, P. Cosyns, and M. E. De Broe. 1994. 
Hypozincemia in depression. Journal of Affective Disorders 31 (2): 135-40.  
Maguire, J., and I. Mody. 2009. Steroid hormone fluctuations and GABA(A)R plasticity. 
Psychoneuroendocrinology 34 Suppl 1 : S84.  
Maillot, F., S. Farad, and F. Lamisse. 2001. [Alcohol and nutrition]. Pathologie Biologie 
49 (9): 683-8.  
Malmgren, R., A. Collins, and C. G. Nilsson. 1987. Platelet serotonin uptake and effects 
of vitamin B6-treatment in premenstrual tension. Neuropsychobiology 18 (2): 83-6.  
Mark, L. P., R. W. Prost, J. L. Ulmer, M. M. Smith, D. L. Daniels, J. M. Strottmann, W. 
D. Brown, and L. Hacein-Bey. 2001. Pictorial review of glutamate excitotoxicity: 
Fundamental concepts for neuroimaging. AJNR, American Journal of 
Neuroradiology 22 (10): 1813-24.  
Masho, S. W., T. Adera, and J. South-Paul. 2005. Obesity as a risk factor for 
premenstrual syndrome. Journal of Psychosomatic Obstetrics and Gynaecology 26 
(1) (Mar): 33-9.  
Masino, S. A., and J. S. Kahle. 2002. Vitamin B6 therapy during childbearing years: 
Cause for caution? Nutritional Neuroscience 5 (4) (Sep): 241-2.  
McEwen, B. S., A. Biegon, P. G. Davis, L. C. Krey, V. N. Luine, M. Y. McGinnis, C. M. 
Paden, B. Parsons, and T. C. Rainbow. 1982. Steroid hormones: Humoral signals 
which alter brain cell properties and functions. Recent Progress in Hormone 
Research 38 : 41-92.  
293 
 
Menkes, D. B., E. Taghavi, P. A. Mason, and R. C. Howard. 1993. Fluoxetine's spectrum 
of action in premenstrual syndrome. International Clinical Psychopharmacology 8 
(2): 95-102.  
Milewicz, Andrzej, and Diana Jedrzejuk. 2006. Premenstrual syndrome: From etiology to 
treatment. Maturitas, 55 (Supplement 1) (11/1): S47-54.  
Miller, Alan. 2008. The methylation, neurotransmitter, and antioxidant connections 
between folate and depression. Alternative Medicine Review 13 (3): 216.  
Miner, Cherri, Eileen Brown, Susan McCray, Jill Gonzales, and Madelaine Wohlreich. 
2002. Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in 
premenstrual dysphoric disorder: A randomized, double-blind, placebo-controlled 
clinical trial. Clinical Therapeutics 24 (3): 417-33.  
Mira, M., P. M. Stewart, and S. F. Abraham. 1988. Vitamin and trace element status in 
premenstrual syndrome. The American Journal of Clinical Nutrition 47 (4) (Apr): 
636-41.  
Mishell, D. R.,Jr. 2005. Premenstrual disorders: Epidemiology and disease burden. The 
American Journal of Managed Care 11 (16 Suppl) (Dec): S473-9.  
Monteleone, P., S. Luisi, A. Tonetti, F. Bernardi, A. D. Genazzani, M. Luisi, F. Petraglia, 
and A. R. Genazzani. 2000. Allopregnanolone concentrations and premenstrual 
syndrome. European Journal of Endocrinology 142 (3): 269-73.  
Moos, R. H. 1968. The development of a menstrual distress questionnaire. Psychosomatic 
Medicine 30 (6) (Nov-Dec): 853-67.  
Mortola, J. F. 1998. Premenstrual syndrome--pathophysiologic considerations. The New 
England Journal of Medicine 338 (4) (Jan 22): 256-7.  
———. 1992. Issues in the diagnosis and research of premenstrual syndrome. Clinical 
Obstetrics and Gynecology 35 (3) (Sep): 587-98.  
Mortola, J. F., L. Girton, L. Beck, and S. S. Yen. 1990. Diagnosis of premenstrual 
syndrome by a simple, prospective, and reliable instrument: The calendar of 
premenstrual experiences. Obstetrics and Gynecology 76 (2) (Aug): 302-7.  
Mortola, J. F., L. Girton, and U. Fischer. 1991. Successful treatment of severe 
premenstrual syndrome by combined use of gonadotropin-releasing hormone agonist 
and estrogen/progestin. The Journal of Clinical Endocrinology and Metabolism 72 
(2) (Feb): 252A-F.  
Murakami, K., T. Mizoue, S. Sasaki, M. Ohta, M. Sato, Y. Matsushita, and N. Mishima. 
2008. Dietary intake of folate, other B vitamins, and omega-3 polyunsaturated fatty 
294 
 
acids in relation to depressive symptoms in japanese adults. Nutrition (Burbank, Los 
Angeles County, Calif.) 24 (2) (Feb): 140-7.  
Murray Kolb, Laura, and John Beard. 2007. Iron treatment normalizes cognitive 
functioning in young women. The American Journal of Clinical Nutrition 85 (3): 
778-87.  
Muti, P., M. Trevisan, A. Micheli, V. Krogh, G. Bolelli, R. Sciajno, H. J. Schnemann, 
and F. Berrino. 1998. Alcohol consumption and total estradiol in premenopausal 
women. Cancer Epidemiology Biomarkers Prevention 7 (3): 189-93.  
Nyberg, S., A. Andersson, E. Zingmark, G. Wahlstrom, T. Backstrom, and I. Sundstrom-
Poromaa. 2005. The effect of a low dose of alcohol on allopregnanolone serum 
concentrations across the menstrual cycle in women with severe premenstrual 
syndrome and controls. Psychoneuroendocrinology 30 (9) (Oct): 892-901.  
Nyberg, S., G. Wahlstrom, T. Backstrom, and I. Sundstrom Poromaa. 2004. Altered 
sensitivity to alcohol in the late luteal phase among patients with premenstrual 
dysphoric disorder. Psychoneuroendocrinology 29 (6) (Jul): 767-77.  
Osterlund, Marie. 2009. Underlying mechanisms mediating the antidepressant effects of 
estrogens. Biochimica Et Biophysica Acta.  
Ozeren, S., A. Coraki, I. Ycesoy, R. Mercan, and G. Erhan. 1997. Fluoxetine in the 
treatment of premenstrual syndrome. European Journal of Obstetrics Gynecology 
and Reproductive Biology 73 (2): 167-70.  
Parry, B. L., S. L. Berga, D. F. Kripke, M. R. Klauber, G. A. Laughlin, S. S. Yen, and J. 
C. Gillin. 1990. Altered waveform of plasma nocturnal melatonin secretion in 
premenstrual depression. Archives of General Psychiatry 47 (12): 1139-46.  
Parry, B. L., R. Hauger, B. LeVeau, N. Mostofi, H. Cover, P. Clopton, and J. C. Gillin. 
1996. Circadian rhythms of prolactin and thyroid-stimulating hormone during the 
menstrual cycle and early versus late sleep deprivation in premenstrual dysphoric 
disorder. Psychiatry Research 62 (2) (May 17): 147-60.  
Paul, T. P., A. McDonnell, and C. Kelly. 2004. Folic acid: Neurochemistry, metabolism 
and relationship to depression. Human Psychopharmacology 19 (7): 477-88.  
Pearlstein, T., and M. Steiner. 2008. Premenstrual dysphoric disorder: Burden of illness 
and treatment update. Journal of Psychiatry & Neuroscience : JPN 33 (4) (Jul): 291-
301.  
Pearlstein, T. B., A. B. Stone, S. A. Lund, H. Scheft, C. Zlotnick, and W. A. Brown. 
1997. Comparison of fluoxetine, bupropion, and placebo in the treatment of 
295 
 
premenstrual dysphoric disorder. Journal of Clinical Psychopharmacology 17 (4) 
(Aug): 261-6.  
Penland, J. G., and P. E. Johnson. 1993. Dietary calcium and manganese effects on 
menstrual cycle symptoms. American Journal of Obstetrics and Gynecology 168 (5) 
(May): 1417-23.  
Petty, F. 1995. GABA and mood disorders: A brief review and hypothesis. Journal of 
Affective Disorders 34 (4): 275-81.  
Piyathilake, C. J., M. Macaluso, R. J. Hine, E. W. Richards, and C. L. Krumdieck. 1994. 
Local and systemic effects of cigarette smoking on folate and vitamin B-12. The 
American Journal of Clinical Nutrition 60 (4): 559-66.  
Poromaa, I. S., S. Smith, and M. Gulinello. 2003. GABA receptors, progesterone and 
premenstrual dysphoric disorder. Archives of Women's Mental Health 6 (1): 23-41.  
Quaranta, S., M. A. Buscaglia, M. G. Meroni, E. Colombo, and S. Cella. 2007. Pilot 
study of the efficacy and safety of a modified-release magnesium 250 mg tablet 
(sincromag) for the treatment of premenstrual syndrome. Clinical Drug Investigation 
27 (1): 51-8.  
Rapkin, A. J. 1992. The role of serotonin in premenstrual syndrome. Clinical Obstetrics 
and Gynecology 35 (3): 629-36.  
Rapkin, A. J., E. Edelmuth, L. C. Chang, A. E. Reading, M. T. McGuire, and T. P. Su. 
1987. Whole-blood serotonin in premenstrual syndrome. Obstetrics and Gynecology 
70 (4): 533-7.  
Rapkin, A. J., M. Morgan, L. Goldman, D. W. Brann, D. Simone, and V. B. Mahesh. 
1997. Progesterone metabolite allopregnanolone in women with premenstrual 
syndrome. Obstetrics and Gynecology 90 (5): 709-14.  
Rapkin, A. J., and S. A. Winer. 2008. The pharmacologic management of premenstrual 
dysphoric disorder. Expert Opinion on Pharmacotherapy 9 (3) (Feb): 429-45.  
Rasgon, N., M. Serra, G. Biggio, M. G. Pisu, L. Fairbanks, S. Tanavoli, and A. Rapkin. 
2001. Neuroactive steroid-serotonergic interaction: Responses to an intravenous L-
tryptophan challenge in women with premenstrual syndrome. European Journal of 
Endocrinology 145 (1): 25.  
Reeves, B. D., J. E. Garvin, and T. W. McElin. 1971. Premenstrual tension: Symptoms 
and weight changes related to potassium therapy. American Journal of Obstetrics 
and Gynecology 109 (7): 1036-41.  
296 
 
Rimm, E. B., E. L. Giovannucci, M. J. Stampfer, G. A. Colditz, L. B. Litin, and W. C. 
Willett. 1992. Reproducibility and validity of an expanded self-administered 
semiquantitative food frequency questionnaire among male health professionals. 
American Journal of Epidemiology 135 (10) (May 15): 1114,26; discussion 1127-36.  
Ritchie, C. D., and R. Singkamani. 1986. Plasma pyridoxal 5'-phosphate in women with 
the premenstrual syndrome. Human Nutrition.Clinical Nutrition 40 (1) (Jan): 75-80.  
Robinson, R. L., and R. W. Swindle. 2000. Premenstrual symptom severity: Impact on 
social functioning and treatment-seeking behaviors. Journal of Women's Health & 
Gender-Based Medicine 9 (7) (Sep): 757-68.  
Robinson, Stephen, Matt Dowell, Dominic Pedulla, and Larry McCauley. 2004. Do the 
emotional side-effects of hormonal contraceptives come from pharmacologic or 
psychological mechanisms? Medical Hypotheses 63 (2): 268-73.  
Rojansky, N., and U. Halbreich. 1991. Prevalence and severity of premenstrual changes 
after tubal sterilization. Journal of Reproductive Medicine 36 (8): 551-5.  
Rosenstein, D. L., R. J. Elin, J. M. Hosseini, G. Grover, and D. R. Rubinow. 1994. 
Magnesium measures across the menstrual cycle in premenstrual syndrome. 
Biological Psychiatry 35 (8): 557-61.  
Rudolph, U., F. Crestani, and H. Mhler. 2001. GABA(A) receptor subtypes: Dissecting 
their pharmacological functions. Trends in Pharmacological Sciences 22 (4): 188-
94.  
Salvini, S., D. J. Hunter, L. Sampson, M. J. Stampfer, G. A. Colditz, B. Rosner, and W. 
C. Willett. 1989. Food-based validation of a dietary questionnaire: The effects of 
week-to-week variation in food consumption. International Journal of Epidemiology 
18 (4) (Dec): 858-67.  
Sanacora, Gerard, Carlos Zarate, John Krystal, and Husseini Manji. 2008. Targeting the 
glutamatergic system to develop novel, improved therapeutics for mood disorders. 
Nature Reviews.Drug Discovery 7 (5): 426-37.  
Sandstead, H. H. 1995. Requirements and toxicity of essential trace elements, illustrated 
by zinc and copper. The American Journal of Clinical Nutrition 61 (3 Suppl): 621-
624S.  
Sawada, T., and K. Yokoi. 2010. Effect of zinc supplementation on mood states in young 
women: A pilot study. European Journal of Clinical Nutrition.  
Schmidt, P. J., G. N. Grover, and D. R. Rubinow. 1993. Alprazolam in the treatment of 
premenstrual syndrome. A double-blind, placebo-controlled trial. Archives of 
General Psychiatry 50 (6) (Jun): 467-73.  
297 
 
Schmidt, P. J., L. K. Nieman, M. A. Danaceau, L. F. Adams, and D. R. Rubinow. 1998. 
Differential behavioral effects of gonadal steroids in women with and in those 
without premenstrual syndrome. The New England Journal of Medicine 338 (4) (Jan 
22): 209-16.  
Schuster, K., L. B. Bailey, J. J. Cerda, and J. F. Gregory. 1984. Urinary 4-pyridoxic acid 
excretion in 24-hour versus random urine samples as a measurement of vitamin B6 
status in humans. The American Journal of Clinical Nutrition 39 (3): 466-70.  
Selhub, J., P. F. Jacques, P. W. Wilson, D. Rush, and I. H. Rosenberg. 1993. Vitamin 
status and intake as primary determinants of homocysteinemia in an elderly 
population. JAMA 270 (22): 2693-8.  
Shamberger, Raymond. 2003. Calcium, magnesium, and other elements in the red blood 
cells and hair of normals and patients with premenstrual syndrome. Biological Trace 
Element Research 94 (2): 123-9.  
Sharma, P., S. Kulshreshtha, G. M. Singh, and A. Bhagoliwal. 2007. Role of 
bromocriptine and pyridoxine in premenstrual tension syndrome. Indian Journal of 
Physiology and Pharmacology 51 (4) (Oct-Dec): 368-74.  
Shin, . 2008. The effect of hand acupuncture therapy and hand moxibustion therapy on 
premenstrual syndrome among korean women. Western Journal of Nursing 
Research.  
Shin, Y. S., R. Rasshofer, B. Friedrich, and W. Endres. 1983. Pyridoxal-5'-phosphate 
determination by a sensitive micromethod in human blood, urine and tissues its 
relation to cystathioninuria in neuroblastoma and biliary atresia. Clinica Chimica 
Acta 127 (1): 77-85.  
Sica, Domenic. 2007. The risks and benefits of therapy with aldosterone receptor 
antagonist therapy. Current Drug Safety 2 (1): 71-7.  
Siwek, Marcin, Dominika Dudek, Ian Paul, Magdalena Sowa-Kućma, Andrzej Zieba, 
Piotr Popik, Andrzej Pilc, and Gabriel Nowak. 2009. Zinc supplementation 
augments efficacy of imipramine in treatment resistant patients: A double blind, 
placebo-controlled study. Journal of Affective Disorders 118 (1-3): 187-95.  
Smallwood, J., D. Ah-Kye, and I. Taylor. 1986. Vitamin B6 in the treatment of pre-
menstrual mastalgia. The British Journal of Clinical Practice 40 (12) (Dec): 532-3.  
Smith, Sheryl. 2002. Withdrawal properties of a neuroactive steroid: Implications for 
GABA(A) receptor gene regulation in the brain and anxiety behavior. Steroids 67 
(6): 519-28.  
298 
 
Smith, Sheryl, Hui Shen, Qi Gong, and Xiangping Zhou. 2007. Neurosteroid regulation 
of GABA(A) receptors: Focus on the alpha4 and delta subunits. Pharmacology 
Therapeutics 116 (1): 58-76.  
Snchez-Villegas, A., J. Doreste, J. Schlatter, J. Pla, M. Bes-Rastrollo, and M. A. Martnez-
Gonzlez. 2009. Association between folate, vitamin B(6) and vitamin B(12) intake 
and depression in the SUN cohort study. Journal of Human Nutrition and Dietetics 
22 (2): 122-33.  
Solomons, N. K. 2001. Dietary sources of zinc and factors affecting its bioavailability. 
Food and Nutrition Bulletin 22 (2): 138.  
Sowa-Kućma, Magdalena, Beata Legutko, Bernadeta Szewczyk, Kinga Novak, Paweł 
Znojek, Ewa Poleszak, Mariusz Papp, Andrzej Pilc, and Gabriel Nowak. 2008. 
Antidepressant-like activity of zinc: Further behavioral and molecular evidence. 
Journal of Neural Transmission 115 (12): 1621.  
Steiner, M., E. Brown, P. Trzepacz, J. Dillon, C. Berger, D. Carter, R. Reid, and D. 
Stewart. 2003. Fluoxetine improves functional work capacity in women with 
premenstrual dysphoric disorder. Archives of Women's Mental Health 6 (1) (Feb): 
71-7.  
Steiner, M., M. Macdougall, and E. Brown. 2003. The premenstrual symptoms screening 
tool (PSST) for clinicians. Archives of Women's Mental Health 6 (3) (Aug): 203-9.  
Steiner, M., and T. Pearlstein. 2000. Premenstrual dysphoria and the serotonin system: 
Pathophysiology and treatment. The Journal of Clinical Psychiatry 61 Suppl 12 : 17-
21.  
Steiner, M., S. J. Romano, S. Babcock, J. Dillon, C. Shuler, C. Berger, D. Carter, et al. 
2001. The efficacy of fluoxetine in improving physical symptoms associated with 
premenstrual dysphoric disorder. BJOG : An International Journal of Obstetrics and 
Gynaecology 108 (5) (May): 462-8.  
Steiner, Meir, Arun Ravindran, Jean-Michel LeMelledo, Diana Carter, Jenny Huang, 
Andrea Anonychuk, and Scott Simpson. 2008. Luteal phase administration of 
paroxetine for the treatment of premenstrual dysphoric disorder: A randomized, 
double-blind, placebo-controlled trial in canadian women. The Journal of Clinical 
Psychiatry 69 (6): 991-8.  
Stewart, A. 1991. Vitamin B6 in the treatment of the premenstrual syndrome--review. 
British Journal of Obstetrics and Gynaecology 98 (3) (Mar): 329-30.  
Stipanuk, Martha H. 2006. Biochemical, physiological, & molecular aspects of human 
nutrition. 2nd ed. St. Louis: Saunders Elsevier.  
299 
 
Sundstrm, I., A. Andersson, S. Nyberg, D. Ashbrook, R. H. Purdy, and T. Bckstrm. 1998. 
Patients with premenstrual syndrome have a different sensitivity to a neuroactive 
steroid during the menstrual cycle compared to control subjects. 
Neuroendocrinology 67 (2): 126-38.  
Szewczyk, Bernadeta, Marta Kubera, and Gabriel Nowak. 2010. The role of zinc in 
neurodegenerative and inflammatory pathways in depression. Progress in Neuro-
Psychopharmacology Biological Psychiatry.  
Szmuilowicz, Emily, Gail Adler, Jonathan Williams, Dina Green, Tham Yao, Paul 
Hopkins, and Ellen Seely. 2006. Relationship between aldosterone and progesterone 
in the human menstrual cycle. The Journal of Clinical Endocrinology and 
Metabolism 91 (10): 3981-7.  
Takeda, Atsushi, and Haruna Tamano. 2009. Insight into zinc signaling from dietary zinc 
deficiency. Brain Research Reviews 62 (1): 33-44.  
Taylor, D. L., R. J. Mathew, B. T. Ho, and M. L. Weinman. 1984. Serotonin levels and 
platelet uptake during premenstrual tension. Neuropsychobiology 12 (1): 16-8.  
Thys-Jacobs, S. 2000. Micronutrients and the premenstrual syndrome: The case for 
calcium. Journal of the American College of Nutrition 19 (2) (Apr): 220-7.  
Thys-Jacobs, S., and M. J. Alvir. 1995. Calcium-regulating hormones across the 
menstrual cycle: Evidence of a secondary hyperparathyroidism in women with PMS. 
The Journal of Clinical Endocrinology and Metabolism 80 (7) (Jul): 2227-32.  
Thys-Jacobs, S., S. Ceccarelli, A. Bierman, H. Weisman, M. A. Cohen, and J. Alvir. 
1989. Calcium supplementation in premenstrual syndrome: A randomized crossover 
trial. Journal of General Internal Medicine 4 (3): 183-9.  
Thys-Jacobs, S., D. McMahon, and J. P. Bilezikian. 2007. Cyclical changes in calcium 
metabolism across the menstrual cycle in women with premenstrual dysphoric 
disorder. The Journal of Clinical Endocrinology and Metabolism 92 (8) (Aug): 
2952-9.  
Thys-Jacobs, S., P. Starkey, D. Bernstein, and J. Tian. 1998. Calcium carbonate and the 
premenstrual syndrome: Effects on premenstrual and menstrual symptoms. 
premenstrual syndrome study group. American Journal of Obstetrics and 
Gynecology 179 (2) (Aug): 444-52.  
Torres, S., C. Nowson, and A. Worsley. 2008. Dietary electrolytes are related to mood. 
The British Journal of Nutrition 100 (5): 1038-45.  
Twomey, P. 2007. Raised serum copper results does not mean excess body copper. 
Journal of Trace Elements in Medicine and Biology 21 (2): 141-.  
300 
 
Ulvik, Arve, Marta Ebbing, Steinar Hustad, ivind Midttun, Ottar Nygård, Stein E. 
Vollset, Kåre H. Bønaa, et al. 2010. Long- and short-term effects of tobacco 
smoking on circulating concentrations of B vitamins. Clinical Chemistry 56 (5): 755-
63.  
van den Berg, H., E. S. Louwerse, H. W. Bruinse, J. T. Thissen, and J. Schrijver. 1986. 
Vitamin B6 status of women suffering from premenstrual syndrome. Human 
Nutrition.Clinical Nutrition 40 (6) (Nov): 441-50.  
Vellacott, I. D., N. E. Shroff, M. Y. Pearce, M. E. Stratford, and F. A. Akbar. 1987. A 
double-blind, placebo-controlled evaluation of spironolactone in the premenstrual 
syndrome. Current Medical Research and Opinion 10 (7): 450-6.  
Vengeliene, V., A. Bilbao, A. Molander, and R. Spanagel. 2008. Neuropharmacology of 
alcohol addiction. British Journal of Pharmacology 154 (2): 299-315.  
Vermaak, W. J., J. B. Ubbink, H. C. Barnard, G. M. Potgieter, H. van Jaarsveld, and A. J. 
Groenewald. 1990. Vitamin B-6 nutrition status and cigarette smoking. The 
American Journal of Clinical Nutrition 51 (6): 1058-61.  
Walker, Ann, M. C. De Souza, G. Marakis, P. A. Robinson, A. P. Morris, and K. M. 
Bolland. 2002. Unexpected benefit of sorbitol placebo in mg intervention study of 
premenstrual symptoms: Implications for choice of placebo in RCTs. Medical 
Hypotheses 58 (3): 213-20.  
Wang, M., S. Hammarback, B. A. Lindhe, and T. Backstrom. 1995. Treatment of 
premenstrual syndrome by spironolactone: A double-blind, placebo-controlled study. 
Acta Obstetricia Et Gynecologica Scandinavica 74 (10) (Nov): 803-8.  
Willett, W. C. 1998. Nutritional epidemiology. Monographs in epidemiology and 
biostatistics., eds. J. Kelsey, M. Marmot, P. Stolley and M. Vessey. Second Edition 
ed. Vol. 30. New York, Oxford: Oxford University Press.  
Willett, W. C., L. Sampson, M. J. Stampfer, B. Rosner, C. Bain, J. Witschi, C. H. 
Hennekens, and F. E. Speizer. 1985. Reproducibility and validity of a 
semiquantitative food frequency questionnaire. American Journal of Epidemiology 
122 (1) (Jul): 51-65.  
Williams, A. L., A. Cotter, A. Sabina, C. Girard, J. Goodman, and D. L. Katz. 2005. The 
role for vitamin B-6 as treatment for depression: A systematic review. Family 
Practice 22 (5) (Oct): 532-7.  
Williams, M. J., R. I. Harris, and B. C. Dean. 1985. Controlled trial of pyridoxine in the 
premenstrual syndrome. The Journal of International Medical Research 13 (3): 174-
9.  
301 
 
Windham, G. C., P. Mitchell, M. Anderson, and B. L. Lasley. 2005. Cigarette smoking 
and effects on hormone function in premenopausal women. Environmental Health 
Perspectives 113 (10) (Oct): 1285-90.  
Wisner, Katherine, Eydie Moses-Kolko, and Dorothy K. Y. Sit. 2010. Postpartum 
depression: A disorder in search of a definition. Archives of Women's Mental Health 
13 (1): 37-40.  
Wittchen, H. U., E. Becker, R. Lieb, and P. Krause. 2002. Prevalence, incidence and 
stability of premenstrual dysphoric disorder in the community. Psychological 
Medicine 32 (1): 119-32.  
Wood, S. H., J. F. Mortola, Y. F. Chan, F. Moossazadeh, and S. S. Yen. 1992. Treatment 
of premenstrual syndrome with fluoxetine: A double-blind, placebo-controlled, 
crossover study. Obstetrics and Gynecology 80 (3): 339-44.  
Woods, N. F., A. Most, and G. K. Dery. 1982. Prevalene of perimenstrual symptoms. Am 
J Public Health 72 (11): 1257-64.  
Woolley, C. S. 2000. Effects of oestradiol on hippocampal circuitry. Novartis Foundation 
Symposium 230 : 173-80.  
Wu, Kuan-Yi, Chia-Yih Liu, and Mei-Chun Hsiao. 2008. Six-month paroxetine treatment 
of premenstrual dysphoric disorder: Continuous versus intermittent treatment 
protocols. Psychiatry and Clinical Neurosciences 62 (1): 109-14.  
Wuttke, W., H. Jarry, V. Christoffel, B. Spengler, and D. Seidlova-Wuttke. 2003. Chaste 
tree (vitex agnus-castus)--pharmacology and clinical indications. Phytomedicine : 
International Journal of Phytotherapy and Phytopharmacology 10 (4) (May): 348-
57.  
Wyatt, K. M., P. W. Dimmock, P. W. Jones, and P. M. Shaughn O'Brien. 1999. Efficacy 
of vitamin B-6 in the treatment of premenstrual syndrome: Systematic review. BMJ 
(Clinical Research Ed.) 318 (7195) (May 22): 1375-81.  
Wyatt, K. M., P. W. Dimmock, and P. M. O'Brien. 2002. Selective serotonin reuptake 
inhibitors for premenstrual syndrome. Cochrane Database of Systematic Reviews 
(Online) (4) (4): CD001396.  
Yehuda, Shlomo. 2010. Iron deficiency and overload : From basic biology to clinical 
medicine : Nutrition and health. New York, N.Y. : Humana Press,.  
Yen, J.Y., S.J. Chang, C.H. Ko, C.F. Yen, C. Chen, Y. Yeh, and C.C. Chen. 2010. The 
high-sweet-fat food craving among women with premenstrual dysphoric disorder: 
Emotional response, implicit attitude and rewards sensitivity. 
Psychoneuroendocrinology 35 (8): 1203-12.  
302 
 
Yokel, R. 2009. Manganese flux across the blood-brain barrier. NeuroMolecular 
Medicine 11 (4): 297-310.  
Yonkers, K. A., U. Halbreich, E. Freeman, C. Brown, J. Endicott, E. Frank, B. Parry, et 
al. 1997. Symptomatic improvement of premenstrual dysphoric disorder with 
sertraline treatment. A randomized controlled trial. sertraline premenstrual dysphoric 
collaborative study group. JAMA 278 (12): 983-8.  
Yonkers, K. A., C. Brown, T. B. Pearlstein, M. Foegh, C. Sampson-Landers, and A. 
Rapkin. 2005. Efficacy of a new low-dose oral contraceptive with drospirenone in 
premenstrual dysphoric disorder. Obstetrics and Gynecology 106 (3) (Sep): 492-501.  
Yonkers, K. A., P. M. O'Brien, and E. Eriksson. 2008. Premenstrual syndrome. Lancet 
371 (9619) (Apr 5): 1200-10.  
Yu, S., R. Ghandour, and Z. Huang. 2004. Herbal supplement use among US women, 
2000. Journal of the American Medical Women's Association 59 (1): 17-24.  
Zarate, C., J.Singh, P. Carlson, N. Brutsche, R. Ameli, D. Luckenbaugh, D.Charney, and 
H. Manji. 2006. A randomized trial of an N-methyl-D-aspartate antagonist in 
treatment-resistant major depression. Archives of General Psychiatry 63 (8): 856-64.  
 
 
 
